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Ra úl González-Domı́nguez, Gregorio Peron, Benjamin Kirkup, Paul A Kroon, 
Cristina Andres-Lacueva, Simone Guglielmetti and Patrizia Riso
Estimated Intakes of Nutrients and Polyphenols in Participants Completing the MaPLE 
Randomised Controlled Trial and Its Relevance for the Future Development of Dietary 
Guidelines for the Older Subjects
Reprinted from: Nutrients 2020, 12, 2458, doi:10.3390/nu12082458 . . . . . . . . . . . . . . . . . . 5
Meropi D. Kontogianni, Aswathy Vijayakumar, Ciara Rooney, Rebecca L. Noad, 
Katherine M. Appleton, Danielle McCarthy, Michael Donnelly, Ian S. Young, 
Michelle C. McKinley, Pascal P. McKeown and Jayne V. Woodside
A High Polyphenol Diet Improves Psychological Well-Being: The Polyphenol Intervention 
Trial (PPhIT)
Reprinted from: Nutrients 2020, 12, 2445, doi:10.3390/nu12082445 . . . . . . . . . . . . . . . . . . 23
Emma L. Wightman, Philippa A. Jackson, Joanne Forster, Julie Khan, Julia C. Wiebe, 
Nigel Gericke and David O. Kennedy
Acute Effects of a Polyphenol-Rich Leaf Extract of Mangifera indica L. (Zynamite) on Cognitive 
Function in Healthy Adults: A Double-Blind, Placebo-Controlled Crossover Study
Reprinted from: Nutrients 2020, 12, 2194, doi:10.3390/nu12082194 . . . . . . . . . . . . . . . . . . 39
Jing Sun, Hong Jiang, Weijing Wang, Xue Dong and Dongfeng Zhang
Associations of Urinary Phytoestrogen Concentrations with Sleep Disorders and Sleep Duration
among Adults
Reprinted from: Nutrients 2020, 12, 2103, doi:10.3390/nu12072103 . . . . . . . . . . . . . . . . . . 55
Nancy Saji, Nidhish Francis, Lachlan J. Schwarz, Christopher L. Blanchard and Abishek B.
Santhakumar
Rice Bran Phenolic Extracts Modulate Insulin Secretion and Gene Expression Associated
with β-Cell Function
Reprinted from: Nutrients 2020, 12, 1889, doi:10.3390/nu12061889 . . . . . . . . . . . . . . . . . . 81
Borkwei Ed Nignpense, Kenneth A Chinkwo, Christopher L Blanchard and 
Abishek B Santhakumar
Black  Sorghum  Phenolic  Extract  Modulates  Platelet  Activation  and  Platelet 
Microparticle Release
Reprinted from: Nutrients 2020, 12, 1760, doi:10.3390/nu12061760 . . . . . . . . . . . . . . . . . . 95
v
Sara Castro-Barquero, Anna Tresserra-Rimbau, Facundo Vitelli-Storelli, Mónica Doménech, 
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Julia Wärnberg, José Alfredo Martı́nez, Luı́s Serra-Majem, Francisco José Tinahones, 
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Plant-based foods are the main source of phytochemicals, including polyphenols, a large family
of compounds with highly diverse chemical structures. The impact of polyphenols, ranging from
simple gallic acid to the most complex proanthocyanidins, on different biological processes has been
irrefutably demonstrated by numerous studies [1].
Multiple approaches, each with their strengths and weaknesses, have been used to investigate
the effects of polyphenols, all making an important and complementary contribution to the field.
In vitro and in vivo experimental models play a vital role in the elucidation of the mechanisms of
action underlying the health benefits observed in human trials. However, their results cannot always
be easily extrapolated to human beings, partly because of considerable interindividual variability and
other external factors. For instance, potential effect-modulating variables, such as sex, age, smoking
habits, body mass index, and hormone levels, need to be identified, as does the influence of other foods,
nutrients and even culinary techniques [1,2]. Additionally, we should not forget the importance of gut
microbiota and genetic polymorphisms, which lead to varied circulating metabolites with different
biological activities and health impacts [3].
A more recent approach is the use of omics, an integration of disciplines such as metabolomics,
genomics, epigenomics, and foodomics based on cutting-edge experimental techniques, including mass
spectrometry. The comprehensive ultra-large data sets they generate allow the scientific community to
answer new and complex questions [4].
Daily dietary intake of polyphenols is thought to be approximately 1 g, although this estimate
is based on subjective food frequency questionnaires, in which participants tend to overestimate
the consumption of healthier items. Moreover, despite the availability of useful and comprehensive
databases on polyphenol content in food, the concentrations depend on a wide range of factors,
including plant variety, ripeness, environmental conditions, cropping systems, cooking, and storage,
all of which add to the complexity of calculating intake [5].
In this Special Issue on “Dietary Polyphenols and Human Health”, a series of 10 papers are presented,
including three literature reviews [6–8] and seven original research papers [9–15]. The described research
contributes to filling some of the gaps in our knowledge about the beneficial effects of dietary polyphenols
on chronic health conditions, notably cardiovascular disease, type 2 diabetes, neurological impairment,
and also certain risk factors.
In their review, Sandoval et al. describe the molecular mechanisms and signaling pathways
involved in the metabolic impact of each group of flavonoids on obesity and related disorders, focusing
on the liver, white and brown adipose tissue and central nervous system [6]. Márquez-Campos et al.
have collected and summarized the available literature on the antidiabetic effects of both parent
flavan-3-ol compounds and their microbial metabolites. The role of microbiota is especially relevant,
as flavan-3-ols are poorly absorbed and their metabolization and absorption largely depend on the
activity of colonic bacteria [7]. In the third review, Domínguez-López et al. explore the effects of
phytoestrogens on human hormone-dependent outcomes throughout the human lifespan, divided
into stages of pregnancy, childhood, adulthood, and the pre- and post-menopause [8].
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Individual phytoestrogens are also the subject of a cross-sectional study by Sun et al., who are
interested specifically in their impact on sleep quality. The association between urinary phytoestrogens
(enterolactone, enterodiol, daidzein, O-desmethylangolensin, equol, and genistein) and sleeping
disorders and sleep duration was examined in adults from the National Health and Nutrition
Examination Survey 2005–2010. Discrepant results were found, depending on the metabolites and the
race and sex of the participants, revealing the need for further studies with prospective cohorts and
clinical trials [9].
Two of the other papers report clinical trials on the effect of polyphenols on the brain. In a study on
psychological well-being (the PPhIT study), Kontogianni et al. concluded that participants with a high
polyphenol intake had fewer depressive symptoms and better general mental and physical health
compared to those on a low-phenolic diet [10]. The crossover study on mood and cognitive function
performed by Wightman et al., where healthy participants received a single dose of a polyphenol-rich
extract obtained from mango leaves (<60% mangiferin), revealed no significant results for mood,
but cognitive function was enhanced [11].
Taking on the challenge of assessing polyphenol intake, Martini et al. used food frequency
questionnaires to compare the nutrients afforded by two different dietary patterns (polyphenol rich and
control) in older participants of the MaPLE study. Their ultimate goal is to develop dietary guidelines to
increase the intake of these bioactive compounds [12]. Castro-Barquero et al. also used food frequency
questionnaires to make a detailed estimation of the polyphenol intake in high cardiovascular risk
participants of the PREDIMEDplus study. Monitoring metabolic syndrome symptoms, they found that
some phenolic groups were inversely associated with better values of blood pressure, fasting plasma
glucose, HDL cholesterol, and triglycerides [13]. Interestingly, both MaPLE and the PREDIMEDplus
studies gave similar values for polyphenol intake.
The final two publications shed light on the mechanism of action of polyphenols. Saji et al. explore
how a rice bran phenolic extract could target metabolic pathways associated with Type 2 diabetes
mellitus, concluding that it modulated the expression of genes involved in β-cell dysfunction and
insulin secretion through different mechanisms [14]. Focusing on the pathogenesis of cardiovascular
diseases, Nignpense et al. performed a clinical trial with healthy volunteers to evaluate the effect of
ingesting a sorghum extract. Although oxidative stress-related endothelial dysfunction and platelet
aggregation were not reduced, a beneficial impact on platelet activation and platelet microparticle
release was observed [15].
The growth of publications on bioactive compounds in the last years reflects the considerable
interest of the scientific community in the field, but a great deal of research still needs to be done.
A better understanding of the health benefits of polyphenols and their mechanisms of action will
lead to improved (and perhaps individualized) nutritional recommendations aimed at enhancing
human health.
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Abstract: The evaluation of food intake in older subjects is crucial in order to be able to verify
adherence to nutritional recommendations. In this context, estimation of the intake of specific dietary
bioactives, such as polyphenols, although particularly challenging, is necessary to plan possible
intervention strategies to increase their intake. The aims of the present study were to: (i) evaluate the
nutritional composition of dietary menus provided in a residential care setting; (ii) estimate the actual
intake of nutrients and polyphenols in a group of older subjects participating in the MaPLE study;
and (iii) investigate the impact of an eight-week polyphenol-rich dietary pattern, compared to an
eight-week control diet, on overall nutrient and polyphenol intake in older participants. The menus
served to the participants provided ~770 mg per day of total polyphenols on average with small
variations between seasons. The analysis of real consumption, measured using weighed food diaries,
demonstrated a lower nutrient (~20%) and polyphenol intake (~15%) compared to that provided
by the menus. The feasibility of dietary patterns that enable an increase in polyphenol intake with
putative health benefits for age-related conditions is discussed, with a perspective to developing
dietary guidelines for this target population.
Keywords: nursing home; residential care; aging; menu; flavonoids; phenolic acids
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1. Introduction
It is well recognized that nutrition plays an important role in health status, with increasing evidence
of associations between intake of specific dietary components and risk of many non-communicable
diseases (NCDs), such as cardiovascular diseases (CVDs), type 2 diabetes, and some types of cancer.
For instance, the Global Burden of Diseases has recently indicated that high intake of sodium, low
intake of whole grains, and low intake of fruits are the leading dietary risk factors for deaths and
disability-adjusted life-years (DALYs) worldwide [1]. These findings have been widely used to prepare
national and international dietary guidelines aimed both at recommending the adequate intake of
energy and nutrients for different targets of population and possibly at reducing the risk for the most
common NCDs [2].
The ageing process affects the nutrient needs of older subjects, whose requirements for some
nutrients may be reduced or increased with respect to younger adults. In this life-stage, a variety of
factors such as sensory losses, chewing and swallowing problems, and medications may compromise
dietary intake and lead to nutritional deficiencies and malnutrition, which has been contributing to the
progression of many diseases and common syndromes in older people [3].
For this reason, specific recommendations have been proposed to meet the nutritional requirements
of this target group; for instance, energy, protein and fibre intake should be individually adjusted by
considering their nutritional status and physical condition and accounting for the presence of specific
disease [4]. In addition to macronutrients, micronutrients also play a fundamental role in promoting
health and preventing NCDs and their deficiencies are often common in aged people for a number of
reasons including reduced food intake or lack of a varied diet, but they are also associated with the
vicious cycle promoted by diseases and pharmacological treatments.
It is noteworthy that these factors may also affect the intake, absorption and/or metabolism of
bioactive compounds such as polyphenols. In this regard, data on polyphenol intake in different older
target groups are not univocal, possibly due to differences in geographical area considered, and in
the individual characteristics in terms of health/disease status, and living conditions, as previously
evidenced [5]. The interest in the assessment of polyphenol intake and the study of their potential
impact on older subjects has been growing by considering several findings suggesting the protective
role they can play against age-related diseases and in the promotion of healthy aging [6]. Regarding the
changes on polyphenol intake with age, conflicting results have been reported so far, with some studies
showing an increased intake [7,8] while others reporting no differences depending on age [9,10].
For the above-mentioned reasons, the nutritional assessment of older people represents a
critical issue, which may be particularly true for those living in residential care settings where the
prevalence of malnutrition has been reported to be extremely variable, ranging from 1.5 to 66.5% [11].
This represents a current clinical and public health concern at both the individual and population
level [12,13]. Several methods have been developed for the assessment of energy and nutrient
intake, including food-frequency questionnaires, food diaries and 24-h dietary recalls, all having
pros and cons to be considered when choosing the best method to use in each specific context [14].
The estimation of micronutrients and bioactives like polyphenols is particularly challenging, mainly
due to methodological issues, including the tool and the database used for the evaluation, as well as the
type of polyphenol under consideration (e.g., total polyphenols versus single classes and subclasses of
polyphenols) [5]. Being able to make accurate estimates of actual polyphenol intake is a fundamental
requirement of developing a better understand of the role of these compounds and their relationship
with health or disease conditions. In addition, this information is crucial to define potential polyphenol
exploitation for the development of dietary strategies to prevent against age-associated diseases.
Based on these premises, the aim of this research was to evaluate the nutritional composition
of nursing home dietary menus and to estimate the actual intake of nutrients and polyphenols in a
group of older subjects living in a residential care setting. The assessments were performed as part of
the MaPLE (Microbiome mAnipulation through Polyphenols for managing Leakiness in the Elderly)
project, funded within the European Joint Programming Initiative “A Healthy Diet for a Healthy
6
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Life” (JPI HDHL), with the aim to investigate benefits of a polyphenol-enriched diet on intestinal
permeability in older subjects. An increased gut permeability, often associated with dysbiosis and
inflammation, could play a role in the development of some age-related conditions. In this regard, it has
been suggested that the intake of polyphenols may represent a promising strategy to improve intestinal
permeability (IP) as demonstrated mainly in experimental studies suggesting the involvement of
these bioactives in both direct and indirect modulatory mechanisms [15]. In this context, a more
accurate estimation of the intake of polyphenols in a vulnerable target such as older subjects, in terms
of amount, sources and distribution across the day and even in different seasons, can be of relevance.
This could enable a better understanding of their potential benefits and the development of specific
recommendations based on findings from dietary intervention studies.
2. Materials and Methods
2.1. Study Design and Population
The study design of the MaPLE randomized controlled trial (RCT) has been previously reported [16].
Briefly, the central hypothesis that this study sought to address was that a polyphenol-enriched dietary
pattern would reduce IP and systemic inflammation and cause beneficial changes in various biomarkers
of cardiometabolic health, and that this would be associated with changes in the gut microbiota in
these older subjects. To this aim, volunteers were randomized to consume a polyphenol-rich diet
(PR-diet) or a control diet (C-diet) for 8 weeks following a cross-over design separated by an 8-week
wash-out. The development of the PR-diet and C-diet has been reported previously [16]. During the
intervention, subjects were given three small portions of polyphenol-rich foods daily as substitutes for
foods with lower polyphenol contents that were part of the C-diet (developed by analyzing the regular
menus provided to the study participants and specifically assessing the nutrient and polyphenol
composition). The characteristics and polyphenol content of the servings provided in the PR-diet for
each product are reported in Table 1. The amount of polyphenols provided was more than double
that deriving from the replaced products. Data shown include total polyphenol content (i.e., TPC)
quantified by analysing products through the Folin–Ciocalteau method [17] and estimates of total
polyphenols (i.e., TP). The estimation of TP was calculated as the sum of flavonoids, phenolic acids,
lignans, stilbenes and other polyphenol classes expressed in mg (aglycone/100 g). The estimations
were performed using an in-house ad hoc database of food composition on polyphenols, compiled
from the USDA (fdc.nal.usda.gov/) for databases (for flavonoids, isoflavones and proanthocyanidins)
and the Phenol-Explorer (PE; www.phenol-explorer.eu) database (for phenolic compounds lignans,
stilbenes and other minor polyphenol classes) through a computer application developed that uses
the relational database system. This methodology has been used and previously described [18–21].
Polyphenols were expressed as mg of aglycones per 100 g.
For the intervention study, all the participants were recruited from residents at Civitas Vitae, a large
residential care setting (OIC Foundation including both nursing homes and independent residencies
for older subjects, Padua, Italy) according to specific inclusion and exclusion criteria. Among inclusion
criteria, subjects had to be aged 60 years and to have increased intestinal permeability evaluated by
serum zonulin level as previously reported [16].
All the participants recruited into the study were self-sufficient and were in good cognitive health.
The Ethics Committee of the Università degli Studi di Milano approved the study protocol (15/02/2016;
ref.: 6/16/CE_15.02.16_Verbale_All-7). All the participants were provided with detailed information
about their involvement in the study and gave their informed consent before beginning the intervention.
The trial was registered in the ISRCTN Registry on 28 April 2017; ISRCTN10214981.
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Table 1. Polyphenol content and composition of each serving of MaPLE products included in the
dietary intervention, expressed as mg per serving.
TPC TP Flavonoids Phenolic Acids Stilbenes Lignans Other
Blood orange juice 178 63.4 42.0 21.4 - - -
Blood orange fruit 178 34.8 23.1 11.8 - - -
Renetta apple 296 225.9 201.2 24.7 - 0.01 -
Renetta apple purée + 167 150.6 134.1 16.5 - 0.00 -
Whole blueberry § 291 259.5 165.1 94.5 - - -
Blueberry purée 259 199.0 163.6 35.4 - 0.0 0.02
Pomegranate juice 189 135.5 55.1 80.3 - - -
Green tea * 146 129.2 116.2 13.0 - 0.08 -
Cocoa powder ◦ 234 92.2 90.5 1.7 - 0.00 0.01
Chocolate callets 337 167.8 165.4 2.4 0.01 - -
§ Frozen whole blueberry product was thawed and prepared before consumption; Blueberry purée was a
ready-to-eat product; ◦ Cocoa powder was dissolved in hot milk or water; * Green tea was prepared by solubilization
of 200 mg of green tea extract in 200 mL of hot water; + Renetta apple purée was prepared in controlled conditions and
stored at −18 ◦C until consumption. TPC, total polyphenol content by Folin–Ciocalteau assay; TP, total polyphenols
determined by USDA and Phenol Explorer databases.
2.2. Nutritional and Polyphenol Composition of the Menus
To estimate the energy and nutrient composition of the planned meals regularly provided, the
weekly menus during different seasons (summer, mid-season and winter) were evaluated (i.e., covering
the whole intervention study). To this aim, Metadieta ® software (Me.te.da srl, S. Benedetto del
Tronto, Italy) was used to include all the recipes and to estimate the nutritional composition of the
different menus.
In addition, the TPC content of the menus was estimated by PE databases with the addition of our
own data (characterized products in Table 1 used for the intervention) and other literature sources for
those ingredients that were not available in those databases [22–24]. TP was instead estimated through
the PE/USDA database, as also described in Section 2.1.
2.3. Evaluation of Actual Energy, Nutrient and Polyphenol Intake
During both intervention periods, weighed food records (WFR) were used to estimate food,
energy, nutrient and polyphenol intake as reported in Section 2.2. In particular, up to six detailed daily
diaries (recording the amount of foods provided and the amount actually consumed by weighing
the leftovers) were analysed for each subject during the two intervention periods. In addition, one
diary was filled in by participants at baseline and scheduled the day of blood drawings and sampling
according to what was previously reported [16].
2.4. Statistical Analysis
Statistical analysis was conducted using the Statistical Package for Social Sciences software
(IBM SPSS Statistics, Version 26.0, IBM corp., Chicago, IL, USA) and R statistical software (version
3.6.). One-way ANOVA was applied to analyse differences between the winter, mid-season and
summer menus provided during the intervention in terms of nutrients and polyphenol composition.
The nonparametric Wilcoxon–Mann–Whitney test with Benjamini–Hochberg correction pairing the
data when possible was performed to ascertain differences at baseline between men and women in
terms of actual intake and to verify the impact of treatment (PR vs. C-diet) and gender (men vs.
women) on both nutrient and polyphenol intake in participants. The level of significance was set at
p ≤ 0.05. All results were expressed as mean ± standard deviation (SD).
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3. Results
Fifty-one older subjects (22 men; 29 women; age ≥ 60 y) successfully completed the entire study,
and the data reported here are for those 51 participants. Dropouts were not due to side effects of the
dietary intervention itself.
3.1. Nutritional Composition of Menus
The nutritional composition of the nursing home menus provided during the intervention is
reported in Table 2. The average estimated daily energy content of the summer menu was 140 kcal
higher than for the winter menu. No differences were detected for the nutrients among seasonal menus,
both when expressed as net quantity or as percentage of energy provided.
Table 2. Mean energy and nutrient composition of the nursing home menus across three seasons and
overall mean composition.
Nutritional Factor Winter Menu Mid-Season Menu Summer Menu Mean Menu
Energy (kcal) 1889 ± 102 a 2012 ± 176 a,b 2028 ± 66 b 1976 ± 133
Total CHO (% of energy) 47.4 ± 3.2 46.4 ± 4.7 46.5 ± 3.0 46.8 ± 3.5
Simple CHO (% of energy) 20.6 ± 2.2 19.8 ± 0.6 20.3 ± 1.4 20.2 ± 1.5
Total protein (% of energy) 18.7 ± 2.5 20.0 ± 2.3 19.6 ± 2.7 19.4 ± 2.5
Animal protein (% of energy) 11.1 ± 2.8 13.4 ± 2.8 12.8 ± 2.5 12.4 ± 0.3
Plant protein (% of energy) 6.2 ± 0.9 6.2 ± 1.1 6.4 ± 0.8 6.3 ± 0.1
Total Lipids (% of energy) 34.1 ± 4.2 33.7 ± 4.1 34.0 ± 4.6 33.9 ± 4.1
SFA (% of energy) 8.7 ± 1.3 8.9 ± 2.0 8.6 ± 1.8 8.7 ± 1.6
MUFA (% of energy) 17.9 ± 3.3 16.9 ± 2.4 17.7 ± 2.2 17.5 ± 2.6
PUFA (% of energy) 3.7 ± 0.8 3.8 ± 0.7 3.9 ± 1.4 3.8 ± 1.0
ω-3 (% of energy) 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.4
ω-6 (% of energy) 3.0 ± 0.9 3.0 ± 0.8 3.2 ± 1.3 3.0 ± 1.0
Total Fibre (g/1000 Kcal) 12.2 ± 2.1 11.6 ± 2.4 12.3 ± 1.7 12.0 ± 2.0
Cholesterol (mg) 264 ± 91 358 ± 134 288 ± 123 303 ± 118
Total proteins (g) 88.1 ± 14.3 100.9 ± 19.6 98.8 ± 11.3 95.9 ± 15.7
Animal protein (g) 56.0 ± 13.8 68.3 ± 20.5 64.8 ± 10.9 63.0 ± 15.7
Plant protein (g) 30.6 ± 4.1 30.9 ± 4.2 32.6 ± 4.0 31.4 ± 4.0
Total lipids (g) 71.2 ± 7.8 75.3 ± 12.5 76.5 ± 12.3 74.3 ± 10.7
SFA (g) 18.3 ± 3.3 19.8 ± 4.6 19.4 ± 4.4 19.1 ± 4.0
MUFA (g) 37.3 ± 5.8 38.0 ± 7.1 40.1 ± 5.8 38.5 ± 6.0
PUFA (g) 7.7 ± 1.6 8.5 ± 2.1 8.7 ± 3.4 8.3 ± 2.4
Total ω-3 (g) 1.4 ± 0.8 1.5 ± 0.9 1.6 ± 0.9 1.5 ± 0.9
Total ω-6 (g) 6.2 ± 1.8 6.7 ± 2.1 7.1 ± 3.0 6.7 ± 3.0
Fibre (g/day) 22.9 ± 4.2 23.2 ± 4.4 24.8 ± 2.9 23.6 ± 3.8
Calcium (mg) 643 ± 254 666 ± 175 638 ± 112 649 ± 180
Iron (mg) 11.9 ± 2.0 14.2 ± 2.9 12.1 ± 1.0 12.7 ± 2.3
Vitamin B12 (mcg) 4.8 ± 2.2 5.3 ± 2.3 6.3 ± 5.1 5.5 ± 3.4
Vitamin C (mg) 225 ± 33 233 ± 28 242 ± 45 233 ± 35
Vitamin E (mg) 13.7 ± 1.9 15 ± 3.2 15.5 ± 2.4 14.8 ± 2.6
Vitamin B1 (mg) 1.4 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 1.5 ± 0.4
Folates (mcg) 342 ± 78 377 ± 138 340 ± 70 353 ± 97
Vitamin B6 (mg) 2.3 ± 0.6 2.7 ± 0.7 2.5 ± 0.4 2.5 ± 0.6
Data represent the daily amounts with the units given in parentheses and are shown as mean ± standard deviation.
Data have been calculated through the Metadieta ® software. Data with different letters in the same row are
significantly different (p < 0.05). CHO, carbohydrates; SFA, saturated fatty acids; MUFA, monounsaturated fatty
acids; PUFA, polyunsaturated fatty acids; ω-3, omega-3 fatty acids; ω-6, omega-6 fatty acids.
Regarding the polyphenol composition of the menu, as shown in Figure 1, no significant differences
were observed among the different seasonal menus, which had an estimated mean TPC of about
770 mg/day.
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Figure 1. Box plot (panel A) showing polyphenol content in the seasonal menus, estimated through
PE/USDA databases and other published data (TP in light blue) and by Folin–Ciocalteau data as
reported in the PE database and other sources (TPC in red); percentage distribution of polyphenol
classes (panel B) in the seasonal menus. Dots represent mild outliers that are more extreme than
Q1 − 1.5 * IQR or Q3 + 1.5 * IQR but are not extreme data (where Q1=quartile 1; Q3=quartile 3;
IQR=interquartile range).
3.2. Actual Energy, Nutrient and Polyphenol Intake at Baseline and during the Intervention
The actual energy, nutrient and polyphenol intake estimated at baseline for women, men and the
whole group of participants is shown in Table 3. Overall, energy intakes, and accordingly nutrient
intakes, were lower than calculated for the estimates based on the foods consumed from the menus,
in keeping with the fact that not all the food was consumed for any particular meal. There were no
significant differences between women and men for any of the dietary variables that were assessed
at baseline. This was also confirmed by analysing the data obtained during the intervention study
(Supplementary Materials Figure S1), except for simple carbohydrates in women and for total lipids
and PUFA in men when comparing intake measured during the PR-diet and the C-diet (p < 0.05).
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Finally, differences were observed in ω-6 fatty acids, iron and calcium intake following the PR-diet in
both women and men.
Table 3. Daily mean energy, nutrient and polyphenol intake at baseline in the whole group of subjects,
in women and men.
Variables All (n = 51) Women (n = 29) Men (n = 22) p-Value †
Energy (kcal) 1582 ± 108 1569 ± 110 1599 ± 105 0.318
Total CHO (% of energy) 50.0 ± 2.7 50.0 ± 2.7 49.8 ± 2.7 0.641
Simple CHO (% of energy) 20.4 ± 3.1 20.3 ± 3.3 20.5 ± 3.0 0.939
Proteins (% of energy) 17.8 ± 0.8 18.0 ± 0.8 17.7 ± 0.9 0.216
Animal proteins (% of energy) 12.1± 1.1 12.2 ± 1.0 11.8 ± 1.1 0.262
Plant proteins (% of energy) 5.7 ± 0.6 5.7 ± 0.6 5.7 ± 0.6 0.864
Total lipids (% of energy) 32.1 ± 2.3 31.9 ± 2.2 32.4 ± 2.5 0.441
SFA (% of energy) 8.6 ± 1.5 8.6 ± 1.4 8.7 ± 1.7 0.655
MUFA (% of energy) 16.3 ± 1.3 16.3 ± 1.1 16.4 ± 1.6 0.834
PUFA (% of energy) 3.2 ± 0.5 3.3 ± 0.6 3.2 ± 0.4 0.435
ω-3 (% of energy) 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.2 0.753
ω-6 (% of energy) 2.5 ± 0.4 2.6 ± 0.5 2.5 ± 0.2 0.341
Total Fibre (g/1000 kcal) 11.2 ± 1.2 11.3 ± 1.1 11.1 ± 1.3 0.458
Cholesterol (mg) 207.7 ± 30.3 204.3 ± 29.9 212.2 ± 30.9 0.682
Total CHO (g) 210.7 ± 21.5 209.6 ± 22.8 212.2 ± 20.1 0.864
Simple CHO (g) 81.0 ± 15.2 80.8 ± 15.4 81.3 ± 15.2 0.954
Proteins (g) 70.3 ± 4.0 70.2 ± 4.0 70.4 ± 4.0 0.849
Animal proteins (g) 47.6 ± 3.9 47.9 ± 3.7 47.2 ± 4.2 0.536
Plant proteins (g) 22.4 ± 2.7 22.2 ± 2.7 22.7 ± 2.8 0.601
Total lipids (g) 56.2 ± 4.9 55.2 ± 3.8 57.5 ± 5.8 0.192
SFA (g) 15.2 ± 3.0 14.9 ± 2.7 15.5 ± 3.3 0.447
MUFA (g) 28.7 ± 2.4 28.3 ± 1.2 29.1 ± 3.4 0.575
PUFA (g) 5.7 ± 0.7 5.7 ± 0.7 5.7 ± 0.8 0.371
Total ω-3 (g) 1.1 ± 0.3 1.1 ± 0.1 1.1 ± 0.4 0.600
Total ω-6 (g) 4.5 ± 0.6 4.5 ± 0.6 4.4 ± 0.5 0.274
Fibre (g/day) 17.8 ± 2.4 17.8 ± 2.2 17.8 ± 2.6 0.932
Calcium (mg) 804 ± 136 808 ± 128 799 ± 147 0.761
Iron (mg) 9.4 ± 0.9 9.4 ± 0.7 9.4 ± 1.0 0.879
Vitamin B12 (μg) 4.2 ± 1.0 4.2 ± 0.4 4.3 ± 1.5 0.394
Vitamin C (mg) 111.8 ± 56.1 115.1 ± 45.2 107.4 ± 68.8 0.464
Vitamin E (mg) 11.4 ± 2.9 11.5 ± 1.3 11.2 ± 4.1 0.327
Vitamin B1 (mg) 0.8 ± 0.2 0.8 ± 0.1 0.7 ± 0.2 0.156
Folates (μg) 302 ± 73 311 ± 54 289 ± 93 0.536
Vitamin B6 (mg) 1.5 ± 0.3 1.5 ± 0.2 1.4 ± 0.3 0.588
Flavonoids (mg) 181.1 ± 137.5 174.4 ± 123.7 190.8 ± 157.8 0.984
Phenolic acids (mg) 130.9 ± 36.0 126.6 ± 28.6 137.1 ± 44.5 0.598
Stilbenes (mg) 0.04 ± 0.06 0.04 ± 0.06 0.04 ± 0.07 0.542
Lignans (mg) 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.737
Other polyphenols (mg) 27.8 ± 4.3 28.0 ± 3.7 27.6 ± 5.0 0.723
All data are presented as mean ± standard deviation (SD); Data with p < 0.05 are significantly different. CHO,
carbohydrates; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty
acids; ω-3, omega-3 fatty acids; ω-6, omega-6 fatty acids. † Comparison between women and men using
Wilcoxon–Mann–Whitney test.
Regarding polyphenols, flavonoids and phenolic acids were the most consumed classes and were
comparable between women and men.
3.3. Polyphenol Intake at Baseline and during Intervention
Figure 2 shows the polyphenol intake at baseline and in the two intervention periods. At baseline,
the intake of TPC was 663.4 ± 147.5 mg/d and comparable between women (669.2 ± 160.1 mg/d) and
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men (655.2 ± 130.8 mg/d). The consumption of PR-products significantly (p < 0.0001) increased the
intake of TPC by about 600 mg/d compared to the C-diet and was comparable in both men and women.
BASELINE PR-DIET C-DIET
Figure 2. Polyphenol intake at baseline and in polyphenol (PR)-diet and control (C)-diet in the whole
group of subjects and stratified by gender. The intake has been estimated using the PE and USDA
databases and other published data (TP in light blue) and by Folin–Ciocalteau data as reported in the
PE database and other sources (TPC in red). Dots represent mild outliers that are more extreme than Q1
− 1.5 * IQR or Q3 + 1.5 * IQR but are not extreme data. Asterisks are extreme data that are more extreme
than Q1 − 3 * IQR or Q3 + 3 * IQR (where Q1=quartile 1; Q3=quartile 3; IQR=interquartile range).
Table 4 shows the contribution of different polyphenol classes to the total polyphenol intake during
the PR and C-diet. Flavonoids were the main subclass increased in the PR-rich diet and accounted
for 74.6%, followed by phenolic acids (23.3%), while lignans and other polyphenols accounted for
the remainder. A treatment effect (p < 0.0001) for total flavonoids and phenolic acids was observed
(Table 4), while a gender effect was observed for stilbenes showing a higher intake in men compared to
women (p = 0.033).
Table 4. Intake of total polyphenols and classes (according to PE/USDA databases) during the PR-diet
and the C-diet.
Title 1 Flavonoids Phenolic Acids Stilbenes Lignans Other Polyphenols
PR-diet
All 634.3 ± 171.8 198.1 ± 52.2 0.2 ± 0.4 0.8 ± 0.3 16.4 ± 5.3
Men 594.6 ± 152.2 201.1 ± 74.3 0.4 ± 0.6 0.7 ± 0.3 16.7 ± 6.3
Women 662.1 ± 163.5 195.9 ± 42.0 0.1 ± 0.2 0.8 ± 0.3 16.2 ± 5.3
p value # 0.098 0.810 0.108 0.206 0.827
C-diet
All 273.8 ± 119.8 128.2 ± 60.9 0.3 ± 0.5 0.9 ± 0.4 17.0 ± 5.4
Men 260.9 ± 109.6 128.8 ± 57.8 0.4 ± 0.4 0.9 ± 0.4 15.9 ± 5.7
Women 282.9 ± 125.6 127.8 ± 63.0 0.2 ± 0.5 0.9 ± 0.4 17.8 ± 4.9
p value # 0.453 0.271 0.033 0.745 0.271
p value † <0.0001 <0.0001 0.386 0.303 0.164
p value ¥ <0.0001 0.001 0.575 0.068 0.807
p value § <0.0001 <0.0001 0.348 0.060 0.331
All data are expressed as mean ± standard deviation (SD); PR, polyphenol-rich diet; C, control diet. † Comparison
between PR-diet vs. C-diet in women. ¥ Comparison between PR-diet vs. C-diet in men. # Comparison between
women and men in PR-diet and C-diet. § Comparison between PR-diet vs. C-diet in all subjects. Comparisons have
been performed using the Wilcoxon–Mann–Whitney test.
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Considering the total polyphenol (TP) contribution from the different meals, in the PR-diet, ~50%
of polyphenol intake derives from snacks and the remaining ~50% from breakfast, lunch and dinner
(Figure 3). In particular, there is a significant contribution to mid-morning and afternoon snacks from
the intake of PR-products. Conversely, during the C-diet, only ~15% of the total polyphenols consumed






Figure 3. Total phenolic contribution from different meals during the polyphenol (PR)-diet and the
control (C)-diet expressed as percentage (Panel A), or expressed as amount in mg during the PR-diet
(in red) and the C-diet (in blue) as estimated through PE/USDA databases and other published data
(Panel B). Dots represent mild outliers that are more extreme than Q1 − 1.5 * IQR or Q3 + 1.5 * IQR but
are not extreme data. Asterisks are extreme data that are more extreme than Q1 − 3 * IQR or Q3 + 3 *
IQR (where Q1=quartile 1; Q3=quartile 3; IQR=interquartile range).
Overall, through the analysis of the menu items provided to the volunteers and recorded in the
WFRs during the two intervention periods and by considering the frequencies of consumption of the
single ingredients, we estimated the main polyphenol sources contributing to the different meal times.
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During the PR-diet, the main foods providing polyphenols at breakfast were fruit and fruit-derived
products (e.g., orange, grape, orange juice, apricot jam, etc.), followed by barley coffee and minor
contributions from coffee and tea. Polyphenol-rich products on the PR-rich diet were occasionally
consumed at breakfast, where green tea, pomegranate juice, chocolate callets and blood orange juice
were the most commonly consumed. For lunch and dinner, the main sources during the PR-diet were
vegetables (e.g., chard, asparagus, broccoli, carrots), extra virgin olive oil, legumes and spices. A few
participants occasionally consumed white wine in small portions (usually 1 glass), which also made a
contribution to the polyphenol intake. PR-rich products were mainly consumed as mid-morning and
mid-afternoon snacks, as reported in Figure 3. During the C-diet, we found similar foods providing
polyphenols at breakfast, lunch and dinner compared to the PR-diet, except for the introduced PR-rich
products. Major differences between the two treatments were largely due to the snack foods because
only fruits and fruit-based products (i.e., juices), cakes (including sometime chocolate-based cakes) or
yogurt were available during the C-diet, whereas a more extensive range of PR-foods were available as
snacks on the PR-rich diet.
4. Discussion
The evaluation of the adequacy of diets in older subjects is of utmost importance not only to
identify possible deviations from desirable nutritional targets but also to contribute to the development
of new recommendations that address gaps in the current guidance. In this context, the MaPLE project
has given us the unique opportunity to assess dietary intake in a well-controlled setting where it is
also possible to analyse the daily menus provided to the residents, while considering all the recipes
and ingredients used for the preparation of the meals. At the same time, long-term residences often
have facilities enabling the measurement of food intake (e.g., by collecting multiple weighed food
records) and this represents the best procedure to estimate actual consumption. Menu planning in
residential care involves modifications of recipes during the year to take account of seasonal changes
in ingredient availability and this may partially affect not only nutritional characteristics in terms of
macro- and micro- nutrients but also food sources of bioactive compounds with potential impact on
host metabolism and other functions.
In the present study, the evaluation of three different menus showed that overall they were
comparable in terms of nutritional composition, and also that they were in line with the dietary
recommendations for older subjects in Italy (i.e., Italian Reference Intake) [2], with some dissimilarities
that are worth highlighting. In regards to total energy, menus provided suitable amounts for the target
population, at least in consideration of the main Italian guidelines developed for dietary management
in residential care [25]. Some studies carried out in nursing homes showed lower energy provided by
menus [26,27], while others reported data higher or similar to our observation [28–30]. The distribution
in macronutrients was consistent with the recommendations: carbohydrates accounted for ~47%
of total energy intake on average (reference intake range: 45–60% energy (E)), although we found
there was a higher intake of simple carbohydrate in comparison with the recommendations (20% E
vs. < 15% E) due to the wide use of fruit juices and hot beverages with added sugars as has been
commonly reported in this target population. Protein intake derived mainly from animal sources
(about two-thirds) and was higher in comparison with the suggested dietary target (1.1 g/kg/day),
while total lipid intake was within the reference intake range (20–35% E). Specifically, SFAs were
in accordance with the national/international recommendation (<10% E), while total PUFAs were
slightly lower than 5% E due to the low intake of ω-6 in favour of higher MUFAs, as can often be
found in the Mediterranean areas. The amount of fibre provided by the menus was slightly lower
than the suggested dietary target of 25 g per day defined by Italian and international guidelines [2,31].
Regarding micronutrients, iron contribution was adequate while, as also reported in the literature,
calcium content in the three menus was lower than the population reference intake (PRI, 1200 mg
for both women and men ≥ 60 years) [2]. However, it is worth noting that these data included only
calcium derived from recipes and did not consider contributions from other sources such as water and
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supplements. Vitamin B1, B6 and B12 provided by menus were higher than reference values, while
folates were slightly lower than the established population reference intake of 400 μg per day. With
regard to antioxidants, vitamins E and C were both adequate, in particular vitamin C largely exceeded
the PRI levels (i.e., 85 mg and 105 mg per day for women and men respectively). Overall, the results
on the nutritional composition of the menus suggest that, although they are generally developed
following specific guidelines, it is still possible to improve the content of critical nutrients such as fibre,
specific micronutrients and bioactives, above all in institutionalised subjects as also reported in the
literature [29,30].
Notably, actual food intake in older subjects can be significantly lower with respect to that provided
by the menus. For these reasons, we also estimated the actual food consumption through the analysis
of detailed and repeated weighed food records. Measured energy and nutrient intake were indeed
lower than that provided through the menus (by about 20%), with no differences between women and
men. In this regard, it is underlined that the subjects enrolled in the present study generally had a good
nutritional status, evidenced also by their anthropometric characteristics (BMI = 26.8 ± 5.5 kg/m2).
The energy intakes we have reported here (mean approximately 1580 kcal) were slightly lower than
those found in the InCHIANTI study, performed on about 1200 free-living older subjects (>65 years) in
Tuscany, in which mean energy intakes ranged from 1764 to 2260 kcal/d and from 1521 to 1793 kcal/d
in men and women, respectively [32]. However, despite the higher energy intake, in the InCHIANTI
study, a large group of subjects reported inadequate intakes of protein, calcium and other nutrients,
which have been independently associated with frailty [33]. In our assessments, the lower food intake
was associated with reduced protein intake (about 0.9 g/kg day on average), increasing the rate of
inadequate intake above all in male subjects (about 22% with intake ≤ 0.71 g/kg per day and only
18% with intake ≥ 1.1 g/kg per day as defined by the suggested dietary target). The consumption of
simple carbohydrates in older subjects was confirmed to be higher than the suggested values, while
the fat intake appeared to be within the suggested intake range, although the amount of ω-6 fatty
acids remained lower than recommended values, as did the intake of calcium, vitamins B1, B6 and
folates. These results confirmed previous observations of a potential risk of long-term inadequate
intake of nutrients that are fundamental for maintenance of functional and metabolic integrity in older
subjects, and that these inadequate intakes are likely due to the actual food intake being significantly
less than the amount of food provided to the care home residents in each meal (i.e., incomplete meal
consumption is likely a major cause). Moreover, there is not only a problem related to overall food
intake but also to specific classes of products that appear to be consumed in lower amounts with
respect to others, for example justifying a low intake of fibre that has been found for most, if not
all, the subjects under study. This is an underestimated consideration that should be a target for
future multidisciplinary research that is able to finally implement guidelines for the achievement of
nutritional targets through traditional or possibly alternative strategies.
A major focus in this study was polyphenols because these compounds have the potential to
provide further specific benefits to the target population under study. It has been reported that there is
a large variation in the polyphenol content of foods available in different periods of the year [34–36],
and for this reason we specifically analysed recipes and ingredients used to develop seasonal menus
and the results obtained showed a relatively comparable amount of these bioactive compounds (about
770 mg per day on average as TPC) among the different seasons. We could not find other data on the
impact of seasonality on polyphenol content of dietary plans provided in long-term residences for
older people, while more literature is available in free-living older subjects. In this regard, in the Blue
Mountains Eye Study, a longitudinal study performed in Australia [35], the authors found that season
did not affect the overall total flavonoid intake in a group of adult and older subjects; however, it was
relatively higher in spring and lower in autumn in line with our results. Conversely, Tatsumi et al. [37]
showed that total antioxidant intake in a Japanese population (39–77 years) was highest in winter
and lowest in summer. The authors attributed this difference to the participants’ selection of food (in
particular fruits and vegetables) but also beverages across seasons.
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In our study, the assessment of actual food consumption at baseline indicated a mean TPC intake
of ~660 mg/d (i.e., evaluated by Folin–Ciocalteau through the PE database and specific literature),
about 15% less than the amount estimated in the menus served to the study participants. Although a
thorough comparison with other published data must be done cautiously because of the differences in
the populations under study and the methods and databases used for estimating the intakes of total
polyphenols and polyphenol classes, the overall actual intake estimated in the present study seems to
be comparable with mean intake observed in the InChianti study [20], but lower with respect to others
previously reported.
In fact, assessments in older subjects estimated polyphenol intakes from 333 mg/day up to
1492 mg/day, as reported previously [5]. For example, in the PREDIMED study evaluating a big cohort
of Spanish older subjects aged 55–80 years, a mean polyphenol intake of 820 ± 323 mg/day expressed
as glycosides was estimated through the PE database, by analysis of food consumption data obtained
from FFQs [38]. With regard to the contribution of the classes, total flavonoid intake is generally the
larger part of the intake, while data available in some studies suggest that up to 30–40% of the total
polyphenol intake can be represented by phenolic acids [5]. Results from the EPIC cohort showed that
older subjects tended to have increased intake of flavonoids, stilbenes, lignans, and other polyphenols
with respect to younger individuals, while no differences were found for total polyphenol intake [7],
and similar findings were reported by Karam and colleagues [8], also showing an impact of gender.
In our study in a controlled setting, the data confirmed that the flavonoid subclass was the greatest
contributor to total polyphenol intake followed by phenolic acids, while no differences were detected
between men and women. Some studies have suggested a higher total and subclass polyphenol intake
in females compared to males [8,10], above all when standardized by energy intake, and this may also
be the reason for the lack of differences in our study. In addition, it is relevant that the overall lower
availability of food alternatives for selection in controlled, with respect to a free-living condition, may
have affected eating behaviour, increasing the comparability of the dietary intake.
With regard to polyphenol food sources, tea and coffee have been underlined as the main
polyphenol contributors in northern European older subjects, while red wine, extra virgin olive oil and
fruit are the main sources in Southern Europe [7,39]. In our evaluation, fruit and fruit juices, vegetable
and extra virgin olive oil represent the main food categories providing polyphenols. In addition,
we could not demonstrate a different selection of polyphenol sources depending on gender, despite
some studies having reported a higher contribution from fruit and vegetables in females compared to
males [8,34]. It is noteworthy that in the nursing home, the intake of coffee and wine was strongly
limited, if not denied, to limit risks associated with caffeine and alcohol consumption and this may
represent an important behavioural difference with respect to what may be observed in free-living
older subjects.
The evaluation of habitual polyphenol intake in the older target group was a fundamental step
in the process of developing a reliable and evidence based polyphenol rich dietary pattern to use for
the intervention trial. In particular, the aim was to approximately double the habitual polyphenol
intake of the nursing home residents when on the PR-rich diet in order to reach amounts in the highest
quantile of intake identified in previous observational studies, where older subjects were included or
specifically considered [7,21,40].
Indeed, the main objective of the MaPLE study was to investigate whether the increased intake
of polyphenols might cause a reduction in intestinal permeability (IP) and inflammation associated
with an improved intestinal microbial ecosystem, also affecting metabolic and functional activities
in the older subjects [16]. In particular, the intervention was developed by replacing three portions
per day of low polyphenol foods/beverages with specific products rich in polyphenols. The selection
of the products was performed by considering different aspects: (i) the total amount of polyphenols
provided, (ii) the contribution of the different polyphenol classes, (iii) the adequate portion of food
able to provide a reliable high dose of polyphenols, and (iv) the possible food preparation in order to
ensure polyphenol bioavailability. Additionally, foods selection was carried out by considering the
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characteristics of the target group and their specific needs in terms of acceptability and suitability in
the context of residential care settings. Through the administration of the selected foods, we provided
mainly flavonoids (approximately four times higher compared to the amount introduced through
the C-diet) and phenolic acids. These bioactives have been suggested as potential modulators of
critical factors and specific targets regulating IP, including the impact on microbiota composition and
activities [15,41]. Overall, our results demonstrate that it is possible to obtain a significant increase in
polyphenol intake in older subjects, through the use of small amounts of well-accepted polyphenol-rich
food products. Moreover, it has been demonstrated that the intake is well tolerated and without
undesirable effects. Participants appreciated the products and were interested in continuing with the
dietary protocol after the end of the trial, suggesting that older people can change their diet if it does
not dramatically modify their eating habits.
An interesting observation highlighted was that older subjects preferred the consumption of
PR-products during the intervention as mid-morning and afternoon snacks. In fact, the protocol
adopted did not fix the timing for the PR-food intake, but the products should have been consumed
within the day according to preferences and/or habits. For this reason, our results give an important
contribution to the development of dietary guidelines for this target population. At the same time,
the analysis of the pattern of consumption of polyphenol-rich foods may also contribute to a better
understanding of chronobiological aspects related to the effect of bioactive compounds. In this regard,
it has been suggested that the inclusion of polyphenols within the meals may have an impact on related
metabolic responses, e.g., through reduction of glucose and lipid levels, inflammation, oxidative stress,
and blood pressure, associated with food intake [42–44]. Consuming most of the polyphenols outside
of the main meals could also affect their bioavailability for direct absorption and their use as substrates
for microbial transformation.
This work has several strengths mainly related to the well-controlled setting of the intervention,
enabling both the evaluation of the nutrient and bioactive content of the menus and the actual intake
during the whole intervention, ensuring high adherence to dietary instructions. Conversely, possible
study limitations include the small sample size and the partial generalizability to free-living community
dwelling older subjects. Finally, the limited food choices available in the main standard menus
provided could have reduced the possibility of showing gender differences.
5. Conclusions and Perspectives
In conclusion, the assessments performed within the MaPLE project have further underlined the
need for a careful revision of dietary menus addressed for older subjects not only to optimize the intake
of essential nutrients, but also of bioactive compounds, such as polyphenols, in order to lower the risk of
chronic diseases and improve specific metabolic and functional activities during aging. In this context,
we have shown that there is a possibility to develop feasible and reliable polyphenol-rich dietary
patterns that can be appreciated and consumed by the older population with excellent compliance,
while assuring a significant increase in the intake of these bioactive compounds. Moreover, the products
and preparations included in the dietary menu have been easily managed in the residential care setting
and this is a practical aspect of relevance for the success of new recommendations.
Further studies are needed to: (i) improve tools available to better estimate polyphenol intake and
enable comparison of different data in the literature, as previously reported [5]; and (ii) improve dietary
recommendations by defining the amount of polyphenol needed in order to obtain, if confirmed,
the postulated health benefits in the older subjects. This is not an easy task and imply a strong research
effort that needs to consider the potential impact of these results for the development of evidence-based
dietary guidelines for the management of age-related conditions.
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Figure S1: comparison of percentage energy and nutrient intake during 8-week polyphenol-rich diet (PR-diet) and
control diet (C-diet) in older women and men.
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Abstract: Mental ill health is currently one of the leading causes of disease burden worldwide.
A growing body of data has emerged supporting the role of diet, especially polyphenols, which have
anxiolytic and antidepressant-like properties. The aim of the present study was to assess the effect of
a high polyphenol diet (HPD) compared to a low polyphenol diet (LPD) on aspects of psychological
well-being in the Polyphenol Intervention Trial (PPhIT). Ninety-nine mildly hypertensive participants
aged 40–65 years were enrolled in a four-week LPD washout period and then randomised to either an
LPD or an HPD for eight weeks. Both at baseline and the end of intervention, participants’ lifestyle
and psychological well-being were assessed. The participants in the HPD group reported a decrease
in depressive symptoms, as assessed by the Beck Depression Inventory-II, and an improvement in
physical component and mental health component scores as assessed with 36-Item Short Form Survey.
No differences in anxiety, stress, self-esteem or body image perception were observed. In summary,
the study findings suggest that the adoption of a polyphenol-rich diet could potentially lead to
beneficial effects including a reduction in depressive symptoms and improvements in general mental
health status and physical health in hypertensive participants.
Keywords: polyphenols; fruits; berries; vegetables; dark chocolate; psychological well-being;
depression; physical health; mental health
1. Introduction
Mental ill health, manifesting itself in a wide range of conditions such as depression, anxiety
and stress [1], represents one of the leading causes of burden of disease worldwide, also substantially
increasing the risk of cardiovascular disease, diabetes and cancer [2–4] and adversely affecting quality
of life (QoL), relationships and the ability to work [5]. Northern Ireland has the highest prevalence of
mental illness within the UK, and psychiatric morbidity is 25% higher than in the UK [6].
Thus, research is required in order to establish inexpensive and effective techniques to reduce the
incidence of mental health problems and to improve the psychological well-being of the population.
Alongside genetic and biological factors, researchers have increasingly begun to examine the role
of lifestyle factors, including dietary intake, in the promotion of psychological well-being and the
Nutrients 2020, 12, 2445; doi:10.3390/nu12082445 www.mdpi.com/journal/nutrients23
Nutrients 2020, 12, 2445
prevention of mental illness [7,8]. Studies that have explored potential associations between nutrient
intake (namely carbohydrates, B vitamins and antioxidants such as vitamins C, E and polyphenols)
or foods rich in these nutrients (e.g., fruits, vegetables, legumes, coffee, chocolate) and psychological
well-being have produced conflicting results [9–12].
Polyphenols, in particular, have gained increasing attention from health researchers in recent
years due to their biological properties, as well as their abundance within the human diet [13].
A growing number of epidemiological studies support a role for polyphenols in the prevention
of chronic non-communicable diseases such as cardiovascular disease (CVD) [14], cancer [15] and
neurodegenerative diseases [14,16]. Furthermore, animal studies have demonstrated the ability of
polyphenols to improve cognitive performance and memory [17,18] and, more recently, these results
have been replicated in human studies [19,20]. Regarding mental health, a growing body of data from
animal and human studies has emerged supporting the role of a variety of dietary polyphenols in
affecting behaviour and mood through anxiolytic and antidepressant-like properties, mediated through
multiple molecular and cellular pathways [21]. Moreover, given that recent studies have demonstrated
the pathophysiological role of oxidative stress and inflammation in the onset and progression of
depression, polyphenols have been examined both in vitro and in vivo as a potential antidepressant
treatment, although randomised controlled trials are still scarce in the field [22,23]. The richest sources
of polyphenols in the human diet include fruits (e.g., berries, grapes, apples and plums), vegetables
(e.g., cabbage, eggplant, onions, peppers), plant-derived beverages including tea, coffee, red wine
and fruit juices (e.g., apple juice), seeds, nuts and chocolate (particularly dark chocolate) [24,25].
In terms of a food-based approach, several of the above-mentioned foods have been studied both in
observational and intervention studies for potential effects on outcomes related to mental well-being,
mood, psychological distress and life satisfaction [26], although, potentially due in part to the great
variation in study design, results are not consistent. Studying diet on a dietary pattern level will be
beneficial in allowing potential complicated or cumulative intercorrelations, interactions and synergies
to be revealed, given that different polyphenols may have different effects on outcomes of mental
health [27–29].
The aim of the present study was to assess the effect of a polyphenol-rich dietary pattern
(comprising fruits, including berries; vegetables and dark chocolate) in comparison to a control
diet (low fruits and vegetables, <2 portions/day, and no dark chocolate) on aspects of psychological
well-being and mental health status including mood, QoL, body image perception and self-esteem as
secondary outcomes measured within the Polyphenol Intervention Trial (PPhIT) [30].
2. Materials and Methods
2.1. Setting and Study Population
PPhIT was a randomised, controlled, parallel-group, single-blinded dietary intervention trial,
primarily designed to test whether increasing overall polyphenol dietary intake would affect
microvascular function and a range of other markers of CVD risk, such as systolic blood pressure and
lipid profile, in patients with hypertension. All participants underwent a full assessment at baseline
(week 0) (described below); then, they entered a washout period, during which they consumed a
low polyphenol diet, and afterwards were randomised to either a low polyphenol diet (LPD) or a
high polyphenol diet (HPD) group for 8 weeks (Figure 1). A full assessment was repeated for all the
participants at the end of the 8-week intervention (week 12), while at the end of the washout period
(week 4), participants also underwent a dietary intake assessment, anthropometric measurements and
blood and urine sample collection.
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Figure 1. CONSORT diagram summarizing flow of participants through the study.
Participants aged 40–65 years, with documented grade I (140–159/90–99 mmHg) or grade II
(160–179/100–109 mmHg) hypertension, were eligible. Participants with diabetes mellitus, acute
coronary syndrome or transient ischaemic attack within three months, pregnancy or lactation, fasting
triglyceride concentration>4 mmol/L, alcohol consumption (>28 units/week for men and>21 units/week
for women), oral anticoagulant therapy or antioxidant supplements, dietary restrictions that would
limit ability to comply with the study diets, body mass index >35 kg/m2 or with an impalpable brachial
artery were excluded from the study. Recruitment for PPhIT began in February 2011 and was completed
by January 2013. All participants were informed about the aims and procedures of the study and gave
their written consent. The study had ethical approval from the Office of Research Ethics Committee
Northern Ireland (ref 10/NIR03/39) and was registered at ClinicalTrials.gov (ref NCT01319786). Details
of the primary aim of the study, population, design, recruitment procedures and main findings have
been published elsewhere [30]. Below, we provide some additional details on selected aspects of the
evaluation that pertain to the analyses reported in this manuscript.
2.2. Dietary Intervention
The intervention commenced with a four-week “washout period” for all participants, during
which they were asked to consume two portions or less of fruits and vegetables (F&V) per day and to
exclude berries and dark chocolate (LPD). At the end of this period, subjects were randomised to either
continue with the above LPD for a further 8-week “intervention period” or to consume an HPD of six
portions of F&V (including one portion of berries per day) and 50 g of dark chocolate per day (Figure 1).
A portion of fruit and vegetables was quantitatively defined using household measures as outlined by
UK guidelines (https://www.nhs.uk/live-well/eat-well/5-a-day-portion-sizes/), i.e., 1 apple, 1 orange,
half a grapefruit or one glass (150 mL) fruit juice, 3 tablespoons of vegetables [31]. All participants in
the HPD had a self-selected weekly delivery of F&V and dark chocolate (Lindt® 70% cocoa) free of
charge to their homes from a local supermarket and were provided with written material regarding
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F&V portion sizes, recipes and sample diet plans. In addition, each participant, regardless of dietary
allocation, was also contacted by telephone at weekly intervals to provide support and encouragement
and to discuss potential barriers encountered in relation to achieving the dietary goals.
Dietary intake and compliance with the intervention were assessed through 4-day food diaries
completed on four occasions: on the four days leading up to the week 0 visit (baseline measurement),
on the four days leading up to the week 4 visit (washout period measurement), at week 8 (intervention
measurement) and on the four days leading up to the final week 12 visit (a second intervention period
measurement). Circulating blood and urine levels of a panel of nutritional biomarkers, with detailed
methodology given below, were also used to assess compliance. Self-reported F&V, berries and dark
chocolate consumed per day (as recorded in the food diaries) were extracted and entered into a
Microsoft Excel spreadsheet. The spreadsheet contained pre-determined formulae which transformed
the actual amounts of F&V and berries consumed into “portions” according to the “5-a-day” message.
2.3. Other Lifestyle Parameters
A “lifestyle and medical” questionnaire was used at week 0 to record participant demographic,
lifestyle and medical information. The questionnaire had 16 items in total and assessed several aspects
including vitamin and mineral supplement usage, smoking and alcohol habits, history of education,
current occupational status, current medication, history of steroid use and, for females, use of hormone
replacement therapy and details of menstrual cycle. Information regarding changes in medication use,
smoking and alcohol patterns, as well as infections/illnesses were also recorded throughout the study.
Participants’ physical activity levels were recorded at weeks 0, 4 and 12 to ensure that habitual
activity levels were not altered for the duration of the study. The Recent Physical Activity Questionnaire
(RPAQ), designed by the Medical Research Council (MRC Epidemiology Unit, Cambridge, UK),
was used to measure physical activity. The questionnaire assesses physical activity within the
preceding four weeks based on three primary areas: activity at home, activity at work (including travel
to and from work) and recreational activities. The RPAQ has been shown to be a valid instrument
for calculating total energy expenditure, physical activity energy expenditure and physical activity
in healthy adults [32]. In terms of analysis, physical activity as recorded in the questionnaire was
converted to total metabolic equivalent of task (MET) hours per day of sedentary, light, moderate and
vigorous activity.
2.4. Anthropometric, Clinical and Biochemical Assessments
Participants attended the Royal Victoria Hospital (Belfast, Northern Ireland, UK) for assessments
on three occasions throughout the study: baseline (week 0), washout period (week 4) and intervention
(week 12). Body weight of participants was measured to the nearest 100 g and height to the nearest
0.5 cm. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2).
Waist circumference (WC) and hip circumference (HC) were tape-measured to the nearest 0.1 cm.
Blood pressure (BP) was measured using an Omron M5-1 automatic BP monitor (Omron Healthcare,
Hoofddorp, The Netherlands). Three consecutive readings were recorded, and a mean BP was
calculated from the 2nd and 3rd readings. To measure the primary endpoint of PPhIT (microvascular
function), venous occlusion plethysmography was conducted on participants by determining forearm
blood flow during incremental intra-arterial infusions of acetylcholine and sodium nitroprusside,
as previously described [30]. Blood samples were also collected. Fasting serum lipid profiles
(total cholesterol, high density lipoprotein (HDL) and triglycerides) were assessed using standard
enzymatic colorimetric assays on an automated Cobas® 8000 Modular system biochemical analyser
(Roche Diagnostics Ltd., West Sussex, UK). Low-density lipoprotein (LDL) cholesterol was calculated
using a standard Friedewald formula [33]. Blood and urine markers of micronutrient status were
assessed at weeks 0 and 12 to objectively measure compliance to the intervention diet. Plasma
vitamin C was measured on a FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany),
adapted from the method of Vuilleumier and Keck [34]. Serum concentrations of six carotenoids
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(α-carotene, β-carotene, β-cryptoxanthin, lutein, lycopene and zeaxanthin) were measured by reverse
phase high performance liquid chromatography (HPLC), as described by Craft [35]. Urine collected
from the volunteers between evening meal and midnight the evening before each study visit was
analysed, including an enzymatic hydrolysis step, to quantify total epicatechin content, using an
Agilent Technologies 1100 series HPLC (Agilent Technologies, Stockport, UK) directly linked to a Waters
Micromass Quattro Ultima Platinum API triple quadrupole mass spectrometer (Waters, Dublin, Ireland).
2.5. Psychological Well-Being, Self-Esteem and Body Image
Aspects of psychological well-being and mental health status were evaluated through several scales
and questionnaires that were completed at weeks 0 and 12. The decision to use these questionnaires
only twice was made for three reasons: (i) the study wished to investigate the effect of the intervention
diet in comparison to normal psychological well-being, rather than psychological well-being under the
controlled conditions of the washout period; (ii) to reduce participants’ burden at week 4 visits, which
were already long (2.5 h) in duration due to vascular function and dietary assessments; (iii) distributing
the surveys at three time points may have been disadvantageous in terms of allowing participants
to become familiar with their format, which may have influenced responses. All questionnaires are
commonly used for assessing various aspects of mental health and psychological well-being in the
general population.
The Positive and Negative Affect Schedule (PANAS) was used for evaluating subjective mood.
The questionnaire measures two distinctive dimensions: positive affect (PA) and negative affect
(NA) [36]. PA is associated with pleasurable engagement with the environment, including feelings of
enthusiasm and alertness as well as feeling active. NA refers to unpleasurable engagement with the
environment, comprising feelings of anger, contempt, disgust, guilt, fear and nervousness. Whilst
related, PA and NA represent two distinct and independent dimensions of mood. Participants were
asked to respond to 10 items representing PA and 10 items representing NA on a five-point scale. Higher
scores represent higher positive and negative affect, respectively. This was the only questionnaire
assessing psychological well-being that was also completed at week 4, in order to monitor psychological
well-being at the end of the washout period.
Depressive symptomology was assessed with the Beck Depression Inventory-II (BDI-II), a 21-item,
self-report questionnaire developed by Beck and colleagues [37]. Each item on the BDI-II has four
statements which relate to the severity of a particular depressive symptom, and respondents are asked
to choose the one statement which best describes how they have been feeling in the preceding two
weeks. Higher scores indicate higher levels of depression (scores 0–13 = minimal; 14–19 = mild;
20–28 =moderate; 29–63 = severe). The shorter version (21 items) of the Depression Anxiety Stress
Scale (DASS-21) was also completed to measure depression, anxiety and stress [38]. The DASS-21
questionnaire was introduced nine months into the recruitment of the participants. DASS-21 has seven
items per subscale and asks participants to rate the extent to which they experienced each emotional
state the preceding week using a four-point Likert scale (0 = Did not apply to me at all, 3 = Applied to
me very much or most of the time). Higher scores are indicative of higher levels of depression, anxiety
and stress.
The Rosenberg Self-Esteem Scale was used as a global measure of self-esteem [39,40].
The questionnaire consists of a ten-item Likert scale, completed using a four-point scale from strongly
agree to strongly disagree. Scores can range from 0 to 30, with higher scores indicating higher
self-esteem. Finally, body image satisfaction was assessed through the Multidimensional Body
Self-Relations Questionnaire—Appearance Scales (MSRQ-AS), a 34-item validated measure of body
image perception for use in general populations (www.body-images.com) [41]. This version contains
five subscales: appearance evaluation (satisfaction with ones looks), appearance orientation (levels of
investment in one’s appearance), overweight preoccupation (weight anxiety, vigilance, dieting etc),
self-classified weight (how one perceives and labels one’s weight) and body area satisfaction (satisfaction
with areas of body). The questionnaire contains a series of statements and asks participants to indicate
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the extent to which each statement applies to them personally, with higher scores generally indicating
greater body image satisfaction.
2.6. Mental and Physical Health
Mental and physical health were assessed with the RAND Medical Outcomes Study 36-item
Short Form Health Survey (SF-36) [42,43]. A total of 36 questions are included in the RAND SF-36
survey and eight key areas are explored in the SF-36 including physical functioning, role limitations
due to physical problems, pain, general health, energy/fatigue, social functioning, role limitations
due to emotional problems and emotional well-being. The raw data were recoded using the RAND
SF-36 scoring instructions available online. Additionally, the eight areas were combined to obtain
the scoring for physical and mental health components. As the eight different components consist
of different numbers of questions, the normal scores were transformed to T-scores, as described by
Hays et al. 1993 [44] and Hays et al. 1995 [45]. Physical functioning, role limitations due to physical
problems, pain and general health were combined to obtain the physical health component and role
limitations due to emotional problems, energy/fatigue, emotional well-being and social functioning
were combined to obtain the mental health component.
2.7. Statistical Analyses
The sample size calculation was based on the PPhIT primary outcome, namely microvascular
function. According to this, detection of a 33% difference between groups in microvascular function,
measured by forearm blood flow responses to an endothelium-dependent vasodilator, with 90% power,
using a 2-tailed test at the 5% significance level, would require 50 participants per group. The current
analysis reports secondary outcomes, for which power calculations were not performed.
Results are expressed as mean ± standard deviation for normally distributed continuous variables
and as medians and interquartile ranges for continuous skewed variables. Categorical variables are
presented as absolute (n) and relative frequencies (%). The normality of variables was checked through
the Shapiro–Wilk test and graphically through histograms. Concentration measures of micronutrients
were logarithmically transformed and were summarised as geometric median and interquartile range.
The principal analysis for each outcome variable was a between-group comparison of change using
independent sample t tests or Mann–Whitney U test for continuous parametric and non-parametric
variables, respectively, and chi-squared test for categorical variables. Within-group comparisons were
performed using paired sample t tests or Wilcoxon signed-rank test for parametric and non-parametric
continuous variables, respectively. Statistical significance was set at p ≤ 0.05. All statistical methods
were conducted using PASW Statistics 18 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. General Results
Ninety-nine participants completed the PPhIT study, including 53 (53.5%) males. Participants had
a mean age of 54.9 ± 6.9 years, with ages ranging from 40 to 65 years. The majority (52%) of the sample
were obese (BMI ≥ 30 kg/m2). In total, 12.1% were current smokers, and 43.4% stated that they had
smoked in the past. Baseline characteristics according to dietary group (LPD versus HPD) are shown
in Table 1. Overall, the groups were similar upon entering the study, with no statistically significant
differences in anthropometric, lifestyle and basic clinical characteristics.
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Table 1. Baseline (week 0) participant characteristics according to the Polyphenol Intervention Trial







Age (years) 55.6 ± 6.8 54.0 ± 7.0 0.25
Sex (males, n (%)) 30 (60.0) 23 (46.9) 0.23
Education (years) 13.9 (12.0, 16.8) 13.6 (13.8, 15.8) 0.57
Body mass index (kg/m2) 29.9 (26.9, 34.6) 31.15 (27.7, 33.5) 0.29
Waist circumference (cm)
Male 106.5 (98.0, 116.3) 105.0 (98.0, 116.0) 0.86
Female 94.0 (85.3, 108.8) 96.0 (89.5, 108.5) 0.56
Current smoker n (%) 5 (10.0) 7 (14.3) 0.55
Use of antidepressants n (%) 7 (14.0) 8 (16.3) 0.79
Systolic blood pressure (mmHg) 143.7 ± 6.6 143.6 ± 8.0 0.95
Diastolic blood pressure (mmHg) 86.9 ± 8.3 85.9 ± 7.1 0.55
Total cholesterol (mmol/L) 5.3 ± 1.2 5.7 ± 1.2 0.10
HDL(mmol/L) 1.4 ± 0.3 1.3 ± 0.4 0.58
LDL(mmol/L) 4.3 ± 1.3 4.6 ± 1.2 0.18
Triglycerides (mmol/L) 1.7 (1.6, 2.1) 1.6 (1.5, 2.0) 0.46
HDL—high-density lipoprotein; LDL—low-density lipoprotein. Continuous variables are summarised as mean
± SD or medians and interquartile ranges. Categorical variables are summarised as n (%). * Between-group
comparisons were made using independent sample t-tests (p < 0.05) or Mann–Whitney U test for continuous
variables and chi-squared tests (p < 0.05) for categorical variables.
During the washout period, no changes were recorded in participants’ physical activity habits,
weight status, smoking habits, medication use or clinical condition compared to baseline in both HPD
and LPD groups (data not shown). Additionally, mood evaluation according to PANAS questionnaire
did not record any change between baseline and end of washout period (both p > 0.05) (data not
shown). F&V intake per day declined significantly during washout, from 2.67 portions at week 0
to 1.38 portions at week 4 within the overall sample (p < 0.001), and significant reductions in blood
levels of vitamin C (p < 0.001) and β-cryptoxanthin (p = 0.05), but not in any of the other carotenoids
measured, were also recorded (data not shown).
Dietary intake of food groups and micronutrients, as well as weight status and physical activity
levels both at baseline and at the end of the intervention period, are presented in Table 2, per intervention
group. At baseline, there was no significant difference in intake of F&V, berries and dark chocolate and
concentration of micronutrients between the LPD and HPD group. By the end of the intervention,
there was a significant increase in intake of F&V, berries and dark chocolate in the HPD group, and the
differences in change in intake between the two groups were statistically significant. Furthermore,
there was a significant increase in the concentration of biomarkers, plasma vitamin C, serum lutein,
β-cryptoxanthin, α-carotene and lycopene and urinary epicatechin over the course of the intervention
in the HPD group, and the differences in the change in the concentration between the LPD and HPD
group were statistically significant. These results indicate good compliance with the intervention diet,
with significant between-group differences in change in all biomarkers measured except β-carotene.
No differences were recorded in change in physical activity and weight status between the two
intervention groups during the intervention.
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3.2. Changes in Aspects of Psychological Well-Being
Changes in measures of psychological well-being between baseline and intervention are illustrated
in Table 3. There were no significant differences in scores of BDI-II, DASS-21 or PANAS between the
LPD and HPD groups at baseline. There was a significant between-group difference (p = 0.01) in
change in depressive symptoms as assessed with BDI-II, but no other significant effects were found
between groups with regards to depression, anxiety or stress measured using the DASS-21 or positive
and negative affect measured with PANAS. Regarding within-group changes, a borderline significant
(p = 0.05) result was detected for a reduction in stress measured by DASS-21 within the HPD group,
as well as an improvement in subjective mood (positive affect) (p = 0.03) measured by PANAS.
3.3. Changes in Self-Esteem and Body Image Perception
There were no significant differences in self-esteem or body image perception scores between
the LPD and HPD groups at baseline. As shown in Table 3, there were also no significant differences
between the HPD and LPD in self-esteem or body image perception scores at the end of the intervention.
3.4. Changes in Health-Related Quality of Life
There were no significant differences between groups at baseline with regards to health-related
quality of life measured using the SF-36. There were statistically significant between-group differences
in change in different component scores (general health (p = 0.03) and energy/fatigue (p = 0.02)) and
the overall summary scores for the physical health component (p = 0.04) and mental health component
(p = 0.01), with more positive changes demonstrated in the HPD group. In the HPD group, there
were also within-group improvements in role limitations due to physical health (p = 0.04), general
health (p = 0.00), energy/fatigue (p = < 0.001), emotional well-being (p = < 0.001) and social functioning
(p = 0.02)
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4. Discussion
Given the high prevalence of mental health problems and the potential effect of dietary
patterns on their onset and/or treatment, the aim of the present study was to assess the effect of
a polyphenol-rich dietary pattern (comprising fruits, including berries; vegetables and dark chocolate)
on aspects of psychological well-being or mental health status, including mood, self-esteem and
body image perception, as secondary outcomes of the PPhIT study. Despite some heterogeneity,
the study findings suggest that the adoption of such a polyphenol-rich diet could potentially lead to
beneficial effects on certain outcomes including depressed mood and physical and mental health in
hypertensive participants.
There was a significant difference in change in depressive symptoms assessed with BDI-II between
the HPD group and the LPD group, indicating a positive effect of the HPD, which is in agreement with
a number of other observational studies focusing on the same outcome measure and polyphenol-rich
foods. In the HPD group, a 66.6% reduction in BDI-II score was observed after the intervention.
Button et al. 2015, using data from three randomised controlled trials (RCT) with a sample of n = 1039,
identified that a 17.5% reduction in score was necessary to observe minimally clinically important
differences [46]. Oliveria et al. (2019) found a negative association between depressive symptoms
measured by BDI and high intake of polyphenol food items [47]. In the Finnish general population
(n = 2011), daily intake of tea was associated with reduced risk of depressive symptoms defined by
BDI scores [48]. Similarly, in the Mediterranean healthy eating, lifestyle and aging (MEAL) study
(n = 1572), the dietary intake of phenolic acid, flavanones and anthocyanin were negatively associated
with depressive symptoms measured using the Center for Epidemiologic Studies Depression Scale
(CES-D-10) [49]. The positive effects observed in the present study may be attributable to other
nutrients found in F&V, berries and dark chocolate which may work independently or synergistically
to influence health outcomes. Brody (2002) found that vitamin C intake over a 14 day period led to a
moderate reduction in depressive symptoms amongst 42 healthy young adults [50]. In our study, there
was a significant difference in plasma vitamin C status between the LPD and HPD group. Similarly,
there were significant increases in serum carotenoids, lutein, zeaxanthin, β-cryptoxanthin and urinary
epicatechin within the HPD group, and some studies have suggested a link between these nutrients
and improvements in psychological well-being including depression [51]. The antidepressant effects of
polyphenols may be associated with both their antioxidant and anti-inflammatory properties, whereby
there is a reduction in free radicals and cytokine dysregulation [12]. Lua and Wong (2012) found that
the consumption of 50 g dark chocolate (70% cocoa) for three days was associated with significant
improvement in depressed mood [52].
The primary outcome of the PPhIT study was to identify whether high consumption of F&V, berries
and dark chocolate could improve microvascular function in hypertensive subjects [30]. High intake
of polyphenol, specifically including F&V, berries and dark chocolate in diet, resulted in significant
improvements in endothelium-dependent (acetylcholine) vasodilator [30]. Depression is often observed
among individuals with vascular diseases such as hypertension, peripheral vascular disease and
coronary artery disease, known as “vascular depression hypothesis” [53]. Studies have reported
morphological changes in vascular structure and altered expression of endothelial cell molecules
such as nitric oxide in patients with depression [53]. In the current study, the improvements in
endothelium-dependent vasodilatation might have also resulted in improvements in depressed mood.
In light of the findings from the BDI-II, it is interesting that no notable effects of the polyphenol-rich
diet were observed on depressed mood measured using the DASS-21 questionnaire in this study.
The DASS-21 questionnaire was introduced as an amendment to PPhIT, given concerns that BDI-II
is used to screen for depression in normal populations or to assess severity of depression in clinical
populations, and therefore it was thought possible by the research team that the tool may not have
been sensitive enough to pick up changes due to diet. Page et al. (2007) showed that DASS-21
has good psychometric properties and is moderately sensitive to changes that result from the
treatment [54]. However, this resulted in a considerably smaller sample size for the analysis of the
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DASS-21 questionnaire (n = 57) compared to BDI-II, which may have had implications in terms of the
associated power available to detect differences between the two diet groups. The DASS-21 also showed
no statistically significant differences in change between groups with regards to stress or anxiety.
Furthermore, for both measures, scores on all scales at the start of the study are low, and negative affect
scores for the PANAS are also low. These low scores are unsurprising in a volunteer sample for a study
intended to improve health but may also have limited our chances of finding effects. Further study in
groups with higher levels of poor psychological health, e.g., those with diagnoses of depression or
anxiety, may be of value.
In the present study, significant improvements in quality of life between the HPD group and the
LPD group measured using the SF-36 health survey questionnaire were found. There were statistically
significant improvements in both physical and mental health components in the HPD group when
compared with the LPD group. Data showing the effect of dietary interventions and especially of
polyphenols/antioxidants on quality of life parameters are sparse and mainly limited to patients with
chronic diseases such as multiple sclerosis, chronic fatigue syndrome and depression. Steptoe et al.
(2004) found that a higher intake of fruits and vegetables through behavioural and nutrition education
counselling was positively associated with physical health status but not mental health status measured
using SF-36 among adults in a low-income neighbourhood [55]. A sub-study of the DASH trial also
found that adhering to a fruit and vegetable-rich diet was associated with improved perception of
quality of life [56]. It is important to acknowledge that while the self-reported improvements in physical
and mental health scores observed within the current sample may be attributed to the foods consumed,
they may also be wholly or partly influenced by taking part in the intervention and increased positivity
that may come from making positive dietary changes. As pointed out in the study by Plaisted et al.
(1999), improvements in QoL might be attributable to participants’ awareness that they are consuming
a healthy diet, which could have contributed to improved self-ratings of general health and mental
health component [56]. In addition, given that depressive symptoms were improved in the HPD group,
the improvements in mental health component may simply mirror these findings.
It is important to consider the results of this study in light of a number of methodological
limitations. Firstly, as the primary purpose of PPhIT was to test the effect of a polyphenol-rich dietary
pattern on microvascular and platelet function, the outcomes discussed here are secondary endpoints.
Hence, as mentioned previously, it is possible that the study may not have been adequately powered
to detect differences between the dietary groups, which may account for some of the null findings
demonstrated. Secondly, the study sample comprised mildly hypertensive participants, which limits
the generalisability of these results to the wider population. Furthermore, it is possible that selection
bias exists within the current sample, given that the volunteers for this study were on the whole
well-educated, and, as is the case with most clinical trials, are likely to have been more motivated with
regard to improving their health than the general population. The participants in the HPD group were
provided with the key intervention foods on a weekly basis, whereas the LPD group received no food
provision as their diet was to remain unchanged. This may have increased the likely compliance of the
HPD group with the intervention. Another limitation of this study was the use of self-report measures
to measure psychological outcomes. Self-report measures can be disadvantageous in that they can
be affected by forms of bias, including response, recall and social desirability bias, which can lead
to inaccurate responses and conclusions [57]. However, given the subjective nature of psychological
well-being, self-reporting is the most suitable method of obtaining information on individuals’ personal
experiences and emotions. The current study employed validated and previously used measures to
collect information on individuals’ personal experiences and emotions [58,59]. Additionally, it must be
noted that the questionnaires described in this study were distributed at week 0 (baseline) and week
12 (intervention). It is possible that the washout period (week 0 to week 4) could have potentially
affected people’s psychological well-being and thus it may have been useful to additionally measure the
endpoints at week 4. However, the decision to distribute the questionnaires at week 0 and week 12 was
made for three main reasons: (i) to reduce participant burden at week 4 visits, which were already long
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(2.5 h) in duration due to vascular function assessment and the dissemination of dietary advice; (ii) the
study wished to investigate the effect of the intervention diet in comparison to normal psychological
status, rather than psychological states under controlled conditions, which would have limited the
applicability of the results; (iii) distributing the outcome measures at three time points may have
been disadvantageous in terms of allowing participants to become familiar with their format, which
may have induced response bias. Another limitation common to most studies analysing self-reported
questionnaire data is the number of variables assessed, which may have increased the chance of type
one errors (identification of the false positive) associated with hypothesis testing.
In contrast, one of the most obvious strengths of this study is its RCT study design. However,
as the randomisation according to the groups only occurred at week 4, the presentation of week 0 data
based on the allocated groups is rather artificial, and this must be considered a limitation. As further
strengths, the study implemented a variety of techniques to encourage and monitor compliance.
As a result of such efforts, participants were demonstrated to have good compliance with both diets,
which was assessed both subjectively and objectively. Furthermore, the study had good retention of
participants, with a less than 5% (n = 5) drop out level, all of which were due to reasons unrelated to
the study.
5. Conclusions
In conclusion, the results from the present RCT trial showed heterogeneous findings regarding the
effect of a polyphenol-rich dietary pattern on aspects of psychological well-being, with positive effects
demonstrated on depressive symptoms and both the physical and mental health status components of
the SF-36 quality of life measure. Further studies with psychological well-being impacts as primary
endpoints, with appropriate study design and sample sizes, are needed in order to confirm the benefits
of a polyphenol-rich dietary pattern on these outcomes.
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Abstract: Extracts made from the leaves of the mango food plant (Mangifera indica L., Anacardiaceae)
have a long history of medicinal usage, most likely due to particularly high levels of the polyphenol
mangiferin. In rodent models, oral mangiferin protects cognitive function and brain tissue from
a number of challenges and modulates cerebro-electrical activity. Recent evidence has confirmed
the latter effect in healthy humans following a mangiferin-rich mango leaf extract using quantitative
electroencephalography (EEG). The current study therefore investigated the effects of a single dose of
mango leaf extract, standardised to contain >60% mangiferin (Zynamite®), on cognitive function
and mood. This study adopted a double-blind, placebo-controlled cross-over design in which
70 healthy young adults (18 to 45 years) received 300 mg mango leaf extract and a matched placebo,
on separate occasions, separated by at least 7 days. On each occasion, cognitive/mood assessments
were undertaken pre-dose and at 30 min, 3 h and 5 h post-dose using the Computerised Mental
Performance Assessment System (COMPASS) assessment battery and the Profile of Mood States
(POMS). The results showed that a single dose of 300 mg mango leaf extract significantly improved
performance accuracy across the tasks in the battery, with domain-specific effects seen in terms
of enhanced performance on an ‘Accuracy of Attention’ factor and an ‘Episodic Memory’ factor.
Performance was also improved across all three tasks (Rapid Visual Information Processing, Serial 3s
and Serial 7s subtraction tasks) that make up the Cognitive Demand Battery sub-section of the
assessment. All of these cognitive benefits were seen across the post-dose assessments (30 min, 3 h,
5 h). There were no interpretable treatment related effects on mood. These results provide the first
demonstration of cognition enhancement following consumption of mango leaf extract and add to
previous research showing that polyphenols and polyphenol rich extracts can improve brain function.
Keywords: cognition; attention; memory; brain; polyphenols; mangiferin; mango leaf extract
1. Introduction
The roots, leaves, fruit and bark of the food plant Mangifera indica (mango) have a long history
of therapeutic use within traditional medicinal systems for a wide range of conditions. For example,
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extracts, teas and infusions made from mango leaves have been used for the treatment of diabetes,
malaria, diseases of the digestive system, lungs, and kidneys, and as a topical treatment for wounds and
burns [1]. The bioactivity of mango leaf extracts may be due to particularly high levels [2] of xanthones.
This group of polyphenols are found in a restricted group of plant species [3], including members of
the Hypericum genus that provide us with a number of medicinal herbal extracts [4], but they are rarely
consumed in the diet, with only a few exceptions other than mango itself (e.g., [5]). The predominant
member of this structural group in mango leaf is mangiferin, a xanthone glucoside that has been shown to
have potential anti-inflammatory, antioxidant, immunomodulatory, neuroprotective, antiproliferative,
antidiabetic, DNA protective, and hypoglycaemic properties [6–10].
Whilst structurally distinct from the flavonoids and other polyphenols that are ubiquitous
in plant derived foods, mangiferin [8,11–14] likely owes its beneficial bioactivity to some similar
mechanisms of action as found in the wider polyphenol group class [15], including interactions with,
and modulation of, diverse components of a wide range of mammalian cellular signal transduction
pathways. These pathways, in turn, control gene transcription and a plethora of cellular responses,
including cell proliferation, apoptosis, and the synthesis of growth factors, and vasodilatory and
inflammatory molecules. In the central nervous system, specific additional interactions attributed
to polyphenols include direct neurotransmitter and neurotrophin receptor and signalling pathway
interactions, and increased synthesis of neurotrophins and vasodilatory molecules, which, in turn,
foster angiogenesis/neurogenesis [15–20]. These mechanisms potentially underlie the observation of
consistent beneficial cardiovascular effects from meta-analyses of multiple intervention studies [21–23],
and demonstrations of improved cognitive function [24–28], following diverse polyphenols.
In line with these mechanistic cellular effects, rodent studies have demonstrated that a single
administration of mangiferin can improve memory in uncompromised rats [29] and that either
single doses or extended supplementation with mangiferin can attenuate the memory deficits or
depressive/anxiety behaviours associated with a range of brain insults and challenges. This includes the
cholinergic antagonist scopolamine [30], sleep deprivation [31], the injection of lipopolysaccharides [32]
and aluminium chloride-induced neurotoxicity in mice [9]. Consistent ex vivo evidence focussing
on the hippocampus also shows that mangiferin can protect rodent neuronal tissue from the
increase in inflammatory cytokines [9,30–32] and the decrease in neurotrophins such as brain-derived
neurotrophic factor (BDNF) [9,31], associated with multifarious brain insults. Similarly, mangiferin has
been shown to protect the rodent brain from lead-induced structural damage and decrease oxidative
stress via interactions within the Nrf2 signalling pathways in rats [10].
A number of recent studies have assessed the potential efficacy of a mango leaf extract
standardized to a minimum of 60% mangiferin (Zynamite®). In terms of physical performance,
several of these studies have assessed the ergogenic effects in humans of both acute [33–36] and
longer-term supplementation [34] with this mango leaf extract combined with the polyphenols
luteolin or quercetin. This research has demonstrated an improved performance during high intensity
exercise [33–35], increased brain oxygenation [33,34], maximal aerobic capacity [33], increased muscle
oxygen extraction [34,35] and the attenuation of muscle damage and improvements in the time course
of decreased muscle performance [37].
With regard to brain function, in rats, oral administration of mango leaf extract attenuated
electroencephalography (EEG) power measured via implanted electrodes (frontal cortex, hippocampus,
striatum, reticular formation) across the spectra and brain regions under investigation, with the
most striking findings in the alpha and beta wavebands. These effects were synergistically
increased by the co-administration of caffeine. A concomitant ex vivo study also demonstrated
that 7 days supplementation with the mango leaf extract lead to increased hippocampal pyramidal cell
excitability [38]. In a subsequent multi-disciplinary series of studies [39], both the ex vivo hippocampal
excitability and the attenuation of EEG spectral power across brain regions in rats were confirmed both
for mango leaf extract and mangiferin, confirming this polyphenol as the likely active component of
the extract. In two subsequent pilot studies (also reported in [39]), both involving 16 healthy young
40
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humans, quantitative EEG was employed at rest and during cognitive task performance 90- and
60-min post-dose respectively. In the first study, in comparison to control, mango leaf extract resulted
in modest reductions in ‘eyes open’ power in delta and theta power, and a more pronounced increase
in power during cognitive task performance, with significant increases in all wavebands across scalp
electrodes interrogating the association cortex. These results were supported by more modest EEG
changes in the second study, but no evidence of a synergistic relationship with caffeine. Cognitive task
performance and mood were not significantly modulated by mango leaf extract.
The extant literature demonstrating functional benefits following polyphenol consumption,
and the previous rodent and pilot human studies assessing the effects of mangiferin and mango leaf
extract described above, suggest that a mango leaf extract with high levels of the polyphenol mangiferin
may exert beneficial effects on human brain function, including the enhancement of cognitive function.
The current exploratory, double-blind, placebo-controlled, balanced crossover study therefore assessed
the effects of a single dose of mango leaf extract (Zynamite®) on cognitive function and psychological
state 30 min, 3 h and 5 h post-dose in a large sample of healthy adults.
2. Methods
2.1. Design
This study adopted a randomised, double-blind, placebo-controlled, balanced crossover design,
in which the acute effects of a single dose of 300 mg mango leaf extract and placebo were assessed
on cognitive function and psychological state/mood at 30 min, 3 h and 5 h post-dose. All study
procedures were reviewed and approved by Northumbria University’s Department of Psychology
Ethics Committee (Ref: 17741) and were conducted according to the principles of the Declaration of
Helsinki. The trial was pre-registered at ClinicalTrials.gov (NCT04299217).
2.2. Participants
The required sample size for the study (N = 72) was calculated (GPower 3.0) on the basis of
delivering adequate power (0.8) to detect a small effect size (f = 0.1). The power to detect the anticipated
medium effect size (f = 0.25) exceeded 0.95.
A total of 75 participants were randomised. Three participants subsequently withdrew from the
study after completing one testing visit. Two participants were removed from the dataset during blind
data review due to a persistent inability to achieve performance criteria across tasks.
The final per-protocol analysis sample therefore comprised 70 participants (F 37/M 33; mean age
26.9 years, range 18–45 years; 5 vegetarians and 1 vegan). All participants self-reported that they
were healthy and free from any relevant medical condition or disease, including psychiatric and
neurodevelopmental disorders; that they were not taking any prescription or illicit drugs, food
supplements or nicotine containing products; that they were not pregnant, lactating or seeking
to become pregnant. Participants were also excluded if they consumed >500 mg caffeine per day
(>6× 150 mL cups of filter coffee), had high blood pressure (>systolic 159 mm Hg or diastolic 99 mm Hg)
or had a body mass index outside of the range 18.5–35 kg/m2. Participant dispositions are shown
in Figure 1.
The final number of participants’ data points (excluding missing data and data points removed
during blind data review) included in the analysis of data from each individual outcome are shown
in the relevant tables.
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Figure 1. Participant disposition.
2.3. Treatments
Zynamite® mango leaf extract is comprised of components within the following ranges:
mangiferin—60–65%; homomangiferin—3–5%; isomangiferin—up to 1%; leaf polysaccharides—6–20%;
hydrolysable and non-hydrolysable tannins—up to 1%; fibre, minerals, moisture—6 to 15%. Details of
the manufacturing process are provided elsewhere [39].
Participants were randomly allocated to receive 300 mg mango leaf extract or placebo (maltodextrin)
in methylcellulose capsules of identical appearance, during each of their two assessment days.
Testing days were separated by a minimum of 7 days to ensure washout. The order in which
participants received the two interventions was counterbalanced across the group via random
allocation to a counterbalancing schedule. Individual treatments were delivered to the trial facility
in individual sealed plastic envelopes, labelled with the participants’ randomisation numbers and visit
(1 or 2) according to the computer-generated double-blind randomisation schedule.
There were no significant adverse events that could be linked to administration of the treatments
and no significant difference in the incidence of minor adverse events (e.g., mild headache) between
the placebo and mango leaf extract treatments.
2.4. Psychological Measures
2.4.1. Cognitive Tasks
All of computerised cognitive/mood assessments were identical, and were carried out via laptop
computers and response boxes using the Computerised Mental Performance Assessment System
(COMPASS, Northumbria University, Newcastle upon Tyne, UK). This software platform incorporates
the presentation of classic and custom computerised cognitive tasks, with fully randomised parallel
versions of each task delivered at each assessment for each individual. A similar selection of tasks has
previously been shown to be sensitive to diverse nutritional interventions [40–43]. Within the 60-min
assessment the participants also completed a 30-min component known as the Cognitive Demand
Battery (CDB), which comprises the prolonged repetition of a series of demanding tasks that assess
working memory, executive function and attention. The objective of this battery is to assess the impact
of treatment on speed/accuracy and mental fatigue during continuous performance of cognitively
demanding tasks. The CDB has also been shown to be sensitive to modulation by a wide range of
nutritional interventions [43–46]. The individual tasks making up the cognitive assessment (including
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the CDB) are shown in Figure 2 and described in more detail in the online Supplementary Materials
(Section I).
Figure 2 also shows the contribution of individual tasks to the principal performance measures,
which were derived by averaging the data (either msec for speed, or % correct/maximum score
for accuracy) from individual tasks into the following global performance outcomes: ‘Speed of
Performance’ and ‘Accuracy of Performance’; and the following cognitive domain factor scores
‘Speed of Attention’, ‘Accuracy of Attention’, ‘Speed of Memory’, ‘Working Memory’, and ‘Episodic
Memory’. The derivation of the global scores and cognitive factors are described in more detail in the
online Supplementary Materials (Section II). These global measures and cognitive domain factors have
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Figure 2. Cognitive assessments. The running order of tasks and their contribution to the cognitive
factors (to the right) and global performance measures (to the left) derived from the overall battery.
The same assessment was completed at the pre-treatment baseline and at 30 min, 3 h and 5 h
post-dose on each assessment day. The selection of tasks took a total of 60 min to complete, with the
Cognitive Demand Battery comprising 30 min of this. The individual tasks are described in more detail
in the supplementary online materials (Section I). Rapid Visual Information Processing task (RVIP).
Visual analogue scale (VAS).
2.4.2. Mood and Psychological State
Before each cognitive assessment, participants completed the Profile of Mood States (POMS-2)
Adult Short Form [47]. As part of the COMPASS battery, and before the cognitive tasks,
participants completed the Visual Analogue Mood Scales (VAMS), a set of 18 visual analogue scales
anchored by pairs of antonymic mood/state adjectives (e.g., Alert–Inattentive; Lethargic–Energetic).
Participants rated where they would position themselves between the adjectives anchoring each
line according to how they felt at that moment. The individual item scores were combined to give
an average (% along the line) score on three factors that had previously been derived by factor analysis:
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‘Alertness’, ‘Tranquillity’ and ‘Stress’. After the cognitive tasks participants also completed a further
four stress visual analogue scales (S-VAS) that required them to rate their current psychological state
between ‘not at all’ and ‘extremely’ with regard to their levels of stress, anxiety, calmness and relaxation.
These were combined into two scores ‘stress/anxiety’ and ‘calm/relaxed’ with a higher score (average %
along the line) representing more of the descriptor.
2.5. Procedure
Participants were required to attend the Brain, Performance and Nutrition Research Centre
(Northumbria University) for three visits. The first visit comprised a screening and training session
where, once written informed consent had been obtained, participants were screened according to the
inclusion/exclusion criteria. Eligible participants then provided lifestyle and demographic data and
their height, weight, waist to hip ratio and blood pressure were measured. They completed a short
training session in which they practiced the cognitive tasks. Practice took the form of three repetitions
of shortened versions of the COMPASS cognitive tasks, followed by the completion of the full-length,
60-min battery twice. During and at the end of the practice session, participants’ performance was
checked against standard minimum performance criteria and additional guidance was provided as
necessary. At the end of this visit, participants were briefed as to what to expect on testing visits and
were provided with pre-testing instructions.
Within four weeks of the screening visit, participants returned to the laboratory for their first
testing visit at an agreed time in the morning that remained consistent across all testing visits.
A maximum of 5 participants were tested on any day, and all participants were visually isolated
in individual testing booths. Participants arrived at the laboratory having refrained from alcohol
for 24 h, caffeine overnight and having consumed a simple breakfast of cereal and/or toast at home
no later than an hour before arrival. Once participants arrived at the lab, they were not permitted
to eat any food (aside from food items provided by the study staff) or drink (except for water) or
chew gum. Continued compliance with the inclusion/exclusion criteria was assessed. This was
followed by completion of the POMS and a 60-min computerised cognitive and mood assessment
(COMPASS—including the 30-min Cognitive Demand Battery (CDB), Visual analogue mood scales
(VAMS) and stress visual analogue scales (S-VAS)—see Figure 2.). Cognitive tasks were completed
with the participants visually isolated from each other. After the first cognitive/mood assessment,
participants consumed their treatment for the day and completed cognitive/mood assessments, identical
to the above, commencing at 30 min, 3 h and 5 h post-dose. An additional, brief, 5-min assessment
investigating the participants’ response to a laboratory stressor, plus pre/post-dose blood sampling
for half of the participants (for quantification of neurotrophins and catecholamines), took place after
the pre-treatment and 30-min post-dose cognitive/mood assessments (For methodology see [48]),
the results of this theoretically distinct investigation are to be reported elsewhere). All participants were
scheduled to return to the laboratory 7 days later, with a maximum allowable leeway of an additional
7 days should exceptional circumstances arise in the meantime. This second testing day was identical
to the previous day, with the exception that participants consumed a different treatment on each of the
two days. The timelines of the testing day are presented in Figure 3.
 
Figure 3. The timelines of the testing day for individual participants, showing the core cognitive
assessment schedule. Profile of Mood States (POMS), 5 min Observed Multi-Tasking Stressor (*OMS)
(methodology and results to be reported elsewhere).
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Participants were provided with a standardised lunch (comprising a cheese sandwich on white
bread, crisps and a custard pot) between the 180 and 300 min post-dose assessments and were given the
option of a snack (hot decaffeinated tea or coffee and digestive biscuits) after completion of the stressor
following the 30-min post-dose assessment. No alternative drinks, snacks or lunches were permitted.
2.6. Analysis
The study statistical analysis plan was formulated before the completion of data collection.
Given the exploratory nature of the study, and the lack of any relevant human data, a small sub-set of
primary outcomes was not pre-defined. Given the study intervention and objectives, a per protocol
analysis was deemed the most appropriate.
All outcomes were analysed using SPSS (version 24.0, IBM corp., Armonk, NY, USA). During blind
data review a number of participants’ individual task datasets were removed due to technical or
performance issues (for details of the issues and number of datasets involved see supplementary
online materials). Prior to the primary analysis of the effects of treatment, pre-dose baseline differences
between treatment were investigated by one-way (treatment group [placebo v mango leaf extract])
paired t tests, or in the case of the Cognitive Demand Battery (CDB) two-way (treatment x repetition)
ANOVA. There were no significant differences between treatment groups at baseline.
For all cognitive and mood measures, the primary analysis of post-dose data was by Linear Mixed
Models (LMM) using the MIXED procedure in SPSS (version 22.0, IBM corp.) with pre-dose baseline
data for each outcome included as a covariate. For all LMM analyses, the ‘compound symmetry’
covariance structure provided the best fit, with the exception of ‘mental fatigue’ from the CDB for
which an autoregressive covariance structure (AR1) was more appropriate.
For the cognitive outcomes derived from the COMPASS battery and the mood outcomes, terms
were fitted for treatment (placebo/mango leaf extract) and assessment (30 min, 3 h, 5 h) and their
interaction. For the CDB measures an additional ‘repetition’ term was added along with the appropriate
interactions. Given that the treatment orders were balanced across the sample, or exactly or nearly
balanced with regard to the participants contributing to each outcome (and given that treatment
carry-over effects were highly unlikely), treatment order was not included as a factor in the analysis.
In order to establish the time course of any effects, pre-defined planned comparisons were
conducted between treatments at each assessment time point (30 min, 3 h, 5 h) with a Bonferroni
adjustment for the number of comparisons undertaken per outcome (i.e., 3). Only those planned
comparisons conducted on data from outcomes that evinced a significant treatment related main or
interaction effect are reported below.
3. Results
3.1. Cognitive Task Global and Factor Outcomes
The global outcomes and cognitive factors derived from the COMPASS battery showed that mango
leaf extract resulted in significantly improved accuracy of performance across tasks and throughout
the testing day (i.e., at 30 min, 3 h and 5 h post-dose). See Figure 4 below. There was a main effect of
treatment on the global Accuracy of Performance measure (representing data from the eleven tasks
that return % accuracy/maximum score data) (F (1, 335) = 22.8, p < 0.001). Reference to the planned
comparisons at each assessment showed that this effect was evident throughout the post-dose testing
period (30 min p = 0.03, 3 h p = 0.02, 5 h p = 0.009). There were also significant main effects in terms of
improved accuracy following mango leaf extract on the Accuracy of Attention factor (F (1, 315) = 16.697,
p < 0.001) and the Episodic Memory factor (F (1, 345) = 6.94, p = 0.009). With regard to the time
course of these effects, whilst the Bonferroni adjusted comparisons of Episodic Memory scores did not
reach significance during the individual assessments, Accuracy of Attention was improved at both the
3 h (p = 0.048) and 5 h (p = 0.01) post-dose assessments. Data (plus F score and p) for the cognitive
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Figure 4. The effects of mango leaf extract on the global outcome measures and factor scores
derived from the Computerised Mental Performance Assessment System (COMPASS) cognitive tasks.
Left-hand panels show the main effect of treatment averaged across assessments; middle panels show
the pre-dose baseline scores; right-hand panels show time course data from each post-dose assessment
for those measures that saw significant effects on the planned comparisons (Bonferroni). The global
Accuracy of Performance measure represents averaged data from the eleven tasks from the battery
that return % accuracy/maximum score data: Accuracy of Attention represents averaged % accuracy
data from the five attention tasks; and Episodic Memory represents averaged % accuracy/recall across
the four long-term memory tasks. *, p < 0.05; **, p < 0.01, ***, p < 0.001 versus placebo. Number of
participants contributing to the measure: Accuracy of Performance, n = 68, Episodic Memory, n = 70,
Accuracy of Attention, n = 64.
3.2. Cognitive Demand Battery (CDB)
In keeping with the improved accuracy seen across the COMPASS task factors, performance
in all three CDB tasks was improved across the testing day following mango leaf extract. See Figure 5.
The Rapid Visual Information Processing task (RVIP) was improved across assessments in terms of
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% of targets accurately detected (F (1, 1071) = 23.186, p < 0.001) with planned comparisons showing
that these effects were apparent at the 30 min (p = 0.047) and 5 h (p = 0.001) assessments, with a trend
towards the same effect at 3 h post-dose (p = 0.059). Performance was also improved on both the Serial
3s task (F (1, 1156) = 10.9, p < 0.001) and Serial 7s task (F (1, 1156) = 9.642, p = 0.002) in terms of number
of correct subtractions across the testing day. Comparisons at each assessment showed that while the
differences between groups did not reach significance during any individual assessment for the Serial
7s task, Serial 3s performance was enhanced at the 3 h assessment (p = 0.014), with a trend towards
the same at 30 min post-dose (p = 0.088). There was no effect on ratings of mental fatigue during
completion of the battery. Data (plus F score and p) for the CDB outcomes are presented in the online







No significant differences during 
individual assessments
Figure 5. The effects of mango leaf extract on the Cognitive Demand Battery outcomes. Each task was
repeated three times per assessment (total Cognitive Demand Battery (CDB) completion time, 30 min per
assessment). Left-hand panels show the main effect of treatment averaged across assessments/repetitions;
middle panels show the pre-dose baseline scores averaged across the three repetitions; right-hand
panels show time course data from each post-dose assessment (averaged across the three repetitions
per assessment) for those measures that saw significant effects on the planned comparisons (Bonferroni)
of mango leaf extract versus placebo. t, p < 0.1; *, p < 0.05; ***; p < 0.001 in comparison to placebo.
Number of participants contributing to the measure: RVIP, n = 64, Serial 3s/7s, n = 69.
3.3. Mood and Psychological State
There were no effects of treatment on any mood parameter (VAMS, S-VAS, POMS), with the
exception of reduced calm/relaxed ratings on the S-VAS following mango leaf extract across testing
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assessments (F (1, 345) = 5.44, p = 0.02). See Figure 6. There were no significant differences on the
comparisons made at each assessment for this outcome. Data from the POMS, VAMS and S-VAS data
are presented in the online Supplementary Materials (Table S3.).
Figure 6. The effects of mango leaf extract on the calm/relaxed stress visual analogue scales (S-VAS)
measure. There were no significant differences on the planned comparisons of data from each
assessment. *, p < 0.05 in comparison to placebo.
4. Discussion
In the current study a single dose of mango leaf extract (Zynamite®) lead to significant, broad
improvements in performance across a battery of cognitive tasks throughout the 6 h following
consumption. There were no interpretable benefits found for any measure of mood/psychological state.
Cognitive improvements were seen on the global Accuracy of Performance measure, which
comprised averaged % accuracy or % maximum score data from 11 computerised tasks. It was also
seen more specifically in the cognitive sub-factors ‘Accuracy of Attention’, representing the overall
% accuracy whilst performing the five attention tasks (excludes simple reaction time) within the
battery and ‘Episodic Memory’, which represents the % recall or accuracy of the four long-term
memory tasks. Performance benefits were also seen across all three of the tasks that make up the
30-min Cognitive Demand Battery, with improved RVIP accuracy and increased numbers of correct
subtractions generated by participants on both the Serial 3s and Serial 7s tasks. These cognitive effects,
taken as a whole, were evident as main effects across the post-dose testing day, which comprised
60 min assessments starting at 30 min, 3 h and 5 h post-dose, without any clear pattern of augmentation
or attenuation over time. There were no benefits seen in terms of increased speed of task performance
on the timed tasks, or indeed on the mood and psychological state measures.
Clearly, one question raised by these results is whether the effects seen here represent a truly global
improvement in accuracy across cognitive domains, or whether they simply reflect the consequences
of improved attention. Certainly, attention and episodic memory are inter-related, with enhanced
attention leading to improved encoding and retrieval of information. It has been suggested that
episodic memory processes are themselves, to an extent, ‘acts of attention’ [49]. As the attention and
episodic memory tasks comprised the majority of the tasks that contributed to the global accuracy
measure, it is possible that the improvements to the latter are simply a reflection of broad improvements
to attention. However, the improvements in Serial 3s and Serial 7s subtraction task performance would
be more difficult to accommodate solely within an attention framework. Whilst both subtraction
tasks have attentional components, they draw more heavily on both working memory and executive
function, particularly the more difficult Serial 7s, which requires greater executive resources in order
to carry out the more complex manipulation of numbers [24]. Enhanced performance on these tasks,
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alongside improved accuracy across the tasks, therefore, seems to confirm that the benefits of mango
leaf extract were seen broadly across cognitive domains.
The results also suggest that the modulation of cerebro-electrical activity (measured using EEG)
seen in healthy adults following a single dose of Zynamite mango leaf extract [39] is most likely
indicative of a benefit to brain function. The cognitive benefits seen here are broadly in line with
previous demonstrations of improved cognitive function following both acute [24–26] and chronic
administration [27,28] of polyphenol rich extracts. Several polyphenol studies also employed the
Cognitive Demand Battery used here (but at a single post-dose time point), with demonstrations
of improved performance across all three tasks following cocoa-flavanols [24], improved Serial 3s
performance following fruit flavanols [50], but no benefits following resveratrol [51]. Of note, the global
performance measures derived from the cognitive tasks utilised here have proved sensitive to the
acute and chronic administration of a Nepalese pepper extract [42] and acute administration of a green
oat extract to middle-aged adults [41]. However, both of these interventions contain other potentially
bioactive phytochemicals alongside polyphenols, and in both cases global speed of performance was
enhanced, rather than the improved global accuracy seen in the current study.
Previous research has demonstrated similarities in EEG cerebro-electrical response following
both mango leaf extract and caffeine in rodents [38], but somewhat different responses to these two
individual treatments in humans [39]. The cognitive effects of caffeine comprise modest but consistent
improvements that are restricted to the performance of tasks measuring attention, with no reliable effect
on other cognitive domains including long-term (episodic) memory [52–55]. Similarly, the duration
of the effects seen following mango leaf extract do not follow the time course of caffeine’s effects,
which would become apparent by 30 min post-dose and would be expected to attenuate by 6 h
post-dose. It is therefore notable that the pattern of cognitive benefits seen in the present study
following the mango leaf extract are broader and longer lasting than those that would be expected
after caffeine.
In terms of mechanism of action, a recent study investigating receptor binding and brain relevant
enzyme inhibition found that mangiferin only significantly inhibited catechol-O-methyl transferase
(COMT), the enzyme responsible for the degradation of catecholamine neurotransmitters [39].
Several other polyphenols that also feature a catechol moiety, including flavanols and oleacein,
have also been shown to inhibit COMT [56,57]. COMT’s catabolic pathway is most prevalent
in brain tissue with low concentrations of catecholamine reuptake transporters, and therefore COMT
inhibition predominantly affects dopaminergic function in the prefrontal cortex and hippocampus [58],
potentially leading to improved working memory, selective attention, and executive function [59].
Clearly, the benefits seen in the current study correspond with these cognitive domains. However,
whilst there is some evidence that COMT inhibitors may modulate these aspects of cognitive
function, the overall pattern is for their effects to be bidirectionally moderated by COMT genotype
(val158met polymorphism) [59–61]. COMT inhibition per se is therefore unlikely to be the primary
mechanism underpinning the straightforward cognitive benefits seen here across a sample of mixed
COMT genotypes.
Other potential ‘direct’ brain-relevant mechanisms of action previously established for mangiferin
include acetylcholinesterase (AChE) inhibition [30,62] or other potential cholinergic mechanisms of
action [63]. Increased acetylcholine activity would be expected to have a beneficial, inter-related effect
on both focussed attention and memory consolidation/retrieval [64] and, therefore, could encompass
many of the effects seen in the current study. However, it is equally likely that the effects seen here
may be related to ‘indirect’ interactions within mammalian cellular signal transduction pathways,
a property that mangiferin shares with other polyphenols [8,11–14]. These interactions potentially
drive downstream modulation of neuroinflammation, neurotransmission, neurotrophin receptor and
signalling pathway interactions, and increased synthesis of neurotrophins and vasodilatory molecules,
leading to increased angiogenesis/neurogenesis and local cerebral blood flow [15–19]. These indirect
cellular interactions may underlie the consistent demonstrations in humans of increased cerebral
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blood-flow [51,65–69] and peripherally measured brain-derived neurotrophic factor [26] seen following
diverse polyphenols. Again, potentially diffuse beneficial effects within the brain could be conceived
as potentially leading to broad benefits to cognitive function across domains, as seen here.
Clearly, a strength of the current study is that it represents the first concerted investigation of the
effects of mangiferin, or indeed any xanthone glycoside, on human cognitive function. Conversely, this
was, by its nature, an exploratory study, and the absence of pre-defined primary outcomes, due to
a lack of previous data to guide their formulation, could be considered a limitation. Certainly the
absence of primary endpoints allows a greater freedom for the interpretation of the results than will be
enjoyed in future research, and it is hoped that the results of the current study will be useful in terms
of directing the research questions and outcomes addressed by more studies involving this compound.
It should also be acknowledged that the results herein relate to a molecule, or group of molecules
(xanthones) that are unlikely to be encountered in meaningful quantities in the typical diet, and therefore
the results can only realistically be extrapolated to supplementation with mangiferin-rich extracts.
Whilst the results tell us little about the benefits of polyphenols consumed as part of the everyday diet
it might be noteworthy that the dose of 300 mg employed here contained an amount of polyphenols
that is achievable through the consumption of polyphenol rich foods.
In conclusion, a single dose of mango leaf extract (Zynamite®) with high levels of the polyphenol
mangiferin, lead to broad improvements in cognitive function that were seen across assessments
spanning from 30 min to 6 h post-dose. These benefits were seen most strikingly in terms of participants’
improved attention and long-term memory task performance and in their extended performance of
cognitively demanding tasks, including those requiring executive function resources.
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Section I: Individual COMPASS and CDB cognitive task descriptions. Section II: Derivation of the global outcome
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Abstract: Current evidence on the relationship of phytoestrogens with sleep is limited and
contradictory. In particular, studies on individual phytoestrogens and sleep have not been reported.
Thus, this study aimed to appraise the associations of individual phytoestrogens with sleep disorders
and sleep duration. This cross-sectional study comprising 4830 adults utilized data from the National
Health and Nutrition Examination Survey 2005–2010. Phytoestrogens were tested in urine specimens.
Sleep disorders and sleep duration were based on a self-reported doctor’s diagnosis and usual sleep
duration. The main analyses utilized logistic and multinomial logistic regression models and a
restricted cubic spline. In the fully adjusted model, compared with tertile 1 (lowest), the odds ratios
(95% confidence intervals (CIs)) of sleep disorders for the highest tertile of urinary concentrations
of enterolactone, enterodiol, and O-desmethylangolensin were 0.64 (0.41–1.00), 1.54 (1.07–2.21),
and 1.89 (1.26–2.85), respectively. Linear inverse, approximatively linear positive, and inverted
L-shaped concentration–response relationships were found between enterolactone, enterodiol, and
O-desmethylangolensin and sleep disorders, respectively. Compared with normal sleep (7–8 h/night),
the relative risk ratio (RRR) (95% CI) of very short sleep for enterolactone was 0.56 (0.36–0.86), and the
RRR (95% CI) of long sleep risk for genistein was 0.62 (0.39–0.99). Furthermore, negative associations
of genistein with sleep disorders and enterolactone with long sleep risk, as well as positive associations
of enterodiol with both long and very short sleep, were observed in the stratified analysis by age
or gender. Finally, a notable finding was that urinary O-desmethylangolensin concentration was
positively related to sleep disorders in both females aged 40–59 years and non-Hispanic Whites but
inversely associated with sleep disorders in both females aged 60 years or over and other Hispanics.
Our findings suggested that enterolactone and genistein might be beneficial for preventing sleep
disorders or non-normal sleep duration among adults, and enterodiol might be adverse toward this
goal. However, the association of O-desmethylangolensin with sleep disorders might be discrepant
in different races and females of different ages.
Keywords: sleep disorders; sleep duration; urinary phytoestrogens; concentration–response;
NHANES
1. Introduction
Sleep disorders, classified into insomnia, central disorders of hypersomnolence, sleep-related
breathing disorders, parasomnias, sleep-related movement disorders, circadian rhythm sleep–wake
disorders, and other sleep disorders [1], are common conditions and can seriously harm human health
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and quality of life [2]. Studies have found that poor sleep (short or long sleep duration, or other
sleep problems) was associated with obesity, cardiovascular disease, diabetes, hypertension, cancer,
and higher mortality [3–8]. Exploration of modifiable factors for reducing the risk of sleep disorders is
urgently required. Estrogen has been a focus of attention due to its influences on the central nervous
system that is involved in regulating sleep [9]. Randomized trials have revealed that estrogen therapy
could reduce sleep disturbances and improve sleep quality [10–12]. Despite the significant beneficial
effect on sleep, the use of estrogen therapy is still very cautious in virtue of its potentially serious health
risks [13–17]. Therefore, as the naturally occurring mimetic agents of estrogen, phytoestrogens have
aroused great interest in their possibility of being estrogen substitutes.
Phytoestrogens are a group of plant-derived bioactive compounds that have estrogenic and
anti-estrogenic effects due to their structures resembling estradiol [18,19] and they are also considered
to be endocrine disruptors [20]. The two principal groups of phytoestrogens comprise lignans
and isoflavones. Lignans mainly originate from oilseeds, dried seaweeds, and whole-grain cereals,
and are metabolized into enterolactone and enterodiol by bacteria in the colon [21,22]. Isoflavones,
which are primarily derived from soya beans, soy products, and legumes, consist of genistin and
daidzin, which can be hydrolyzed into genistein and daidzein, respectively, where daidzein is
further metabolized into O-desmethylangolensin (O-DMA) or equol by gut microbiota [22]. Different
individuals have different capabilities to produce phytoestrogens via microbial synthesis due to the
complex interaction of the colonic environment with internal and external factors [23,24]; for example,
only approximately 30–50% of individuals can produce equol via gut bacterial metabolism [25].
Additionally, these metabolites can also be directly obtained from some animal products, such as
dairy [26,27].
Thus far, several trial studies have explored the relationship between total isoflavone
supplementation and sleep in climacteric women or androgen-deprived prostate cancer patients, with
mixed findings, including improvement of sleep problems [28–31], no significant association [32–34],
and even insomnia aggravation [35]. Only two observational studies have evaluated the association
of total isoflavone consumption with sleep status among general adults and results showed that
total isoflavone consumption was positively related to sleep quality and optimal sleep duration in
Japanese adults and inversely associated with long sleep duration in Chinese adults [36,37]. However,
no epidemiological study to date has appraised the relationship between lignans and sleep. Only several
animal experiments have found the sedative and hypnotic effects of the lignan component [38,39].
Moreover, individual phytoestrogens have unequal biological activities and estrogen receptor (ER)
affinities [40,41]. Studies have reported divergent associations between individual phytoestrogens
and disease [42–46]. Thus, individual phytoestrogens may also have diverse impacts on sleep,
and investigating the relationships with sleep among individual phytoestrogens may be more
meaningful. Meanwhile, investigating phytoestrogens via dietary evaluation made it difficult to
include all food origins and did not take into account the metabolic transformation of intestinal
flora, causing inexact individual exposure; therefore, it is necessary to assess phytoestrogens based
on biomarkers to reflect the true exposure. Additionally, the concentration–response relationships
of phytoestrogens with sleep were also unknown. Therefore, the present study aimed to: first,
appraise the associations between the urinary concentrations of individual phytoestrogens and sleep
disorder risk among U.S. adults by utilizing data from the National Health and Nutrition Examination
Survey (NHANES) 2005–2010; second, to explore the concentration–response relationships of them;
third, to explore the gender, age, and race differences in the associations; and finally, to evaluate the
associations of individual phytoestrogens with sleep duration.
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2. Materials and Methods
2.1. Study Population
The NHANES is a cross-sectional, complex, multistage, and stratified probability sampling design
representing the non-institutionalized U.S. civilian population, which aims to investigate the health
status and nutrition condition of Americans [47,48]. The NHANES collects data via examinations
implemented in the mobile examination center (MEC) and via household interviews. All of the
participants provided informed consent and the protocol of investigation was authorized by the
Research Ethics Review Board of the National Center for Health Statistics.
This study chose three-cycle data (NHANES 2005–2006, 2007–2008, and 2009–2010) to create the
current sample because the data of sleep and urinary phytoestrogens were measured simultaneously
only in the three cycles. A total of 31,034 individuals were enrolled in the NHANES 2005–2010, where the
number of participants aged 18 years and over was 18,318. A subsample of approximately one-third of
all NHANES participants aged six years or over was chosen to measure urinary phytoestrogens, leaving
5496 participants. Among them, 666 individuals were further ruled out, including participants with
missing sleep data (n = 24), lactating or pregnant females (n = 199), females with both ovaries removed
(n = 269), and individuals using sedative-hypnotic drugs (n = 174). Ultimately, 4830 participants
(age ≥ 18 years) with phytoestrogen data were analyzed in the current study (Figure 1).
 
Figure 1. Flowchart of the screening process of eligible participants from the National Health and
Nutrition Examination Survey 2005–2010.
2.2. Urinary Phytoestrogens Measurement
Spot urine specimens were collected in the MEC and urinary concentrations of individual
phytoestrogens (enterolactone, enterodiol, daidzein, O-DMA, equol, and genistein) were tested in the
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one-third subsample of all NHANES participants aged six years or over by utilizing high-performance
liquid chromatography–atmospheric pressure photoionization–tandem mass spectrometry during the
NHANES 2005–2010. More details are available in the laboratory procedure manual [49]. Studies have
revealed that phytoestrogen concentrations in spot urine are reliable biomarkers for phytoestrogen
intake [23,50,51].
To correct for urine dilution, phytoestrogen concentrations were creatinine-standardized and
expressed as μg/g creatinine [52]. Urine creatinine was measured by utilizing the Beckman CX3 during
2005–2006 but the Roche ModP was used since 2007; therefore, we adjusted creatinine 2005–2006 for
the comparability of creatinine between 2005–2006 and 2007–2010 using the equations recommended
by the NHANES [53].
2.3. Sleep Disorders and Sleep Duration Assessments
The sleep disorder investigations were administered by utilizing a computer-assisted personal
interviewing system by trained interviewers in the home. Participants were classified into the sleep
disorder groups based on a self-reported doctor diagnosis, and this classification method was used
by prior published studies [54,55]. Sleep duration was categorized as 7–8 h/night (normal sleep),
<5 h/night (very short sleep), 5–6 h/night (short sleep), and ≥9 h/night (long sleep) based on the
self-reported usual sleep duration at night [54,56].
2.4. Covariates
The covariates gender, age, marital status, race, occupation, family income, educational level, body
mass index (BMI), smoking status, alcohol consumption, use of female hormones, physical activity,
caffeine intake, C-reactive protein, hypertension, depressive symptoms, and diabetes were chosen
based on previous literature to control for potential confounding effects [12,36,57]. The details of the
classification and criteria for covariates are displayed in Table S1.
2.5. Statistical Analysis
To explicate the complexity of the sampling design and create the estimated values of national
representativeness, a primary sampling unit, strata information, and specific sampling weights for the
one-third subsample were utilized in the present analyses. According to the analytical guideline [58],
the new six-year weights were generated by dividing the two-year environmental weights by three
and were applied in this study due to the combination of three two-year NHANES cycles.
The distribution types of continuous variables were identified using Kolmogorov–Smirnov
normality tests. Numbers (percentages) and medians (interquartile ranges) were used to describe the
qualitative data and non-normal quantitative data, respectively. Chi-square tests and Mann–Whitney
U tests were performed to compare percentages for qualitative data and averages for non-normal
quantitative data between the non-sleep disorders group and the sleep disorders group, respectively.
Urinary concentrations of individual phytoestrogens were segmented into tertiles based on their
distributions in the present population, with tertile 1 (lowest) being the referent. First, logistic
regression analyses were conducted to appraise the relationships between urinary phytoestrogens
and sleep disorders, along with calculating the odds ratios (ORs) and 95% confidence intervals
(CIs). Six phytoestrogens were entered into model 1 simultaneously for controlling for potentially
confounding effects. Model 2 additionally adjusted for gender and age, and model 3 was further
adjusted for marital status, race, occupation, family income, educational level, BMI, smoking status,
alcohol consumption, use of female hormones, physical activity, caffeine intake, C-reactive protein,
hypertension, depressive symptoms, and diabetes. The concentration–response relationships of urinary
phytoestrogens with sleep disorders were evaluated using restricted cubic spline functions of three
knots (the 25th, 50th, and 75th percentiles of the exposure distributions) in model 3. Second, multinomial
logistic regressions were utilized to evaluate the associations between urinary phytoestrogens and
sleep duration in model 3, with normal sleep (7–8 h/night) being the referent. Third, considering
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the significant differences in sleep between different age groups and genders [59,60], we conducted
stratified analyses by age (18–39, 40–59, and ≥60 years) and gender, as well as by age group separately
for females and males, respectively. Finally, given that the intestinal metabolism of phytoestrogens
may differ depending on the race [61], a stratified analysis by race (Mexican American, non-Hispanic
Whites, non-Hispanic Blacks, and other Hispanics) was also performed. Statistical analyses were
performed utilizing Stata 15.0 (Stata Corporation, College Station, TX, USA), and p < 0.05 (two-sided)
suggested statistical significance.
3. Results
The characteristics of the participants in this study across sleep disorders are displayed in Table 1.
In total, 4830 eligible individuals were analyzed, and the prevalence of sleep disorders was 6.25%.
Except for family income and alcohol consumption, other characteristics were significantly different
between the sleep disorders group and the non-sleep-disorders group. Individuals with the following
characteristics were more likely to experience sleep disorders: older, male, non-Hispanic White,
married or living with a partner, smoker, obese, hypertension, depressive symptoms, diabetes, higher
education level, less physical activity, higher C-reactive protein concentration, higher caffeine intake,
without work, and women using female hormones. Except for family income, alcohol consumption,
and smoking status, other characteristics were significantly different between the male sleep disorders
group and the male non-sleep-disorders group. However, there were significant differences between
the female sleep disorders group and the female non-sleep-disorders group only in terms of age, BMI,
use of female hormones, hypertension, depressive symptoms, and diabetes.
Table 2 presents the weighted ORs with 95% CIs for sleep disorders according to the tertiles of
urinary phytoestrogen concentrations. In model 1, the urinary concentrations of enterolactone and
genistein were inversely associated with sleep disorders, while the urinary O-DMA concentration
was positively related to sleep disorders. After an additional adjustment for gender and age in model
2, the results were concordant with model 1. In the fully adjusted model (model 3), the negative
association between the genistein concentration and sleep disorders was no longer significant, and
the enterolactone concentration was still inversely associated with sleep disorders, while the urinary
concentrations of enterodiol and O-DMA were positively related to sleep disorders. Compared with
tertile 1 (lowest), the fully adjusted ORs (95% CIs) for sleep disorders for the highest tertile of urinary
concentrations of enterolactone, enterodiol, and O-DMA were 0.64 (0.41–1.00), 1.54 (1.07–2.21), and
1.89 (1.26–2.85), respectively.
The concentration–response relationships of the urinary concentrations of enterolactone, enterodiol,
and O-DMA with sleep disorders are depicted in Figures 2–4, respectively. The urinary enterolactone
concentration was linearly negatively associated with sleep disorders (p-nonlinearity = 0.849). The
association began to show statistical significance when the enterolactone concentration reached around
904 μg/g creatinine (OR: 0.66, 95% CI: 0.43–0.99) (Figure 2). However, an approximately linear
positive relationship was observed between the urinary enterodiol concentration and sleep disorders
(p-nonlinearity = 0.274), and when the enterodiol concentration reached around 86 μg/g creatinine (OR:
1.68, 95% CI: 1.00–2.83), the relationship began to present statistical significance (Figure 3). There was a
nonlinear positive (inverted L-shaped) association between urinary O-DMA concentration and sleep
disorders (p-nonlinearity = 0.033). The OR of sleep disorders increased with increasing urinary O-DMA
concentrations, and it arrived at a plateau when the O-DMA concentration was above approximately
13 μg/g creatinine (OR: 1.90, 95% CI: 1.09–3.31) (Figure 4).
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Table 2. Weighted odds ratios (95% confidence intervals) for sleep disorders across tertiles of urinary




Cases/Participants Model 1 a Model 2 b Model 3 c
Enterolactone
Tertile 1 (<160.53) 107/1612 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 96/1609 0.83 (0.54–1.25) 0.78 (0.52–1.18) 0.99 (0.63–1.56)
Tertile 3 (≥621.68) 99/1609 0.64 (0.42–0.96) * 0.57 (0.38–0.85) ** 0.64 (0.41–1.00) *
Enterodiol
Tertile 1 (<21.52) 91/1611 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 103/1609 1.21 (0.88–1.65) 1.18 (0.86–1.62) 1.28 (0.86–1.91)
Tertile 3 (≥70.27) 108/1610 1.34 (0.88–2.05) 1.35 (0.89–2.07) 1.54 (1.07–2.21) *
Daidzein
Tertile 1 (<24.22) 83/1611 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 106/1609 1.46 (0.82–2.61) 1.48 (0.83–2.63) 1.18 (0.65–2.15)
Tertile 3 (≥108.62) 113/1610 1.30 (0.61–2.79) 1.32 (0.62–2.81) 1.12 (0.54–2.30)
O-Desmethylangolensin
Tertile 1 (<1.04) 84/1624 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 102/1613 1.33 (0.88–2.02) 1.32 (0.86–2.03) 1.38 (0.84–2.27)
Tertile 3 (≥9.06) 116/1593 1.65 (1.05–2.61) * 1.68 (1.06–2.65) * 1.89 (1.26–2.85) **
Equol
Tertile 1 (<3.75) 84/1613 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 119/1612 1.21 (0.83–1.74) 1.16 (0.79–1.71) 1.01 (0.66–1.56)
Tertile 3 (≥9.73) 99/1605 0.86 (0.57–1.30) 0.84 (0.55–1.28) 0.76 (0.52–1.12)
Genistein
Tertile 1 (<12.35) 104/1626 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 85/1601 0.60 (0.40–0.91) * 0.58 (0.38–0.88) * 0.68 (0.41–1.12)
Tertile 3 (≥50.00) 113/1603 0.80 (0.46–1.38) 0.74 (0.42–1.29) 0.78 (0.41–1.46)
a Six phytoestrogens (tertiles) were entered into model 1 simultaneously. b Model 2 additionally adjusted for age
and gender. c Model 3 further adjusted for race, education, marital status, occupation, family income, body mass
index, physical activity, alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female
hormones, C-reactive protein (mg/dL), and caffeine intake (mg/day). * p < 0.05, ** p < 0.01.
Figure 2. Concentration–response relationship of the urinary enterolactone concentration with sleep
disorders. The solid line represents the estimated odds ratios (ORs) and the dashed lines represent
their 95% confidence intervals. The relationship was adjusted for gender, age, marital status, race,
occupation, family income, educational level, body mass index, smoking status, alcohol consumption,
use of female hormones, physical activity, caffeine intake, C-reactive protein, hypertension, depressive
symptoms, diabetes, and the other five phytoestrogens (tertiles).
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Figure 3. Concentration–response relationship of the urinary enterodiol concentration with sleep
disorders. The solid line represents the estimated odds ratios (ORs) and the dashed lines represent
their 95% confidence intervals. The relationship was adjusted for gender, age, marital status, race,
occupation, family income, educational level, body mass index, smoking status, alcohol consumption,
use of female hormones, physical activity, caffeine intake, C-reactive protein, hypertension, depressive
symptoms, diabetes, and the other five phytoestrogens (tertiles).
Figure 4. Concentration–response relationship of the urinary O-desmethylangolensin concentration
with sleep disorders. The solid line represents the estimated odds ratios (ORs) and the dashed lines
represent their 95% confidence intervals. The relationship was adjusted for gender, age, marital
status, race, occupation, family income, educational level, body mass index, smoking status, alcohol
consumption, use of female hormones, physical activity, caffeine intake, C-reactive protein, hypertension,
depressive symptoms, diabetes, and the other five phytoestrogens (tertiles).
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The associations of urinary phytoestrogen concentrations with sleep disorders stratified by age and
gender are shown in Tables 3 and 4, respectively. In the fully adjusted model, the urinary enterolactone
concentration was still inversely associated with sleep disorders in females (OR: 0.45, 95% CI: 0.21–0.94).
Meanwhile, the urinary enterodiol concentration was still positively related to sleep disorders among
middle-aged adults (40–59 years) (OR: 2.56, 95% CI: 1.12–5.84) and females (OR: 3.79, 95% CI: 1.83–7.87),
and the O-DMA concentration was still positively associated with sleep disorders in young adults
(18–39 years) (OR: 4.16, 95% CI: 1.58–10.97). Additionally, there was a negative association between the
genistein concentration and sleep disorders in middle-aged adults (40–59 years) (OR: 0.34, 95% CI:
0.13–0.88). There were no significant associations between the urinary phytoestrogen concentrations
and sleep disorders in males and older adults (≥60 years). To further describe the gender difference in
the associations of the urinary concentrations of enterolactone and enterodiol with sleep disorders,
the concentration–response relationships of them for males and females are presented in Figure 5a,b and
Figure 6a,b, respectively. The urinary enterolactone concentration was linearly negatively associated
with sleep disorders in females (p-nonlinearity = 0.283) (Figure 5a) and the enterodiol concentration
was positively related to sleep disorders for females in a nonlinear manner (p-nonlinearity < 0.001)
(Figure 6a), whereas the associations were not significant in males (Figures 5b and 6b).
Table 3. Weighted odds ratios (95% confidence intervals) for sleep disorders across tertiles of urinary





Cases/Participants Model 1 a Model 2 b Model 3 c
Age (18–39 years)
Enterolactone
Tertile 1 (<160.53) 33/767 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 23/683 0.60 (0.26–1.38) 0.60 (0.26–1.38) 0.86 (0.36–2.02)
Tertile 3 (≥621.68) 15/467 0.40 (0.16–0.97) * 0.40 (0.16–1.01) 0.65 (0.27–1.56)
Enterodiol
Tertile 1 (<21.52) 28/732 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 24/620 1.55 (0.79–3.03) 1.57 (0.81–3.05) 1.62 (0.73–3.57)
Tertile 3 (≥70.27) 19/565 1.35 (0.63–2.92) 1.39 (0.64–3.00) 1.21 (0.46–3.15)
Daidzein
Tertile 1 (<24.22) 16/679 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 32/661 1.88 (0.77–4.57) 1.89 (0.78–4.58) 1.17 (0.58–2.36)
Tertile 3 (≥108.62) 23/577 0.86 (0.30–2.49) 0.87 (0.31–2.47) 0.88 (0.18–4.30)
O-Desmethylangolensin
Tertile 1 (<1.04) 19/707 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 21/621 1.23 (0.59–2.58) 1.24 (0.59–2.60) 1.34 (0.68–2.66)
Tertile 3 (≥9.06) 31/589 3.27 (1.39–7.70) ** 3.28 (1.40–7.68) ** 4.16 (1.58–10.97) **
Equol
Tertile 1 (<3.75) 27/694 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 22/631 0.89 (0.41–1.94) 0.89 (0.42–1.93) 0.78 (0.36–1.70)
Tertile 3 (≥9.73) 22/592 0.72 (0.32–1.64) 0.73 (0.32–1.65) 0.44 (0.16–1.15)
Genistein
Tertile 1 (<12.35) 19/701 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 30/650 1.08 (0.52–2.24) 1.08 (0.52–2.24) 1.18 (0.45–3.09)
Tertile 3 (≥50.00) 22/566 1.20 (0.49–2.93) 1.20 (0.49–2.94) 1.29 (0.31–5.39)
Age (40–59 years)
Enterolactone
Tertile 1 (<160.53) 39/533 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 37/468 0.89 (0.48–1.66) 0.89 (0.48–1.64) 1.00 (0.54–1.83)
Tertile 3 (≥ 621.68) 33/486 0.63 (0.31–1.29) 0.67 (0.33–1.38) 0.58 (0.28–1.22)
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Cases/Participants Model 1 a Model 2 b Model 3 c
Enterodiol
Tertile 1 (<21.52) 30/470 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 37/515 0.97 (0.53–1.75) 1.00 (0.56–1.78) 1.33 (0.62–2.87)
Tertile 3 (≥70.27) 42/502 1.29 (0.69–2.40) 1.36 (0.73–2.53) 2.56 (1.12–5.84) *
Daidzein
Tertile 1 (<24.22) 36/521 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 30/469 1.20 (0.49–2.94) 1.14 (0.47–2.79) 1.37 (0.46–4.05)
Tertile 3 (≥108.62) 43/497 1.37 (0.43–4.34) 1.32 (0.42–4.19) 1.22 (0.31–4.74)
O-Desmethylangolensin
Tertile 1 (<1.04) 31/522 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 35/481 1.84 (0.89–3.80) 1.86 (0.90–3.83) 1.65 (0.64–4.27)
Tertile 3 (≥9.06) 43/484 1.90 (0.92–3.93) 2.00 (0.98–4.05) 1.92 (0.78–4.76)
Equol
Tertile 1 (<3.75) 32/534 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 40/487 1.17 (0.62–2.19) 1.20 (0.64–2.26) 1.07 (0.46–2.51)
Tertile 3 (≥9.73) 37/466 0.90 (0.48–1.70) 0.95 (0.50–1.80) 1.07 (0.51–2.24)
Genistein
Tertile 1 (<12.35) 47/526 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 19/474 0.35 (0.16–0.77) * 0.34 (0.15–0.78) * 0.34 (0.13–0.88) *
Tertile 3 (≥50.00) 43/487 0.65 (0.21–1.97) 0.65 (0.21–2.00) 0.50 (0.17–1.48)
Age (≥60 years)
Enterolactone
Tertile 1 (<160.53) 35/312 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 36/458 0.87 (0.46–1.63) 0.80 (0.42–1.53) 1.21 (0.53–2.77)
Tertile 3 (≥621.68) 51/656 0.60 (0.34–1.06) 0.58 (0.32–1.03) 0.84 (0.38–1.90)
Enterodiol
Tertile 1 (<21.52) 33/409 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 42/474 1.21 (0.67–2.16) 1.22 (0.68–2.20) 1.01 (0.52–1.96)
Tertile 3 (≥70.27) 47/543 1.26 (0.67–2.37) 1.34 (0.71–2.50) 0.88 (0.43–1.78)
Daidzein
Tertile 1 (<24.22) 31/411 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 44/479 1.93 (0.85–4.36) 1.88 (0.82–4.29) 1.27 (0.48–3.35)
Tertile 3 (≥108.62) 47/536 2.36 (0.65–8.53) 2.26 (0.63–8.16) 1.59 (0.43–5.93)
O-Desmethylangolensin
Tertile 1 (<1.04) 34/395 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 46/511 0.73 (0.38–1.38) 0.75 (0.39–1.44) 0.78 (0.33–1.80)
Tertile 3 (≥9.06) 42/520 0.66 (0.34–1.29) 0.70 (0.35–1.39) 0.87 (0.34–2.28)
Equol
Tertile 1 (<3.75) 25/385 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 57/494 1.41 (0.79–2.54) 1.41 (0.78–2.55) 1.01 (0.42–2.45)
Tertile 3 (≥9.73) 40/547 0.75 (0.36–1.56) 0.76 (0.37–1.59) 0.56 (0.25–1.24)
Genistein
Tertile 1 (<12.35) 38/399 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 36/477 0.60 (0.29–1.26) 0.60 (0.29–1.25) 0.77 (0.29–2.06)
Tertile 3 (≥50.00) 48/550 0.51 (0.16–1.61) 0.53 (0.17–1.64) 0.86 (0.19–3.85)
a Six phytoestrogens (tertiles) were entered into model 1 simultaneously. b Model 2 additionally adjusted for
gender. c Model 3 further adjusted for race, education, marital status, occupation, family income, body mass index,
physical activity, alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones,
C-reactive protein (mg/dL), and caffeine intake (mg/day). * p < 0.05, ** p < 0.01.
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Table 4. Weighted odds ratios (95% confidence intervals) for sleep disorders across tertiles of urinary





Cases/Participants Model 1 a Model 2 b Model 3 c
Females
Enterolactone
Tertile 1 (<160.53) 40/698 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 36/706 0.52 (0.24–1.14) 0.53 (0.24–1.16) 0.56 (0.25–1.26)
Tertile 3 (≥621.68) 40/844 0.36 (0.19–0.68) ** 0.32 (0.17–0.61) ** 0.45 (0.21–0.94) *
Enterodiol
Tertile 1 (<21.52) 28/649 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 33/728 1.90 (1.04–3.48) * 1.81 (0.98–3.32) 2.70 (1.60–4.55) ***
Tertile 3 (≥70.27) 55/871 2.89 (1.54–5.42) ** 2.79 (1.46–5.31) ** 3.79 (1.83–7.87) **
Daidzein
Tertile 1 (<24.22) 21/708 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 51/745 2.16 (0.93–5.00) 2.33 (1.01–5.39) * 1.82 (0.77–4.30)
Tertile 3 (≥108.62) 44/795 1.71 (0.56–5.20) 1.82 (0.59–5.55) 1.44 (0.48–4.28)
O-Desmethylangolensin
Tertile 1 (<1.04) 27/697 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 41/753 1.70 (0.82–3.52) 1.68 (0.79–3.57) 2.04 (0.95–4.37)
Tertile 3 (≥9.06) 48/798 2.00 (1.00–3.99) 1.94 (1.00–3.76) 2.09 (0.96–4.56)
Equol
Tertile 1 (<3.75) 31/669 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 47/752 1.36 (0.74–2.48) 1.30 (0.71–2.37) 1.25 (0.57–2.73)
Tertile 3 (≥9.73) 38/827 0.85 (0.41–1.78) 0.80 (0.38–1.68) 0.62 (0.28–1.35)
Genistein
Tertile 1 (<12.35) 33/720 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 39/723 0.60 (0.31–1.17) 0.57 (0.29–1.12) 0.59 (0.25–1.38)
Tertile 3 (≥50.00) 44/805 0.62 (0.27–1.42) 0.57 (0.25–1.30) 0.61 (0.23–1.57)
Males
Enterolactone
Tertile 1 (<160.53) 67/914 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 60/903 1.16 (0.67–1.99) 1.08 (0.63–1.85) 1.58 (0.86–2.91)
Tertile 3 (≥621.68) 59/765 1.11 (0.65–1.88) 0.93 (0.54–1.61) 0.92 (0.46–1.83)
Enterodiol
Tertile 1 (<21.52) 63/962 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 70/881 0.99 (0.64–1.52) 0.94 (0.61–1.46) 0.92 (0.51–1.65)
Tertile 3 (≥70.27) 53/739 0.88 (0.52–1.50) 0.85 (0.51–1.42) 0.92 (0.56–1.53)
Daidzein
Tertile 1 (<24.22) 62/903 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 55/864 1.10 (0.58–2.06) 1.07 (0.58–1.98) 0.88 (0.48–1.64)
Tertile 3 (≥108.62) 69/815 1.02 (0.41–2.52) 1.01 (0.42–2.45) 1.05 (0.44–2.50)
O-Desmethylangolensin
Tertile 1 (<1.04) 57/927 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 61/860 1.17 (0.65–2.11) 1.15 (0.65–2.04) 1.05 (0.53–2.05)
Tertile 3 (≥9.06) 68/795 1.57 (0.88–2.80) 1.58 (0.89–2.80) 1.58 (0.89–2.79)
Equol
Tertile 1 (<3.75) 53/944 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 72/860 1.12 (0.70–1.81) 1.06 (0.65–1.73) 0.79 (0.47–1.35)
Tertile 3 (≥9.73) 61/778 0.91 (0.54–1.54) 0.88 (0.52–1.48) 0.86 (0.47–1.58)
Genistein
Tertile 1 (<12.35) 71/906 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 46/878 0.59 (0.36–0.97) * 0.57 (0.35–0.93) * 0.74 (0.41–1.33)
Tertile 3 (≥50.00) 69/798 1.04 (0.52–2.10) 0.96 (0.48–1.91) 0.96 (0.42–2.20)
a Six phytoestrogens (tertiles) were entered into model 1 simultaneously. b Model 2 additionally adjusted for age.
c Model 3 further adjusted for race, education, marital status, occupation, family income, body mass index, physical
activity, alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones (only in
females), C-reactive protein (mg/dL), and caffeine intake (mg/day). * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 5. Concentration–response relationship of the urinary enterolactone concentration with sleep
disorders for females (a) and males (b). The solid line represents the estimated odds ratios (ORs) and
the dashed lines represent their 95% confidence intervals. The relationship adjusted for age, marital
status, race, occupation, family income, educational level, body mass index, smoking status, alcohol
consumption, use of female hormones (only in females), physical activity, caffeine intake, C-reactive
protein, hypertension, depressive symptoms, diabetes, and the other five phytoestrogens (tertiles).
Figure 6. Concentration–response relationship of the urinary enterodiol concentration with sleep
disorders for females (a) and males (b). The solid line represents the estimated odds ratios (ORs) and
the dashed lines represent their 95% confidence intervals. The relationship adjusted for age, marital
status, race, occupation, family income, educational level, body mass index, smoking status, alcohol
consumption, use of female hormones (only in females), physical activity, caffeine intake, C-reactive
protein, hypertension, depressive symptoms, diabetes, and the other five phytoestrogens (tertiles).
Furthermore, the associations between the urinary phytoestrogen concentrations and sleep
disorders stratified by age group separately for males and females are shown in Table 5. The urinary
O-DMA concentration was positively associated with sleep disorders in males aged 18–39 years (OR:
6.57, 95% CI: 2.06–20.99) and females aged 40–59 years (OR: 15.14, 95% CI: 2.99–76.65), whereas the
O-DMA concentration was inversely related to sleep disorders in females aged 60 years or over (OR:
0.25, 95% CI: 0.10–0.58). The urinary enterodiol concentration was positively related to sleep disorders
in females aged 18–39 (OR: 6.52, 95% CI: 1.69–25.23) and 40–59 years (OR: 13.66, 95% CI: 2.06–90.70).
Furthermore, the urinary equol concentration was inversely associated with sleep disorders in females
aged 18–39 years (OR: 0.08, 95% CI: 0.01–0.84), and daidzein concentration was positively related to
sleep disorders in females aged 60 years or over (OR: 10.67, 95% CI: 1.88–60.44).
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Table 5. Weighted odds ratios (95% confidence intervals) for sleep disorders across tertiles of urinary





Cases/Participants Model 3 a Cases/Participants Model 3 a
Age (18–39 years)
Enterolactone
Tertile 1 (<160.53) 18/444 1.00 (reference) 15/323 1.00 (reference)
Tertile 2 (160.53 to <621.68) 13/353 1.65 (0.53–5.08) 10/330 0.54 (0.14–2.14)
Tertile 3 (≥621.68) 9/200 1.12 (0.27–4.69) 6/267 0.46 (0.10–2.14)
Enterodiol
Tertile 1 (<21.52) 19/434 1.00 (reference) 9/298 1.00 (reference)
Tertile 2 (21.52 to <70.27) 12/328 0.90 (0.28–2.89) 12/292 6.52 (1.69–25.23) **
Tertile 3 (≥70.27) 9/235 1.28 (0.36–4.59) 10/330 1.84 (0.50–6.80)
Daidzein
Tertile 1 (<24.22) 12/381 1.00 (reference) 4/298 1.00 (reference)
Tertile 2 (24.22 to <108.62) 16/327 0.86 (0.38–1.93) 16/334 2.35 (0.60–9.22)
Tertile 3 (≥108.62) 12/289 0.45 (0.09–2.25) 11/288 5.07 (0.52–49.84)
O-Desmethylangolensin
Tertile 1 (<1.04) 10/395 1.00 (reference) 9/312 1.00 (reference)
Tertile 2 (1.04 to <9.06) 12/311 1.28 (0.39–4.18) 9/310 1.18 (0.37–3.72)
Tertile 3 (≥9.06) 18/291 6.57 (2.06–20.99) ** 13/298 0.74 (0.12–4.45)
Equol
Tertile 1 (<3.75) 15/396 1.00 (reference) 12/298 1.00 (reference)
Tertile 2 (3.75 to <9.73) 9/318 0.44 (0.15–1.33) 13/313 1.37 (0.38–4.88)
Tertile 3 (≥9.73) 16/283 0.74 (0.29–1.86) 6/309 0.08 (0.01–0.84) *
Genistein
Tertile 1 (<12.35) 13/386 1.00 (reference) 6/315 1.00 (reference)
Tertile 2 (12.35 to <50.00) 15/337 1.60 (0.54–4.73) 15/313 1.10 (0.29–4.10)
Tertile 3 (≥50.00) 12/274 1.70 (0.37–7.85) 10/292 0.59 (0.12–2.81)
Age (40–59 years)
Enterolactone
Tertile 1 (<160.53) 25/304 1.00 (reference) 14/229 1.00 (reference)
Tertile 2 (160.53 to <621.68) 24/260 1.90 (0.74–4.88) 13/208 0.50 (0.16–1.53)
Tertile 3 (≥621.68) 17/209 1.15 (0.36–3.61) 16/277 0.32 (0.10–1.03)
Enterodiol
Tertile 1 (<21.52) 23/272 1.00 (reference) 7/198 1.00 (reference)
Tertile 2 (21.52 to <70.27) 24/272 1.04 (0.32–3.42) 13/243 3.02 (1.10–8.30) *
Tertile 3 (≥70.27) 19/229 1.47 (0.43–5.00) 23/273 13.66 (2.06–90.70) **
Daidzein
Tertile 1 (<24.22) 25/281 1.00 (reference) 11/240 1.00 (reference)
Tertile 2 (24.22 to <108.62) 15/262 2.04 (0.45–9.16) 15/207 1.65 (0.41–6.72)
Tertile 3 (≥108.62) 26/230 2.94 (0.38–22.73) 17/267 0.85 (0.13–5.75)
O-Desmethylangolensin
Tertile 1 (<1.04) 25/297 1.00 (reference) 6/225 1.00 (reference)
Tertile 2 (1.04 to <9.06) 18/252 0.56 (0.18–1.79) 17/229 11.50 (2.14–61.72) **
Tertile 3 (≥9.06) 23/224 0.68 (0.21–2.20) 20/260 15.14 (2.99–76.65) **
Equol
Tertile 1 (<3.75) 21/316 1.00 (reference) 11/218 1.00 (reference)
Tertile 2 (3.75 to <9.73) 27/251 0.88 (0.27–2.86) 13/236 0.95 (0.29–3.12)
Tertile 3 (≥9.73) 18/206 1.28 (0.43–3.80) 19/260 0.77 (0.26–2.31)
Genistein
Tertile 1 (<12.35) 30/285 1.00 (reference) 17/241 1.00 (reference)
Tertile 2 (12.35 to <50.00) 10/256 0.29 (0.05–1.61) 9/218 0.20 (0.04–1.00)
Tertile 3 (≥50.00) 26/232 0.43 (0.06–3.03) 17/255 0.38 (0.07–2.05)
Age (≥60 years)
Enterolactone
Tertile 1 (<160.53) 24/166 1.00 (reference) 11/146 1.00 (reference)
Tertile 2 (160.53 to <621.68) 23/290 1.59 (0.63–4.04) 13/168 1.37 (0.43–4.40)
Tertile 3 (≥621.68) 33/356 0.77 (0.34–1.75) 18/300 1.47 (0.29–7.40)
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Cases/Participants Model 3 a Cases/Participants Model 3 a
Enterodiol
Tertile 1 (<21.52) 21/256 1.00 (reference) 12/153 1.00 (reference)
Tertile 2 (21.52 to <70.27) 34/281 0.98 (0.44–2.20) 8/193 1.18 (0.26–5.28)
Tertile 3 (≥70.27) 25/275 0.48 (0.20–1.16) 22/268 2.00 (0.71–5.57)
Daidzein
Tertile 1 (<24.22) 25/241 1.00 (reference) 6/170 1.00 (reference)
Tertile 2 (24.22 to <108.62) 24/275 0.47 (0.16–1.39) 20/204 13.45 (2.89–62.50) **
Tertile 3 (≥108.62) 31/296 0.80 (0.13–4.79) 16/240 10.67 (1.88–60.44) **
O-Desmethylangolensin
Tertile 1 (<1.04) 22/235 1.00 (reference) 12/160 1.00 (reference)
Tertile 2 (1.04 to <9.06) 31/297 1.16 (0.37–3.66) 15/214 0.27 (0.06–1.19)
Tertile 3 (≥9.06) 27/280 1.19 (0.33–4.37) 15/240 0.25 (0.10–0.58) **
Equol
Tertile 1 (<3.75) 17/232 1.00 (reference) 8/153 1.00 (reference)
Tertile 2 (3.75 to <9.73) 36/291 0.69 (0.23–2.08) 21/203 2.05 (0.63–6.68)
Tertile 3 (≥9.73) 27/289 0.72 (0.28–1.83) 13/258 0.49 (0.12–1.97)
Genistein
Tertile 1 (<12.35) 28/235 1.00 (reference) 10/164 1.00 (reference)
Tertile 2 (12.35 to <50.00) 21/285 0.75 (0.22–2.53) 15/192 0.71 (0.14–3.53)
Tertile 3 (≥50.00) 31/292 1.29 (0.16–10.26) 17/258 0.41 (0.06–2.82)
a Adjusted for education, marital status, occupation, family income, body mass index, physical activity, alcohol use,
smoking status, depressive symptoms, diabetes, hypertension, use of female hormones (only in females), C-reactive
protein (mg/dL), caffeine intake (mg/day), and the other five phytoestrogens (tertiles). * p < 0.05, ** p < 0.01.
The associations between the urinary phytoestrogen concentrations and sleep disorders stratified
by race are displayed in Table 6. An interesting finding was that the urinary O-DMA concentration
was positively related to sleep disorders in non-Hispanic Whites (OR: 2.16, 95% CI: 1.31–3.55) but
inversely associated with sleep disorders in other Hispanics (OR: 0.13, 95% CI: 0.02–0.86). Furthermore,
the urinary enterolactone concentration was negatively related to sleep disorders (OR: 0.56, 95% CI:
0.33–0.95), while the enterodiol concentration was positively associated with sleep disorders (OR: 1.89,
95% CI: 1.13–3.13) in non-Hispanic Whites and the equol concentration was positively related to sleep
disorders in other Hispanics (OR: 3.22, 95% CI: 1.11–9.30).
Table 6. Weighted odds ratios (95% confidence intervals) for sleep disorders across tertiles of urinary
phytoestrogen concentrations stratified by race (National Health and Nutrition Examination Survey
2005–2010).
Phytoestrogen Concentrations (μg/g Creatinine) Cases/Participants Model 3 a
Mexican American
Enterolactone
Tertile 1 (<160.53) 9/298 1.00 (reference)
Tertile 2 (160.53 to <621.68) 11/347 2.24 (0.28–17.56)
Tertile 3 (≥621.68) 19/308 2.47 (0.54–11.42)
Enterodiol
Tertile 1 (<21.52) 9/366 1.00 (reference)
Tertile 2 (21.52 to <70.27) 15/315 1.64 (0.85–3.17)
Tertile 3 (≥70.27) 15/272 1.91 (0.56–6.50)
Daidzein
Tertile 1 (<24.22) 10/359 1.00 (reference)
Tertile 2 (24.22 to <108.62) 12/292 0.72 (0.14–3.83)
Tertile 3 (≥108.62) 17/302 1.03 (0.11–9.46)
O-Desmethylangolensin
Tertile 1 (<1.04) 7/401 1.00 (reference)
Tertile 2 (1.04 to <9.06) 18/312 2.00 (0.53–7.61)
Tertile 3 (≥9.06) 14/240 2.16 (0.73–6.39)
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Phytoestrogen Concentrations (μg/g Creatinine) Cases/Participants Model 3 a
Equol
Tertile 1 (<3.75) 13/421 1.00 (reference)
Tertile 2 (3.75 to <9.73) 17/331 0.64 (0.17–2.45)
Tertile 3 (≥9.73) 9/201 0.37 (0.09–1.48)
Genistein
Tertile 1 (<12.35) 10/341 1.00 (reference)
Tertile 2 (12.35 to <50.00) 13/314 2.26 (0.35–14.60)
Tertile 3 (≥50.00) 16/298 2.00 (0.14–28.91)
Non-Hispanic White
Enterolactone
Tertile 1 (<160.53) 57/673 1.00 (reference)
Tertile 2 (160.53 to <621.68) 59/681 1.00 (0.60–1.67)
Tertile 3 (≥621.68) 57/859 0.56 (0.33–0.95) *
Enterodiol
Tertile 1 (<21.52) 43/606 1.00 (reference)
Tertile 2 (21.52 to <70.27) 62/765 1.52 (0.88–2.63)
Tertile 3 (≥70.27) 68/842 1.89 (1.13–3.13) *
Daidzein
Tertile 1 (<24.22) 45/684 1.00 (reference)
Tertile 2 (24.22 to <108.62) 62/771 1.12 (0.55–2.29)
Tertile 3 (≥108.62) 66/758 0.95 (0.41–2.21)
O-Desmethylangolensin
Tertile 1 (<1.04) 44/638 1.00 (reference)
Tertile 2 (1.04 to <9.06) 60/798 1.48 (0.76–2.90)
Tertile 3 (≥9.06) 69/777 2.16 (1.31–3.55) **
Equol
Tertile 1 (<3.75) 39/493 1.00 (reference)
Tertile 2 (3.75 to <9.73) 67/729 0.97 (0.57–1.64)
Tertile 3 (≥9.73) 67/991 0.76 (0.47–1.22)
Genistein
Tertile 1 (<12.35) 60/696 1.00 (reference)
Tertile 2 (12.35 to <50.00) 48/766 0.63 (0.34–1.16)
Tertile 3 (≥50.00) 65/751 0.86 (0.42–1.76)
Non-Hispanic Black
Enterolactone
Tertile 1 (<160.53) 20/388 1.00 (reference)
Tertile 2 (160.53 to <621.68) 17/385 1.11 (0.48–2.55)
Tertile 3 (≥621.68) 17/256 0.86 (0.26–2.89)
Enterodiol
Tertile 1 (<21.52) 23/423 1.00 (reference)
Tertile 2 (21.52 to <70.27) 16/338 0.81 (0.29–2.25)
Tertile 3 (≥70.27) 15/268 0.79 (0.40–1.57)
Daidzein
Tertile 1 (<24.22) 16/371 1.00 (reference)
Tertile 2 (24.22 to <108.62) 24/331 2.05 (0.57–7.36)
Tertile 3 (≥108.62) 14/327 0.91 (0.16–5.32)
O-Desmethylangolensin
Tertile 1 (<1.04) 15/338 1.00 (reference)
Tertile 2 (1.04 to <9.06) 17/331 2.53 (0.86–7.50)
Tertile 3 (≥9.06) 22/360 2.23 (0.49–10.14)
Equol
Tertile 1 (<3.75) 20/486 1.00 (reference)
Tertile 2 (3.75 to <9.73) 23/327 0.99 (0.44–2.26)
Tertile 3 (≥9.73) 11/216 0.54 (0.17–1.75)
Genistein
Tertile 1 (<12.35) 24/411 1.00 (reference)
Tertile 2 (12.35 to <50.00) 16/313 0.51 (0.20–1.28)
Tertile 3 (≥50.00) 14/305 0.73 (0.18–3.02)
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Phytoestrogen Concentrations (μg/g Creatinine) Cases/Participants Model 3 a
Other Hispanic
Enterolactone
Tertile 1 (<160.53) 16/159 1.00 (reference)
Tertile 2 (160.53 to <621.68) 8/135 1.34 (0.38–4.75)
Tertile 3 (≥621.68) 4/119 0.45 (0.03–6.95)
Enterodiol
Tertile 1 (<21.52) 13/159 1.00 (reference)
Tertile 2 (21.52 to <70.27) 6/123 0.25 (0.05–1.31)
Tertile 3 (≥70.27) 9/131 2.76 (0.49–15.59)
Daidzein
Tertile 1 (<24.22) 9/147 1.00 (reference)
Tertile 2 (24.22 to <108.62) 7/141 1.43 (0.21–9.83)
Tertile 3 (≥108.62) 12/125 18.97(0.50–719.28)
O-Desmethylangolensin
Tertile 1 (<1.04) 15/171 1.00 (reference)
Tertile 2 (1.04 to <9.06) 6/120 0.13 (0.02–0.86) *
Tertile 3 (≥9.06) 7/122 0.10 (0.01–1.32)
Equol
Tertile 1 (<3.75) 8/130 1.00 (reference)
Tertile 2 (3.75 to <9.73) 8/137 0.46 (0.13–1.70)
Tertile 3 (≥9.73) 12/146 3.22 (1.11–9.30) *
Genistein
Tertile 1 (<12.35) 7/132 1.00 (reference)
Tertile 2 (12.35 to <50.00) 6/144 0.58 (0.12–2.72)
Tertile 3 (≥50.00) 15/137 0.30 (0.03–2.91)
a Adjusted for age, gender, education, marital status, occupation, family income, body mass index, physical activity,
alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones, C-reactive
protein (mg/dL), caffeine intake (mg/day), and the other five phytoestrogens (tertiles). * p < 0.05, ** p < 0.01.
Table 7 presents the weighted relative risk ratios (RRRs) with 95% CIs of sleep duration according
to tertiles of the urinary phytoestrogen concentrations. In the fully adjusted model, compared with
normal sleep (7–8 h/night), the urinary enterolactone concentration was negatively associated with very
short sleep (<5 h/night) (RRR: 0.56, 95% CI: 0.36–0.86), and the genistein concentration was inversely
related to a long sleep risk (≥9 h/night) (RRR: 0.62, 95% CI: 0.39–0.99).
The associations of urinary phytoestrogen concentrations with sleep duration stratified by age
and gender are shown in Tables 8 and 9, respectively. In the fully adjusted model, compared with
normal sleep, the urinary enterolactone concentration was still negatively associated with very short
sleep among young adults (18–39 years) (RRR: 0.24, 95% CI: 0.09–0.61) and a long sleep risk among
older adults (≥60 years) (RRR: 0.49, 95% CI: 0.29–0.84). The urinary genistein concentration was
still inversely associated with a long sleep risk in middle-aged adults (40–59 years) (RRR: 0.10, 95%
CI: 0.02–0.56) and males (RRR: 0.51, 95% CI: 0.30–0.87). The urinary enterodiol concentration was
positively related to very short sleep among young adults (18–39 years) (RRR: 2.73, 95% CI: 1.20–6.21)
and a long sleep risk in females (RRR: 2.14, 95% CI: 1.11–4.13).
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Table 7. Weighted relative risk ratios (95% confidence intervals) for sleep duration (reference, 7–8












Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 0.98 (0.64–1.50) 1.15 (0.86–1.54) 1.46 (0.93–2.28)
Tertile 3 (≥621.68) 0.56 (0.36–0.86) ** 0.94 (0.69–1.27) 0.78 (0.45–1.33)
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 1.35 (0.76–2.42) 1.09 (0.84–1.40) 1.04 (0.65–1.67)
Tertile 3 (≥70.27) 0.97 (0.54–1.76) 1.04 (0.77–1.39) 1.46 (0.88–2.40)
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 1.02 (0.49–2.13) 1.08 (0.85–1.37) 1.10 (0.63–1.93)
Tertile 3 (≥108.62) 1.49 (0.48–4.63) 1.29 (0.83–2.03) 1.15 (0.54–2.43)
O-Desmethylangolensin
Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.43 (0.83–2.47) 1.01 (0.82–1.26) 1.05 (0.67–1.64)
Tertile 3 (≥9.06) 0.82 (0.36–1.88) 0.86 (0.61–1.21) 1.44 (0.80–2.56)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 1.01 (0.71–1.44) 1.04 (0.81–1.33) 1.06 (0.69–1.62)
Tertile 3 (≥9.73) 0.89 (0.50–1.58) 1.05 (0.84–1.31) 0.92 (0.60–1.41)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 0.94 (0.47–1.89) 1.10 (0.85–1.43) 0.62 (0.39–0.99) *
Tertile 3 (≥50.00) 1.05 (0.44–2.53) 0.95 (0.65–1.40) 0.62 (0.33–1.15)
a Adjusted for age, gender, race, education, marital status, occupation, family income, body mass index, physical
activity, alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones,
C-reactive protein (mg/dL), caffeine intake (mg/day), and the other five phytoestrogens (tertiles). * p < 0.05,
** p < 0.01.
Table 8. Weighted relative risk ratios (95% confidence intervals) for sleep duration (reference, 7–8
h/night) across tertiles of the urinary phytoestrogen concentrations stratified by age (National Health












Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 0.69 (0.30–1.59) 0.96 (0.62–1.48) 2.21 (0.99–4.90)
Tertile 3 (≥621.68) 0.24 (0.09–0.61) ** 0.78 (0.45–1.36) 1.33 (0.53–3.33)
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 2.73 (1.20–6.21) * 1.20 (0.72–2.01) 0.72 (0.33–1.58)
Tertile 3 (≥70.27) 0.81 (0.25–2.63) 1.00 (0.59–1.69) 1.63 (0.71–3.77)
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 1.24 (0.28–5.41) 1.05 (0.72–1.52) 0.58 (0.19–1.73)
Tertile 3 (≥108.62) 1.94 (0.19–19.60) 1.34 (0.65–2.74) 1.09 (0.35–3.36)
71












Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.75 (0.54–5.73) 1.03 (0.69–1.53) 0.64 (0.27–1.52)
Tertile 3 (≥9.06) 1.21 (0.24–6.20) 0.84 (0.52–1.34) 1.28 (0.54–3.08)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 1.67 (0.70–4.00) 1.09 (0.71–1.67) 0.88 (0.44–1.76)
Tertile 3 (≥9.73) 0.69 (0.23–2.03) 1.03 (0.67–1.59) 0.68 (0.32–1.45)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 1.52 (0.46–5.00) 1.21 (0.79–1.83) 1.35 (0.59–3.08)
Tertile 3 (≥50.00) 1.61 (0.36–7.19) 0.91 (0.46–1.79) 0.92 (0.31–2.71)
Age (40-59 years)
Enterolactone
Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 1.32 (0.70–2.49) 1.44 (0.87–2.38) 1.98 (0.98–4.03)
Tertile 3 (≥621.68) 0.87 (0.37–2.05) 1.25 (0.80–1.94) 0.55 (0.19–1.58)
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 0.95 (0.40–2.29) 0.97 (0.65–1.44) 0.69 (0.24–1.94)
Tertile 3 (≥70.27) 0.59 (0.23–1.55) 0.93 (0.65–1.33) 1.45 (0.69–3.07)
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 0.77 (0.26–2.27) 1.12 (0.64–1.96) 2.42 (0.96–6.12)
Tertile 3 (≥108.62) 1.69 (0.39–7.36) 1.45 (0.62–3.42) 3.92 (0.55–27.81)
O-Desmethylangolensin
Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.37 (0.59–3.17) 0.87 (0.59–1.26) 1.54 (0.58–4.11)
Tertile 3 (≥9.06) 0.43 (0.12–1.60) 0.71 (0.35–1.44) 1.41 (0.56–3.58)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 0.41 (0.14–1.22) 0.98 (0.65–1.48) 1.42 (0.68–2.96)
Tertile 3 (≥9.73) 0.65 (0.25–1.73) 0.95 (0.67–1.36) 1.14 (0.37–3.55)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 0.73 (0.27–2.01) 1.09 (0.68–1.76) 0.14 (0.05–0.40) ***
Tertile 3 (≥50.00) 0.85 (0.23–3.17) 1.00 (0.53–1.86) 0.10 (0.02–0.56) *
Age (≥60 years)
Enterolactone
Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 1.75 (0.62–4.94) 1.07 (0.61–1.87) 0.61 (0.29–1.30)
Tertile 3 (≥621.68) 1.27 (0.52–3.10) 0.81 (0.52–1.27) 0.49 (0.29–0.84) *
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 0.45 (0.16–1.30) 1.09 (0.65–1.84) 1.56 (0.82–2.96)
Tertile 3 (≥70.27) 1.38 (0.63–3.02) 1.11 (0.66–1.88) 1.64 (0.92–2.93)
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 0.94 (0.11–7.95) 1.07 (0.61–1.88) 1.35 (0.68–2.68)
Tertile 3 (≥108.62) 0.62 (0.04–10.32) 1.08 (0.46–2.55) 0.62 (0.26–1.48)
72












Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.21 (0.47–3.14) 1.53 (0.92–2.53) 1.33 (0.72–2.45)
Tertile 3 (≥9.06) 0.75 (0.17–3.22) 1.21 (0.64–2.27) 1.38 (0.66–2.89)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 1.26 (0.52–3.06) 0.95 (0.54–1.67) 1.07 (0.48–2.40)
Tertile 3 (≥9.73) 1.93 (0.81–4.62) 1.10 (0.66–1.86) 1.16 (0.59–2.26)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 0.89 (0.14–5.68) 0.84 (0.47–1.51) 0.50 (0.23–1.09)
Tertile 3 (≥50.00) 1.77 (0.15–21.09) 0.73 (0.37–1.42) 1.32 (0.59–2.94)
a Adjusted for gender, race, education, marital status, occupation, family income, body mass index, physical activity,
alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones, C-reactive
protein (mg/dL), caffeine intake (mg/day), and the other five phytoestrogens (tertiles). * p < 0.05, ** p < 0.01,
*** p < 0.001.
Table 9. Weighted relative risk ratios (95% confidence intervals) for sleep duration (reference, 7–8 h/night)
across tertiles of the urinary phytoestrogen concentrations stratified by gender (National Health and












Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 0.69 (0.38–1.27) 0.99 (0.63–1.55) 1.55 (0.83–2.87)
Tertile 3 (≥621.68) 0.61 (0.31–1.20) 0.91 (0.62–1.35) 0.74 (0.35–1.54)
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 1.39 (0.70–2.77) 0.77 (0.53–1.13) 1.03 (0.56–1.90)
Tertile 3 (≥70.27) 0.91 (0.42–1.99) 0.99 (0.61–1.59) 2.14 (1.11–4.13) *
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 1.50 (0.58–3.89) 0.85 (0.57–1.28) 0.79 (0.34–1.86)
Tertile 3 (≥108.62) 1.69 (0.35–8.12) 0.72 (0.41–1.28) 0.75 (0.27–2.10)
O-Desmethylangolensin
Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.33 (0.63–2.80) 1.25 (0.83–1.87) 1.19 (0.64–2.20)
Tertile 3 (≥9.06) 0.87 (0.32–2.39) 1.23 (0.77–1.97) 2.23 (0.95–5.26)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 0.90 (0.44–1.85) 0.95 (0.71–1.27) 1.12 (0.64–1.97)
Tertile 3 (≥9.73) 0.54 (0.25–1.16) 0.76 (0.53–1.09) 0.74 (0.39–1.40)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 0.58 (0.26–1.31) 1.50 (0.93–2.41) 0.70 (0.34–1.45)
Tertile 3 (≥50.00) 0.70 (0.17–2.85) 1.37 (0.76–2.46) 0.70 (0.29–1.69)
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Tertile 1 (<160.53) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (160.53 to <621.68) 1.48 (0.70–3.13) 1.29 (0.89–1.88) 1.20 (0.65–2.23)
Tertile 3 (≥621.68) 0.50 (0.23–1.13) 0.94 (0.62–1.42) 0.89 (0.44–1.82)
Enterodiol
Tertile 1 (<21.52) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (21.52 to <70.27) 1.31 (0.60–2.87) 1.40 (0.99–1.99) 1.05 (0.56–1.98)
Tertile 3 (≥70.27) 0.95 (0.39–2.28) 1.06 (0.73–1.54) 0.93 (0.47–1.84)
Daidzein
Tertile 1 (<24.22) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (24.22 to <108.62) 0.63 (0.23–1.76) 1.28 (0.87–1.88) 1.72 (0.82–3.59)
Tertile 3 (≥108.62) 1.14 (0.24–5.40) 1.87 (0.95–3.65) 1.79 (0.68–4.72)
O-Desmethylangolensin
Tertile 1 (<1.04) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (1.04 to <9.06) 1.59 (0.65–3.87) 0.90 (0.69–1.16) 0.94 (0.50–1.76)
Tertile 3 (≥9.06) 0.75 (0.21–2.68) 0.70 (0.46–1.04) 0.83 (0.38–1.82)
Equol
Tertile 1 (<3.75) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (3.75 to <9.73) 1.07 (0.64–1.79) 1.06 (0.74–1.51) 0.95 (0.49–1.82)
Tertile 3 (≥9.73) 1.22 (0.66–2.26) 1.29 (0.92–1.81) 1.18 (0.62–2.27)
Genistein
Tertile 1 (<12.35) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Tertile 2 (12.35 to <50.00) 1.55 (0.61–3.93) 0.90 (0.63–1.29) 0.51 (0.30–0.87) *
Tertile 3 (≥50.00) 1.78 (0.68–4.62) 0.81 (0.51–1.27) 0.51 (0.25–1.02)
a Adjusted for age, race, education, marital status, occupation, family income, body mass index, physical activity,
alcohol use, smoking status, depressive symptoms, diabetes, hypertension, use of female hormones (only in females),
C-reactive protein (mg/dL), caffeine intake (mg/day), and the other five phytoestrogens (tertiles). * p < 0.05.
4. Discussion
To our knowledge, the current study was the first evaluation of the associations between the
urinary concentrations of individual phytoestrogens (enterolactone, enterodiol, daidzein, O-DMA,
equol, and genistein) and sleep disorders and sleep duration among general American adults.
This study was based on data from the NHANES 2005–2010 and found that the urinary enterolactone
concentration was linearly inversely associated with the risk of sleep disorders, while the enterodiol
concentration was positively related to sleep disorders in an approximately linear manner and the
O-DMA concentration was positively associated with sleep disorders in a nonlinear (inverted L-shaped)
manner. The urinary enterolactone concentration was negatively associated with very short sleep,
and the genistein concentration was inversely related to a long sleep risk. Furthermore, a negative
association of the urinary genistein concentration with sleep disorders was observed in middle-aged
adults (40–59 years). The urinary enterolactone concentration was inversely associated with a long
sleep risk among older adults (≥60 years), while the enterodiol concentration was positively related to
a long sleep risk in females and very short sleep in young adults (18–39 years). Finally, an interesting
finding was that the urinary O-DMA concentration was positively related to sleep disorders in both
females aged 40–59 years and non-Hispanic Whites, but was inversely associated with sleep disorders
in both females aged 60 years or over and other Hispanics.
There has been no epidemiological study that has appraised the relationship of total lignans
or individual lignans (enterolactone or enterodiol) with sleep disorders to date. However, animal
experiments have indicated that a lignan component could increase sleep duration and decrease
sleep latency via modulating the γ-aminobutyric acid (GABA)-ergic system [38,39], which supports
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our findings that enterolactone was negatively associated with sleep disorders and very short sleep,
and enterodiol was positively related to a long sleep risk in females. We also found that enterolactone
was inversely associated with a long sleep risk among older adults (≥60 years), while enterodiol was
positively associated with sleep disorders in the whole population and very short sleep in young
adults (18–39 years). This seems to suggest that enterolactone might be beneficial for preventing both
long and very short sleep, whereas enterodiol might be adverse toward this goal. However, further
comparisons were difficult due to limited prior studies.
Some studies have evaluated the association between total isoflavone consumption and sleep
but the results were contradictory. A study with a cross-sectional design performed in Japanese
adults found that the intake of isoflavone was positively related to sleep quality and optimal sleep
duration [36]. Another longitudinal study of Chinese adults reported that isoflavone intake was
inversely related to falling asleep in the daytime in females and long sleep duration in both genders [37],
which was similar to our result regarding genistein and a long sleep risk. Several trial studies also
showed that isoflavone supplementation alleviated insomnia or sleep disorders among climacteric
women [28–31]. However, other trial studies of isoflavone supplementation in climacteric women
or androgen-deprived males found no significant improvement in insomnia or sleep quality [32–34].
Meanwhile, another randomized, placebo-controlled, double-blinded trial over six months performed
on climacteric women indicated that insomnia was more frequent in the isoflavone supplementation
group [35], and the longitudinal study reported that soy milk (one of the main food sources for
isoflavone intake in the study) was positively related to falling asleep in the daytime among males [37].
Similarly, we found a positive association between O-DMA and sleep disorders.
Thus far, little is known about individual isoflavones (daidzein, O-DMA, equol, and genistein) and
sleep. The current study found discrepant associations of them with sleep disorders, where O-DMA
was positively associated with sleep disorders, and genistein was negatively associated with sleep
disorders in middle-aged adults (40–59 years). Likewise, there were also differential relationships
between them and sleep duration, where only genistein was significantly inversely related to a long
sleep risk, and no significant associations were found between daidzein, O-DMA, and equol and sleep
duration in this study. Variable abilities in different individuals regarding the metabolic transformation
of isoflavones [23], diverse biologic activities, and ER affinities of these metabolites (O-DMA and equol),
as well as other individual isoflavones (daidzein and genistein) [40,41], and discrepant associations
between them and sleep disorders or sleep duration may partially lead to the contradictory findings of
prior studies focusing only on total isoflavones. Furthermore, potential gender, age, and race differences
regarding these associations may also partially contribute to the prior contradictory findings.
The underlying mechanisms of the associations of phytoestrogens with sleep are unclear, where
the following are several possible explanations. Estrogen can influence the synthesis and transport of
serotonin [62] that is involved in the regulation of wakefulness and sleep [63], and studies have revealed
that estrogen therapy alleviates sleep disturbances and improves sleep quality [10,11]. Therefore,
phytoestrogens may affect the sleep–wake cycle through their estrogenic or anti-estrogenic effects [19],
which may also explain the discrepant relationships of individual phytoestrogens with sleep disorders
or sleep duration. A notable finding in our study was that the urinary O-DMA concentration was
positively related to sleep disorders in females aged 40–59 years but was inversely associated with sleep
disorders in females aged 60 years or over, which may be partly attributed to the anti-estrogenic and
estrogenic effects of phytoestrogens, depending on the level of endogenous estrogen [64]. We also found
that the urinary O-DMA concentration was positively related to sleep disorders in non-Hispanic Whites
but was inversely associated with sleep disorders in other Hispanics, which may be partially due to the
race difference in the compositions of gut microbiota and daidzein-metabolizing phenotypes [61,65].
Equol has estrogenic activities [66], which may partly contribute to the inverse association of equol with
sleep disorders in females aged 18–39 years, while the mechanisms for the positive association between
equol and sleep disorders in other Hispanics need to be investigated. Furthermore, the inter-individual
variation of phytoestrogen metabolism by gut microbiota [67] may also contribute to the complexity of
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these results. The above-mentioned mechanisms may partly explain our findings, and further studies
on the related mechanisms remain necessary.
This study has several advantages. First, the phytoestrogen assessments were based on urinary
biomarkers, which reflected all food origins of phytoestrogens and took into account the metabolic
transformation of intestinal flora, representing true and biologically effective exposures. Second, the
relationships with sleep disorders or sleep duration were evaluated for individual phytoestrogens
(enterolactone, enterodiol, daidzein, O-DMA, equol, and genistein), which made up for the fact that
previous epidemiological studies did not investigate the relationship of lignans with sleep and focused
only on total isoflavones while ignoring the potential differences of individual isoflavones. Third,
our findings were based on data from the NHANES, which was carefully designed, of high quality,
and nationally representative. Fourth, concentration–response relationships between individual
phytoestrogens and sleep disorders were appraised in this study. Fifth, we further explored gender, age,
and race differences in the associations of individual phytoestrogens with sleep disorders. Additionally,
we adjusted for a wide range of confounders to control for potential confounding bias.
However, several potential limitations should also be considered. First of all, the cross-sectional
design precludes the possibility of causal inference. Second, although phytoestrogen concentrations in
spot urine are reliable biomarkers for phytoestrogen intake [23,50,51], it might be difficult to accurately
reflect long-term intake information because spot urine was collected only once. Nonetheless, studies
have demonstrated that phytoestrogen concentrations in spot urine are relatively stable and significantly
related to dietary phytoestrogen intake over the long term [68,69]. Third, the sleep disorders assessment
was via a self-reported doctor diagnosis, which might involve recall bias, and self-reported usual
sleep duration might be not objective enough; however, objective sleep measurement, such as
polysomnography, may be difficult to implement in large-scale surveys. Fourth, although three-cycle
data with national representativeness were combined and the sample was relatively large, the case
group might still be not enough due to the lower prevalence, which might lead to bias. Furthermore,
although we adjusted multiple covariates, measurement errors and other factors affecting sleep quality
might influence the present findings. However, the present results were approximate in the three
models, suggesting that the results might be robust and exposure factors might be independently
associated with sleep. Finally, we could not further explore the relationships between phytoestrogens
and specific types of sleep disorders in virtue of the limited sleep disorders data.
5. Conclusions
The current findings suggested that the urinary enterolactone concentration was linearly inversely
associated with the risk of sleep disorders among American adults, whereas the enterodiol and
O-DMA concentrations were positively related to sleep disorders in approximately linear and inverted
L-shaped manners, respectively. Meanwhile, the urinary enterolactone concentration was negatively
associated with very short sleep and the genistein concentration was inversely related to a long sleep
risk. Furthermore, a negative association of urinary genistein concentration with sleep disorders was
observed in middle-aged adults. The urinary enterolactone concentration was inversely associated
with a long sleep risk among older adults, while the enterodiol concentration was positively related to
a long sleep risk in females and very short sleep in young adults. Finally, a notable finding was that the
association of the urinary O-DMA concentration with sleep disorders was different between females
aged 40–59 years and females aged 60 years or over, as well as between non-Hispanic Whites and
other Hispanics. It may be meaningful and vital to choose more specific individual phytoestrogens,
not choosing total lignans or isoflavones for preventing or improving sleep problems, and to match
target groups given the potentially differential associations of individual phytoestrogens with sleep,
as well as the gender, age, and race differences in the associations. Prospective cohort or trial studies
evaluating the relationships of individual phytoestrogens with sleep are warranted to confirm the
current findings.
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Abstract: Oxidative stress is known to modulate insulin secretion and initiate gene alterations
resulting in impairment of β-cell function and type 2 diabetes mellitus (T2DM). Rice bran (RB)
phenolic extracts contain bioactive properties that may target metabolic pathways associated with
the pathogenesis of T2DM. This study aimed to examine the effect of stabilized RB phenolic extracts
on the expression of genes associated with β-cell function such as glucose transporter 2 (Glut2),
pancreatic and duodenal homeobox 1 (Pdx1), sirtuin 1 (Sirt1), mitochondrial transcription factor
A (Tfam), and insulin 1 (Ins1) in addition to evaluating its impact on glucose-stimulated insulin
secretion. It was observed that treatment with different concentrations of RB phenolic extracts
(25-250 μg/mL) significantly increased the expression of Glut2, Pdx1, Sirt1, Tfam, and Ins1 genes
and glucose-stimulated insulin secretion under both normal and high glucose conditions. RB phenolic
extracts favourably modulated the expression of genes involved in β-cell dysfunction and insulin
secretion via several mechanisms such as synergistic action of polyphenols targeting signalling
molecules, decreasing free radical damage by its antioxidant activity, and stimulation of effectors or
survival factors of insulin secretion.
Keywords: rice bran; phenolic extracts; β-cell function; gene expression; insulin secretion
1. Introduction
Glucose homeostasis is regulated by a sequence of events within the pancreatic β-cells, which
result in the secretion of insulin [1]. Typically, in the postprandial state, increased levels of glucose
in plasma can initiate pancreatic β-cells to secrete insulin, consequently suppressing hepatic glucose
output and increasing peripheral tissue glucose uptake [2]. However, impairment of glucose-stimulated
insulin secretion as a result of oxidative stress and inflammation can result in β-cell dysfunction
and insulin resistance, subsequently leading to the pathogenesis of type 2 diabetes mellitus (T2DM) [3].
There are several essential genes involved in insulin secretion pathways that are specifically expressed
in pancreatic β-cells. They are known to be involved in the processes leading to insulin release from
the initial glucose entry into the β-cells followed by mitochondrial adenosine triphosphate (ATP)
generation and potassium and calcium membrane depolarization leading to exocytosis events [4].
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They include, glucose transporter 2 (Glut2) [5], pancreatic and duodenal homeobox 1 (Pdx1) [6], sirtuin
1 (Sirt1) [7], mitochondrial transcription factor A (Tfam) [8], and insulin 1 (Ins1) [9].
The Glut2 gene is located in the pancreatic plasma membrane and functions as a glucose transporter
as part of the glucose-sensing mechanism for the stimulation of insulin secretion [2]. The Pdx1 gene
plays an important role in mitochondrial embryonic development and β-cell differentiation and is
known to regulate the expression of a variety of different pancreatic endocrine genes, including
Glut2 [10]. The Sirt1 gene is known to serve as a key energy redox sensor involved in generating ATP
that helps promote glucose-stimulated insulin secretion in pancreatic β-cells and potentially contribute
to β-cell adaptation in response to insulin resistance [1]. In the liver, skeletal muscles, and white adipose
tissues, the Sirt1 gene has key functions that include regulation of glucose production, improvement in
insulin sensitivity via fatty acid oxidation, and control of the production of adipokines [7]. The Tfam
gene plays an essential role in the maintenance of mitochondrial DNA (mtDNA) and replication [11].
Altered mitochondrial function is known to result in a defective oxidative metabolism, which seems to
be involved in visceral fat gain and the development of insulin resistance [12]. Moreover, the Tfam
gene is also involved in insulin exocytosis events by maintaining appropriate ADP/ATP ratio [4].
The Ins1 gene and its transcription factors are regulated by the circulating levels of glucose [9]. It
encodes the production of insulin that plays a vital role in the regulation of carbohydrate and lipid
metabolism [13]. Therefore, a disruption in the function of these genes (Glut2, Pdx1, Sirt1, Tfam,
and Ins1) in the pancreatic β-cells is known to impair insulin secretion and result in the development
of T2DM.
Recent studies have shown the potential of plant-derived phenolic compounds in ameliorating
β-cell dysfunction via their antioxidant and free radical scavenging properties [14–16]. Exposure of
polyphenols to β-cells has also been responsible for the modulation of several signalling proteins,
including transcription factors, protein kinase, and ion channels [17].
Rice bran (RB), a by-product of the rice milling process, is usually discarded or used as animal
feed [18]. However, the bran layer is composed of several bioactive phytochemicals, including
polyphenols and phenolic acids [19]. Although RB phenolic extracts are believed to target metabolic
pathways associated with T2DM, the mechanisms behind its effect on gene expression under normal
and diabetic conditions have not been investigated. This study aimed to determine the effect of
RB phenolic extracts on the expression of genes (Glut2, Pdx1, Sirt1, Tfam, and Ins1) associated with
insulin secretion pathways and on glucose-stimulated insulin secretion under normal and high
glucose conditions.
2. Materials and Methods
2.1. Chemicals and Reagents
All chemicals and reagents used in this study were purchased from Promega Corporation
(Madison, WI, USA), Bio-Rad (Hercules, CA, USA), or Sigma-Aldrich (St Louis, MO, USA).
2.2. Rice Bran Phenolic Extract Preparation
Commercially stabilized RB (drum-dried), from an Australian grown Reiziq rice variety,
was obtained from SunRice Australia, courtesy of their milling plant in Leeton, NSW, Australia
and subsequently stored at 4 ◦C until further analysis. Phenolic compounds were extracted from
stabilized RB using an acetone/water/acetic acid (70:29.5:0.5, v/v) mixture, the characterization of which
has been described elsewhere [18]. It is known to contain several bioactive compounds including
ferulic acid, p-coumaric acid, caffeic acid, vanillic acid, syringic acid, sinapic acid, feruloyl glycoside,
shikimic acid, ethyl vanillate, tricin, and their isomers. The extract was reconstituted in 50% dimethyl
sulfoxide (DMSO) and stored at −20 ◦C before starting cell culture studies.
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2.3. Cell Culture Conditions
INS-1E cells were maintained in RPMI 1640 media containing 11.1 mM glucose and supplemented
with 2 mM L-Glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 0.05 mM β-mercaptoethanol, 10%
Fetal Bovine Serum, and 1% 10,000 U/mL Penicillin–10 mg/mL Streptomycin from Sigma-Aldrich (St
Louis, MO, USA) at 37 ◦C in 5% CO2 and used before reaching passage 45.
2.4. Cytotoxicity Assay
The cytotoxicity of RB phenolic extracts was examined using a resazurin red cytotoxicity assay
wherein INS-1E cells were seeded into 96-well plates at a density of 50,000 cells per well and incubated
for 24 h in the RPMI 1640 complete media. The cell count for experimental seeding was achieved with
a Muse® Cell Analyzer from Luminex Corporation (Austin, TX, USA). INS-1E cells were then treated
with 200 μL of freshly prepared RB phenolic extracts at various concentrations (25, 50, 100, 250, 500, 750,
and 1000 μg/mL) for 6 h. Hydrogen peroxide (5 mM) was used as a positive control and 0.25% DMSO
served as a negative control. Subsequently, all the treatment wells were emptied before adding 200 μL
of resazurin red solution (14 mg/L) to each well and incubated for an additional 4 h at 37 ◦C in 5%
CO2. The absorbance was measured on a microplate reader (FLUOstar Omega microplate reader, BMG
Labtech, Offenburg, Germany) at 570 and 600 nm against a resazurin red blank. The percentage of cell
viability was calculated as described by Saji, Francis [20]. Each treatment was measured in octuplicate.
2.5. Expression of Genes Associated with β-Cell Function
2.5.1. Experimental Design
Two experimental conditions simultaneously tested were normal glucose treatment (11.1 mM) to
represent a normal β-cell function and high glucose treatment (25 mM) to represent β-cell dysfunction
under glucotoxic stress [4,15]. INS-1E cells were seeded at a density of 500,000 cells per well into
6-well plates and incubated for 24 h. To induce glucotoxicity, INS-1E cells were further subjected to
48 h incubation in RPMI 1640 complete media containing 25 mM glucose. Cells under both normal
and high glucose conditions were treated for 6 h with RB phenolic extracts (25, 50, 100, and 250 μg/mL)
and 0.125% DMSO served as the negative control. Each treatment was measured in quintuplicate.
2.5.2. Gene Expression Analysis
Total ribonucleic acid (RNA) extraction was conducted using the SV Total RNA Isolation System
according to the manufacturer’s instructions (Promega, Madison, WI, USA). RNA quality was
determined using a NanoDrop™ 2000 c Spectrophotometer from Thermo Fisher Scientific (Waltham,
MA, USA). Then, cDNA synthesis was conducted using a GoScript™ Reverse Transcriptase, according
to the manufacturer’s instructions (Promega, Madison, WI, USA).
Primers used for quantitative real-time polymerase chain reaction (qPCR) examinations are
listed in Table 1. All of the qPCR primers were adapted from [21], designed using Primer3 software,
and synthesized by Sigma-Aldrich (St Louis, MO, USA). The amplification efficiency was determined
to be between 90–110% for all the primers before starting qPCR.
Gene expression was conducted in the CFX96 Touch™ Real-Time PCR Detection System
(Bio-Rad) using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad) detection according to
the manufacturer’s instructions. The cycling conditions comprised 95 ◦C for 3 min, 95 ◦C for 10 s,
and 60 ◦C for 30 s repeated for 39 cycles. The melt curve was generated at 65 ◦C for 5 s and 95 ◦C for 50
s. The endpoint or cycle threshold (Ct) values were obtained for all genes tested. The mean normalized
expression of genes was determined using the Q-gene software application, as described by Muller,
Janovjak [22]. TfIIβ served as the reference gene.
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Table 1. The nucleotide sequences of the PCR primers used to assay gene expression by qPCR.
Gene Forward Primer Reverse Primer
Glut2 TCAGCCAGCCTGTGTATGCA TCCACAAGCAGCACAGAGACA
Pdx1 CCGCGTTCATCTCCCTTT C CTCCTGCCCACTGGCTTT T
Sirt1 CAGTGTCATGGTTCCTTTGC CACCGAGGAACTACCTGA T
Tfam GGGAAGAGCAAATGGCTGAA TCACACTGCGACGGATGA GA
Ins1 TGCTCACCCGCGACCTT GTTCATATGCACCACTGGACTGAA
TfIIβ GTTCTGCTCCAACCTTTGCCT TGTGTAGCTGCCATCTGCACT T
2.6. Glucose-Stimulated Insulin Secretion
The preparation of supernatant for the glucose-stimulated insulin secretion assay was adapted
from a previous study conducted by Bhattacharya, Oksbjerg [15] with slight modifications. Briefly,
INS-1E cells were seeded into a 24-well plate at a density of 1 × 105 cells/well and incubated for
24 h or until 70–80% confluency was reached. The cells were treated with DMSO control and RB
extracts at different concentrations (25–250 μg/mL) and incubated for 6 h. Cells were then starved with
a Krebs-Ringer bicarbonate buffer (125 mM NaCl, 5.9 mM KCl, 1.28 mM CaCl2, 1.2 mM MgCl2, 25 mM
HEPES, and 0.1% BSA at pH 7.4) containing 5 mM glucose for 1 h. Glucose-stimulated insulin secretion
was then induced by treating cells with a Krebs-Ringer bicarbonate buffer containing either 11.1 mM
or 25 mM glucose for 1 h. The supernatant containing secreted insulin was collected and stored at −20
◦C until further analysis. Insulin secretion was measured using a Rat Ins1/Insulin ELISA Kit purchased
from Sigma-Aldrich (St Louis, MO, USA) according to the manufacturer’s instructions. Each treatment
was measured in sextuplicate.
2.7. Statistical Analysis
Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by
post-hoc Tukey’s multiple comparisons test using GraphPad Prism 7 software (GraphPad Software Inc,
San Diego, CA, USA) at a level of p < 0.05. The results are reported as mean ± standard deviation (SD).
3. Results
3.1. Cytotoxicity of RB Phenolic Extracts on INS-1E Cells
The cell viability of INS-1E cells 6 h post-exposure (Figure 1) to various concentrations of RB
phenolic extracts did not display any cytotoxic effect on the INS-1E cells at the lower concentrations
tested (25–250 μg/mL). However, higher concentrations (500–1000 μg/mL) displayed a reduction in
cell viability. Optimal, non-toxic concentrations of RB extract were determined to be between 25–250
μg/mL under both normal and high glucose conditions.
Figure 1. INS-1E cell viability 6 h post-exposure to various concentrations of RB phenolic extracts.
(a) Normal glucose conditions, (b) High glucose conditions (n = 8). Data are presented as Mean ± SD.
Dimethyl sulfoxide, DMSO; Hydrogen Peroxide, H2O2; Insulin-secreting rat insulinoma cell, INS-1E;
Rice bran, RB.
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3.2. Effect of RB Phenolic Extracts on Expression of Genes Associated with β-Cell Function
3.2.1. Expression of the Glut2 Gene
Under normal glucose conditions, a significant increase (p < 0.01) in the expression of the Glut2
gene was observed after treatment with 50 and 100 μg/mL of RB phenolic extracts when compared to
that of the control. Under high glucose conditions, a significant increase (p < 0.0001) in the expression
of the Glut2 gene was also observed after treatment with 25–250 μg/mL of RB phenolic extracts when
compared to that of the control (Figure 2).
Figure 2. Effect of RB phenolic extracts on the expression of the Glut2 gene under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n =
5). The level of significance is indicated by the asterisks, whereby * p < 0.05, ** p < 0.01. Data are
presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin-secreting rat insulinoma cell, INS-1E;
Glucose transporter 2, Glut2; Rice bran, RB.
3.2.2. Expression of the Pdx1 Gene
A significant increase (p < 0.05) in the expression of the Pdx1 gene was observed after treatment
with 50 and 100 μg/mL of RB phenolic extracts under normal glucose conditions when compared
to that of the control. A significant increase (p < 0.001) in the expression of the Pdx1 gene was also
observed after treatment with 25–250 μg/mL of RB phenolic extracts under high glucose conditions
when compared to that of the control (Figure 3).
Figure 3. Effect of RB phenolic extracts on the expression of the Pdx1 gene under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n
= 5). The level of significance is indicated by the asterisks, whereby * p < 0.05, ** p < 0.01, *** p <
0.001. Data are presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin promoter factor 1, Pdx1;
Insulin-secreting rat insulinoma cell, INS-1E; Rice bran, RB.
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3.2.3. Expression of the Sirt1 Gene
There was no significant increase in the expression of the Sirt1 gene observed under normal
glucose conditions when compared to that of the control. However, under high glucose conditions,
a significant increase (p < 0.0001) in the expression of the Sirt1 gene was observed after treatment with
25–250 μg/mL of RB phenolic extracts when compared to that of the control (Figure 4).
Figure 4. Effect of RB phenolic extracts on the expression of the Sirt1 gene under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n =
5). The level of significance is indicated by the asterisks, whereby * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001. Data are presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin-secreting rat
insulinoma cell, INS-1E; Rice bran, RB; Sirtuin 1, Sirt1.
3.2.4. Expression of the Tfam Gene
Under normal glucose conditions, a significant increase (p < 0.001) in the expression of the Tfam
gene was observed after treatment with 25–250 μg/mL of RB phenolic extracts when compared to that of
the control. However, under high glucose conditions, a significant increase (p < 0.05) in the expression
of the Tfam gene was only observed after treatment with 25 μg/mL of RB phenolic extracts when
compared to that of the control (Figure 5).
Figure 5. Effect of RB phenolic extracts on the expression of the Tfam gene under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n = 5).
The level of significance is indicated by the asterisks, whereby * p < 0.05, ** p < 0.01, *** p < 0.001. Data
are presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin-secreting rat insulinoma cell, INS-1E;
Mitochondrial transcription factor A, Tfam; Rice bran, RB.
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3.2.5. Expression of the Ins1 Gene
RB extract did not alter the expression of the Ins1 gene under normal glucose treatment. However,
under high glucose conditions, a significant increase in the expression of the Ins1 gene was observed
after treatment with 50 μg/mL (p < 0.01) and 100 μg/mL (p < 0.001) of RB phenolic extracts when
compared to that of the control (Figure 6).
Figure 6. Effect of RB phenolic extracts on the expression of the Ins1 gene under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n =
5). The level of significance is indicated by the asterisks, whereby ** p < 0.01, *** p < 0.001. Data are
presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin 1, Ins1; Insulin-secreting rat insulinoma
cell, INS-1E; Rice bran, RB.
3.3. Glucose-Stimulated Insulin Secretion
Glucose-stimulated insulin secretion was observed to significantly increase after treatment with
25 (p < 0.0001), 50 (p < 0.0001), 100 (p < 0.0001), and 250 (p < 0.05) μg/mL of RB phenolic extracts
under normal glucose conditions when compared to that of the control. Similarly, under high glucose
conditions, a significant increase in glucose-stimulated insulin secretion was also observed after
treatment with 25 (p < 0.0001), 50 (p < 0.05), and 100 (p < 0.05) μg/mL of RB phenolic extracts when
compared to that of the control (Figure 7).
Figure 7. Effect of RB phenolic extracts on glucose-stimulated insulin secretion under normal and high
glucose conditions in INS-1E cells. (a) Normal glucose conditions, (b) High glucose conditions (n = 6).
The level of significance is indicated by the asterisks, whereby * p < 0.05, **** p < 0.0001. Data are
presented as Mean ± SD. Dimethyl sulfoxide, DMSO; Insulin-secreting rat insulinoma cell, INS-1E;
Rice bran, RB.
87
Nutrients 2020, 12, 1889
4. Discussion
Prolonged exposure of pancreatic β-cells to a high glucose environment is known to result in
oxidative stress, consequently leading to the downregulation of pancreatic genes, in turn causing
impaired β-cell function and insulin secretion [16]. Plant-derived phenolic compounds via their
antioxidant, free radical scavenging and metal chelating properties have been observed to target
metabolic pathways associated with the pathogenesis of T2DM [14]. The present study demonstrated
that RB phenolic extracts effectively alter β-cell function in insulin-secreting cells by modulating
the expression of genes and insulin secretion. It was observed that RB phenolic extracts upregulated
the expression of key genes associated with β-cell function, including Glut2, Pdx1, Sirt1, Tfam, and Ins1
both under normal and high glucose-induced stress conditions (Figures 2–6).
The Glut2 gene primarily acts as a glucose transporter and the decreased expression of the Glut2
gene is directly proportional to the loss of glucose-stimulated insulin secretion [5]. In this study,
a significant increase in the expression of the Glut2 gene was observed under normal conditions
compared to that in high glucose conditions. This may have been caused by the increase in glucotoxic
stress created by the high glucose environment, resulting in a reduced ability to maintain normal
functioning as a glucose transporter. Nevertheless, a significant up-regulation of the Glut2 gene was
observed under both conditions compared to those of the respective controls after treatment with
varying concentrations of RB extract (Figure 2). Similarly, studies in which phenolic compounds
derived from M. pumilum var. alata extracts and purified phenolic compounds such as resveratrol
were tested improved β-cell function, and insulin signalling was observed as a result of increased
expression of the Glut2 gene in the pancreas [21,23]. This is most likely due to the polyphenols
targeting the exchange of calcium ions resulting in the exocytosis of insulin-containing granules,
thereby favourably modulating β-cell function [5,24].
Pdx1 gene expression is essential for the homeostatic regulation of the glucose-sensing system in
β-cells [6]. It is also essential for survival and differentiation ofβ-cells as it primarily acts by upregulating
the transcription of severalβ-cell-specific genes, including the Ins and Glut2 genes [25]. Results obtained
from this study show that under both normal and high glucose conditions, a significant upregulation
of the Pdx1 gene was evident after treatment with RB phenolic extracts (Figure 3). Upregulation
of the Pdx1 gene has been observed elsewhere, in which administration of Teucrium polium extract,
known to contain phenolic compounds with strong antioxidant and anti-inflammatory effects, was
found to reverse the symptoms of streptozotocin-induced diabetes in rats [26]. Another study, wherein
the effect of gallic acid against glucolipotoxicity and insulin secretion was examined, showed that
pre-treatment with different concentrations of gallic acid was found to increase insulin secretion
and resulted in the upregulation of the Pdx1 gene in RINm5F β-cells [27]. Reduction in insulin
secretion has been attributed to the c-Jun N-terminal kinase (JNK) pathway activation under oxidative
stress conditions. JNK activation as a result of oxidative stress results in forkhead box protein O1
(FOXO1) phosphorylation, and the nuclear localization of the FOXO1protein leads to a reduction in
the expression of the Pdx1 gene [28]. As an adequate expression of the pancreatic Pdx1 gene is essential
to maintain the proper function of insulin-producing β-cells, inhibition of the JNK pathway is crucial.
As phenolic compounds are recognized to modulate the regulation of the JNK pathway [26], it is
likely that the observed upregulation of the Pdx1 gene by RB-derived phenolic extracts resulted from
an inhibition of the JNK pathway.
The Sirt1 gene is known to be a major contributor to the metabolic regulation of a cell via lipid
metabolism and insulin secretion [7]. In the current study, under high glucose conditions, a significant
increase in the expression of the Sirt1 gene was observed after treatment with RB phenolic extracts
(Figure 4). Sun, Zhang [29] demonstrated that resveratrol improved insulin sensitivity by repressing
the protein tyrosine phosphatase (PTP) constitute and PTP1B transcription at the chromatin level (on
the Sirt1 gene) under normal versus insulin-resistant conditions. Hence, it is believed that upregulation
of the Sirt1 gene as a result of treatment with RB phenolics can potentially target PTP1B ranscription
consequently improving insulin sensitivity.
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Any disruption to the Tfam gene in the pancreatic β-cell is known to result in impaired insulin
secretion, reduced β-cell mass, and, consequently, the development of T2DM [8]. The current study
shows a significant increase in the expression of the Tfam gene under normal and high glucose conditions
post-treatment with RB phenolic extracts (Figure 5). In an in vivo study where rats were gavaged
with pterostilbene, Tfam gene expression was significantly increased in addition to improvements
to glycaemic control and insulin resistance [30]. Furthermore, the treatment of INS-1E cells with
resveratrol also displayed marked potentiation of glucose-stimulated insulin secretion as a result
of the up-regulation of Tfam [21]. From the above studies, it is believed that RB phenolics have
the potential to enhance the efficiency of mitochondrial function via interaction with transcription
factors such as Tfam.
Appropriate regulation of the Ins1 gene is essential for central insulin signalling as it is an anorectic
gene that encodes for the production of the insulin hormone that plays a vital role in the regulation
of carbohydrate and lipid metabolism [31]. Chronic exposure to high glucose conditions can reduce
the expression of the Ins1 gene in β-cells and is often accompanied by the decreased binding activity
of the β-cell-specific transcription factor, Pdx1 [32]. In the current study, although there was no
significant increase in Ins1 gene expression after RB extract treatment under normal glucose conditions,
the expression of the Ins1 gene was significantly upregulated under high glucose conditions (Figure 6).
Similarly, an in vivo study by the author of [33] also demonstrated blueberry-leaf extract rich in
chlorogenic acid and flavonol glycosides attenuates glucose homeostasis and improves pancreatic
β-cell function by increasing the expression of several genes including Ins1. Polyphenols present
in common spices, such as cinnamon, cloves, turmeric, and bay leaves, due to their doubly-linked
procyanidin type-A polymers, have also shown an insulin-like activity in vitro [34]. The mechanism of
cinnamon’s insulin-like activity may be in part due to increases in the amounts of insulin receptor
β and Glut4 expression [34]. Some of the polyphenols present in cinnamon include caffeic, ferulic,
p-coumaric, protocatechuic, and vanillic acids [35], a similar phenolic profile observed in the RB
samples used in this study [18]. Therefore, it is likely that the effects observed in this study may
be due to the insulin-like activity displayed by the polyphenols present in RB individually or via
synergistic bioactivity.
Hormones such as insulin and amylin are co-secreted by β-cells in a fixed molecular ratio
that provides circulating energy in the form of glucose and stored energy in the form of visceral
adipose tissue [36]. However, conditions such as obesity, T2DM, and pancreatic cancer result in
an increase in the amount of amylin relative to the insulin, which can disturb the regulation of
energy homeostasis [36]. It was observed that under normal and high glucose-induced conditions, RB
phenolic extracts significantly increased glucose-stimulated insulin secretion (Figure 7). Bhattacharya,
Oksbjerg [15] also observed a similar trend where caffeic acid, naringenin, and quercetin significantly
increased glucose-stimulated insulin secretion under hyperglycaemic and glucotoxic conditions in
INS-1E cells. Similarly, several other phenolic compounds such as ferulic acid [37] and p-coumaric
acid [38] have also been shown to increase insulin secretion both in vitro and in vivo, respectively. In
this study, it was observed that RB phenolic compounds increase the expression of both the Ins1 gene
and the secretion of insulin in INS-1E cells under high glucose conditions. Since the Ins1 gene is known
to encode for the production of insulin hormone, this may indicate that there may be a correlation
between insulin secretion and the expression of the Ins1 gene.
Furthermore, it was observed that lower doses of the RB extract used in this study favourably
modulated β-cell function associated gene expression and insulin secretion when compared to
the higher doses in vitro. This phenomenon may be explained through the effect of hormesis, a biphasic
dose-response to an environmental agent, wherein glucose-stimulated insulin secretion was observed
to have a stimulatory or beneficial effect at low doses and an inhibitory or toxic effect at high doses
of RB extract [39]. Dietary polyphenols are known to have strong cytoprotective effects, however,
the hormetic role of dietary antioxidants in free radical-related diseases have demonstrated that under
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uncontrolled nutritional supplementation, gene induction effects and the interaction with detoxification
responses can result in a negative response by generating more reactive and harmful intermediates [40].
As a result of hindrance by cereal matrices, most of the bound phenolic compounds present in
cereal grains are usually not readily accessible by digestive enzymes, leading to low bioavailability [41].
Studies have demonstrated that this could be improved by increasing their accessibility through
suitable processing techniques, for example, thermal treatments [18,41]. The RB sample examined in
this study was previously studied with respect to several thermal treatments. Of the treatments studied,
drum drying resulted in the optimal antioxidant activity and was therefore selected for the current
investigation [18]. The drum-dried RB samples resulted in a total free phenolic content of 362.17 ±
34.16 gallic acid equivalent (GAE)/100 g of RB with antioxidant activity of 975.33 ± 20.24 Fe2+/100 g of
RB and a total bound phenolic content of 160.65 ± 5.52 GAE/100 g of RB with antioxidant activity of
551.91 ± 8.82 Fe2+/100 g of RB. This was much higher compared to that of a non-treated sample that
had a total free phenolic content of 238.26 ± 30.34 GAE/100 g of RB with antioxidant activity of 621.76
± 26.76 Fe2+/100 g of RB and a total bound phenolic content of 222.94 ± 3.74 GAE/100 g of RB with
antioxidant activity of 712.37 ± 14.57 Fe2+/100 g of RB [18].
5. Conclusions
This study has demonstrated that RB phenolic compounds, under both normal and glucotoxic
conditions, significantly increase the expression of genes associated with β-cell function, in addition
to increasing glucose-stimulated insulin secretion. RB phenolic compounds could play an important
role in modulating the expression of genes involved in β-cell dysfunction and insulin secretion via
several mechanisms, including (1) Synergistic action of polyphenols and phenolic acids by targeting
signalling molecules, including transcription factors, consequently modulating mitochondrial potential;
(2) Reducing free radical damage related to β-cell dysfunction via their antioxidant activity; and (3)
Stimulation of effectors or survival factors of insulin secretion. RB phenolic extracts present as
a promising preventive/therapeutic target in the treatment of glucotoxicity induced β-cell dysfunction.
More in vivo studies are warranted to confirm the bioactivity of RB phenolic compounds.
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Abstract: Platelet hyper-activation and platelet microparticles (PMPs) play a key role in the
pathogenesis of cardiovascular diseases. Dietary polyphenols are believed to mimic antiplatelet
agents by blunting platelet activation receptors via its antioxidant phenomenon. However, there
is limited information on the anti-platelet activity of grain-derived polyphenols. The aim of the
study is to evaluate the effects of sorghum extract (Shawaya short black 1 variety), an extract
previously characterised for its high antioxidant activity and reduction of oxidative stress-related
endothelial dysfunction, on platelet aggregation, platelet activation and PMP release. Whole
blood samples collected from 18 healthy volunteers were treated with varying non-cytotoxic
concentrations of polyphenol-rich black sorghum extract (BSE). Platelet aggregation study utilised
5 μg/mL collagen to target the GPVI pathway of thrombus formation whereas adenine phosphate
(ADP) was used to stimulate the P2Y1/P2Y12 pathway of platelet activation assessed by flow cytometry.
Procaspase-activating compound 1 (PAC-1) and P-selectin/CD62P were used to evaluate platelet
activation- related conformational changes and degranulation respectively. PMPs were isolated from
unstimulated platelets and quantified by size distribution and binding to CD42b. BSE treatment
significantly reduced both collagen-induced platelet aggregation and circulatory PMP release at
40 μg/mL (p < 0.001) when compared to control. However, there was no significant impact of BSE on
ADP-induced activation-dependent conformational change and degranulation of platelets. Results
of this study suggest that phenolic rich BSE may confer cardio-protection by modulating specific
signalling pathways involved in platelet activation and PMP release.
Keywords: black sorghum; polyphenols; platelets; platelet microparticles; atherosclerosis
1. Introduction
According to a World Health Organisation report, cardiovascular diseases accounted for an
estimated 31% of deaths globally with majority being a result of stroke or heart attack [1,2]. In clinical
settings, treatment involves blunting the activity of platelets using antiplatelet drugs. These drugs
interfere with the thrombotic pathophysiology—wherein a rupture of an atherosclerotic plaque triggers
platelet hyper-activation resulting in unwanted clot formation and occlusion of the blood vessel.
Macrovesicles referred to as platelet microparticles (PMPs) are released following platelet activation
and can contribute to the thrombotic situation [3,4].
The several signalling pathways involved in platelet activation and thrombus formation
include receptor-agonist pathways such as P2Y1/P2Y12-ADP, GPVI-collagen, PAR1-thrombin and the
COX-1-thromboxane [5]. An agonist such as collagen when exposed by atherosclerotic plaque may
activate nearby platelets by binding to their GPVI receptor resulting in complex intracellular signalling
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that produce a conformational change (indicated by GPIIb/IIIa receptor expression), degranulation
(indicated by P-selectin secretion) and subsequent formation of platelet aggregates [5]. In addition, PMP
released upon activation possess adhesive and pro-coagulant platelet-derived receptors that further
enhance thrombus formation, thereby acting as biomarkers of platelet activation [3]. The common
antiplatelet agents, clopidogrel and aspirin, used in clinical treatments inhibit platelet activation
and its circulating biomarkers by selectively targeting P2Y1/P2Y12-ADP and COX-1-thromboxane
respectively [6]. Unfortunately, because of the unresponsiveness and side effects associated
with administration there have been considerable research in dietary bioactive agents known as
polyphenols [7].
One such example of a polyphenol-rich functional food is sorghum whole grain. Although mainly
used as animal feed, studies have demonstrated that it possesses anti-inflammatory, anti-cancer and
antioxidant properties which add value to it as a food for human consumption [8]. Sorghum of
different types exist that are classified based on the pigmentation of the pericarp and vary in their
phenolic content [9]. The polyphenols found in sorghum that contribute to its bioactivity include
flavonoids, hydroxybenzoic acids and hydroxycinnamic acid [8]. Furthermore Francis et al. [10] recently
demonstrated that black sorghum rich in catechins and their derivatives may confer cardioprotective
properties. The treatment of human umbilical vein cells with flavonoid-rich extract was found to
prevent oxidative stress-related endothelial dysfunction through the modulation of gene expression.
Furthermore, these cardio-protective benefits of polyphenols apply in the context of platelet
function. Several studies have demonstrated that polyphenols may inhibit platelet activation,
adhesion, degranulation and aggregation by targeting specific thrombogenic pathways for example
P2Y1/P2Y12-ADP, GPVI-collagen, PAR1-thrombin and the COX-1-thromboxane. As reviewed by Ed
Nignpense et al. [11] many of the studies that investigate the polyphenol impact on platelet function
and PMP generation utilise aggregometry and flow cytometry. However there is limited research on
sorghum-derived polyphenols in modulating biomarkers of platelet activation. This study aims to
investigate the impact of black sorghum derived polyphenol extracts on collagen-induced platelet
aggregation, ADP-induced platelet activation and PMP generation.
2. Materials and Methods
2.1. Research Ethics
The study protocol was approved by the Charles Sturt University Human Research Ethics
Committee (HR17012) and the Institutional Biosafety Committee (19HB02). The study was performed
in compliance with relevant laws and institutional guidelines.
2.2. Volunteer Recruitment
Eighteen healthy volunteers between 18–65 years of age (9 males and 9 females) were recruited
from Charles Sturt University and the local community. Informed consent was obtained from all
participants prior to commencement of the study. The criteria for recruitment involved normal health
status with no history of conditions such as cardiovascular, metabolic, liver or lung disease. Other
parameters that could affect the integrity of the analysis such as alcohol consumption, smoking,
pregnancy, allergies or venepuncture difficulty were considered during the recruitment process.
A health screening questionnaire was used to assess the already mentioned parameters. A dietary
questionnaire (adapted from WINTEC and NZ academy of sport) was used to assess the usual dietary
intake of volunteers and to avoid recruitment of participants on a high antioxidant diet. The cut-off
figure for each type of food listed in the questionnaire was based on nutrient reference ranges for
Australia and New Zealand—recommended daily nutrient intake values.
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2.3. Blood Collection and Processing
After fasting for at least 8 h, whole blood was collected from each participant by a trained
phlebotomist into a tri-potassium ethylene diamine tetra-acetic acid (EDTA-1.8 mg/mL concentration)
anticoagulant tube (Vacuette Greiner Bio-one, Interpath Services, Heidelberg West, VIC, Australia) and
a tri-sodium citrate (28.12 g/L concentration) anticoagulant tube (Becton, Dickson and Company, North
Ryde, NSW, Australia). A 20-mL syringe (Becton, Dickson and Company, North Ryde, NSW, Australia)
and 21-gauge 1.5-inch needle (Terumo Medical Corporation, Macquarie Park, Australia) were used to
draw blood from the median cubital vein. The purpose of choosing a larger gauge was to avoid the
activation of platelets while drawing or dispensing blood. Utmost care was taken to ensure samples
were not obtained through a traumatic collection and that none contained obvious clots. In addition,
care was taken to ensure minimal specimen handling and agitation in order to prevent artefactual
platelet activation. The first 2 mL of blood was discarded before drawing into the tri-sodium citrate
tubes in order to avoid the risk of collecting platelets activated by venepuncture. Tri-sodium tubes
were used for aggregometry and flow cytometry assays whereas the EDTA was used to perform full
blood examinations.
2.4. Full Blood Examination
Using an Abbott CELL-DYN Emerald 22 Haematology Analyser (Abbott Diagnostics, Illinois, USA),
a full blood examination (FBE) was performed on all samples. The FBE results of volunteers indicated
that the blood cell parameters were within normal reference ranges as determined by the Royal College
of pathologists of Australia. Individuals with cell counts, especially platelet counts, outside of the
reference range were excluded from the study. Quality control validation and maintenance were all
performed according to the Abbott CELL-DYN Emerald 22 Haematology Analyser manual.
2.5. Extraction of Black Sorghum Polyphenols
Sorghum (Sorghum bicolor) samples of six different pericarp varieties were obtained from glasshouse
trials conducted by Curtin University, Perth, Western Australia. Six pigmented varieties of sorghum were
cultivated under the same conditions, grown in a glasshouse equipped with Lumisol Clear AF cover
(200 μm thick, at a transparency of ca UV-A 94%, UV-B 84% and photosynthetic active radiation (PAR,
400-700 nm) 93% [8]. Extraction and analysis of phenolic composition and antioxidant activity were
performed previously using methods described by Rao et al. [8]. Among the different sorghum varieties,
the black pericarp variety (Shawaya short black 1) was selected for this study because of its relatively high
antioxidant activity when analysed with ferric reducing antioxidant power (FRAP; 20.19 ± 2.69 mg/g TE)
and 2,2-dipheny-1-picrylhydrazyl (DPPH; 18.04± 3.53 mg/g TE) antioxidant assays (Supplementary Figure
S1, Tables S1 and S2). The highest level of polyphenols found in the BSE included catechin derivatives,
catechins and pentahydroxyflavanone-(3->4)-catechin-7-O- glucoside (Supplementary Table S2). Stock
concentrations of BSE (20 mg/mL in 50% DMSO) were diluted in phosphate buffered saline (PBS) to
achieve desired concentrations (5 μg/mL, 20 μg/mL and 40 μg/mL) in whole blood. Desired concentrations
were selected based on viability studies done by Francis et al. [10].
2.6. Whole Blood Platelet Aggregometry
Platelets in whole blood were stimulated for aggregation using 5 μg/mL collagen exogenous platelet
agonists (DSKH Australia Pty. Ltd., Hallam, VIC, Australia) to investigate the effect of BSE treatment on the
platelet aggregation. Five hundred microliters of citrated whole blood were added to 100 μL of 0.1% DMSO
control (Sigma-Aldrich, Castle Hill, NSW, Australia) or BSE stock concentrations (5 μg/mL, 20 μg/mL and
40 μg/mL) and mixed with 400 μL of saline. The sample was then incubated at 37 ◦C for 20 min. Using a
Chrono-log model 700 lumi-aggregometer (DKSH Australia Pty. Ltd., Hallam, VIC, Australia) the samples
were analysed by means of electrical impedance (ohms) to determine the amount of platelet aggregation
occurring in the sample over a 6-min time period (Supplementary Figure S2).
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2.7. Flow Cytometry
2.7.1. Standardisation
Flow-check fluorospheres were run as quality control for optimal laser alignments. Antibody
capture beads (Anti-Mouse Ig, K CompBeads, BD Biosciences, North Ryde, NSW, Australia) were
used for single colour compensation controls in order to achieve optimal compensation. Megamix
beads (0.1 μm, 0.3 μm, 0.5 μm, 1 μm) from Biocytex, Marseille, France were used as per manufacturer’s
instructions to set up an appropriate gating to detecting microparticles. They were run before each
PMP analysis.
2.7.2. Measurement of Platelet Activation-Dependent Conformational Change and Degranulation
The effects of BSE on ADP-induced platelet activation were analysed and interpreted using a
Gallios flow cytometer (Beckman Coulter, Inc., Lane Cove NSW, Australia). The protocols were adopted
from the method described by Santhakumar et al. [12] with some modifications. Platelet activation and
thrombogenic indicators were assessed via activation-dependent platelet monoclonal antibodies (mAbs)
purchased from Becton, Dickinson and Company, North Ryde, NSW, Australia. Procaspase activating
compound-1 (PAC-1)-fluorescein isothiocyanate-fluorescein isothiocyanate was used to detect platelet
activation-related conformational change and P-selectin/CD62P-allophycocyanin highlighted activation
dependent degranulation. CD42b-phycoerythrin identified the GPIb-IX-V receptor, a common receptor
found on the surface of all platelets, activated and resting included. A decreased expression of mAb
exhibits alleviation of thrombogenesis. Within 5 min of collection tri-sodium citrated whole blood was
used for assay preparation to avoid artefactual activation of platelets. A volume of 40 μL of blood was
incubated with DMSO control or the various BSE concentration for 20 min at 37 ◦C in the dark. A 10-μL
mixture of all three monoclonal antibodies (3.33 μL each of PAC-1, CD62P and CD42b) was added to
blood samples and incubated for 20 min at room temperature in the dark. To induce platelet activation,
10 μM ADP (Helena laboratories Pty. Ltd., Mt Waverly, VIC, Australia) was added, and samples
were incubated for a further 15 min in the dark at room temperature, after which erythrocytes were
lysed (575 μL of 10 % lysing solution). Samples were thoroughly vortexed to ensure homogeneity and
incubated in the dark at room temperature for a further 15 min and then analysed. In all, 10,000 platelet
events were acquired, gated based on light scatter and CD42b mAb expression and activated platelets
were articulated as mean fluorescence intensity (MFI) (Supplementary Figure S3).
2.7.3. Measurement of Circulatory PMPs
Using the microparticle gating established with Megamix beads, PMPs were identified and
quantified by size distribution and binding to CD42b (Supplementary Figure S4). The protocol for
circulatory PMP analysis was adapted from Lu et al. [13]. A volume of 1 mL whole blood was
added to micro-centrifuge tubes in the presence of PGE1 (120 nmol/L; Sigma-Aldrich, Castle Hill,
NSW, Australia). PGE1 was added to prevent artefactual activation during centrifugation. The blood
samples were incubated with the respective 100 μL BSE concentrations and DMSO control for 20 min
at 37 ◦C in the dark. Each sample was then centrifuged for 15 min at a 1000 rpm and the resultant
platelet rich plasma (PRP) was discarded. The remaining blood was spun a further 15 min at 3000 rpm.
The supernatant rich in PMPs (40 μL) was collected into flow tubes and incubated with 4 μL of CD42b
and 6 μL of stain buffer (Becton, Dickson and Company, North Ryde, NSW, Australia) in dark room for
15 min. Four percent formaldehyde was used to fix any activation of platelets left in the supernatant.
After a 10-min incubation period the samples were run for PMP analysis on the flow cytometer.
2.8. Statistical Analysis
A two-way ANOVA following Tukey’s post comparison test was performed using GraphPad
Prism version 8.0 for Windows (GraphPad Software, La Jolla, California, USA). A minimum sample
size of 14 participants in total was required for 80% power to detect a 5% variation in the laboratory
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parameters measured where a 3–5% standard deviation exists in the population, assuming an alpha
error of 0.05. All the data were expressed as mean ± standard deviation (SD). Differences between the
groups were significant when p < 0.05. Any significant statistical interactions were included in the
analysis where applicable.
3. Results
The baseline parameters including full blood counts for all 18 participants were within normal
reference ranges set by the Royal College of Pathologists of Australasia (Table 1) [14].
Table 1. Baseline full blood counts of participants.
Parameters Mean ± SD
Age (years) 26 ± 8
WBC (× 109/L) 5.5 ± 1.3
Neutrophil (%) 48.6 ± 9.5
Lymphocytes (%) 37.8 ± 9.2
Monocytes (%) 10.6 ± 2.3
Eosinophils (%) 2.8 ± 1.3
Basophils (%) 0.1 ± 0.1
RBC (× 1012/L) 4.6 ± 0.5
Haemoglobin (g/L) 147.9 ± 16.1
PCV (%) 0.41 ± 0.04
MCV (fL) 90.0 ± 3.5
MCH (pg) 35.8 ± 15.2
MCHC (g/dL) 360.1 ± 6.0
RDW (%) 14.9 ± 0.8
Platelet count (× 109/L) 248.3 ± 50.0
MPV 8.41 ± 0.89
Values are represented as mean ± Standard deviation (SD). RBC, red blood cell, PCV, packed cell volume, MCV,
mean cell volume, MCH, mean cell haemoglobin, MCHC, mean cell haemoglobin concentration, RDW, red cell
distribution width, MPV, mean platelet volume.
3.1. Effect of BSE on Whole Blood Platelet Aggregation and Platelet Activation
BSE at 40 μg/mL concentration significantly reduced platelet aggregation stimulated by collagen
by 19 % (p = 0.0004) (Figure 1). BSE at lower concentrations did not exhibit any significant reduction
in aggregation.
It was observed that whole blood treatment with the varying concentrations of BSE did not
significantly affect ADP-induced platelet conformational change and degranulation indicated by PAC-1
and P-selectin expression respectively (Supplementary Figures S5 and S6).
3.2. Effect of BSE on Circulatory PMPs
BSE at a concentration of 40 μg/mL significantly reduced the amount of circulatory PMPs in whole
blood by 47% (p = 0.0008). Lower concentrations of BSE did not exhibit any significant reduction to the
amount circulatory PMPs (Figure 2).
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Figure 1. The effect of varying concentrations of BSE on collagen-induced aggregation. BSE at 40 μg/mL
significantly reduced platelet aggregation (5.3 ± 1.3; p value = 0.0004). BSE at 5 μg/mL and 20 μg/mL
did not reduce platelet aggregation when compared to control (p value > 0.1). N = 18 and data is
represented in aggregation (Ohms) versus BSE concentrations. *** signifies statistical significance
p < 0.001 compared to control. Error bars expressed as mean ± SD.
Figure 2. The effect of varying concentrations of BSE on circulatory PMP production in vitro. BSE at
40 μg/mL significantly reduced the amount of circulatory PMPs (<24190 ± 4935, p = 0.0008). BSE at
5 μg/mL and 20 μg/mL did not reduce platelet aggregation when compared to control (p value > 0.1).
N = 14 and data are represented in number of PMP events versus BSE concentrations. *** signifies
statistical significance p < 0.001 compared to control. Error bars expressed as mean ± SD.
4. Discussion
There is growing interest in understanding the therapeutic benefits of functional foods. Sorghum
for example is one of the functional foods that is showing promise in this area. With sorghum-derived
polyphenols already having demonstrated anti-inflammatory, anti-cancer and antioxidant properties,
the current study aimed to evaluate the effects of polyphenol-rich BSE on platelet function in terms of
aggregation, conformational change, degranulation and circulatory PMP production [8–10]. It was
observed that BSE significantly inhibited collagen-induced platelet aggregation and decreased the
release of circulatory PMPs but did not have a significant effect on ADP-induced platelet conformational
change or degranulation. Although these results do not reflect a typical dose-dependent inhibition,
they suggest a potential role of BSE polyphenols at optimum concentrations to interfere with pathways
in the GPVI-collagen signalling and the release of circulatory PMPs but little or no effect on P2Y1/
P2Y12-ADP pathway.
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To the best of our knowledge only a few studies have investigated the antiplatelet effects of
sorghum extracts. Li, Yu and Fan et al. [15] extracted alditols and monosaccharides from sorghum
vinegar to evaluate their anti-aggregation activity using the turbidimetric method. Results from
their study indicated a significant dose-dependent inhibition of aggregation via multiple agonists,
arachidonic acid, collagen, ADP and thrombin. Furthermore, a different study by Fan et al. [16]
reported in vitro inhibition of ADP- and thrombin- induced rabbit platelet aggregation by methanolic
extracts of aged sorghum vinegar with the half maximal inhibitory concentrations (IC50) of 1.7 ± 0.3
and 8.9 ± 1.9 mg/mL respectively. When rats were orally administered the extracts (>100 mg/kg),
both collagen- and epinephrine-induced pulmonary thrombosis were inhibited. In comparison with
the present study it is to be noted that these studies employed platelet-rich plasma rather than
whole blood hence not accounting for the possible involvement of other blood cells and extracellular
mediators involved in thrombus formation. In addition, sorghum vinegar extracts were used at higher
concentrations; milligrams compared to micrograms used in this study. This raises the question of
bioavailability and the importance of employing physiological concentrations of extracts.
Although the BSE concentration of 40 μg/mL at which antiplatelet effect were observed is relatively
lesser in concentration than used in the other studies, the most bioactive compounds with respect to
antioxidant activity were catechins and other flavonoids which are usually considered to have low
bioavailability [8]. It has been suggested that the total plasma polyphenol concentration rarely exceeds
1 μM and that their antiplatelet effects are only found at high non-physiological concentrations (greater
than 50 μM) [17,18]. However, it is likely that these plasma concentrations are underestimations
due to the ability of polyphenols to bind to the surface of red blood cells and thereby exert their
bioactivity [19]. Furthermore polyphenols (structurally related to catechin) and their metabolites have
been shown to inhibit platelet function in vitro [20]. This highlights the possibility of sorghum catechins
and their metabolites having antiplatelet effects in vivo despite bioavailability concern. Interestingly,
an in vivo human dietary intervention trial compared consumption of red and white wholegrain
sorghum-based pasta to a control pasta in order to investigate its acute effect on the total phenol content
and antioxidant activity in the plasma of healthy subjects [21]. Results showed that when compared to
the control pasta, the red sorghum pasta showed significantly increased net plasma phenolic content
and antioxidant activity post consumption (from 216.90 ± 2.62 at baseline to 269.40 ± 2.33 at 2 h;
p < 0.001), thus demonstrating a plausible correlation between antioxidant activity and sorghum
polyphenol consumption—which in turn may contribute to antiplatelet effects.
The antiplatelet effects was observed with BSE-included inhibition of collagen-induced aggregation
and circulatory PMP production but no effect on ADP-induced platelet activation. The absence of
antiplatelet effects on the P2Y1/ P2Y12-ADP activation pathway suggests that BSE polyphenols are
not mimicking the action of drugs such as clopidogrel that antagonise P2Y12 receptor activation [22].
However, the inhibition of collagen-induced aggregation suggest that BSE polyphenols interfere
with GPVI-collagen signalling pathways by either blunting the GPVI receptor directly or by other
mechanisms [5]. Previous studies have demonstrated that flavonoids, specifically quercetin and
catechin, can act synergistically to inhibit collagen-induced aggregation by blunting the associated
burst of H2O2 and subsequent PLC activation [23,24]. Thus, a possible mechanism of inhibition
BSE flavonoids may be a synergistic antagonism of the positive feedback activation of intracellular
signals triggered by H2O2. Moreover, it has been shown that the phosphorylation cascade initiated
by collagen can be inhibited by flavonoids [25,26]. Flavones, especially apigenin and luteolin, by
virtue of a double bond in the C2-C3 and the keto group in C4 can also inhibit collagen-induced
activation by antagonizing the TxA2 receptor activation which is also involved in the positive feedback
loop [27]. Besides inhibition of the GPVI-collagen signalling, BSE polyphenols showed inhibition of
the circulatory PMP production.
To the best of our knowledge, this is the first study investigating the effect of sorghum-derived
polyphenols on PMP production. In contrast to this study, other PMP studies have employed the
use of Annexin V as well as the platelet specific antibody CD42b, to identify pro-coagulant PMPs
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by their phosphatidylserine expression and to limit background noise [28]. However, because of the
heterogeneity of PMPs, not all PMPs express phosphatidylserine [29]. Moreover, the measurement of
CD42b-positive PMPs alone is significant as its increase has been associated with an increased risk
of coronary heart disease [30]. From the current study, the significant inhibition of CD42b-positive
circulatory PMPs observed in vitro may be attributed to the antioxidant properties of BSE polyphenols.
It is believed that the inhibition of PMP generation may be the result of neutralisation of H2O2,
scavenging of other free radicals or interaction with intracellular signalling leading to PMP release.
The juxtaposition of both the present study and that of an earlier study by Francis et al. [10]
highlights the multifaceted role of BSE polyphenols in cardio-protection. The group investigated the
effects of BSE polyphenols on the expression of antioxidant- and inflammatory-linked genes involved
in endothelial dysfunction under oxidative stress. Results indicated that BSE polyphenols alleviate
oxidative stress–induced damage to endothelial cells. Since vascular dysfunction is a precursor to
cardiovascular diseases, the current study builds upon earlier findings by exhibiting the antiplatelet
effects of BSE. In the context of endothelial dysfunction, platelet activation and circulatory PMPs
play central roles in the pathogenesis of atherothrombosis. The disruption of the plaque exposes
collagen that binds to the GPVI receptor resulting in platelet activation and subsequent thrombus
formation [31]. Circulatory PMPs may contribute to thrombosis via GPIb-IX-V receptor binding and
have a pro-inflammatory effect to promote the development of the plaque [32]. Therefore, by reducing
collagen-induced platelet aggregation and circulatory PMP generation, BSE polyphenols may be
displaying the potential to augment thrombosis.
5. Conclusion and Future Considerations
In summary, the present study contributes to the growing body of literature on bioactivity of
sorghum polyphenols and highlights possible mechanisms of antiplatelet action that may result in
cardiovascular health benefits. Because of the ability to reduce collagen-induced platelet activation and
circulatory PMP generation, BSE polyphenols demonstrate the potential to interfere with pathological
processes involved in vascular disorders and thrombotic complications. However, a larger panel of
agonist for the flow cytometry and aggregometry studies will aid to further elucidate antiplatelet
mechanisms. Because of the bioavailability concerns, well-controlled dietary intervention trials
using larger sample sizes to evaluate the antiplatelet effects of sorghum consumption in healthy and
pro-thrombotic populations are warranted to justify our findings. Because of the varied phenolic
profiles of the different sorghum varieties, further research comparing the antiplatelet therapeutic
potential of different grains is also warranted. Furthermore, this study attest to the measurement of
circulatory PMPs as a biomarker of platelet activation to assess the bioactivity of functional foods.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/6/1760/s1,
Figure S1: Characterisation of phenolic compounds in BSE. Ultra-high-performance liquid chromatography
(UHPLC) was employed to quantify the different phenolic compounds identified by the peak (on top). An online
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) was coupled with UHPLC to quantify the relative
antioxidant activity (peaks below) of each compound identified, Figure S2: A report derived from the collagen
induced platelet aggregation study using the Chrono-log model 700 lumi-aggregometer (DKSH Australia Pty. Ltd,
Hallam, VIC, Australia). The blue tracing represents the control (whole blood with no BSE) and the black tracing
represents the whole blood pre-treated with 5 μg/mL BSE. The addition of BSE reduced the maximum platelet
aggregation expressed in Ohms from 15 ohms to 11 ohms, Figure S3: A report from the ADP-induced platelet
activation analysis using Kaluza Flow Cytometry Software (Beckman Coulter, Brea, CA, USA). Results indicate
the gating of whole platelet population (CD42b positive events) and the proportion of activated platelets indicated
by PAC-1 and P-selectin expression, Figure S4: A report from the PMP analysis using Kaluza Flow Cytometry
Software (Beckman Coulter, Brea, CA, USA). Microparticle gating was established using Megamix beads of
standard sizes. PMPs were distinguished from other microparticles by size (0.5 μm - 0.9 μm) and expression of
CD42b. The number of CD42b positive events in the microparticle gate was used to quantify the PMPs, Figure S5:
The effect of varying concentrations of BSE on PAC-1 expression. BSE did not significantly reduce ADP-induced
platelet conformational change detected by PAC-1 expression (p values > 0.1 compared to control) N=14 and data
is represented in mean fluorescence intensity (MFI) versus BSE concentrations. Error bars expressed as mean ± SD,
Figure S6: The effect of varying concentrations of BSE on P-selectin expression. BSE did not significantly reduce
ADP-induced platelet degranulation detected by P-selectin expression (p values > 0.1 compared to control ) N=14
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and data is represented in mean fluorescence intensity (MFI) versus BSE concentrations Error bars expressed as
mean ± SD, Table S1: Phenolic composition and antioxidant activity of sorghum varieties on as is basis, Table S2:
List of top ten phenolic compounds identified in the black sorghum phenolic rich extracts by Q-TOF LC/MS and
quantified using UHPLC-Online ABTS system (Adapted from Rao et al., 2018).
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BSE Black sorghum extract
COX-1 Cyclooxygenase-1
DMSO Dimethyl sulfoxide
EDTA Ethylene diamine tetra-acetic acid
FBE Full blood examination
GAE Gallic acid equivalents
MCH Mean cell haemoglobin
MCHC Mean cell haemoglobin concentration
MCV Mean cell haemoglobin
MFI Mean fluorescence intensity
MPV Mean platelet volume
PAR Protease-activated receptor
PAC-1 Procaspase activating compound-1
PBS Phosphate buffered saline
PCV Packed cell volume
PGE1 Prostaglandin E1
PMP Platelet microparticle
RBC Red blood cell
SD Standard deviation
WBC White blood cell
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Abstract: Dietary polyphenol intake is associated with improvement of metabolic disturbances.
The aims of the present study are to describe dietary polyphenol intake in a population with metabolic
syndrome (MetS) and to examine the association between polyphenol intake and the components
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of MetS. This cross-sectional analysis involved 6633 men and women included in the PREDIMED
(PREvención con DIeta MEDiterranea-Plus) study. The polyphenol content of foods was estimated
from the Phenol-Explorer 3.6 database. The mean of total polyphenol intake was 846 ± 318 mg/day.
Except for stilbenes, women had higher polyphenol intake than men. Total polyphenol intake was
higher in older participants (>70 years of age) compared to their younger counterparts. Participants
with body mass index (BMI) >35 kg/m2 reported lower total polyphenol, flavonoid, and stilbene
intake than those with lower BMI. Total polyphenol intake was not associated with a better profile
concerning MetS components, except for high-density lipoprotein cholesterol (HDL-c), although
stilbenes, lignans, and other polyphenols showed an inverse association with blood pressure, fasting
plasma glucose, and triglycerides. A direct association with HDL-c was found for all subclasses
except lignans and phenolic acids. To conclude, in participants with MetS, higher intake of several
polyphenol subclasses was associated with a better profile of MetS components, especially HDL-c.
Keywords: polyphenols; metabolic syndrome; Mediterranean diet; glignans; stilbenes;
HDL-cholesterol
1. Introduction
Polyphenols are plant-derived molecules characterized by the presence of one or more aromatic
rings and attached hydroxyl groups [1]. They are classified into five subclasses according to their
chemical structure, including flavonoids and nonflavonoids subclasses defined as phenolic acids,
stilbenes, lignans, and other polyphenols. These bioactive compounds are responsible for some health
and sensory properties of foods, such as bitterness, astringency, and antioxidant capacity. The intake
of phenolic compounds and their food sources is highly variable and depends on dietary patterns,
sex, socioeconomic factors, and the native foods of each region [2]. The Mediterranean diet (MedDiet)
is characterized by a high intake of phenolic compounds because MedDiet interventions promote
the intake of phenolic rich and plant-based products, such as legumes, vegetables, fruits, nuts and
wholegrain cereals, and promote the use of extra virgin olive oil as the main source of fat. It has been
suggested that phenolic compounds are partly responsible for the beneficial effects attributed to the
MedDiet [3].
The metabolic syndrome (MetS) is defined as a cluster of metabolic disturbances, which include
impaired glucose metabolism, elevated blood pressure, and low level of HDL-c, dyslipidemia, and
abdominal obesity [4]. Sedentary lifestyle, smoking, and unbalanced diets are well-known modifiable
risk factors for MetS, and lifestyle interventions in those areas, especially dietary interventions based
on the MedDiet [3–6], might improve this condition. Considering the chronic low-grade inflammation
and oxidative stress observed in MetS, polyphenols are good candidates to improve the condition
because of their antioxidant and anti-inflammatory properties [7]. Moreover, several epidemiological
studies have observed a negative association between polyphenol intake and MetS rates [8]. Regarding
MetS components, an adequate intake of phenolic compounds has been shown to improve lipid profile
and insulin resistance, and decrease blood pressure levels and body weight [8,9].
Despite the fact that phenol-rich dietary patterns are effective in improving some MetS components,
there is no single phenolic compound or extract able to improve all the components of MetS [10].
Nevertheless, given the complexity of MetS and the heterogeneity of polyphenols, more large
randomized trials with MetS patients are needed to evaluate the effect of polyphenol intake in reducing
MetS complications, and whether intake of the different polyphenol subclasses could be associated with
improvements in MetS components, because each subtype has different absorption and metabolism [11].
Therefore, the aims of our study were firstly to describe polyphenol intake in 6633 participants
with MetS from the PREvención con DIeta MEDiterranea-Plus (PREDIMED-Plus) trial and to identify
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the main food sources of polyphenols in those participants, and secondly to examine whether higher
intakes of some polyphenol sub-classes are associated with MetS components in this population.
2. Materials and Methods
2.1. Design of the Study
A cross-sectional analysis of the baseline data of participants included in the PREvención con
DIeta MEDiterranea-Plus (PREDIMED-Plus) study was performed. The profile of the cohort, recruiting
methods, and data collection processes have been described elsewhere [12] and on the website
http://predimedplus.com. The study protocol was approved by the 23 recruiting centers Institutional
Review Boards and registered in 2014 at the International Standard Randomized Controlled Trial
Number registry (http://www.isrctn.com/ISRCTN89898870). All participants provided written informed
consent before joining the study.
2.2. Participants
A total of 6874 subjects were recruited and randomized in the 23 recruiting centers between
September 2013 and December 2016. Primary care medical doctors from primary care centers of
the National Health System assessed potential participants for eligibility. Eligible participants were
men (aged 55–75 years) and women (aged 60–75 years) with overweight or obesity (body mass index
[BMI] ≥27 and <40 kg/m2) and at least three components of MetS according to the comprehensive
definition of the International Diabetes Federation; National Heart, Lung, and Blood Institute; and
American Heart Association (2009) [4]. Exclusion criteria were documented history of cardiovascular
diseases (CVD), having a long-term illness, drug or alcohol use disorder, a BMI of 40 or higher, a
history of allergy or intolerance to extra virgin olive oil or nuts, malignant cancer, inability to follow
the recommended diet or physical activity program, history of surgical procedures for weight loss,
and obesity of known endocrine disease (except for treated hypothyroidism). Of the total sample of
6874 randomized participants, 241 participants were excluded from the current analysis (Figure 1):
53 without food-frequency questionnaire (FFQ) data at baseline, and 188 participants who reported
energy intake values outside the predefined limits (<3347 kJ [800 kcal]/day or >17,573 kJ [4000 kcal]/day
for men; <2510 kJ [500 kcal]/day or >14,644 kJ [3500 kcal]/day for women) [13].
Figure 1. Flowchart of the participants.
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2.3. Estimation of Dietary Polyphenol Intake
The total dietary polyphenol intake and polyphenol subclasses were obtained at baseline by the
143-item FFQs used in the PREDIMED-Plus study. As described elsewhere [14], dietary polyphenol
intake was estimated following these steps: (1) All foods from the FFQ with no polyphenol content,
or only traces, were excluded; (2) recipes were calculated according to their ingredients and portions
using traditional MedDiet recipes; (3) when an item from the FFQ included several foods (e.g., oranges
and tangerines), the proportion of intake was calculated according to data available in the national
survey; (4) no retention or yield factors were used to correct weight changes during cooking because
this was already taken into account in the FFQ; (5) the polyphenol content in 100 g of each food
item was obtained from the Phenol-Explorer database (version 3.6) [15]; (6) finally, the individual
polyphenol intake from each food was calculated by multiplying the content of each polyphenol by the
daily consumption of each food. Total polyphenol intake was calculated as the sum of all individual
polyphenol intakes from the food sources reported in the FFQ.
The data used to calculate polyphenol intake was obtained by chromatography of all the
phenolic compounds, except proanthocyanidins, the content of which was obtained by normal-phase
high-performance liquid chromatography. In the case of lignans and phenolic acids in certain foods
(i.e., swiss chard, chickpeas, plums, and strawberry jam), data corresponding to chromatography after
hydrolysis was also collected, since these treatments are needed to release phenolic compounds that
could otherwise not be analyzed. Total and polyphenol subclass intakes were adjusted for energy
intake (kcal/day) using the residual method [13].
2.4. Measurements and Outcome Assessment
Data on age, sex, educational levels, anthropometric measurements, dietary habits and
lifestyle were collected at baseline. Anthropometric measurements were measured according to
the PREDIMED-Plus protocol. Weight was recorded with participants in light clothing without shoes
or accessories using a high-quality calibrated scale. Height was measured with a wall-mounted
stadiometer. Waist circumference was measured midway between the lowest rib and the iliac crest.
The BMI was calculated as weight (kg) divided by the square of height (m2).
Physical activity and sedentary behaviors were evaluated using the validated Regicor Short
Physical Activity Questionnaire [16] and the validated Spanish version of the Nurses’ Health Study
questionnaire [17], respectively.
Information related to sociodemographic and lifestyle habits, individual and family medical
history, smoking status, medical conditions, and medication use was evaluated using self-reported
questionnaires. Sociodemographic and lifestyle variables were categorized as follows: age (three
categories: <65, 65–70, or >70 years), educational level (three categories: primary, secondary, or
high school), physical activity level (three categories: low, moderate, or high), BMI (three categories:
27.0–29.9, 30.0–34.9, or ≥35 kg/m2), and smoking status (three categories: never, former, or current
smoker).
Blood samples were collected after overnight fasting. Biochemical analyses were performed to
determine plasma glucose (mg/dL), glycated hemoglobin (%), HDL-c (mg/dL), and triglyceride (mg/dL)
levels using standard laboratory enzymatic methods. Low-density lipoprotein cholesterol (LDL-c;
mg/dL) was calculated using the Friedewald formula whenever triglyceride levels were less than 300
mg/dL. Blood pressure measurements were obtained after the participant had rested for five minutes.
Each measurement was obtained with a validated semiautomatic oscillometer (Omron HEM-705CP),
ensuring the use of the proper cuff size for each participant.
2.5. Statistical Analysis
Descriptive statistics were used to define the baseline characteristics of the participants.
The database used was the PREDIMED-Plus baseline database generated in September 2018.
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Continuous variables are expressed as mean ± SD. Categorical variables are expressed as number (n)
and percentage (%). Comparisons among quartiles of dietary polyphenol intake used the Pearson chi
square test (χ2) for categorical variables or one-way ANOVA for continuous variables. The associations
between dietary polyphenol intake and MetS components were analyzed by linear regression models
to determine differences between quartiles of polyphenol subclass intake. The results of the regression
models are expressed as unstandardized β-coefficients. For regression models, polyphenol and
polyphenol subclasses are expressed as quartiles of energy-adjusted dietary intake. We used robust
variance estimators to account for intra-cluster correlation in all linear models, considering members
of the same household as a cluster. All regression models were adjusted for potential confounders.
Model 1 was adjusted for sex, age, recruiting center, and members of the same household. Model 2
was additionally adjusted for physical activity level, BMI (except for waist circumference criteria),
smoking status, and educational level. We additionally adjusted for anti-diabetic treatment when
assessing glycemia and antihypertensive treatments when assessing blood pressure. Lastly, model 3
was additionally adjusted for total energy intake (continuous, kcal/day), saturated fatty acids (g/day),
and distilled drinks alcohol intake (g/day). In model 3, the analysis of glycemia was additionally
adjusted for dietary simple sugar intake (g/day), whereas the analysis of systolic and diastolic blood
pressures was also adjusted for dietary sodium intake (mg/day). The normality of the continuous
outcomes and standardized residuals was assessed with the Shapiro–Wilk test. Values are shown as
95% confidence interval (CI) and significance for all statistical tests was based on bilateral contrast set
at p < 0.05. The P value for linear trends was computed by fitting a continuous variable that assigned
the median value for each quartile in regression models. The descriptive analyses shown in Tables 1–3
were performed using SPSS software version 22.0 (Chicago, IL, USA) and the regression analysis was
performed using Stata software version 16 (StataCorp LP, College Station, TX, USA).
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3. Results
The present study was conducted on 6633 participants from the PREDIMED-Plus study. The mean
age was 65.0 ± 4.9 years, and mean BMI was 32.5 ± 3.44 kg/m2. Table 1 shows the main characteristics of
the participants according to quartiles of dietary total polyphenol intake. We observed that participants
included in the highest quartile of polyphenol intake (>1019.3 mg/day) were mainly men and former
smokers with a higher educational level (all three p < 0.001). We observed an inverse trend in the
relationship between polyphenol intake and BMI (p = 0.02), whereas this trend was direct for waist
circumference (p = 0.01) and body weight (p < 0.001). Moreover, fewer participants with insulin and
nonsteroidal anti-inflammatory drug treatment were observed in the highest quartile of polyphenol
intake (both p = 0.01).
Total polyphenol intake was 846± 318 mg/day, of which 58.0% were flavonoids (491± 253 mg/day),
33.1% phenolic acids (280 ± 131 mg/day), and the rest other polyphenols, stilbenes, and lignans (70.8 ±
41.5, 2.13 ± 3.92, and 1.53 ± 0.56 mg/day, respectively). The mean of the total polyphenol aglycone
intake was 620.9 ± 273.5 mg/day. Table 2 shows the contribution (%) of each polyphenol subclass and
polyphenol aglycones. The highest contributor to total polyphenol intake was hydroxycinnamic acids
(30.9%). Regarding flavonoids, flavanols were the main contributors (24.1% from proanthocyanidins,
3.32% catechins, and 0.08% of theaflavins), followed by flavanones (9.83%), flavones (8.65%), flavonols
(6.40%), and anthocyanins (5.14%). Additionally, tyrosols represented 6.19% of the total polyphenol
intake, being the most abundant polyphenol classified within the group of other polyphenols.
The main food sources for each polyphenol subclass are also shown in Table 2. In the case
of flavonoids, the most important contributors to the intake of proanthocyanidins were fruits and
chocolate and its derivatives. Fruits (mainly oranges and orange juice) were the greatest contributors
of flavanones, while vegetables (mainly onion, spinach, and lettuce) were the greatest contributors
of flavones. Red wine, olives, tea, and wholegrain cereals were also important contributors to the
remaining subclasses. Coffee was the most significant contributor of phenolic acids, especially of
hydroxycinnamic acids, followed by olives and red wine. Stilbenes were mainly provided by red
wine (91.9%). Lignans were widely distributed among foods, with extra virgin olive oil, fruits, and
vegetables the main contributors. The main contributors of other polyphenols were olives, olive oil,
cereals, coffee, and alcoholic beverages (mainly beer and red wine).
Table 3 shows the energy-adjusted intake of total polyphenols and the main subclasses by sex,
age, BMI, level of physical activity, educational level, and smoking status. Total polyphenol intake
was significantly higher in women due to their high intake of flavonoids (p < 0.001), whereas men
consumed more phenolic acids (p = 0.003), stilbenes, and other polyphenols. The intake of total
polyphenols, flavonoids, and lignans increased with age (p= 0.002, p< 0.001, and p= 0.006, respectively).
Interestingly, participants with the highest BMI (>35 kg/m2) showed the lowest total polyphenol
(p = 0.042), flavonoid (p = 0.004), and stilbene intake (p < 0.001), whereas phenolic acid intake was
significantly higher in this group (p = 0.006). The level of physical activity was directly associated with
total polyphenol intake (p < 0.001) and with all polyphenol classes except for phenolic acids (p < 0.001
in all cases except p = 0.03 for other polyphenols). Participants with a higher educational level (high
school) showed higher total polyphenol, flavonoid, and stilbene intake (p < 0.001 in all cases). Current
smokers reported a significantly higher intake of coffee than non-smokers (p < 0.001) and, consequently,
showed a significantly higher intake of phenolic acids (p < 0.001). Otherwise, the smokers group
showed significantly lower intake of flavonoids and lignans than their counterparts (p < 0.001, both).
The associations between dietary polyphenol intake and MetS components after full adjustment
are shown in Figure 2. High flavonoid and low phenolic acid intake were associated with lower waist
circumference (p = 0.02 and p < 0.001, respectively). The highest intake of other polyphenols was
significantly and inversely associated with systolic (p = 0.001) and diastolic blood pressure levels
(p = 0.002). An inverse association was found between fasting plasma glucose levels and lignans
(p = 0.04). Positive associations were found between HDL-c levels and all polyphenol classes except
for phenolic acid and lignan intake. Lastly, triglyceride concentration was inversely associated with
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lignans and stilbenes (p = 0.006 and p = 0.004, respectively). Changes in the linear regression models
after adjustment are shown in the Supplementary Table (Supplementary Table S1).
 
Figure 2. Energy-adjusted subclasses of dietary polyphenol intake by metabolic syndrome components
(standardized β-coefficients [95% Confidence Intervals]).
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4. Discussion
In this cross-sectional study of the PREDIMED-Plus study, we showed that high intake of some
polyphenol subclasses was inversely associated with levels of the MetS components. These associations
were especially observed for the subclasses whose contribution to total polyphenol intake was lower,
such as other polyphenols, lignans, and stilbenes. Previous epidemiological studies have investigated
the association between dietary polyphenol intake and MetS components in healthy populations or
those at high risk of CVD, but to our knowledge there are no previous studies on these associations in
subjects previously diagnosed with MetS.
In our study, the polyphenol intake was 846 ± 318 mg/day, and the intake was highest for
flavonoids (58% of total), followed by phenolic acids (33.1%), similar to results of other Spanish
cohorts [14,18]. By contrast, the total polyphenol intake was considerably lower than the intake
observed in Mediterranean countries of the EPIC Study (1011 mg/day) [19], the SU.VI.MAX cohort
study (1193 mg/day) [20], and the data from other studies conducted in non-Mediterranean countries,
such as the UK National Diet and Nutrition Survey Rolling Programme for participants of similar age
(1053 mg/day) [21]. The main noteworthy difference between our results and those of other countries
was the relevant contribution of seeds, olives and olive oil, and red wine [14,20], while coffee, tea, and
cocoa products are the foods most commonly observed in non-Mediterranean countries [22–24].
In addition to the differences observed according to geographical location and dietary habits,
sociodemographic and lifestyle habits significantly influence the quantity and profile of intake of
polyphenol subclasses. The intake of total polyphenols, particularly flavonoids and lignans, increased
with age compared to younger participants (<65 years), although Grosso et al. reported the opposite
observation [23]. In addition, BMI was inversely associated with total polyphenol intake, mainly
with lower flavonoid and stilbene intake. This finding was also reported in the TOSCA.IT and EPIC
studies [19,25].
The intake of polyphenol subclasses has been reported to have an impact on MetS
components [26,27]. Even though flavonoids were the principal contributors of total polyphenol
intake in our study, no associations were found with any of the MetS components, except for an
inverse association with waist circumference. Similar findings were described in the HELENA
study [28], where flavonoid intake was associated with lower BMI. Research on the mechanisms of
action involved in the anti-obesogenic properties of flavonoids suggests that the improvements in
glucose homeostasis are promoted by reducing insulin resistance and decreasing oxidative stress
levels [29]. Phenolic acid intake was associated with higher fasting plasma glucose levels and waist
circumference. These results are opposite from those observed in the HAPIEE cohort study, which
described the beneficial effects of phenolic acid on the overall risk of developing MetS and lowering
blood pressure [30]. Nevertheless, it must be taken into account that the dietary intake of phenolic acids
and total polyphenol in the mentioned study doubled the amount estimated in our results, probably
because of the higher intake of tea and its contribution to phenolic acid intake compared to our study
population [23]. In Mediterranean countries, dietary intake of stilbenes is relatively high compared to
other countries [19], with red wine being their main source (>90%). In this setting, higher stilbene
intake was associated with higher HDL-c levels, but since HDL-c is the best-established cardiovascular
protective factor by alcohol consumption, we cannot exclude that the alcohol content of red wine may
interfere with this result [31]. In the PREDIMED study, the intake of red wine was associated with
improvements in four out of five MetS criteria (i.e., elevated abdominal obesity, low HDL-c levels,
high blood pressure, and high fasting plasma glucose levels) [32]. Other studies also found an inverse
association between abdominal adiposity and stilbene intake, BMI, and waist circumference [30,33]. As
a mechanistic pathway for stilbenes, resveratrol has shown potential anti-obesogenic effects decreasing
adipocyte proliferation while activating lipolysis and β-oxidation [34]. However, the association
with lower body weight and waist circumference observed in the present study and the promising
effects against obesity associated with polyphenol intake observed in other studies were not clinically
relevant [35]. Our results showed an inverse association between fasting glucose and lignans, and
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an increase in HDL-c levels and lower levels of systolic and diastolic blood pressure measurements
for other polyphenols. The same finding was described in a Brazilian cohort for hypertension and
other polyphenols [36]. In contrast with our results, flavonoids, mainly anthocyanins, showed greater
antihypertensive effects in another study [37]. Finally, the association between lignan intake and fasting
glucose levels was not demonstrated to be linked with the diagnosis of type 2 diabetes (T2D) in the
EPIC study [38], but this inverse association aligned with the results observed in the PREDIMED cohort
and PREDIMED-Plus study [39,40]. The potential mechanism of action underlying this association
might be explained by the improvements observed in gut microbiota. This assumption was also
observed in a study of US women [41], showing an inverse association between levels of gut microbiota
metabolites from dietary lignan intake and T2D incidence.
Interestingly, in our study we found an association between intake of all polyphenol subclasses
except phenolic acids and lignans and higher HDL-c levels. These associations were also found with
total polyphenol intake in the TOSCA.IT study in T2D subjects [25] and in a similar cohort of participants
at high cardiovascular risk [42]. We also observed that triglyceride levels were inversely associated
with stilbene and lignan intake. Despite the fact that the antioxidant properties of polyphenols for the
prevention of LDL-c oxidation are well described, the effects of dietary polyphenols on the reduction
of total cholesterol levels or triglycerides are controverted [43].
The major strengths of the present study are its large sample size, the multicenter design, and
the use of the Phenol-Explorer as the most comprehensive food composition database on dietary
polyphenols [15]. In prior studies, the FFQ was validated to evaluate total polyphenol intake in
both clinical and cross-sectional studies [44]. Our study has also some limitations. First, it used a
cross-sectional design which does not allow attributing conclusions to plausible causes. In order to
establish causality, a randomized controlled trial based on the intake of different polyphenol subclasses
should be performed. Second, potential residual confounding and the lack of generalizability of
the results to other populations than middle-aged to elderly people with higher BMI and MetS are
limitations. Third, the use of the FFQ may have led to a misclassification of the exposure due to
self-reported information of food intake and to the fact that some polyphenol-rich foods are grouped
in the same item (e.g., spices). Nevertheless, the FFQ used has been validated in the adult Spanish
population and showed good reproducibility and validity [45]. Fourth, other factors that affect food
polyphenol content, such as bioavailability, variety, ripeness, culinary technique, storage, region, and
environmental conditions, were not collected.
Even though recent research postulates that polyphenols are effective in improving MetS, no
single phenolic compound or food has an impact on all the MetS components, suggesting that healthy
and polyphenol-rich dietary patterns such as the MedDiet may be an adequate strategy for MetS
management. This research might be useful for setting dietary and health counseling for MetS
patients, especially those with low HDL-c levels. The use of a consensus methodology and polyphenol
database might facilitate this in future studies. Future large-scale clinical trials are needed to clarify the
underlying mechanisms of action and establish safe doses for the potential health effects described.
5. Conclusions
This study provides detailed information about the relationship between polyphenol intake and
the components of MetS in a population of overweight or obese adults. Higher intake of all the
subclasses of polyphenols was associated with a better profile of the components of MetS, especially
with HDL-c levels.
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Abstract: Dietary phytoestrogens are bioactive compounds with estrogenic activity. With the
growing popularity of plant-based diets, the intake of phytoestrogen-rich legumes (especially
soy) and legume-derived foods has increased. Evidence from preclinical studies suggests these
compounds may have an effect on hormones and health, although the results of human trials are
unclear. The effects of dietary phytoestrogens depend on the exposure (phytoestrogen type, matrix,
concentration, and bioavailability), ethnicity, hormone levels (related to age, sex, and physiological
condition), and health status of the consumer. In this review, we have summarized the results of human
studies on dietary phytoestrogens with the aim of assessing the possible hormone-dependent outcomes
and health effects of their consumption throughout a lifespan, focusing on pregnancy, childhood,
adulthood, and the premenopausal and postmenopausal stages. In pregnant women, an improvement
of insulin metabolism has been reported in only one study. Sex hormone alterations have been
found in the late stages of childhood, and goitrogenic effects in children with hypothyroidism.
In premenopausal and postmenopausal women, the reported impacts on hormones are inconsistent,
although beneficial goitrogenic effects and improved glycemic control and cardiovascular risk markers
have been described in postmenopausal individuals. In adult men, different authors report goitrogenic
effects and a reduction of insulin in non-alcoholic fatty liver patients. Further carefully designed
studies are warranted to better elucidate the impact of phytoestrogen consumption on the endocrine
system at different life stages.
Keywords: isoflavones; soy; dietary flavonoids; lignans; flaxseeds; endocrine; stages of life; estrogenic;
polyphenols; health
1. Introduction
Phytoestrogens are polyphenolic molecules with a structural similarity to endogenous human
hormones, hence their estrogenic activity. The main dietary source of these plant secondary metabolites
is legumes (particularly soy), and to a lesser extent fruits, vegetables, and cereals [1]. Figure 1 shows the
most common phytoestrogens in diet. According to their origin, lignins are classified into plant lignans
(e.g., pinoresinol, secoisolariciresinol, matairesinol, and sesamin) and enterolignans (e.g., enterodiol
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and enterolactone), which are metabolized from plant lignans by intestinal bacteria [1]. Although
ingested in lower quantities than isoflavones and lignans, prenylflavonoids from beer and coumestans
from soy are also regarded as polyphenols with estrogenic activity.
Figure 1. Classification and examples of the most common dietary phytoestrogens. Images are the
chemical structures of genistein, coumestrol, and enterodiol.
The intake of phytoestrogens has increased due to the widespread use of soy products for human
consumption and as cattle food [2]. In Europe, the lowest average intake of phytoestrogens occurs in
Mediterranean countries, whereas consumption in Northern countries is 0.76 mg/day [3]. The highest
soy-derived isoflavone intakes worldwide are still in China and Japan, where the population consumes
an average of 15–50 mg per day, compared to only about 2 mg per day in Western countries [4,5].
The promising health effects of soy have driven some people in developed countries to consume it as
an alternative to meat or dairy products.
Dietary phytoestrogens are digested in the small intestine, where they are poorly absorbed.
Those that reach the liver are conjugated and circulate in the plasma until excretion in urine. Thos that
are not absorbed are metabolized by the gut microbiota into lower weight compounds [1]. The diversity
of food matrices (from pure compounds to complex foods) used in clinical studies could also lead to
different results although interindividual variability seems more determinant. It has been demonstrated
that phytoestrogen extraction from complex food matrices, such as those with high content of sugars
and proteins, is more difficult in in vitro studies; however, no clear differences regarding food matrices
were observed in humans [6]. Nevertheless, results using pure compounds must be extrapolated
carefully because not only is the matrix different, but also the concentration, which is higher in
pure extracts.
Results from human studies suggest that phytoestrogens may lower the risk of osteoporosis,
some cardiometabolic diseases, cognitive dysfunction, breast and prostate cancer, and menopausal
symptoms by modulating the endocrine system (Figure 2). However, some authors describe phytoestrogens
as endocrine disruptors and believe their beneficial effects have been overestimated [2,5,7]. This ambiguity
could be partially due to the variability of published studies, as the beneficial or harmful effects of
phytoestrogens depend on the exposure (type, amount consumed, and bioavailability), ethnicity,
hormonal status (age and sex and physiological condition), and health status of the consumer [2,5,7].
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Figure 2. Summary of potential health outcomes of phytoestrogens through the modulation of the
endocrine system in (a) thyroids, (b) liver, (c) ovaries, (d) bones, (e) hypothalamic–pituitary–gonadal
axis, (f) pancreas, (g) fat tissue, (h) prostate. FSH: follicle-stimulating hormone; GnRH: gonadotropin-
releasing hormone; IGF-1: insulin growth factor 1; LH: luteinizing hormone; OC: osteocalcin;
PE: phytoestrogens; PSA: prostate-specific antigen; SHBG: stimulating hormone-binding globulin;
T3: triiodothyronine; T4: thyroxine; TPO: thyroperoxidase.
A plausible mechanism of action for phytoestrogens is estrogen receptor (ER) binding. The effects
of isoflavones, which have a five-fold greater affinity for β-ER than α-ER [8], on the endocrine system
may be through modulation of the hypothalamic-pituitary axis [9]. However, not all the biological
effects of phytoestrogens involve estrogen receptors. They can also activate serotonergic and insulin-like
growth factor (IGF) receptors 1, induce free radical binding and modify tyrosine kinases, cycle adenosine
monophosphate (cAMP), phosphatidylinositol-3 kinase (PI3K)/Akt, mitogen-activated protein (MAP)
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kinases, transcription of nuclear factor-kappa β (NF-Kβ), as well as promote DNA methylation and
affect histone and RNA expression. In addition, phytoestrogens can act as intracellular regulators
of the cell cycle and apoptosis. Thus, due to their antioxidant, antiproliferative, antimutagenic,
and antiangiogenic roles, phytoestrogens can improve health [10]. In addition, some authors observed
that estrogen and androgen seem to be involved in breast and prostate cancer regulating proliferative
and migratory signaling, such as Src/PI3K. Hormonal therapy response may vary depend on interactions
between estrogen or androgen receptors and proteins, according to hormone levels [11–13].
This integrative review aims to synthesize the results obtained by human studies and assess the
potential hormone-related health effects of dietary phytoestrogens throughout the human lifespan.
2. Effects of Phytoestrogen Intake on Sex Hormones
The anti-estrogenic activity of phytoestrogens is due to their structural similarity with 17-β-
estradiol (E2), the main female sex hormone [5]. As well as interacting with ERs, phytoestrogens can
affect the secretion of gonadotropin-releasing hormone (GnRH) [14]. Phytoestrogens could disrupt the
endocrine system by interfering with the hypothalamic–pituitary–gonadal axis, which controls estrogen
secretion. The hypothalamus releases GnRH and stimulates the pituitary to produce follicle-stimulating
hormone (FSH) and luteinizing hormone (LH), gonadotropins that promote the secretion of estrogen,
progesterone, and testosterone by the ovaries or testes. Low estrogen levels are a signal for the
hypothalamus to release GnRH, whereas high levels provide a negative feedback [15]. Therefore,
the presence of exogenous compounds structurally similar to E2 may interfere with this system.
Some studies have focused on how phytoestrogen affects urinary estrogen metabolites, some of
which may be involved in the development of breast cancer. In particular, the ratio of 2-hydroxyestrone
(2-OH-E1) to 16α-hydroxyestrone (16α-OH-E1) (2:16α-OH-E1) is considered a useful biomarker of
estrogen-related cancer risk. A major 2:16α-OH-E1 ratio is related to lower risk of breast cancer.
Previously, it was observed that a higher concentration of 16α-OH-E1 was associated with breast and
endometrial cancer, while an increase of metabolite 2-OH-E1 seems to inhibit the carcinogenesis [16].
Phytoestrogens have also been reported to affect sex hormones through ER-independent
mechanisms of action, such as by altering hormone-binding globulin (SHBG) levels. Circulating
estrogens and androgens are mostly bound to albumin and SHBG, with only a small fraction remaining
free. As estrogens and androgens are only biologically active in their free form, SHBG affects steroidal
activity. In vitro studies have shown that isoflavonoids stimulate the synthesis of SHBG by liver cancer
cells [17], but available data from human studies are inconclusive [18,19]. In addition, phytoestrogens
inhibit aromatase and other enzymes involved in the synthesis of steroid hormones [20].
Preclinical studies have suggested that phytoestrogens influence sexual function and the incidence
of cancer associated with the reproductive system such as ovarian and breast cancer [21], but the results
of cross-sectional studies and clinical trials are conflicting [22,23]. In addition to factors such as dose,
type, and bioavailability, the effects of phytoestrogens on sexual function could also depend on the life
stage of the consumer, as explained below.
2.1. Pregnancy
The results of a longitudinal study that measured E2, estriol (E3), testosterone, and isoflavones
in urine and serum from 194 pregnant women weakly support the initial hypothesis that genistein
and daidzein would reduce levels of E2 and testosterone at the 10th week of gestation. Additionally,
sex hormones quantified in umbilical cord serum were not related to isoflavones (genistein, daidzein,
and equol) measured at delivery [24].
2.2. Children
Dietary phytoestrogens seem to be transferred from maternal blood to the fetus, but there is
no evidence that they alter sex hormones in infants [25–27]. Although isoflavone bioavailability in
this sensitive period may be higher than in adults [28], no estrogenic effects were observed in infants
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fed with a soy formula [29–31]. Nevertheless, a cross-sectional study carried out in children aged
3–6 years reported an increase of androgens in girls and a decrease of estrogens in boys consuming
higher amounts of soy and isoflavones [25]. In a crossover trial conducted in girls aged 8–14 years,
the consumption of a high-soy diet for 8 weeks significantly increased dehydroepiandrosterone (DHEA)
concentrations but not other sexual hormones. Although the level of all sex hormone metabolites
excreted was very low, positive correlations with the intervention were found, being higher for total
androgens than for estrogens and pregnanediol [32].
2.3. Men
A cross-sectional study in randomly selected Japanese men found a negative association between
soy product consumption and E2 serum concentrations, but no link was observed with peripheral
concentrations of androgen hormones [33]. In a randomized clinical study in Japanese healthy male
volunteers consuming 60 mg per day of soy isoflavones, no changes in serum levels of E2 and total
testosterone were observed compared to the baseline at the end of the 3-month intervention. However,
serum levels of SHBG increased and free testosterone and dihydrotestosterone decreased [34].
There is weak evidence that phytoestrogens contribute to reducing the risk of prostate cancer
(PCa). Several observational studies have found a negative association between the consumption of
phytoestrogens (soy and its isoflavones) and the levels of prostate-specific antigen (PSA) in blood [35].
PSA, a protein produced by the prostate gland, is used as a marker to detect PCa, although its levels
also increase with benign prostate hypertrophy. In a randomized controlled trial, a reduction in PSA
levels was observed in men with PCa after consuming soy isoflavones for a mean of 23 days [36].
However, longer studies (minimum 3 weeks and maximum 12 months) did not find beneficial effects
on PSA levels after a soy isoflavone intervention [37–40], nor were changes in PSA plasma levels
observed in PCa patients that consumed rye bran bread for 3 weeks [41].
There is a relationship between sex hormones and the pathogenesis of PCa. High levels of
androgens, which promote prostate cell growth, may contribute to the risk of PCa in some men.
Some epidemiological studies suggest that low levels of testosterone are associated with a lower risk of
PCa [42,43]. A meta-analysis of 32 studies published in 2010 by Hamilton-Reeves et al. reported that
the consumption of isoflavones had no significant effect on circulating testosterone or free testosterone
levels in men [44], in agreement with other clinical trials evaluating phytoestrogen intake in PCa
patients [37,39–41]. Nor have effects on dihydrotestosterone been described [36,40]. However, in an
open-labeled, non-randomized clinical trial of men with higher levels of PSA, free testosterone was
depleted after 12 months of daily consumption of 141 mg of isoflavones in soy milk [38].
Recent studies have pointed to a protective role of estrogens in PCa development and progression,
alone or in synergy with androgens [45]. Several studies have focused on the beneficial effect of
soy isoflavones, specifically genistein and daidzein, as these components can act as weak estrogens.
A 6-month randomized controlled study evaluating the effects of isoflavone on men at high risk of
developing advanced PCa found an increase in concentrations of the estrogen hormones estrone
(E1), E2, 2-hydroxi-estradiol (2-OH-E2), and 16α-OH-E1. An increase in the 2:16α-OH-E1 ratio was
also reported, which is related to a reduced risk of estrogen-mediated cancer. No differences were
observed for 2-methoxyestradiol (2-ME2), 1-methoxyestrone (2-ME1), E3 and 2-OH-E1 [46]. Conversely,
Bylund A. et al. reported that levels of E2, FSH, and LH in PCa patients remained unaltered after a
3-week rye bran bread intervention [41].
2.4. Premenopausal Women
In agreement with the potential anti-estrogenic effect of phytoestrogens, some authors have
observed a significant decrease in estrogen levels after the consumption of soy products [18,22,47–49].
In a randomized controlled cross-over trial conducted in 12 healthy premenopausal women,
those consuming a high-soy diet for three menstrual cycles had lower urinary concentrations of
total estrogens (E1, E2, E3), and some metabolites compared to individuals on a low-soy diet [22].
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Although significant correlations were obtained between serum levels of unconjugated estrogens,
and urinary conjugated and unconjugated estrogen metabolites, the large intra-subject variability
in urinary estrogen levels limits its use as a biomarker [50]. Similarly, a fall in the circulating levels
of E2 after the consumption of a soy-rich diet has been reported [47–49]. In a cross-sectional study,
Kapiszewska M. et al. found an association between low salivary E2 concentrations and the intake
of black tea (only or plus green tea), catechins, theaflavins, and epigallocatechin gallate (EGCG),
being more pronounced in premenopausal women living in urban areas than in those living in
rural areas [51]. As well as a decline in estrogens, a significant decrease in progesterone levels
after phytoestrogen consumption has been observed [47–49,52]. Conversely, other clinical trials and
observational studies do not report any modifications of sex hormones attributed to the consumption
of dietary soy-isoflavones [14,19,23,53–58].
It has been proposed that changes in estrogen levels induced by dietary phytoestrogens could
depend on the individual capacity to produce equol [59,60], mainly the S-equol enantiomer, due to its
high affinity for β-ER [61]. Accordingly, Duncan et al. reported that premenopausal equol excretors
had a lower risk of breast cancer compared to non-excretors [60].
In summary, it is still uncertain if a phytoestrogen-rich diet triggers an imbalance of estrogen and
progesterone concentrations. In randomized controlled crossover trials, no significant changes were
observed in the progesterone/E2 ratio in women who consumed a soy diet for two menstrual cycles [56],
whereas the ratio increased after the intake of 10 g/day of flaxseeds for three menstrual cycles [62].
The status of sex hormones can also be an indicator of breast cancer risk. Although measuring
estrogen and progesterone concentrations in nipple aspirate fluid may be better than using serum
samples to detect dietary-associated changes in the breast, the correlation between dietary phytoestrogen
and estrogens was poor in both matrices [58]. On the other hand, the scant evidence for an increase in the
2:16α-OH-E1 ratio after the consumption of soy and flaxseed suggests such high-phytoestrogen foods
may have a protective role against breast cancer [22,48,63]. In the same vein, Xu et al. observed a decrease
in the ratio of genotoxic metabolites (16α-OH-E1, 4-hydroxyestradiol (4-OH-E2), and 4-hydroxyestrone
(4-OE-E1)) and total estrogens [22]. However, no effects on biomarkers related to breast cancer risk
have been reported in other studies [23,56,59].
Inconclusive effects of phytoestrogen supplementation in the form of soy protein powder (low and
high doses) on the concentrations of FSH and LH have been observed. Both hormones decreased
after low- but not high-isoflavone diets [18], as well as after the consumption of soy products [52,64].
However, other studies found no significant changes in FSH and LH concentration after phytoestrogen
supplementation [14,23,48,49,53–55].
Most authors have not found any effects of a phytoestrogen-rich diet on circulating levels of
androgens [23,53,56,57,64,65]. Two clinical trials did report a decrease of DHEA-sulfate concentrations
in healthy premenopausal women after 1 to 3 months on a diet high in soy and soy products [18,47].
In contrast, in a randomized controlled clinical trial (RCT) conducted in healthy premenopausal women
consuming 10 g/day of flaxseeds for three menstrual cycles, an increase in serum levels of testosterone
in the mid-follicular phase was observed [62]. Overall, there is no solid evidence supporting the
influence of phytoestrogens on SHBG [19,23,49,52,53,55–57,62,64–66], although a weak increase has
been described [18,67,68].
A prolonged menstruation after regular intake of phytoestrogens has been reported [62,68],
but most studies indicate no significant changes in menstrual cycle length or concentration
of prolactin [18,23,53,56,57,62,65,66].
2.5. Postmenopausal Women
Menopausal transition is caused by the depletion of ovarian follicles and their responsiveness to the
pituitary gonadotropins FSH and LH. This results in low serum levels of the ovarian hormones estrogen
and progesterone, and also an increase in FSH concentrations due to the disruption in the negative
feedback regulating the hypothalamic–pituitary–gonadal axis [69]. These hormonal changes are
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responsible for several menopausal symptoms, such as vasomotor symptoms, hot flushes, and vaginal
dryness, as well as long-term disorders like osteoporosis, cardiovascular diseases, and breast cancer.
In postmenopausal women there is little evidence supporting the hypothesis that phytoestrogens
affect sex hormone levels. Numerous studies have reported that phytoestrogens—including isoflavones,
flavonoids, and lignans—do not affect estrogen or progesterone concentrations in postmenopausal
women [7,14,19,70–95]. However, other clinical studies did find that isoflavone administration produced
significant changes in E2 [96,97] or progesterone concentrations [98]. Two other postmenopausal
studies suggested that flaxseed lignans may reduce E2 and E1 sulfate [99] in healthy women, and E1
concentrations in obese and overweight women [100]. Tormala R. et al. (2008) also reported lower
E1 concentrations after soy protein supplementation in tibolone-using postmenopausal women who
were equol producers [101]. In one epidemiological study, the relationship between isoflavone intake
and peripheral E2 concentrations was assessed in postmenopausal women, and urinary excretion of
daidzein, genistein, and glycitein and serum levels of daidzein and glycitein were associated with
lower plasma E2 levels. Interestingly, these associations were stronger in 18 postmenopausal women
with the CC genotype for ESR1 Pvull polymorphism, suggesting that genes influence diet effects [102].
Phytoestrogen effects on urinary estrogen metabolites have been studied in order to assess their
potential protective role against breast cancer. One of the most recent studies reports an increase in the
2:16α-OH-E1 ratio after red clover-derived isoflavone supplementation in postmenopausal osteopenic
women [103]. These results are consistent with prior research that found an increase in the 2:16α-OH-E1
ratio after flaxseed supplementation [104,105]. Other studies, however, did not find any difference
in the ratio after phytoestrogen supplementation in postmenopausal women [81,95], and one even
reports a lower ratio [106].
Other hormones affected by the disruption of the hypothalamic–pituitary–gonadal axis are the
gonadotropins FSH and LH, which according to different clinical trials are not affected by phytoestrogen
supplementation [14,79,82,83,107–109]. Only Crisafulli A et al. found lower gonadotropin levels after
54 mg/day of genistein supplementation for 6 months in 60 postmenopausal women compared to the
control group [110].
Whereas some clinical studies found that isoflavone consumption increased SHBG levels in
postmenopausal women [18,71,96,110], others concluded the opposite. Thus, Wu A.H. et al. (2012)
and Uesugi S et al. report lower concentrations of SHBG in healthy postmenopausal women after
supplementation with EGCG or isoflavones [91,97], but most of the studies found no association
between SHBG levels and phytoestrogen intake [19,78,79,81,83,85,86,88,95,99,100,102,108,109,111–113].
Lastly, results from epidemiological studies support the hypothesis that some phytoestrogens may
have a positive influence on SHBG. Monroe K.R. et al. showed that plasma enterolactone levels were
associated with higher concentrations of SHBG in postmenopausal Latina women [114]. Low et al.
also reported higher concentrations of SHBG in postmenopausal women with higher urinary excretion
of lignans, but no association was found with the excretion of other phytoestrogens, such as isoflavones,
equol, or O-desmethylangolesin (O-DMA) [115].
To date, most of the few human studies evaluating phytoestrogen effects on androgens in
postmenopausal women have found no associations between phytoestrogen intake and androgen
peripheral concentrations [74,82,85,86,91,109,116]. Yet Basaria S. et al. reported a decrease in
testosterone levels after 12 weeks of isoflavone supplementation, results that were supported by Kapoor
R. et al. only in normal-weight postmenopausal women consuming pomegranate for 3 weeks [111,113].
Bioavailable testosterone remained unchanged in both trials. Furthermore, Wu W.H. et al. also reported
lower levels of DHEA-sulphate, an androgen precursor, in postmenopausal women after a 5-week
intervention with sesame lignans [81].
3. Effect of Phytoestrogen Intake on Thyroid Hormones
It is not clearly established if phytoestrogen consumption alters the hypothalamic–pituitary–
thyroid axis and triggers goitrogenic effects in humans [9,117]. A randomized, double-blind, and cross-
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over trial carried out in 60 patients with subclinical hypothyroidism and an adequate iodine intake
reported an advance to overt hypothyroidism in 10% of cases (6 females) after administering soy
protein with isoflavones for 8 weeks [118]. Nevertheless, soy isoflavones appear not to affect euthyroid
populations with an optimal iodine status [9,117]. Controversial results have been obtained by studies
in healthy humans, who did not experience anti-thyroid or any other effects after consuming dietary
phytoestrogens, particularly isoflavones. The evidence for the impact of phytoestrogens on thyroid
function according to the life stage is provided below.
3.1. Pregnant Women
A cross-sectional study found no association between soy consumption in early pregnancy and
the development of thyroid dysfunction or autoimmunity in 505 women living in areas with an optimal
intake of iodine [119]. However, further studies in countries with iodine deficiency are needed.
3.2. Children
A cross-sectional study in children aged 8–15 years in an iodine-deficient region of the Czech
Republic did not obtain conclusive results. Although levels of free thyroxine (free-T4) increased
after a higher intake of soy, a positive correlation was observed between serum daidzein levels
and thyroid stimulating hormone (TSH) [120]. In a retrospective study, children with congenital
hypothyroidism fed with soy formula had a higher concentration of TSH compared to those fed with
non-soy formula [121]. Nevertheless, a study in 12 hypercholesterolemic children consuming toffee
candies containing isoflavone extract for 8 weeks did not find any effect on TSH, triiodothyronine (T3),
or T4 levels [122].
3.3. Men
Two clinical trials showed that products with a high phytoestrogen content had anti-thyroid
effects in male populations [123,124]. Hampl R. et al. observed a significant increase of serum TSH
in young males after supplementation with 2 g/kg body weight/day of boiled unprocessed natural
soybeans for 7 days [123]. Similarly, significant changes in TSH (increasing) and free-T4 (decreasing)
were found in men with type-2 diabetes mellitus and compensated hypogonadism after consumption
of 15 g/day of soy protein isoflavones for 3 months [124].
3.4. Premenopausal Women
No significant changes in thyroid function were found in healthy and obese premenopausal
women consuming soy isoflavones for periods of 1 week to 6 months [53,123,125], but reduced free-T3
levels were found in healthy young females following a high-soy diet for three menstrual cycles [126].
3.5. Postmenopausal Women
A randomized, double-blind and parallel trial conducted in 120 postmenopausal women reported
a significant increase in TSH and a decrease of free-T4 after the intake of 66 mg/day of soy isoflavones
for 6 months [124]. Jayagopal V. et al. obtained similar results in a cross-over design trial involving
32 postmenopausal women with type-2 diabetes mellitus consuming twice the amount for half the
duration [109]. Another parallel RCT conducted by Mittal et al. in oophorectomized women showed a
decrease in free T3 after a 12-week intervention with 75 mg/day isoflavone [127]. Other authors found
no significant differences in the level of thyroid hormones, but other thyroid-related parameters such
as thyroxine-binding globulin (TBG) and the T3:T4 ratio were altered, indicating possible goitrogenic
activity derived from phytoestrogen consumption [18,108]. In addition, Sosvorová et al. observed the
presence of mono-iodinated derivatives of daidzein and genistein in urine after daily consumption
of isoflavonoids for 3 months, which could explain the entry of genistein and daidzein in human
thyroid follicles and thyroperoxidase modification [108]. However, other RCT observed no significant
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changes in thyroid function after isoflavone intake [84,128–130]. Nor was an effect reported in
longer studies (1 to 3 years of duration) after the administration of different doses of isoflavones
(2–200 mg/day) [74,93,131–133], possibly because adaptation to long-term changes in dietary isoflavone
intake triggers endocrine autoregulation [95].
4. Effect of Phytoestrogen Intake on Cardiometabolic Risk-Related Hormones
Cardiometabolic diseases encompass a set of dysfunctions affecting the cardiovascular system.
These are not limited to hard cardiovascular events such as coronary heart disease, myocardial infarction,
and stroke, but also include cardiovascular risk factors, namely obesity, insulin resistance, endothelial
dysfunction, atherosclerosis, lipid profile, or non-alcoholic fatty liver disease, among others [134].
Obesity is usually the first risk factor that triggers chronic low-grade inflammation, which plays a
crucial role in systemic metabolic dysfunction. Adipose tissue and adipocytes are dysfunctional
in obese individuals, causing the secretion of pro-inflammatory adipokines that contribute to
chronic inflammation and subsequently to the progression of cardiometabolic disorders like
insulin resistance [135–137].
Another condition that increases the odds of suffering cardiovascular diseases is type-2 diabetes
mellitus, which involves alterations in intestinal sensitivity to insulin and glucagon-like peptide-1
(GLP-1), as does its previous state, insulin resistance. GLP-1 has a variety of metabolic effects,
including the glucose-dependent stimulation of insulin secretion, and is also involved in cardiovascular
health [138]. Insulin, an anabolic hormone secreted in the pancreas, also regulates carbohydrate
metabolism, participates in the storage of free fatty acids in adipose tissue, and enhances protein
synthesis, increasing amino acid uptake by tissues [139].
Some authors have studied whether phytoestrogens can decrease the levels of pro-inflammatory
adipokines such as leptin and resistin or increase adiponectin, an anti-inflammatory hormone,
as well as regulate the secretion of insulin, glucagon, and ghrelin. Ghrelin, a recently discovered
hormone related to cardiovascular health, is involved in feeding behavior, energy homeostasis, and
carbohydrate metabolism. It therefore participates in body weight maintenance, which is crucial for
vascular health [140].
4.1. Pregnancy
Only one study has evaluated the relationship between phytoestrogens and cardiovascular
health during pregnancy. Shi et al. analyzed the association between urinary concentrations of
isoflavonoids and cardiometabolic risk markers using data from 299 pregnant women from the
NHANES cohort [141]. Those in the fourth quartile of isoflavones had lower levels of insulin and
insulin resistance compared to women in the first quartile. None of the individual isoflavonoids
(daidzein, equol, and O-desmethylangolensin) in urine were significantly associated with insulin levels.
4.2. Adults
To date, two American cross-sectional studies have examined the relationship between
phytoestrogens and cardiovascular-related hormones in healthy adults. In one, only lignan intake
seemed to be associated with lower fasting insulin in men [142], whereas the other study reported no
significant differences [143]. Ferguson et al. took a different approach, inducing transient endotoxemia
in young and healthy volunteers and then analyzing the ability of dietary phytoestrogens to reverse the
inflammatory response. They found a significant decrease of insulin sensitivity with the higher intake
of isoflavones. The participants were asked to follow a healthy diet but did not receive counseling
related to soy food intake. Moreover, similar trends were found in two independent cohorts (MECHE
and NHANES) [144].
Six RCTs have evaluated the effect of phytoestrogens on cardiovascular health. The participants
in four studies were at high cardiovascular risk [145–148], in one they were men with increased
risk of colorectal cancer [149], and in the other they were healthy men [150]. Interventions included
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isoflavones [149,150], soy nuts [145], daidzein [146], genistein [148], and S-equol [147] administered
for periods ranging from 4 weeks to 6 months. Three of the trials found no significant effects on
insulin, leptin, or adiponectin [145–147]. However, Amanat et al. report that a daily dose of 250 mg of
genistein administered to non-alcoholic fatty liver patients for 8 weeks reduced insulin levels [148].
Maskarinec et al. concluded that men who consumed soy early in life had higher levels of leptin,
although no association was observed with soy intake during adulthood [150]. Finally, the results
of the trial with subjects at high colorectal cancer risk suggested that isoflavones might reduce the
insulin-growth factor but only in equol producers [147].
4.3. Postmenopausal Women
Most studies on phytoestrogen intake and cardiometabolic hormones have evaluated insulin and
insulin resistance (HOMA-IR) in postmenopausal women. The largest observational study included
301 women from The Netherlands and used food frequency questionnaires to assess dietary isoflavone
and lignan intake. Individuals with a high lignan diet had lower blood pressure but no significant
associations with insulin were observed [151]. In another cross-sectional study women in the highest
quartile of lignan or enterolactone intake had better anthropometric profiles and insulin sensitivity [152].
Among published clinical trials, a research group from Italy has carried out several studies
monitoring cardiovascular risk factors in women receiving 54 mg of genistein. After a 6-month
intervention in 60 healthy women, a decrease in insulin and insulin resistance was observed [110].
Similar results were obtained after 12 and 24 months of intervention in a related study in 389 osteopenic
postmenopausal women, who received the same dose of genistein plus calcium and vitamin D [153],
the values remaining consistent after an extra year of follow-up in a sub-cohort [154]. Examining the
role of metabolic status, Villa et al. divided the intervention group into normo- and hyperinsulinemic
patients and found that genistein improved insulin sensitivity indexes only in in the latter [71]. Similarly,
women with metabolic syndrome who consumed 54 mg of genistein had lower levels of fasting insulin
and HOMA-IR, and higher levels of adiponectin than the placebo group [155,156]. More recently,
a research group from Iran assessed the effectiveness of 108 mg of genistein on different metabolic
factors in 54 women with type-2 diabetes mellitus in a 12-week intervention. As in the other studies,
genistein reduced insulin sensitivity [157].
Other RCTs have used soy isoflavones instead of genistein, administering daily doses of 40–160 mg,
far higher than the phytoestrogen intake reported in observational studies. For example, in one RCT the
mean daily isoflavone intake in the highest tertile was 11.4 mg [151] as opposed to a total mean intake
of 0.06 mg in an observational study [152]. Most of the trials with isoflavones have been performed
in healthy postmenopausal women for durations ranging from 8 weeks to 24 months. Generally,
the studied vascular-related hormones are leptin, adiponectin, and insulin, although in few cases,
ghrelin and resistin have also been evaluated. Results from these trials are ambiguous. Whereas most
report no significant changes in any of the aforementioned hormones [158–160], others have found
beneficial effects on insulin markers in the treatment group compared to the control [118,161–163], or a
significant increase in adiponectin peripheral levels [164]. Overall, we can conclude that phytoestrogen
therapy did not change hormone levels in obese postmenopausal women [70,165], whereas among
diabetic women in a randomized cross-over trial there was a significant decrease in insulin resistance
in the soy consumers compared to the placebo group [109].
5. Effect of Phytoestrogen Intake on Hormones Related to Stress Response
No significant changes in cortisol were observed in healthy women or in those at cardiometabolic
risk after consuming soy isoflavones for 2–6 months [18,23,53,95,126]. However, differences between
equol excretors and non-excretors have been described in premenopausal women, levels being lower
in those who produce this metabolite [60].
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6. Effect of Phytoestrogen Intake on Hormones Related to Bone Remodeling
Estrogen plays a key role in bone metabolism, contributing to bone mass acquisition in puberty
and helping to maintain normal bone density in adulthood [166]. Given that phytoestrogens are
structurally similar to estrogens, they can bind to ERs in bone and exert estrogenic actions [167].
Most studies examining the impact of phytoestrogens on bone health measure osteocalcin (OC),
a metabolic regulatory hormone secreted by osteoblasts, as it is a sensitive biomarker for bone
formation [168]. Parathyroid hormone (PTH), secreted by the parathyroid glands, plays an important
role in calcium and phosphate metabolism. As well as stimulating bone turnover, there is increasing
evidence that PTH may also promote bone formation [169].
6.1. Children
Early-life exposure to soy protein formula did not produce any change in OC and PTH in a clinical
study of 48 children [29]. Even though the available data suggest that phytoestrogen intake does not
affect bone-related hormones in early stages of life, more studies are needed to clarify this relationship.
6.2. Premenopausal Women
The reported effects of dietary phytoestrogen on bone health in premenopausal women are
inconsistent. Kwak H.S. et al. found an increase in serum OC after the administration of 120 mg/day
of soy-isoflavones for three menstrual cycles. They also observed that high genistein-excretors in
the soy group had higher concentrations of OC, suggesting that individual variation may affect
the metabolism and functions of isoflavones [54]. However, previous studies report unaltered OC
levels [170,171], indicating a need for more research on the phytoestrogen effects on bone metabolism
in premenopausal women.
6.3. Postmenopausal Women
After menopause, estrogen concentrations decrease dramatically, triggering a greater risk of
osteoporosis [172]. Phytoestrogens might improve bone health due to their estrogenic effects, and it
has been hypothesized that they could reduce the risk of osteoporosis. Chiechi L.M. et al. and
Scheiber M.D. et al. report an increase in OC concentrations in postmenopausal women who consumed
a soy-rich diet for 6 and 3 months, respectively. Although uncorroborated by the majority of studies,
these results indicate a stimulation of osteoblast activity and suggest that soy may have beneficial
effects on bone health [173,174]. It has been suggested that longer treatments may be necessary to
produce any change in bone metabolism, but to date neither shorter nor longer studies have reported
any alterations in OC related to phytoestrogen intake [74–77,96,97,107,170,175–179].
In contrast, beneficial effects on bone metabolism through mechanisms of action not involving
OC have been described in healthy postmenopausal women [77,97,175–179]. Lambert M.N.T. et al.
demonstrated that red clover-derived isoflavones combined with probiotics attenuated estrogen-
deficient bone mineral density loss and improved bone turnover even in postmenopausal women with
osteopenia [177]. Moreover, a recent meta-analysis and systematic review of RCT with perimenopausal
and postmenopausal women concluded that isoflavones can be effective in preserving bone mineral
density and attenuating accelerated bone resorption [103]. A possible explanation for these contrasting
results could be that estrogens are predominantly antiresorptive agents, so the beneficial effects of
phytoestrogens may arise from decreased bone resorption by osteoclasts rather than increased bone
formation by osteoblasts.
Lastly, administration of isoflavones or genistein alone for 1 to 24 months did not alter PTH in
postmenopausal women [78,92,180–183]. Only a cross-sectional study carried out with Chinese women
found that postmenopausal women with a high intake of isoflavone had lower serum PTH levels [184].
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7. Effect of Phytoestrogen Intake on Insulin-Like Growth Factors
Insulin growth factor 1 (IGF-1) is part of the growth hormone (GH)—IGF-1 axis and is mostly
produced in the liver in response to GH stimulation. Among many other functions, IGF-1 binds its
receptor on osteoblasts and enhances bone formation, so any changes in this hormone will have an
impact on bone health [185]. Consequently, some studies have used IGF-1 and its binding proteins
IGFBP-1 and IGFBP-3 as bone turnover biomarkers.
In addition, several epidemiological studies have shown that higher levels of IGF-1 are associated
with an increased risk of different types of cancer. IGF-1 exerts its actions by binding to the IGF-1
receptor, which is expressed in most tissues of the body and stimulates cell proliferation (Cohen DH
2012). Apart from higher levels of IGF-1, several cancers also overexpress its receptor IGF-1R, which has
a negative impact on their progression. IGF-2 also appears to be associated with gastrointestinal and
gynecological tumors [186].
It has been hypothesized that phytoestrogens may interfere with the IGF system through
their effects on steroid hormone physiology or by disrupting GH and IGF signaling [187]. However,
the limited evidence in humans is inconclusive, as studies have found both positive and negative results.
7.1. Premenopausal Women
To date, only two RCTs have evaluated phytoestrogen effects on IGF-1 and its binding proteins in
premenopausal women. In the first study, groups of 14 women consumed soy protein isolates providing
8 mg (control), 65 mg (low dose), or 130 mg (high dose) of isoflavones daily for three menstrual cycles.
The low dose significantly increased IGF-1 concentrations compared to the high dose only in the
periovulatory phase of the menstrual cycle, although no value was significantly different compared
to the control group. A similar result was obtained with IGFBP-3; its concentrations were increased
by the low dose diet compared with the high dose in the early follicular phase, but they did not
differ from those of the control group [170]. The other study assessed the effects of red clover-derived
isoflavone supplementation on IGF-1, IGFBP-1, and IGFBP-3 and its role in breast cancer prevention.
This one-month intervention resulted in a non-significant reduction in IGF-1, but this was likely due to
differences in IGF-1 levels at baseline between the placebo and the control group. Interestingly, the IGF
status was found to be influenced by the stage of the menstrual cycle [188].
Epidemiological data does not support a phytoestrogen effect on IGF levels either. A Japanese
cross-sectional study reported that there was no correlation between soy products and isoflavone
intake and serum IGF-1 and IGFBP-3 in 261 premenopausal women [189]. Another observational
study in women living in Japan and Hawaii also failed to find an association between tofu intake and
IGF-1, IGFBP-3, and IGF-1 molar ratio in premenopausal women [190].
7.2. Postmenopausal Women
Most clinical studies on IGFs in postmenopausal women have failed to find a protective effect of
phytoestrogens against osteoporosis, breast cancer, or colorectal cancer. One of the most recent found
no impact on IGF-1 in women with osteopenia after a 24-month intervention [183], which is consistent
with other studies reporting that isoflavone supplementation did not alter the IGF system [170,188,191].
Similar results have been obtained for lignan consumption. After administering flaxseed lignans for
3 months, Lucas E.A. et al. found that IGF-I and IGFBP-3 levels were unaltered [88]. An RCT in which
103 postmenopausal women consumed 400 or 800 mg of EGCG for 2 months found no significant
changes in IGF-1 or IGFBP-3, although the latter tended to increase in both groups [91].
In contrast with these results, a study comparing the effects of soy protein and milk-based protein
reported that both supplements increased IGF-1 levels. Further stratification showed that soy protein
had a more pronounced effect on women who were not on hormone replacement therapy [192].
A cross-sectional study found an association between phytoestrogens and growth factors, specifically
an inverse association between tofu intake and IGF-1 levels and the molar ratio in postmenopausal
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women, whereas no changes were observed in those who had never used hormone replacement
therapy [190]. However, a similar observational study performed in participants of the Singapore
Chinese Health Study did not find any association between soy intake and the IGF-1, IGFBP-3, and IGF
molar ratio [193].
7.3. Men
It is well established that higher circulating IGF-1 levels are associated with an increased risk of
PCa [194], and most studies assessing phytoestrogen effects on adult men have consequently focused
on PCa patients. In one of two clinical trials with PCa patients, no changes in IGF-1 or IGFBP-3 were
observed after a 3–6-month intervention consisting of 200 mg/day of soy isoflavones [37] and in the
other Bylund A. et al. (2003) also found that IGF-1 levels remained unaltered after the administration
of rye bran bread for 3 weeks [41]. Conversely, a cross-sectional study with 312 men reported a positive
association between soy intake and the IGF-1, IGFBP-3, and IGF molar ratio [193].
8. Conclusions
This review has summarized the results of studies on the effects of dietary phytoestrogens
on endocrine regulation in humans. Although preclinical studies (in vitro and in animal models)
show phytoestrogens to be potentially estrogenic compounds, triggering anti-estrogenic effects in the
organism, the results of epidemiological studies are ambiguous.
The impact of phytoestrogens can vary according to the life stage (Figure 3). There is particular
concern about how they may affect pregnant women, as this has been poorly studied. Soy isoflavones
appear not to have any influence on sex and thyroid hormones, bone remodeling and IGF. However,
a study focused on cardiometabolic risk reported a decrease in the level of insulin and insulin resistance
in pregnant women consuming higher amounts of isoflavones. Although phytoestrogens transfer from
maternal blood to the fetus, no effects have been observed in early life. Nor have endocrine changes
been found in infants fed with soy formula, except in a retrospective study carried out in the first year
of life of infants with congenital hypothyroidism, which reported an increase of TSH but no conclusive
effects on thyroid function. Nevertheless, consumption of phytoestrogens in conditions of insufficient
iodine and hypothyroidism may negatively affect thyroid function and favor endocrine imbalance,
although such effects have not been observed in euthyroid individuals living in areas with enough
supply of iodine. In later stages of childhood, an increase of androgens and decrease of estrogens
associated with dietary phytoestrogens have been observed in girls and boys, respectively.
In adulthood, endocrine changes arising from phytoestrogen consumption are unclear, although
goitrogenic activity has been observed in men. Effects on sex hormones and IGFs in men are ambiguous,
as studies report contradictory results. PCa risk in patients with PCa was unaltered, whereas equol
producers with colorectal cancer risk showed a decrease of IGF. Results regarding cardiometabolic
risk-related hormones are inconclusive in healthy subjects. Although higher levels of leptin have been
reported in early life, no association has been identified in adulthood. However, a reduction in insulin
levels was found in patients with non-alcoholic fatty liver.
In premenopausal women, usually studied separately from postmenopausal women, uncertain
results have been obtained regarding sex hormones, breast cancer protection, and bone remodeling.
Nor has evidence been provided for phytoestrogens affecting IGF levels. Whereas no significant
changes in thyroid function were observed, a decrease of free-T3 was found in healthy young
females. Among stress response-related hormones, no significant changes in cortisol are described
in healthy women or in those at cardiometabolic risk, but a lower production of cortisol is reported
in equol-excretors. In postmenopause, the results reported for sex hormones are also ambiguous.
However, possible goitrogenic activity derived from phytoestrogen consumption opens up a path
for future research. Apart from that, an ameliorative effect has been observed in the cardiometabolic
profile of hyperinsulinemic patients, individuals with metabolic syndrome and diabetes. Regarding
bone remodeling, the effects of phytoestrogens on OC concentrations are unclear, and their beneficial
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impact may arise instead from reducing bone resorption by osteoclasts. The results obtained for PHT
and IGF are unconvincing, precluding the drawing of any conclusions.
In general, the available evidence for an association between dietary phytoestrogens and endocrine
biomarkers is inconclusive. The disparity in results may be due to differences in the type and
concentration of the compounds administered and the variety of matrices, which could influence
phytoestrogen bioavailability and consequently the effect on hormonal function. Also, while most
studies analyze circulating hormones, others report the urinary excretion of metabolites. There is a
clear need for further carefully designed studies to elucidate the effects of phytoestrogen consumption
on the endocrine system.
 
Figure 3. Summary of the effects of dietary phytoestrogens at different life stages. NAFLD: non-alcoholic
fatty liver disease.
9. Future Directions
Based on the available literature, we can conclude that intake of phytoestrogens does have some
physiological effects in humans related to hormone regulation, but like hormones, the benefits depend
on the stage of life. Some factors such as dose and type of compounds, as well as matrices englobing
these phytoestroestrogens (food, capsule, etc.) affect their bioavailability and, therefore, the observed
results. Most of the research is focused on postmenopausal women and only some have explored the
effects during pregnancy and early stages of life. For instance, the effect of phytoestrogen intake on
pubertal development has been poorly studied and could lead to interesting results. In order to do
that, well-designed intervention trials are key to shed some light on this topic, especially regarding
associations that are controversial.
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Abstract: The prevention and treatment of obesity is primary based on the follow-up of a healthy
lifestyle, which includes a healthy diet with an important presence of bioactive compounds such
as polyphenols. For many years, the health benefits of polyphenols have been attributed to their
anti-oxidant capacity as free radical scavengers. More recently it has been described that polyphenols
activate other cell-signaling pathways that are not related to ROS production but rather involved
in metabolic regulation. In this review, we have summarized the current knowledge in this field
by focusing on the metabolic effects of flavonoids. Flavonoids are widely distributed in the plant
kingdom where they are used for growing and defensing. They are structurally characterized by two
benzene rings and a heterocyclic pyrone ring and based on the oxidation and saturation status of the
heterocyclic ring flavonoids are grouped in seven different subclasses. The present work is focused
on describing the molecular mechanisms underlying the metabolic impact of flavonoids in obesity
and obesity-related diseases. We described the effects of each group of flavonoids in liver, white and
brown adipose tissue and central nervous system and the metabolic and signaling pathways involved
on them.
Keywords: non-alcoholic fatty liver disease; obesity; flavonoids; lipid metabolism; metabolic
regulation; adipose tissue; brain
1. Introduction
Overnutrition and unhealthy diets together with physical inactivity cause an impairment in the
metabolic homeostasis that lead to the development of pathologies such as obesity, type 2 diabetes,
cardiovascular diseases (CVD) and more recently this kind of lifestyle has also been linked to
neuroinflammation and neurodegenerative diseases [1–5].
The metabolic syndrome (MetS) is the medical term used to define the concomitance in
an individual of some of the following alterations: hyperglycemia and/or insulin resistance,
arterial hypertension, dyslipidemia and central or abdominal obesity [6]. It is currently one of
the main public health problems worldwide and its incidence increases significantly each year,
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affecting almost 25% of the adult population today and has been directly associated to a greater risk of
suffering from CVD or type 2 diabetes among others [3].
Obesity is one of the most important trigger for many of the other alterations include in the MetS.
Obesity is essentially caused by an imbalance between energy intake and energy expenditure that
initially causes an expansion of the white adipose tissue (WAT) to store the overfeed as triglycerides (TG).
Some evidences indicate that at some point, WAT fails to adequately keep the surplus of nutrients and
together with an insufficient differentiation of new adipocytes lead to an off-WAT accumulation of
lipids in peripheral relevant organs. This ectopic accumulation of lipids causes lipotoxicity that may
be, at least in part, responsible of the metabolic obesity-related metabolic dysfunctions [7]. It seems
obvious that defects in WAT functionality together with peripheral lipotoxicity are the key points
in the onset of metabolic syndrome (MetS) [8]. Looking for a way to restore lipid homeostasis and
reduce lipotoxicity but also to diminish adipose tissue inflammation and macrophage infiltration many
research groups are focused on identifying specific dietary patterns or foods capable to counteract
these effects to finally revert obesity and its comorbidities.
Furthermore, it has been described that long-term hyperglycemia and diabetes complications
induce impairments in the hippocampal synaptic plasticity as well as cognitive deficits [9] and increase
the risk for Alzheimer disease [10,11] and depressive illness [12]. On the other side, diet-induced
hypothalamic inflammation and mitochondrial dysfunction result in the onset and development of
obesity and related metabolic diseases. It has been shown that, in rats, high fat diet (HFD) induces
metabolic inflammation in the central nervous system (CNS), particularity in the hypothalamus [13].
The prevention of MetS and obesity is primary based on the follow-up of a healthy lifestyle,
which includes, among other recommendations, a healthy diet. In this context, the Mediterranean
Diet (DietMEd) has shown beneficial effects on the prevention and treatment of MetS and obesity by
reducing chronic low-grade inflammation, improving endothelial function and reducing cardiovascular
risk [14–16]. The study of Prevention with Mediterranean Diet (Predimed) has shown that high
adherence to this nutritional profile is effective in the primary and secondary prevention of CVD,
diabetes and obesity [17–24]. DietMed is characterized by a high consumption of foods rich in bioactive
compounds such as polyphenols to whose have been attributed a large part of the health effects of this
diet [18,23,25–28].
In this review, we have summarized the current knowledge on the metabolic effects of a specific
group of polyphenols, the flavonoids, and the molecular mechanisms underlying these effects.
Concretely, the main goal of the present work is to describe the molecular mechanisms underlying
the anti-obesity effects of flavonoids in three target organs/tissues: liver, adipose tissues (WAT and
brown adipose tissue (BAT)) and central nervous system (CNS).
We choose a high variety of obesity models, sources and doses of flavonoids to identify the metabolic
and signaling pathways involved in the effects of each subclass of flavonoids (anthocyanins, flavanols,
flavanones, flavonols, isoflavones, flavones and chalcones) in these tissues/organs. Only studies in
humans and experimental approaches whit animal models from the last years have been included,
thus avoiding cell culture experimental approaches except when relevant.
2. Polyphenols and Metabolism
Polyphenols are the most abundant phytochemicals in nature. They are widely distributed
in fruits, vegetables, and highly present in foods like legumes, cocoa, some cereals as well as in some
beverages, such as tea, coffee and wine [29]. Polyphenols are not essential nutrients for humans but
research in nutrition, including epidemiological studies, randomized controlled trials, in vivo and
in vitro assays with animal models and cell lines, has shown that long-term and acute intakes can have
beneficial effects on weight management and chronic diseases such as CVD, obesity, type 2 diabetes,
the onset and development of some cancers and cognitive function [13,30–37].
The effects of polyphenols are directly related to their bioavailability. It is assumed that just
the 5%-10% of the total dietary polyphenol intake is absorbed directly through the stomach and/or
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small intestine, the rest reaches the colon where they are transformed by the microbiota [38–40].
After being absorbed, polyphenols undergo phase I and II metabolism (sulfation, glucuronidation,
methylation, and glycine conjugation) in the liver [29]. Polyphenol metabolites derived from liver
metabolism may interact, among others, with adipose tissue, pancreas, muscle, and liver, where they
exert their bioactivity.
Polyphenols have been divided in two main families: flavonoids and non-flavonoids, that are
subdivided into several subclasses. For many years, the health benefits of polyphenols have been
attributed to their anti-oxidant capacity as free radical scavengers. More recently it has been described
that polyphenols activate other cell-signaling pathways that are not related to ROS production but
rather involved in metabolic regulation [23,41].
Flavonoids
Flavonoids are widely distributed in the plant kingdom when are used for vegetables for growing
and defensing. They are structurally characterized by two benzene rings and a heterocyclic pyrone
ring and based on the oxidation and saturation status of the heterocyclic ring flavonoids are grouped
in seven different subfamilies (Table 1).
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Flavonoids are abundant in food and beverages highly consumed by human population
including fruits, vegetables, tea, cocoa or wine [42] and in global are the bioactive compounds
more largely associated with a reduced risk of all-cause mortality, type 2 diabetes [43–46], CVD [36,47],
obesity and its comorbidities such as non-alcoholic fatty liver disease (NAFLD) [48–50] and more
recently they have been described as potential therapeutic agents against cognitive pathologies such as
Alzheimer’s disease (AD) [42,51,52] or cerebrovascular alterations [47].
The molecular mechanisms underlying the beneficial effects of flavonoids have been widely
studied and, in many cases, involved the activation of the AMP-activated protein kinase (AMPK).
AMPK is a key enzyme for the control of lipid metabolism and adipogenesis. AMPK phosphorylation
and activation promote catabolic processes such as FAO, glucose uptake, or glycolysis as well as
inhibits anabolic pathways such as fatty acid synthesis or gluconeogenesis [53].
3. Anthocyanins
Anthocyanins are natural pigments and are responsible for the red-blue color of several flowers,
fruits (mainly berries and grapes), roots, seeds (beans) but also of some leaves and cereal grains where
they are found in low concentrations. Cyanidin, delphinidin, malvidin and their derivates are the most
commonly studied anthocyanins [29,42,54–56].
Anthocyanins have shown antioxidant and anti-inflammatory properties but also positive effects
in obesity and its comorbidities [57–60]. Several studies have demonstrated that the intake of
anthocyanins by itself or of anthocyanins-rich foods such as berries is able to prevent CVD [61],
to reduce body fat accumulation, to improve glucose tolerance/insulin sensitivity, to diminish the levels
of fasting glucose, to control body weight in humans and rodents [57,59,62–72] and to increase energy
expenditure and fatty acid oxidation (FAO) in mice and humans [59,73–76]. Globally, anthocyanins
and anthocyanins-rich foods are able to improve metabolic homeostasis. More recently, anthocyanins
have also revealed promising effects on cognitive function [51,77–79].
Part of the anthocyanins metabolic effects occur by regulating adipogenesis, increasing FAO, lipolysis,
thermogenesis and mitochondrial biogenesis, regulating satiety and reducing lipogenesis in different
tissues and organs and enhancing energy expenditure and body weight progression [74–76,80–83] Dietary
supplementation with anthocyanins improves the lipid profile by favorably controlling the circulating
levels of TG, total cholesterol, LDL-cholesterol and HDL-cholesterol [84].
3.1. Anthocyanins Improve the Metabolic Hemostasis in Obesity: The Liver Response
Non-alcoholic fatty liver disease (NAFLD) is characterized by an excessive accumulation of lipids
in the livers. Its onset is closely related to obesity where an imbalance between fatty acids input and
output causes initially a hepatic steatosis that can progress to NAFLD, non-alcoholic steatohepatitis
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(NASH), fibrosis, cirrhosis and in some cases hepatocarcinoma. Anthocyanins and anthocyanins-rich
foods extracts or juices have demonstrated in several studies their ability to reduce the hepatic
content of TG and lipids [85,86] and their capacity to modulate hepatic metabolism to protect against
NAFLD [62,87–89]. Although in most of the published approaches performed with rodent models
of obesity or NAFLD, anthocyanins or anthocyanin-rich fruits or extracts significatively reduced the
hepatic lipid content and ameliorated the hepatic steatosis profile of these animals [88,90–92] some
ineffective approaches have also been described [93–95].
The beneficial effects of anthocyanins in the liver have been linked to the activation of the AMPK,
the upregulation of glycolytic and FAO genes and the downregulation of the gluconeogenic and
lipogenic genes among others [70–72,96,97].
Mulberry anthocyanin extract administration to type 2 diabetic mice increased the activity
of AMPK/peroxisome proliferator-activated receptor gamma coactivator 1 alfa (PGC1α)/p38
mitogen-activated protein kinase (MAPK) and reduced the activity of the acetyl-CoA carboxylase
enzyme (ACC), a rate-limiting enzyme of fatty acid synthesis, and of the mammalian target of rapamycin
(mTOR) that is involved in protein synthesis regulation and insulin signaling [96]. Similar effects were
described in HFD-fed hamsters, where Mulberry water extracts exerted anti-obesity effects by inhibiting
lipogenesis (downregulation of fatty acid synthase (FASN) and 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase) and upregulating PPARα and CPT1A [81]. On its side, honeyberry
(Lonicera caerulea) extract (HBE) also decreased lipid accumulation in the liver of HFD-obese mice.
HBE downregulated the hepatic expression of lipogenic genes such as sterol regulatory element-binding
protein-1 (Srebp-1c), CCAAT/enhancer-binding protein alpha (C/ebpα), Pparγ, and Fasn as well as upregulated
the mRNA and protein levels of CPT1a and PPARα, thus enhancing FAO. As mulberry anthocyanin
extract, HBE treatment also increased the phosphorylation of AMPK and ACC thus activating and
inhibiting these enzymes respectively [98]. On the other hand, in NAFLD-induced rats, blackberry
extracts improved insulin sensitivity and dyslipidemia, ameliorated triglyceride and lipid peroxide
accumulation and suppressed the mRNA expression of genes involved in fatty-acid synthesis (Fasn
and Srebp-1c) [88]. Finally, purple sweet potato reduced the protein levels of FASN and of the cluster of
differentiation 36 (CD36), inactivated the C/EBPβ, restored AMPK activity and increased the protein
levels of CPT1a in livers of HFD-fed mice, thus indicating decreased lipogenesis and fatty acid uptake
and enhanced FAO [62].
Regarding glucose metabolism, protein-bound anthocyanin compounds of purple sweet potato
ameliorate hyperglycemia in obese and diabetic mice by regulating hepatic glucose metabolism.
Anthocyanin compounds of purple sweet potato induced the hepatic protein levels of p-AMPK, glucose
transporter type 2 (GLUT2), insulin receptor α (IRα), glucokinase (GK), as well as the expression
of phosphofructokinase (Pfk) and pyruvate kinase (Pk), while gluconeogenic genes, glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (Pepck) were downregulated [99]. Further, Saskatoon
berry normalized liver expression of Gk and glycogen phosphorylase and increased G6Ppase in diet-induced
MetS rats, thus suggesting that Saskatoon berry regulated glycolysis, gluconeogenesis and glycogenesis
to improve MetS [100].
Although most of the experimental approaches have been done using anthocyanins-rich extracts,
pure compounds have been also analyzed. Cyanidin-3-glucoside (C3G) administration to C57BL/6J
obese mice fed a HFD and db/db mice diminished the triglyceride hepatic content and steatosis [73,101],
through the blockade of the c-Jun N-terminal kinase activation (JNK) and the promotion of
the phosphorylation and nuclear exclusion of the transcription factor Forkhead box protein O1
(FoxO1) [101].
All these data confirm the impact of anthocyanins and even in a more significative way of
the anthocyanin-rich foods on metabolism. These effects can be added to their anti-inflammatory,
antiapoptotic, pro-autophagic and antioxidant properties in steatotic livers [59,62,102–104].
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3.2. Anthocyanins in Adipose Tissue: The Activation of BAT and the Browning of WAT
The impairment of adipose tissue function is strongly associated with the development of obesity
and insulin resistance (IR). The activation of BAT and the browning in WAT are considered potential
strategies to counteract the metabolic alterations linked to the obese phenotype. Both actions are
mechanisms to increase the energy expenditure (EE) through the induction of lipolysis, FAO and
thermogenesis and consequently efficient ways to reduce the ectopic lipid accumulation and the
lipotoxicity [105–108].
Part of the beneficial effects of anthocyanins on diet-induced obesity are due to their impact
on adipose depots. Anthocyanidins regulate lipolysis, FAO, lipogenesis and adipose tissue
development [76,109–111]. They affected the adipokines secretion [112], modified the adipocytes-gene
expression [33,113,114]. Moreover, anthocyanins are able to improve WAT functionality, to induce
browning in WAT [33,57,82,115] or to increase the BAT mass or its activity [57,109,115], thus regulating
energy expenditure [59,73]. Moreover, in WAT, anthocyanins ameliorate the obesity-associated
inflammation [57,59,116].
In WAT, an anthocyanin-rich bilberry extract ameliorated hyperglycemia and insulin sensitivity
through the activation of AMPK that resulted in an increase of the glucose transporter 4 (GLUT4) [72].
On its side, C3G-enriched Aronia melanocarpa extract reduced food intake and WAT weight in HFD-fed
mice but also suppressed adipogenesis. These animals showed a downregulating in the expression
levels of C/ebpα, Srebp1c, Acc, ATP-citrate lyase, Pgc1α, Fasn, and adipocyte protein 2 (Ap2) as well
as in the circulating levels of leptin [111]. In the same way, in HFD-induced obese mice model,
the dietary supplementation with maqui (Aristotelia chilensis) improved the body weight gain and
glucose metabolism at least in part by modifying the expression of the carbohydrate responsive element
binding protein β (Chrebpβ), the fibroblast growth factor 21 (Fgf21) and adiponectin as well as of the lipogenic
and FAO genes [82]. Globally, the maqui supplementation induced the browning of the subcutaneous
WAT (scWAT) [82].
The induction of browning is a common phenotype in obese rodent models treated with
anthocyanins or anthocyanins-rich foods. The thermogenic and mitochondrial markers were also
increased in the inguinal WAT (iWAT) of high fat-high fructose (HF/HFD)-fed mice treated with C3G,
thus indicating the browning of this adipose tissue depot and suggesting an increased heat production
and energy expenditure (EE) [117]. In db/db mice, C3G and vanillic acid exerted similar effects:
increased EE, limited weight gain and upregulated expression of Ucp1 and other thermogenic and
mitochondrial markers, thus indicating the induction of brown-like adipocytes development in the
scWAT [73] or iWAT [115]. Freeze dried raspberry decreased WAT hypertrophy induced by HFD and
promoted the browning of WAT as it is showed by a higher expression of beige markers such as Ucp1,
PR-Domain zinc finger protein 16 (Prdm16), Cytochrome C, Cell death inducing DFFA like effector A (Cidea),
and Fatty acid elongase 3(Elovl3), elevated levels of PGC-1α and Fibronectin type III domain-containing
protein 5 (FNDC5)/irisin, and an activation of the AMPK/Sirtuin 1 (SIRT1) pathway [33]. AMPK and
Sirt1 are important sensors of the energy status that together with PGC-1α regulate energy homeostasis
and stimulate FNDC5/irisin expression, thus inducing beige adipogenesis [118]. The regulation of
adipogenesis through the AMPK/SIRT1 pathway has also been described in HFD fed mice treated with
maize extract rich in ferulic acid and anthocyanins [119].
In WAT, anthocyanins and anthocyanin-rich foods also improve the inflammatory profile.
The administration of a black soybean testa extracts (BBT) to diet-induced obese mice decreased
fat accumulation, and the expression of Acc and C/ebpα and increased the levels of lipolysis
proteins such as lipoprotein lipase (LPL), hormone-sensitive lipase (HSL) in mesenteric fat but
also showed anti-inflammatory effects [109]. Similar effects were observed in humans where the
administration of BBT to overweight or obese individuals decreased the abdominal fat measured as
waist and hip circumference and improved the lipid profile [110]. The anti-inflammatory effects have
been also achieved with sweet cherry anthocyanins and blueberry (Vaccinium ashei) anthocyanins.
These anthocyanins reduced the body weight gain, the size of adipocytes and the leptin secretion
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in HFD-fed mice but also expression of Il-6 and Tnfa genes, thus indicating an amelioration of the
deleterious effects of a HFD [114,120].
Besides their effects on WAT, anthocyanins and anthocyanins-rich food also impact on BAT where
they promote its activity. In high fructose/HFD-fed animals, besides inducing the browning of WAT,
C3G attenuated the development of obesity by promoting the tremorgenic capacity of BAT. C3G
upregulated the expression of thermogenic markers such as Ucp1, induced the mitochondrial biogenesis
and function and finally increased the EE [117]. In db/db mice, C3G and vanillic improved cold
tolerance and enhanced BAT activity and induced mitochondrial biogenesis. In BAT, anthocyanin and
anthocyanin-rich foods upregulated the expression of thermogenic markers (Ucp1, Prdm16, Cidea . . . ),
lipid metabolism (Cpt1a, Hsl, adipose triglyceride lipase (Atgl)), mitochondrial markers (mitochondrial
transcription factor A (Tfam), Nuclear Respiratory Factor 1 and 2 (Nrf1 and Nrf2) . . . ) and transcriptional
regulators or coactivators of these processes (Pparα, Pgc1β, Pgc1α . . . ) [73,115].
3.3. In the Central Nervous System (CNS) Anthocyanins Have Been Related to Neuroprotective Effects as Well
as in Feeding Behavior
The neuroprotective activity of anthocyanins has been widely evidenced in several epidemiological
studies and their potential for the prevention of many neurodegenerative diseases such as Parkinson’s
disease (PD) and Alzheimer’s disease (AD) has been suggested [77,78]. The neuroprotective effects
of anthocyanins and C3G correlate with the regulation of molecules upstream of nitric oxide
(NO) production, neuroinflammatory response and oxidative stress [79,121–123].
It has been demonstrated that C3G and malvidin 3-O-glucoside (M3G) inhibited the
hyperphosphorylation of Tau protein in Alzheimer’s disease [124] and berries supplementation have
shown neurocognitive benefits in older adults at risk for dementia with mild cognitive impairment [125].
Recent studies highlighted an anti-depressive effect of a maqui-berry extract in a mouse model of a
post-stroke depression. In this case the maqui effects were associated to its antioxidant capacity [126].
Otherwise, anthocyanins extracted from dried fruits of Lycium ruthenicum Murr have demonstrated a
protective role in cerebral ischemia/reperfusion injury in rats [127] by inhibiting cell apoptosis and
reducing edema and inflammation.
Besides their role in neuroprotection, anthocyanins modulate the feeding behavior. In rats,
anthocyanins from black soybean increase the expression of the gamma-aminobutyric acid B1 receptor
(GABAB1R) and decrease the expression of neuropeptide Y (NPY) in the hypothalamus, thus modulating
the food intake behavior/body weight control. The upregulation of GABABR1 is followed by a decrease
of the activated protein kinase A (PKA) and the phosphorylated cAMP-response element binding
protein (CREB), both located downstream of GABAR1 [83]. In a similar way, the administration of an
anthocyanin-rich black soybean testa (Glycine max (L.) Merr.) to diet-induced obese mice decreased
food intake [109].
4. Flavanols
Flavanols are present in cocoa, tea, red wine, beer and several fruits such as grapes,
apricots, apples where they are responsible for their astringency [128]. Flavanols exist as
monomers named catechins or as polymers named proanthocyanins. The monomeric forms
include: catechin (−)-epicatechin (EC), (−)-epigallocatechin gallate (EGCG), (−)-epigallocatechin (EGC),
and (−)-epicatechin gallate (ECG). The proanthocyanins, also known as tannins, are more complex
structures (dimers, oligomers, and polymers of catechins) and can be transformed to anthocyanins [29].
Like other flavonoids, flavanols are absorbed between the small intestine and the colon depending on
their physicochemical properties and structure [129].
Flavanols possess a health claim related to their role in maintaining the elasticity of blood vessels
that was approved in 2014 by the European Food Safety Authority (EFSA) [130].
In humans and animal models, flavanols or flavanols-rich foods (mainly, cocoa or tea derivates)
have demonstrated the ability to reduce body weight, decrease waist circumference and fat percentages,
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improve glucose metabolism in individuals with type 2 diabetes, obesity or MetS and increase energy
expenditure [75,131–139]. One of the most described molecular mechanism underlying theses effects
are the activation of the AMPK enzyme [140].
Due to the high amount of publications including flavanols and metabolism we just included a
representative group of the most recently published and the ones that deepen more on the molecular
mechanisms underlying the beneficial effects of flavanols.
4.1. Flavanols Improve Hepatic Steatosis and Glucose/Lipid Metabolism in Obesity Models
In humans and several rodent models of obesity, flavanols have been able to improve blood lipid
profile and protect liver from excessive fat deposition and hepatic steatosis [136,141–146]. These effects
have been related mostly with an activation of the AMPK and the protein kinase B (PKB/Akt)
pathways that finally lead to the suppression of lipogenesis by modulating the expression of Srebp1c,
cAMP-response element-binding protein regulated transcription coactivator 2 (Crtc2), and stearyl coenzyme A
dehydrogenase-1 (Scdh1) or the activity of ACC, the inhibition of gluconeogenesis by affecting the levels
of PepcK and G6pase and the increment of FAO by increasing the Cpt1a levels. Moreover, flavanols
are able to improve cholesterol homeostasis through the regulation of several enzymes from the
cholesterol synthesis and bile acids metabolism apart from the modulation of the mRNA expression of
apolipoprotein B100 and ATP-binding cassette transporter A1. Most of the approaches included have
been done using tea extracts or cocoa flavanols but other extracts with a more diverse composition of
flavonoids have been also described in this section [137,143,147–151].
Theabrownin from Pu-erh tea in combination with swinging improved serum lipid profile and
prevent development of obesity and insulin resistance in rats fed a high-fat-sugar-salt diet and subjected
to a 30-min daily swinging. A transcriptomic analysis in the liver indicated that theabrownin together
with exercise activated circadian rhythm, PKA, AMPK, and insulin signaling pathway, increased
the levels of cAMP and accelerated the consumption of sugar and fat [142]. Similar results were
obtained with HFD-fed mice supplemented with Yunkang green tea and subjected to treadmill
exercise. These animals showed a reduction in the body weight gain and liver weight, a lower level of
blood glucose, serum total cholesterol (TC), TG, insulin and ALT and an improvement in the fatty liver
and hepatic pro-inflammatory profile compared to HFD group. Supplemented and exercised-animals
showed a downregulation of the lipid synthesis genes (Srebp1c, Fasn, Acc), and an improvement of the
hepatic insulin signaling [143].
Furthermore, in obese Zucker rats fed with a HFD and treated with green tea polyphenols
a significant reduction on fasting insulin, glucose and lipids and an improvement of the NAFLD
were observed. Livers of treated rats had lower levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), of inflammatory markers and of TG content and exhibited less lipid droplets.
These improvements have been related to an activation of the AMPK pathway and the inhibition
of the hepatic lipogenesis (higher levels of the inactive p-ACC and lower levels of SREBP1c) [152].
These effects on lipid metabolism were also observed after the administration of Benifuuki (a tea that
contains methylated catechins such as epigallocatechin-3-O-(3-O-methyl) gallate (EGCG3′’Me) to high
fat/high sucrose diet-fed mice. Benifuuki treatment lowered the levels of TG and NEFA in serum and
liver and reduced the expression of hepatic lipogenic genes (Srebp-1c, Acc1, Fasn and Stearoyl-CoA
desaturase 1(Scd1)) [153]. In parallel the use of Euterpe oleracea Mart.-derived polyphenols, known by
the popular name of açai and rich in catechin and polymeric proanthocyanins, when administered to
HFD-fed mice [154] or a pistachio-diet supplementation to diet-induce obese mice exhibited similar
impact on lipid metabolism and gene expression modulation [150].
Finally, Oliogonol, a flavanol-rich lychee fruit extract, significantly reduced hepatic lipid content
(less lipid droplets and ballooning by downregulating the Pparγ and, Srebp1c mRNA levels [155]
probably via the inhibition of the mTOR activity promoted by the activation of the AMPK enzyme [156].
Moreover, oligonol improved hepatic insulin sensitivity by reducing the phosphorylation of glycogen
synthase kinase 3a (GSK3a) and the phosphatase and tension homologue (PTEN) in HFD-induced
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obese mice [155] as well as inhibiting the mTOR/S6K cascade. The activation of the mTOR/S6K
phosphorylates and desensitizes the insulin receptor substrate 1 (IRS1) [157]. In a similar way,
GC-(4→8)-GCG, a proanthocyanidin dimer from Camellia ptilophylla improved hepatic steatosis and
hyperlipidemia in HFD-induced obese mice [158].
Besides on hepatic lipogenesis, tea extracts also impact in FAO. The administration of tea water
extracts from green tea, yellow tea, white tea, black tea, raw pu-erh tea and oolong tea decreased TG and
total cholesterol levels in serum and liver as well as the hepatic lipid content. Supplemented animals
displayed less lipid droplets, the activation of the AMPK and the upregulation of the Cpt1a together
with the inhibition of the FASN enzyme. These treatments also reduced the inflammation profile linked
to HFD [149]. Similar results were obtained with grape seed procyanidin B2 (GSPB2) and a polyphenol
extract from Solanum nigrum that contains among other different catechins. In db/db mice, GSPB2
decreased body weight and improved the lipid profile in serum (TG, total cholesterol and free fatty
acids (FFA)) but also reduced hepatic lipid droplets and TG accumulation. The proposed mechanism
implied the AMPK activation, the ACC phosphorylation and Cpt1a overexpression, thus inhibiting FA
synthesis and increasing FAO [159]. In a similar way, the Solanum nigrum polyphenol extract inhibited
lipogenesis and enhanced FAO (upregulation of Cpt1a and Pparα) through the AMPK cascade [151].
In different animal models of obesity and insulin resistance, EGCG has shown the capacity
to improve glucose homeostasis, to inhibit gluconeogenesis, FA and cholesterol synthesis and to
increase FAO [147,148]. In HFD and STZ-induced type 2 diabetes, EGCG downregulated Pepck and
G6Pase and inhibited SREBP1c, FASN and ACC1. The mechanism underlying these effects is not
yet well understood but it has been suggested that EGCG would activate the PXR/CAR-mediated
phase II metabolism that through a direct or indirect mechanism would suppress gluconeogenesis
and lipogenesis [147]. Moreover, in HFD Wistar rats, EGCG diminished the liver weight, the hepatic
hyperlipidemia, animals showed less lipid droplets, reduced serum levels of ALT and AST, TG,
total cholesterol and better profile of LDL/HDL but also an ameliorated oxidative stress. In this case,
EGCG activated SIRT1, FoXO1 and regulate SREBP2 activity to suppress hepatic cholesterol synthesis.
These data point out the downregulation of SREBP2 expression under the SIRT1/FOXO1 signaling
pathway as a mechanism to reduce the cholesterol content [148]. Furthermore, EGCG also decreased
bile acid reabsorption, which decreased the intestinal absorption of lipids [160]. In the same way,
EC administered to a high-fat high cholesterol diet rats reduced serum levels of total cholesterol,
LDL and TG while increased HDL [161]. Moreover, EC intake also reduced serum levels of ALT and
AST enzymes, the lipid peroxidation and the pro-inflammatory cytokines levels, thus indicating an
improvement in the liver functionality. The proposed mechanism of EC included the downregulation
of the nuclear receptor liver-X-receptor (LXR), the FASN enzyme and the SIRT1 protein but also the
blockade of the Insig-1-SREBP-SCAP pathway that drives the SREBP2 maturation [161].
4.2. Flavanols in Adipose Tissue: Less Adiposity and More Energy Expenditure: The Browning Effect
In humans, some studies described the capacity of green tea to reduce body weight and abdominal
fat accumulation [162,163], influence on the body fat mass index, waist circumference, total fat mass and
energy expenditure through the induction of browning or BAT activity [164–166] but also to regulate
ghrelin secretion and adiponectin levels, to control appetite and decrease nutrient absorption [135,167].
In rodents, the administration of grape seed-derived proanthocyanins to Wistar rats reduced
the body weight by limiting food intake and activating EE in scWAT [168] and it has been widely
described that in rodent models of obesity, flavanols are able to affect the lipid metabolism of WAT
and BAT. Global effects of flavanols in adipose tissues lead to a decrease in adiposity, specially of the
WAT depots and in adipocyte size by reducing adipogenesis, the release of adipokines such as leptin
and resistin, the modulation of lipid metabolism and the induction of browning [153,155,158,169–174].
In BAT, flavanols caused the activation of thermogenesis and FAO [172–176].
As has been mentioned before, in WAT, flavanols modified lipid metabolism. EGCG reduced
the expression of genes related with de novo lipogenesis (Acc1, Fasn, Scd1, C/ebpβ, Pparγ and Srebp1c),
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increased the expression of genes involved in lipolysis (Hsl) and lipid oxidization (Pparα, Acetyl-CoA
oxidase (Acox)2, and medium-chain acyl-CoA dehydrogenase (Mcad)) in epididymal (eWAT) and
scWAT and highly upregulated the expression of delta-9 desaturase, the enzyme responsible to convert
saturated fatty acids to monounsaturated [177]. The activation of the AMPK in HFD-EGGC-treated
mice indicated that at least in part the changes in lipid metabolism observed were due to the AMPK
phosphorylation [177]. In scWAT, although EGCG increased lipolysis (Hsl) and FAO (Cpt1a) [168,178],
some lipogenic genes (Acc1, Fasn, Scd1, Pparγ, and Srebp1) has been detected upregulated at the mRNA
level but no at protein level [178]. These data suggested that EGCG might have different effects in
scWAT and eWAT. Finally, pistachio-diet supplementation to diet-induce obese mice also ameliorated
the HFD-induced expression of Srebp1c, Pparγ, and Fatp [150].
Besides its effects in the liver, the GC-(4→8)-GCG inhibited the expansion of all WAT depots
in HFD fed mice. Adipocytes from eWAT were smaller and some of the main adipocyte-associated
transcription markers were downregulated (Srebp1c, C/ebpα and Pparγ), thus indicating a better
WAT functionality [158]. The GC-(4→8)-GCG-supplemented mice showed an upregulation of the
adiponectin and a downregulation of the leptin mRNA levels as well as an improved inflammatory
profile with less macrophage infiltration [158].
Regarding the browning effect of flavanols it has been published that EC increased mitochondrial
biogenesis, fatty acid metabolism and upregulated the expression of BAT-specific markers (Prdm16, Dio2,
Ucp1 and Ucp2) in WAT in a way that depends on phosphorylation and deacetylation cascades [170].
The authors demonstrated that EC supplementation upregulated the mitochondrial related proteins
p-SIRT1, SIRT1, SIRT3, PGC1α, PPARγ, TFAM, NRF1, NRF2, complex II, IV and V and mitofilin [170].
In a similar way, a polyphenolic extract from green tea leaves (GTE) ameliorated the body weight
gain caused by a HFD with no changes in calorie intake but reducing the adiposity and the adipocyte
size in WAT and BAT. GTE supplementation induced BAT markers in scWAT (higher mRNA levels
of Pgc1α, Cbp/p300-interacting transactivator 1 (Cited1) and Prdm16 and of UCP1 protein) and reduced
HFD-induced whitening in BAT (lower expression of adipogenic markers C/ebpα and Ap2 and
upregulation of Pgc1α and vascular endothelial growth factor-A(165) (Vegfa165)) [171]. These animals
also showed an improvement in the inflammatory profile in scWAT and BAT. Finally, a Grape pomace
extract (GPE) showed the capacity to induce browning (upregulation of Pgc1α, Pparγ, Prdm16 and
Ucp1) in the eWAT of HFD-fed rats [179,180].
Besides tea extracts also cacao components are able to induce browning and BAT activation.
Concretely, theobromine alleviated diet-induced obesity in mice by inducing a brown-like phenotype
in the iWAT and activated lipolysis and thermogenesis in BAT. In HFD fed mice theobromine inhibited
phosphodiesterase-4 (PDE4D) activity in adipose tissue, thus increasing β3-adrenergic receptor (AR)
signaling pathway and EE [172]. The inhibition of PDE increases the cellular levels of cAMP levels
thus activating the β-AR cascade and finally PKA and UCP1 activity [181].
The capacity of flavanols on activating BAT has been described even with a single dose of a flavanol
mixture that included catechins and B type procyanidins or by administering individual components
by itself [182]. In these animals, Ucp1 mRNA expression in BAT and levels of catecholamines in
plasma were significantly increased via SNS stimulation but with varying efficacy depending on
the stereochemical structure of flavanols [182]. It should be noted that prolonged ingestion of
a catechin-rich beverage increased the BAT density with a decrease in extramyocellular lipids in
humans [183]. EGCG-supplemented diet-induced obese mice exhibited higher body temperature and
more mitochondrial DNA (mtDNA) content in BAT together with an upregulation of the genes related
to fatty acid metabolism, thermogenesis and mitochondrial biogenesis (Ucp1, Ucp2, Prdm16, Cpt1β,
Pgc-1α, Nrf1, and Tfam) [184,185] and a downregulation of Acc. These effects have been related to an
increased activity of the AMPK in BAT [184].
Thermogenesis can also be induced by a polyphenol-rich green tea extract (PGTE) through a
mechanism that depends on adiponectin signaling. The treatment with this extract reversed part
of the obesity phenotype in WT mice but no in adiponectin KO mice (AdipoKO). PGTE treatment
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increased EE, BAT thermogenesis, and promoted browning phenotype in the scWAT of WT mice but
these effects were blunted in AdipoKO mice [176].
Some data regarding BAT activation by catechins in humans have also described. Different
approaches have been done to demonstrate the effects of green tea extract and caffeine over
thermogenesis and body weight [186,187]. Short- and long-term effects have been studied with
different results and effectiveness but suggesting that catechins and caffeine may act synergistically to
control body weight and induce thermogenesis [175,188]. It has been proposed that the thermogenic
response to green tea extracts or its components would be mediated, in BAT, by the direct stimulation
of the β-adrenergic receptor (β-AR) cascade through the inhibition of the enzyme catechol-O-methyl
transferase (COMT), which degrades catecholamines. On its side, caffeine inhibited PDE, thus inducing
a sustained activation of the PKA and its downstream cascade [175].
4.3. Flavanols Consumption Induces Energy Expenditure in Peripheral Organs through the Sympathetic
Nervous System Activation
Part of the anti-obesity effects of flavanols have been also related to their influence on sympathetic
nervous system (SNS) activity. The SNS activation by green tea catechins (GTC) has been associated
to their capacity to inhibit COMT. The inhibition of COMT leads to a prolonged activation of the
sympathetically-response and of the β-adrenergic cascade that produces cAMP and the activation of
the PKA. Caffeine, in turn, is able to inhibit the PDE activity which drives to a sustained activation
of the PKA and its downstream response [175]. Then, both effects act synergistically to increase EE,
lipolysis and FAO as has been described in the above sections. Some other mechanisms to describe
the anti-obesity effects of flavanols include the modulation of food intake. It has been demonstrated
that grape-seed proanthocyanins extract (GSPE) reduced food intake in rats fed a cafeteria diet.
These animals showed an activation of the STAT3 protein which upregulated the pro-opiomelanocortin
(Pomc) expression, thus improving the leptin resistance [189].
Moreover, GSPE supplementation reduced the neuroinflammation and increased the expression of
SIRT1 [189]. Flavanols has been described as active molecules against diet-induced neuroinflammation.
The induction of neuroinflammation and cognitive impairment in rats by feeding them with a high
salt and cholesterol diet (HSCD) could be in part reversed by the treatment with different doses of an
enriched-tannins fraction of the Indian fruit Emblica officinalis. Treatment with this tannin-enriched
gooseberry reversed the HSCD-induced behavioral and memory disturbances, neuronal cell death and
reduced the levels of cognitive impairment markers. [190]. In the same way, it has been published that,
in mice, EGCG attenuated the neuronal damage and insulin resistance caused by a high fat/high fructose
diet (HF/HFD). In this case, EGCG upregulated the IRS-1/AKT and the extracellular-signal-regulated
kinase (ERK)/CREB/Brain-derived neurotrophic factor (BDNF) signaling pathways. In longer nutritional
interventions with the HF/HFD, EGCG was capable to inhibit the MAPK and NF-κB pathways, as well
as the expression of inflammatory mediators, such as TNF-α to reverse the neuroinflammation [191].
Similar results were obtained with EGCG-HFD dietary supplementation. The authors demonstrated
that EGCG ameliorated the HFD-induced obesity in part by attenuating hypothalamic inflammation
through the inhibition of NF-kB and Signal transducer and activator of transcription 3 (STAT3)
phosphorylation, as well as the expression and release of inflammatory cytokines, such as TNF-a, IL-6,
and IL-1b [185].
Finally, EGCG alleviated part of the cognitive deficits in a mixed model of familial Alzheimer’s
disease (AD) and type 2 diabetes mellitus (T2DM). The AD mice model APP/PS1 fed with a HFD
showed an improvement in peripheral parameters such as insulin sensitivity but also in central memory
deficits when treated with EGCG. Synaptic markers and CREB phosphorylation were increased because
of an amelioration in the unfolded protein response (UPR) activity via a downregulation of the
activation factor 4 (ATF4) levels. Moreover, EGCG decreased brain amyloid β (Aβ) production and
plaque burden by increasing the levels of α-secretase (ADAM10) and reduced the neuroinflammation
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in these animals [192]. Finally, green tea extracts can modulate the redox status of the CNS in obese
and lean rats [193].
5. Flavanones
Flavanones are a subfamily of flavonoids widely distributed in citrus fruits such as grape,
tomatoes, and oranges and are the responsible of the bitter taste of their peel and of their juice.
As other flavonoids, flavanones show strong health benefits due to its antioxidant activity but
also exhibit antiviral, antimicrobial, antiatherogenic, anti-inflammatory antidiabetic and anti-obesity
properties [45,48,75,194,195]. Flavanones are mainly found as aglycones or as glycosylated
derivatives [196]. The most studied flavanones are hesperidin, naringenin but also eriodyctiol,
isosakuranetin and taxifolin.
Hesperidin and its aglycone, hesperetin are found in citrus fruits, such as limes and
lemons, tomatoes and cherries and have demonstrated antidiabetic, neuroprotective, antiallergic,
anti-inflammatory anticarcinogenic besides their well-established antioxidant capacity [45,197]
Naringenin and its aglycone naringin are found to be more abundant in citrus fruits such as
grapefruit orange, lemon but also in tomatoes. Naringenin and derivates have been associated with
beneficial effects in cardiovascular diseases, osteoporosis, cancer and have showed anti-inflammatory,
antiatherogenic, lipid-lowering, neuroprotective, nephroprotective, hepatoprotective and antidiabetic
properties [198,199].
5.1. Flavanones-Dietary Supplementation Ameliorates the NAFLD in Humans
Frequently, liver diseases are initiated by oxidative stress, inflammation and lipid accumulation
that lead to an excessive production of extracellular matrix followed by a progression to fibrosis,
cirrhosis and hepatocellular carcinoma [200]. In the last years, several studies have demonstrated the
capacity of different flavanones to ameliorate liver diseases.
To analyze the positives effects of flavanones in liver different approaches have been used.
Some authors worked with hepatic chemical-induced damage being the most used the streptozotocin
injection to mice or rats [199,201]. Other authors induced liver damage with diet [199] or worked
with genetically obese models. Although flavanones demonstrated positive effects in the different
approaches, in this review we focused on the experimental approaches where the liver disease has
been induced by diet or where genetically obese-models has been used. Experiments with naringenin,
hesperidin and eriodyctiol has been done to evaluate the impact of this flavanones’ consumption in
NAFLD or liver steatosis.
Naringenin has showed the capacity to restore the activities of liver hexokinase, PK, G6Pase and
Fructose 1,6-bisphosphatase from rats fed a high fructose diet to levels similar to healthy non-diabetic
animals [202]. In this animal model, naringenin also enhanced liver protein tyrosine kinase (PTK),
while reduced protein tyrosine phosphatase (PTP) activity [202]. In addition, administration of
naringenin to HF/HSD-fed rats increased the protein levels of PPARα, CPT1a and UCP2 [203]. In a
similar way, naringenin increased FAO and the AMPK activity in HFD fed mice where ameliorated the
metabolic alterations caused by diet [204]. Similar results were obtained in high-fat/high-cholesterol
(HFHC) fed Ldlr -/- mice. In lean Ldlr -/- mice, naringenin induced weight loss and reduce calorie intake,
enhanced EE and increased hepatic FAO by upregulating Pgc1α, Cpt1a and Hsl, thus indicating that
naringenin is also effective in non-obese models [195]. In HFD fed Ldlr -/-, naringenin increased FAO
and reduced lipogenesis. Hepatic Srebp1c and Acox1 mRNA levels were downregulated, while Fgf21,
Pgc1α, and Cpt1a were upregulated by naringenin [205]. Later on, it was published that naringenin
prevented obesity, hepatic steatosis, and glucose intolerance in an FGF21-independent way [206].
More recently, it has been described that in obese-mice naringin decreased hepatic liver content (TG
and total cholesterol) and activated the AMPK enzyme resulting in reduced expression and protein
levels of liver SREBP1C, SREBP2, but increased LDLR. Moreover, these mice showed reduced plasma
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levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), leptin, insulin, and LDL-C compared
to obese non-treated mice [207].
Besides naringenin, naringin and hesperidin effects in liver have also been evaluated. Hesperidin
and naringin supplementation in db/db and ob/ob mice regulated hepatic gluconeogenesis and glycolysis,
as well as lipid metabolism [208]. Hesperidin stimulated PPARγ, increased the hepatic GK activity
and glycogen concentration and reduced the hepatic levels of Glut2 as well as increased the expression
of Glut4 in WAT [46,208,209]. Moreover, hesperidin prevented hepatic steatosis in western diet-fed rats
by preventing the upregulation of lipogenesis-related genes Srebf1, and Scd1 caused by Western diet
and the downregulation of Pparα and Cpt1a expression and CPT1a protein levels [210]. Most of these
effects were blunted when hesperidin is combined with capsaicin [210].
In diet-induced obese mice treated with neohesperidin the expression and secretion of FGF21
and the activity of the AMPK/SIRT1/PGC-1α axis were improved [211]. Treatment with neohesperidin
improved the steatotic state (less and smaller lipid droplets), reversed the downregulation of hepatic
Pparα levels while increased the levels of the hepatic Fgf21 expression and its plasma levels. Finally,
neohesperidin treatment phosphorylated AMPK, resulting in a rise of the HFD-downregulated proteins
SIRT1 and PGC1α [211]. On its side, eriodyctiol has also demonstrated effects on diet-induced obesity.
Diet-induced obese mice supplemented with eriodyctiol showed a reduction of hepatic TG, fatty acids
and the size and number of lipid droplets accompanied with an increased fecal excretion of cholesterol
and fatty acids [212]. It is worth to mention that eriodyctiol decreased the enzymatic activity of malic
enzyme (ME), FASN, phosphatide phosphohydrolase (PAP) and downregulated the expression of
Srepb1c, Acc and Fasn [212]. These data indicate that eriodyctiol improved the hepatic steatosis caused
by a HFD by decreasing hepatic lipogenesis and increasing the hepatic FAO. On the other hand,
alpinetin, an O-methylated flavanone, improved HFD-induced NAFLD via ameliorating oxidative
stress, inflammatory response and lipid metabolism. Alpinetin decreased Scd1, Fasn, Srebp1c, Lxrα,
Elovl2 and Irs1 expressions, and increased PPARα levels [213].
In humans a randomized placebo-controlled, double-blind clinical trial with NAFLD patients
shown the effect of hesperidin supplementation [214]. Patients who follow healthy lifestyle habits and
supplemented their diet with hesperidin have a significant reduction of ALT, glutamyl-transferase,
total cholesterol, hepatic steatosis, C reactive protein and TNFα, proving the scope of hesperidin [214].
One of the possible mechanisms underlying the effects of flavanones on metabolism goes through the
FGF21 and AMPK/Sirt1/PGC1α signaling axis.
5.2. Flavanones Induce Browning in Adipose Tissue
As other flavonoids, flavanones can also modulate lipid metabolism in adipose tissue as well as
induce browning in WAT, and activate in BAT [166] as well as reduce the characteristic obese-macrophage
infiltration in adipose tissue [215].
In HFD fed mice, hesperetin supplementation on its side showed metabolic health effects in
adipose tissue, concretely is able to reduce mesenteric adipose weight and decrease leptin levels [216].
In this case, lipid metabolism was not changed nor in liver nor in WAT. On the other hand, a characteristic
of obesity is the recruitment of immune cells by adipose tissue that leads to metabolic disorders such
as insulin resistance. In a short-term HFD mice model, naringenin can suppress neutrophil and
macrophage infiltration into adipose tissue [215]. Concretely it can inhibit the expression of several
chemokines like MCP-1 and MCP-3 [217]. Eriodyctiol (ED) supplementation on its side lowered the
adiposity in diet-induced obese mice by regulating gene expression. ED-supplemented mice showed
reduced weight of all the WAT depots but also a downregulated expression of adipocyte genes involved
in lipid uptake (Cd36, and Lpl) and lipogenesis (Srebp1, Acc, and Scd1), an upregulation of the Ucp1,
with no changes in FAO genes such as Adrb3, Cpt2, Pgc1α, Pgc1β, and Cox8b genes [212].
Another beneficial effect of flavanones in adipose tissue is related to EE and thermogenesis.
It has been demonstrated that in human white adipocytes and in scWAT a treatment with naringenin
increased the expression of genes associated with thermogenesis and FAO, including Atgl and Ucp1 as
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well as Pgc1α and Pgc1β that can mediate the PPARδ-dependent transcriptional responses involved in
mitochondrial biogenesis and uncoupling phenotype. Moreover, naringenin administration increased
the expression of insulin sensitivity-related proteins such as Glut4, adiponectin, and Chrebp [218].
These data indicate that naringenin may promote the conversion of human WAT to a brown/beige
adipose tissue. Similarly, in HFD-obese mouse model, the induction of brown-like adipocyte
formation on WAT was described by supplementing the diet with a flavanones-rich extract from
Citrus reticulata [219]. The main phytochemical components of a water extraction of Citrus reticulata
in were synephrine, narirutin, hesperidin, nobiletin, and tangeretin. Among flavanones, citrus also
contain synephrine that is an alkaloid which binds to β3AR in adipose tissue promoting lipolysis
and thermogenesis [220]. Dietary supplementation with this citrus extract reduced body weight
gain, epididymal fat weight, fasting blood glucose, serum levels of TG and total cholesterol,
and lipid accumulation in liver and WAT as well as activated FAO and induced the browning
phenotype [219]. These animals showed increased levels of Ucp1 in the iWAT and an upregulation of
Prdm16, transmembrane protein 26 (Tmem26), cluster of differentiation 137 (CD137), and Cidea [219].
In the same way it has been published that hesperidin induced browning in retroperitoneal WAT
(rWAT) but not in iWAT of Western diet-fed rats. Hesperidin decreased the size of adipocytes and
induced the formation of multilocular and positive-UCP1 and CIDEA brown-like adipocytes. Besides
the induction browning, hesperidin also enhanced the expression of Ucp1 in BAT [221]. In contrast,
it has been recently published a study where not hesperidin but its monoglycosyl has the capacity
to induce brown-like adipocyte formation in HFD-fed mice [222]. In this case, α-monoglucosyl
hesperidin increased EE and reduced body fat accumulation by stimulating the browning phenotype
in the iWAT. iWAT adipocytes of supplemented mice exhibited a multilocular phenotype and were
UCP1-positive cells. The iWAT of these animals also showed increased levels of COXIV. No effects
were observed in BAT nor in other WAT depots [222].
In a human randomized double-blind placebo-controlled trial with moderate high BMI subjects,
it’s shown that glycosylated hesperidin decreased significantly abdominal and subcutaneous fat area
when is supplemented with caffeine [223].
5.3. Flavanones Are Neuroprotective against Several CNS Injuries
There is low information about the effects of flavanones on CNS to combat obesity. It has been
demonstrated that quercetin, naringenin and berberine can modulate glucose homeostasis in the brain
of STZ-induced diabetic rats through the regulation of glucose transporters and other key components
of insulin signaling pathway [224].
Most of the studies that show the neuroprotective role of flavanones have been performed
using animal with CNS-induced injuries. In a rat model of global cerebral ischemia reperfusion (I/R),
pinocembrin (a honey flavanone) exerted antioxidant, anti-inflammatory and anti-apoptotic effects. [225]
as well as inhibited autophagy on the hippocampus [226]. Moreover, naringenin and eriodyctiol exert
effects in ischemic stroke, promoting cortical cell proliferation, inhibiting apoptosis and reducing
oxidative stress in rodent models [227,228]. In a similar way, the induction of neurotoxicity by
lipopolysaccharide (LPS) administration in mice can be ameliorated by the coadministration of
hesperetin or naringenin that reduced the expression of inflammatory cytokines, attenuated the
generation of reactive oxygen species/lipid peroxidation and enhanced the antioxidant capacity in
CNS [229,230]. Furthermore, hesperetin enhanced synaptic integrity, cognition and memory processes
by increasing the levels p-CREB, postsynaptic density protein-95 (PSD-95) and syntaxin proteins [229]
and naringenin decreased the acetylcholinesterase (AChe) activity [230]. Other mental stresses such as
social defeat stress, depression and autistic-like behaviors can also be counteract with flavanones in
rodent models [231–233]. Hesperidin and naringenin have demonstrated positive effects by increasing
the resilience through a reduction in the levels of interleukins and corticosterone thus suppressing the
chronic inflammation caused by kynurenine pathway related to depression [234] and inhibiting the
AChe activity, the oxidative stress as well as neuroinflammation [235].
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6. Flavonols
Flavonols are widely distributed in plants and are present as minor compound in many
polyphenol-rich foods. Their synthesis is stimulated by light and they accumulate in the skin
of fruits and vegetables being absent in the flesh. The main dietetic flavonols are quercetin, kaempferol,
isorhamnetin, fisetin, and myricetin [48,236,237].
Quercetin is found in capers, lovage (Levisticum officinale) apples, seeds of tomatoes, berries,
red onions, grapes, cherries, broccoli, pepper, coriander, citrus fruits, fennel, flowers, leaves pepper
and teas (Camellia sinensis) and it is the skeleton of other flavonoids, such as hesperidin, naringenin,
and rutin. Rutin, rutoside or sophorin are the glycosylated form of quercetin and can be extracted
from buckwheat, oranges, grapes, lemons, limes, peaches, and berries [238]. Kaempferol is abundant
in apples, grapes, onions, tomatoes, teas, potatoes, beans, broccoli, spinaches, and some edible berries.
Isorhamnetin is commonly found in medicinal plants such as ginko (Ginkgo biloba), sea-buckthorn
(Hippophae rhamnoides) and Oenanthe javanica. Myricetin is found in teas, wines, berries, fruits and
vegetables. Fisetin is abundant in apples, grapes, persimmon, cucumber, onions and strawberries.
Finally, morin is present in Prunus dulcis, Chlorophora tinctoria L., and fruits such as guava and figs [45].
As other groups of flavonoids, flavonols have shown healthy effects. They exhibit anticarcinogenic,
anti-inflammatory, and antioxidant activities but also anti-obesity and antidiabetic properties in animal
models and in humans where flavonols consumption has been associated to a lower risk of type 2
diabetes [43,236–243]. Some flavonols inhibited carbohydrate absorption thus lowering postprandial
blood glucose mainly through the inhibition of the α-glucosidase activity but also by inhibiting
glucose transporters (GLUT2, SGLT1) or other enzymes such as maltase or saccharase [236]. Finally, a
combination of quercetin and resveratrol have shown the capacity to reduce obesity in HFD-fed rats by
modulating gut microbiota [244].
Due to the high number of publications and previous reviews [45,48,238], in the present work
only the most recent data have been included.
6.1. Flavonols Exert Beneficial Effects on Lipid Steatosis by Regulating Lipid Metabolism, Inflammation and
Oxidative Stress
Quercetin enhanced hepatic insulin sensitivity and reduced liver fat content and ameliorated
hepatic steatosis [245]. Quercetin diminished the mRNA and protein levels of CD36 and MSR1,
upregulated the levels of LC3II and downregulated p62 and mTOR thus suggesting an autophagy
lysosomal degradation as the potential hepatoprotective mechanism of quercetin [245]. From another
point of view the effects and mechanisms of quercetin against NAFLD were analyzed through a
metabolomic approach [246]. Treatment with quercetin decreased AST and ALT levels in serum and
reduced lipid droplets and hepatocyte swelling in rats fed a high fat/high sucrose diet. A metabolomic
analysis indicated that quercetin modified fatty acid- inflammation- and oxidative stress-related
metabolites among others. In this case, the effects of quercetin were more evident in 30-day NAFLD
induction than in 50 days, thus indicating that dietary quercetin may be beneficial in early stages of
NAFLD development [246]. Besides the effects of quercetin alone there are several studies where
quercetin is used in combination with other compounds. The beneficial effects of quercetin in
NAFLD development increased synergistically when quercetin is administered within benifuuki, a
tea that contains EGCG. Both compounds administered to rats fed high fat/high cholesterol diet were
more effective to downregulate Fasn and Scd1 showing higher effects on their lipid-lowering effects
alone [247]. In a similar way, the combination of quercetin with resveratrol ameliorated fatty liver in
rats by improving the antioxidant capacity of the liver [248]. Finally, a combination of borage seed oil
(as a source of linoleic (18:2n-6; LA) and gamma-linolenic (18:3n-6; GLA) acids and quercetin improved
liver steatosis in obese rats [249].
On its side, isoquercetin (IQ), a glucoside derivative of quercetin has demonstrated beneficial effects
in NAFLD by improving hepatic lipid accumulation via an AMPK dependent way in HFD-induced
NAFLD rats [250]. Concretely, IQ treatment enhanced the phosphorylation of AMPK and ACC and
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reversed the downregulation of liver kinase β1 (LKβ1) and Calcium/calmodulin-dependent protein
kinase kinase-1 (CaMKK1) caused by HFD. The activation of AMPK modulated the expression of
lipogenic and lipolytic genes, such as Fasn, Srebp1c, Pparγ and Cpt1a. Moreover, IQ supplementation
upregulated PPARα and downregulated nuclear factor-kB (NF-kB) protein levels [250].
As quercetin, kaempferol is also able to reduce lipid accumulation in liver of obese rodent models.
In dyslipidemia-induced mice, kaempferol inhibited PKB (Akt) and SREBP-1 activities and blocked
the Akt/mTOR pathway, thus inducing hepatic autophagy and decreasing hepatic lipid content [251].
Similarly, in ApoE deficient mice fed with a HFD, kaempferol attenuated metabolic syndrome via
interacting with LXR receptors and inhibiting posttranslational activation of SREBP-1. Both effects
contributed to the reduction of plasma and serum TG [252].
Other flavonols with positive effect in the liver are fisetin, dihydromyricetin or rutin. Obese rats fed
with a high fat/high sucrose diet and supplemented with fisetin showed a decreased in body weight and
hepatic lipid content as well as an improvement in the lipid profile (low levels of TG, total cholesterol,
LDL) and liver functionality (reduced levels of ALT and AST). The hepatic nuclear receptor 4α
(HNF4α) has been pointed out as the key factor in the hepatic effects of fisetin. Fisetin upregulated
Hnf4a gene expression, increased nuclear lipin-1 levels. Moreover, fisetin promoted FAO, diminished
FASN activity, enhanced hepatic antioxidant capacity and decreased the hepatic poly (ADP-ribose)
polymerase 1 (PARP1) activity, a DNA repair enzyme, and thioredoxin-interacting protein (TXNIP)
that is important for maintaining the redox status [253]. Through the regulation of SIRT3 signaling,
dihydromyricetin have showed the ability to ameliorate NAFLD in HFD-fed mice. Dihydromyricetin
increased Sirt3 expression via activation of the AMPK/PGC1α/estrogen-related receptor α (ERRα)
cascade thus improving mitochondrial capacity and restored redox homeostasis [254]. In a similar way,
rutin lowered TG content and the abundance of lipid droplets in NAFLD-induced HFD fed mice.
Rutin treatment restored the expression of Pparα and Cpt1a and Cpt2, while downregulated Srebp-1c,
diglyceride acyltransferase 1 and 2 (Dgat-1 and 2 and Acc. These effects enhanced FAO and diminished
lipid synthesis. In addition, rutin repressed the autophagy in the liver [255]. On its side, the rutin
derivate, troxerutin (TRX), has also demonstrated effectiveness against metabolic disorders in a rat
model of hereditary hypertriglyceridemia (HHTg) non-obese model of MetS [256]. The treatment
with TRX lowered the levels of hepatic cholesterol and reduced the expression of cholesterol and lipid
synthesis genes (Hydroxymethylglutaryl-CoA reductase (Hmgcr), Srebp2 and Scd1) as well as decreased
lipoperoxidation and increased the activity of antioxidant enzymes [256]. Moreover, these animals
exhibited higher levels of adiponectin in serum [256].
Besides the effects of flavonols by itself, favonols-rich extracts have also been tested in fatty
liver-associated diseases. A Sicyos angulatus extract that contains kaempferol as the main flavonol
administered to a HFD-induced obese mice lowered plasma levels of ALT and AST and the hepatic lipid
content. The Sicyos angulatus extract impacted on lipid metabolism by repressing the expression of genes
related to fatty acid and TG synthesis (Acc1, Fasn Scd1 and Dgat) and of the key transcription factors that
regulate lipogenesis (Srebp-1c and Pparγ) [257]. Another source of kaempferol, quercetin and derivates
is Sanglan Tea (SLT), a Chinese medicine-based formulation consumed for the effective management
of obesity-associated complications. It has been demonstrated that dietary SLT supplementation
prevented body weight gain and fatty liver and ameliorated insulin resistance in HFD-induced
obese mice. SLT improved the serum lipid profile (lower levels of TG, Total cholesterol and LDL)
and reduced the ALT and AST circulating levels. The liver of these animals displayed less lipid
droplets and a downregulation of the lipogenic genes (Lxrα, Fasn, Acacb, Srebf-1, and Scd1) and the
adipogenesis-related genes (Pparγ, C/ebpα and Ap2) that are induced under HFD [258].
In a similar way, the flower of Prunus persica commonly known as peach blossom has demonstrated
that capacity to reduce body weight, abdominal fat mass, serum glucose, ALT, AST, and liver
and spleen weights compared to a HFD fed mice. This flower is rich in flavonoids and phenolic
phytochemicals with chlorogenic acid, kaempferol, quercetin and its derivatives as its major compounds.
The supplementation with this flower suppressed hepatic expression of lipogenic genes (Scd1, Scd2,
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Fasn) and increased the mRNA levels of FAO genes (Cpt1a), thus modifying he lipid metabolism in
HFD-fed mice [259]. Furthermore, a mulberry leaf powder also showed effects on liver gene expression
in a mice model of hepatic steatosis induced by a western diet. Liver weight, plasma TG and liver
enzymes ALT and AST were reduced in treated-animals. A global hepatic gene expression analysis
revealed that supplemented mice displayed a downregulation in inflammation-related genes and an
upregulation in liver regeneration-related genes [260]. Finally, a 70% ethanol extract from leaves of
Moringa oleifera (MO) that contains different flavonols and flavones such as quercetin and kaempferol
and their derivates. reduced glucose and insulin but also the total cholesterol, TG and LDL serum and
increased the HDL in high-fat diet obese rats as well as downregulated hepatic expression of Fasn and
Hmgcr [261].
Through a network pharmacological approach Nie et al. [262] highlighted that Chaihu shugan
powder (CSP) may exert its beneficial effects against NAFLD through the interaction of its main
compounds with nuclear receptors. Through a molecular docking approach, they screened
PPARγ, FXR, PPARα, RARα and PPARδ and quercetin, kaempferol, naringenin, isorhamnetin and
nobiletin interactions. To confirm the results of docking, an in vivo approach was done using
NAFLD-induced rats. The NAFLD-induced rats treated with CSP exhibited ameliorated effects in
body weight, hepatic histopathology and serum and liver lipids. Moreover, the mRNA levels of Pparγ,
FXR, Pparα and Rarαwere modified suggesting nuclear receptors regulation as a potential molecular
mechanism underlying the effects of CSP [262].
Adiponectin signaling and AMPK activation have been also pointed out as possible mechanisms
underlying the effects of flavonols in the liver. An extract of black soybean leaves (EBL), which
mainly contains quercetin glycosides and isorhamnetin glycosides was administered to HFD-fed mice.
EBL supplementation reduced body weight, fasting glucose, TG, total cholesterol and non-esterified
fatty acid levels as well as hepatic steatosis. EBL supplementation increased the levels of adiponectin and
the expression of adiponectin-receptors in the liver (AdipoR1 and AdipoR2) thus restoring adiponectin
signaling pathway [263]. Downstream of the adiponectin signaling there is the activation of AMPK
and FAO, the suppression of fatty acid synthesis and the improvement of insulin signaling [264].
Moreover, the mRNA levels of Pgc1, Pparα, Pparδ, Pparγ, Acc, Fasn, Cpt1a, Glut2, FoxO1 and Irs1 were
partially or totally normalized in HFD-EBL-supplemented animals [263].
Finally, it has been described that part of the mechanisms involving the hepatic beneficial effects
of flavonols may be mediated by gut microbiota. An experimental approach of gut microbiota
transplantation revealed a gut–liver axis where the Akkermansia genus have a key role on the quercetin
protecting effects against obesity-associated NAFLD development. [247]. In a similar way, kaempferol
blunted part of the effects of HFD in gut microbiota diversity. HFD fed mice displayed a reduced
microbial diversity that it is mostly reversed by kaempferol [265]. Furthermore, IQ combined with
inulin attenuated weight gain, improved glucose tolerance and insulin sensitivity and reduced lipid
accumulation in the liver, adipocyte hypertrophy in WAT and diminished the circulating levels of
leptin in HFD-fed mice probably through the modulation of gut microbiota [266].
6.2. Flavonols Impact on WAT Where They Modulate Lipid Metabolism and Induce Browning
Several studies with animal models showed that flavonols can protect mice or rats from HFD obesity
by reducing body weight gain and lipid accumulation in WAT via reducing inflammation, modifying
lipid metabolism, increasing EE, inducing browning of WAT and activating BAT [174,242,267–269].
Quercetin and quercetin-rich red onion (ROE) ameliorated diet-induced WAT expansion and
inflammation in HFD-fed mice [270]. Quercetin and ROE ameliorated adipocyte size and number
compared to HFD fed mice in WAT depots and induced a multilocular phenotype typical of BAT [270].
Moreover, quercetin and ROE diminished the HFD-increased levels of leptin. Besides its impact on
adipose tissue phenotype, quercetin and ROE supplementation also attenuated the inflammatory profile
induced by HFD in WAT [270]. Similarly, a quercetin-rich supplement administered to diet-induced
obese rats decreased body fat and adipocyte size of the perirenal WAT as well as increased adiponectin
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circulating levels [271]. Quercetin-rich supplement attenuated the upregulation of genes related to
lipid synthesis such as Acc, Fasn, HMG-CoA reductase, Lpl, Ap2, and Fatty acid transporter protein 1
(Fatp1) caused by HFD; and upregulated the HFD-downregulated genes such as Atgl, Hsl, Ampk, Acox,
Pparα, and Cpt1a [271]. In diet-induced obese mice quercetin administration decreased plasma TG
levels without affecting food intake, body composition, or EE [272]. Quercetin enhanced the uptake
of [3H]-oleate derived from labeled lipoprotein-like particles in the scWAT [272]. On the other side
Perdicaro et al. demonstrated that quercetin attenuated adipose tissue hypertrophy, reduced the
adipocyte size but activated the adipogenesis in HFD-fed rats. Quercetin supplemented rats showed
increased levels of angiogenic (Vascular endothelial growth factor 1 and 2 (Vegf1, Vegf2) and adipogenic
(Pparg and C/ebpa) markers but also mitigated inflammation, and reticulum stress [273].
Together with their capacity to modulate lipid metabolism, flavonols are also able to induce
browning in WAT depots. Quercetin treatment increased the expression of Ucp1, Pgc1α and Elovl3 in
WAT [272,274]. In a similar way, the administration of onion peel extract (rich in quercetin) to HFD-fed
mice upregulated markers of BAT (Prdm16, Pgc1α, Ucp1, Fgf21, Cidea) in perirenal and scWAT [275].
It has been described that the induction of browning was mediated at least in part through the activation
of the AMPK and the SIRT1 or via sympathetic stimulation. The quercetin-supplemented HFD-fed mice
displayed higher levels of plasma norepinephrine and of PKA protein levels in scWAT [274]. Besides the
activation of PKA signaling, it has been described that quercetin also increased SIRT1 protein levels and
pAMPK in visceral WAT [276]. Although most of the studies showed positive effects of quercetin, this
flavonol did not induce significant effects on the adipose tissue weights of rats fed an obesogenic diet
except when combined with resveratrol (RSV). The treatment with quercetin and RSV but not with just
quercetin or RSV promoted multilocular UCP1-positive adipocytes that also displayed increased levels
of browning markers (Cidea, bone morphogenic protein 4 (Bmp4), Homeobox C9 (Hoxc9), Solute Carrier
Family 27 Member 1 (Slc27a1), Tmem26 and proton/amino acid symporter (Pat2)) and genes related to
catabolic pathways (Atgl and ATP synthase subunit delta (Atp5d)) in perirenal WAT. Regarding BAT,
the supplementation with RSV and quercetin upregulated Cidea and Ucp1 expression, thus indicating
more thermogenic capacity in this tissue [277].
It is worth to mention that quercetin effectiveness is specie dependent. Studies in rats usually
showed more effects than in mice whilst in humans the results are still unclear. In rodent models the
levels of quercetin reached after its administration are higher than in humans [269]. Similar to quercetin,
isoquercetin (IQ), a quercetin glycoside with greater bioavailability than quercetin, also exerts positive
effects in WAT. In normal diet-fed mice IQ supplementation decreased WAT weight and increased
pAMPK levels in WAT as well as in liver and muscle. Moreover, IQ reduced the expression of Pparγ,
C/ebpα, C/ebpβ and Srebp1 whilst increased the expression of Ucp2, Pgc1α, Prdm16, Sirt1 and Cpt1a
in WAT, suggesting less adipogenesis, enhanced FAO and browning [278].
On its side, rutin administration to db/db mice and diet-induced mice reduced body weight gain
and improved adiposity (smaller lipid droplets) mainly by increasing EE [279]. These animals exhibited
higher core temperature when submitted to a cold environment indicating enhanced BAT activity.
Rutin-treated animals overexpressed BAT markers (Ucp1, Cidea, Prdm16), FAO-related genes (Cpt1a,
Mcad, Pparα and Pgc1α), mitochondrial biogenic transcription factors (tfam, Nrf1, Nrf2) and more
copies of mitochondrial DNA in BAT [279]. Besides BAT, rutin also affected scWAT, where induces
browning (upregulation of BAT-specific genes, including Ucp1, Pgc1α, Pgc1β, Cpt1a, Pparα, Tfam,
Nrf1 and Nrf2...) [279]. The molecular mechanism underlying these effects may go through the
Sirt1 activation. It has been demonstrated that rutin was able to directly bind to Sirt1 protein and
activate the SIRT/PGC1α/NRF2/Tfam signaling pathway [279]. On the other hand, rutin combined
with exercise (treadmill running) in diet-induced obese mice increased the mRNA levels of adiponectin,
the protein levels of PPARγ, the binding immunoglobulin protein (BIP), and the phosphorylated form
of c-Jun terminal quinase (JNK) and reduced disulfide-bond A oxidoreductase-like protein (DsbA-L).
These profile indicated an improvement on the ER stress and on adipose tissue functionality [280].
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When instead of flavonols, plant extracts were used similar effects were observed. A 70% ethanol
extract of Moringa oleifera (MO) that mainly contains quercetin, kaempferol and their derivates induced
the expression of Glut4, adiponectin, omentin and upregulated Pparα and melanocortin-4 receptor (MC4R)
on the WAT of diet-induced obese rats. [261]. Cuscuta pedicellata and some of its isolated compounds,
including kaempferol, quercetin and some derivates were suggested to have an anti-obesity effect in
HFD-fed rats. Supplemented animals showed a reduction in HOMA-IR and oxidative stress as well as
exhibited an upregulation of Ucp1 and Cpt1a expression in BAT [281]. Finally, through a high-throughput
metabolomic approach it has been described that the consumption of a hawthorn ethanol extract that
contains chlorogenic acid, hyperoside, isoquercetin, rutin, vitexin, quercetin, and apigenin affected
several metabolic pathways including: fatty acid biosynthesis, galactose metabolism, biosynthesis of
unsaturated fatty acids, arginine and proline metabolism, alanine, aspartate and glutamate metabolism,
glycerolipid metabolism and steroid biosynthesis [282].
6.3. Flavonols: Neuroprotection in Neurodegenerative Diseases
Flavonols have shown neuroprotective effects in neurodegenerative diseases. Quercetin, rutin
and some other flavonols have exhibited positive effects against pathologies such as Alzheimer’s
Disease (AD), Parkinson’s disease, Huntington’s Disease, multiple sclerosis, brain ischemic injury,
epilepsy neurotoxins but also for aging cognitive alterations [238,283–288]. Furthermore, flavonols
have also demonstrated beneficial effects in the CNS alterations caused by HFD.
It is well-known that HFD induces oxidative stress in brain that may lead to
neurodegenerative diseases. In HFD-fed mice, quercetin ameliorated the cognitive and memory
impairment and enhanced the expression of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K),
PKB/Akt, Creb, and brain-derived neurotrophic factor (Bdnf) [289]. In a similar way, in HFD-fed mice,
Acer okamotoanum and its main bioactive compound isoquercitin improved cognitive function by
inhibiting the ROS production, the lipid peroxidation and nitric oxide formation, thus reducing oxidative
stress [290]. Furthermore, it has been described that obesity induces hypothalamic inflammation and
activates microglia. In diet-induced obese mice, quercetin supplementation reduced the levels of
inflammatory cytokines and microglia activation markers in the hypothalamus [291]. Quercetin has
also showed positive effects in streptozotocin (STZ)-induced AD rats where improved memory
impairment and the anxiogenic-like behavior induced by STZ. In these rats, quercetin prevented
the acetylcholinesterase (AChE) overactivity and the increased malondialdehyde levels caused by
STZ [292]. Finally, quercetin showed capacity to modulate several kinases signaling cascades involved
in synaptic plasticity such as the PI3K/Akt, protein kinase C (PKC) and mitogen-activated protein
kinase (MAPK) [293].
7. Isoflavones
Isoflavones, also known as phytoestrogens, are flavonoids with a limited distribution in
plant kingdom. They are found in leguminous plants such as soybean, kudzu, red clover, fava beans,
alfalfa, chickpeas or peanuts but also soy-based foods (tofu, soymilk, miso . . . ) and some pants such
the Puerariae genus [42,294]. Genistein and daidzein are the most representative dietary isoflavones.
Although there are several human clinical studies studying soy isoflavone consumption and diabetes
the data obtained are not conclusive. Some evidence suggests that long-term intake of isoflavones
may improve insulin resistance in type 2 diabetic patients and have anti-obesity effects [295–299].
In animal studies, isoflavones have showed antidiabetic and anti-obesity activities [45,236,297,300].
The beneficial effects of isoflavones include the improvement of insulin sensitivity, lipid profile and
adiposity [45,49,301–303].
7.1. Isoflavones Reduced H Steatosis by Modulating Lipid Metabolism
Like many of the other flavonoids, isoflavones also exert an hepatoprotective action [49]. A recent
publication using data of the National Health and Nutrition Examination Survey from 1999 to 2010 in
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the USA describes an inverse correlation between urinary genistein levels and serum ALT levels in
males but not in females [304]. On the other hand, in NAFLD-rodent models, genistein supplementation
decreased fat accumulation, inflammation, hepatic steatosis and liver fibrosis in animal models and in
humans [302]. These effects on hepatic steatosis have been described both in short- and long-term
interventions [305].
One of the mechanisms proposed is the blockade of aldose reductase (AR)/polyol pathway. It has
been described that some isoflavones are AR inhibitors. The inhibition of the AR/polyol pathway
reduces fructose production and hepatic fat accumulation in high glucose diets as well as improved
PPARα activity and enhanced FAO, thus attenuating liver steatosis in HFD-obese models [306].
Moreover, the blockade of AR/polyol pathway reduced the CYP2E1-mediated oxidative stress [306].
Other mechanism suggested for isoflavones is the downregulation of PPARγ and fat-specific protein 27
(FSP27) together with a reduction of fatty acid synthesis and increased lipolysis [307]. This mechanism
was described in female rats fed with a 20% casein-diet and supplemented with soy isoflavones [307].
Effects via the activation of AMPK has been also described for genistein [308,309].
Hepatic activation of AMPK drives to an inhibition of cholesterol and fatty acid synthesis and
an enhancement of FAO [310]. In high fat/high sucrose-fed rats, genistein improved lipid metabolism
and ameliorated hepatic lipid accumulation. P-AMPK and p-ACC were increased while SREBP1 protein
levels were decreased. Moreover, genistein downregulated the expression of Fasn, glycerol-3-phosphate
acyltransferase (Gpat) as well as upregulated Pparα, Cpt1a and Acox [309]. A similar effect on NAFLD
has been described with Puerarin, a major bioactive isoflavone compound isolated from the roots of
the Pueraria lobata. Puerarin attenuated NAFLD development in high fat/high sucrose-fed mice via
the activation of the Poly(ADP-ribose) polymerase 1 (PARP-1)/PI3K/Akt signaling pathway and lately
the improvement of the mitochondrial function [311]. In HFD-obese mice, puerarin reduced TG, total
cholesterol and leptin serum levels as well as decreased the hepatic lipid content. Puerarin inactivated
FASN and activated AMPK, CPT and HSL as well as increased the protein levels of PPARγ. These data
indicated that puerarin regulated lipid metabolism by reducing lipid synthesis and enhancing lipid
consumption [312].
Positive effects on NAFLD has been also observed by combining soluble soybean polysaccharides
and genistein. This combination increased the bioavailability of genistein and administered to HFD-fed
mice prevented weight gain, oxidative stress inflammation and dyslipidemia. These effects on lipid
profile have been related to an activation of AMPK and PPARα/PPARγ pathways and changes in the
mRNA levels of Fasn, Acc, Srebp1c and adipose differentiation-related protein (Adrp) [313].
Besides genistein some of its derivatives are also active. Sophoricoside, a genistein derivate
isolated from the Sophora japonica L, has been tested in high fructose-fed mice. Administration of
sophoricoside diminished body and liver weight as well as reduced hepatic cholesterol and TG
and serum levels of ALT, AST and LDL whilst increased the levels of circulating HDL. Moreover,
the livers of treated-mice displayed a better inflammatory profile and an increased antioxidant
capacity [314]. Calycosin, an o-methylated isoflavone showed positive effects against NAFLD-induced
in HFD-fed mice. Calycosin improved insulin sensitivity, decreased the levels of ALT and AST and
increased the levels of adiponectin. In the liver, calycosin blocked gluconeogenesis and lipogenesis by
suppressing PEPCK G6Pase, SREBP1c and FASN, as well as induced the expression of Gsk3β, Glut4,
increased the phosphorylation of Irs1 and Irs2 and activated farnesoid X receptor (FXR) [315].
Similar to isolated compounds, soy isoflavones (that includes genistein, daidzein and glycitein) or
a soy protein preparation also reverted hepatic steatosis when administered to obese female Zucker or
HFD-obese rats. Soy isoflavones reduced hepatic lipid accumulation, improved serum levels of ALT
and downregulated Srebp1c and Fasn levels as well as increased the protein levels of PPARα indicating
less lipogenesis and more FAO [316]. In a similar way, the intake of soy protein with isoflavones
decreased the liver steatosis, reduced the levels of AST and ALT and increased the levels of leptin in
female Zucker obese rats [305].
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Apart from the effects of isoflavones on lipid metabolism they also exhibit anti-inflammatory
properties. Genistein protected against NAFLD by targeting the arachidonic acid cascade that is
responsible for the chronic inflammation [317]. Genistein supplementation to HFD-fed mice blocked
the synthesis of ciclooxigeanse-1 activity and thromboxane A2 [317]. Other mechanism to explain
the anti-inflammatory effect of genistein is the promotion of miR-451 [318]. In humans a randomized
controlled trial described that genistein supplementation improved the inflammatory state in NAFLD
patients [319].
7.2. Isoflavones Ameliorate the Weight Gain in Diet-Induced Obesity Models and Improve Lipid Metabolism in
Adipose Tissue
It has been widely described that isoflavones are able to control food satiety and appetite,
to ameliorate the body weight gain and fat accumulation in rodent models of obesity, to modulate
fatty acid metabolism and to induce browning and BAT activation which make its use in nutritional
interventions as a promising approach for weight management therapies [269]. Isoflavones reach
and affect adipose tissue as it was demonstrated through a whole-transcriptome microarray analysis
of the perigonadal WAT from mice fed either control diet or a soybean extract diet containing a
genistein/daidzein mix. This study described the impact of soy isoflavones on adipose tissue describing
437 downregulated genes and 546 upregulated [320].
In HFD-fed rats, soy isoflavones attenuated diet-induced obesity mainly by reducing the visceral
WAT depot (lower hypertrophy and less lipid accumulation). Soy isoflavones supplementation
downregulated fat synthesis (reduced SREBP1 protein levels) and upregulated lipolysis (increased
ATGL protein levels) in visceral WAT via the activation of AMPK and the inhibition of SREBP1 [321].
In a similar way, 6,8-diprenylgenistein (DPG), a major isoflavone of Cudrania tricuspidata fruits decreased
the body weight of HFD-induced obese mice at least in part by the suppression of de novo lipogenesis
via the AMPK activation [322]. This isoflavone reduced the expression of lipogenic genes by regulating
Pparγ and C/EBPα transcriptional activity as well as leptin and adiponectin levels. DPG also regulated
ACC and HMGCR [322].
Isoflavones are also present in fermented soy products. The heathy properties of these products
have been also evaluated. Fermented soybean meal (SBM) administered to HFD-fed rats showed
positive effects on the obese profile of these animals. The body weight gain, as well as weights of
abdominal and epididymal fat were reduced. Also, the lipid profile was improved. Supplemented
rats exhibited lower levels of TG, total cholesterol and LDL and higher levels of HDL compared to
HFD-non supplemented rats. Moreover, in WAT, there were a decrease on the hepatic lipogenesis
(downregulation of Fasn and Acc) and an increase on lipolysis (upregulation of Lpl) [323].
Besides their effects on lipid metabolism, isoflavones also induce browning and BAT
activation [166]. Genistein administration to HFD-fed mice reduced body weight gain and scWAT
mass and induced the expression of Ucp1 and Cidea in WAT, indicating a browning phenotype [324].
Genistein may induce the browning phenotype by a direct upregulation of Ucp1 expression or through
an indirect pathway that would imply irisin signaling. Irisin is a myokine that induces the expression
of Ucp1 and Tmem26 in preadipocytes [325]. This indirect mechanism describes an induction of
the PGC-1α/FNDC5 pathway in skeletal muscle that lead to an increase of irisin production and
secretion [325].
Formononetin and puerarin also modulate adipogenesis and thermogenesis. Formononetin
attenuated visceral fat accumulation and increased EE in HFD-fed mice [326,327]. In vitro,
this isoflavone downregulated Pparγ, C/ebpα and Srebp1 probably via AMPK/β-catenin signal
transduction pathway that drove its antiadipogenic effect [326]. Moreover, formononetin induced
Ucp1 expression in primary culture of mouse adipocytes [327]. In a similar way, Puerariae lobata
root extracts (PLR) activated browning in iWAT and regulated BAT activity [328]. PLR treatment
caused weight loss and improved glucose metabolism in diet-induced obese mice as well as increased
EE. In BAT, PLR upregulated Ucp1 expression (but no other thermogenic markers) and in iWAT
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induced the expression of BAT markers (Ucp1, Pparγ1, Pparγ2 and Pparα), thus indicating a brown-like
phenotype [328].
Several studies focused on describing the mechanisms underlying the isoflavones’ effects have
been performed in ovariectomized mice or rats. These models mimic menopausal stage in humans
and are useful to analyze the potential role of isoflavones to counteract the increase of the adipose
tissue that takes place during this period of life. In these rodent models, isoflavones exert positive
effects on body weight gain and food intake as well as in fat pats enlargement [297]. In HFD-fed
ovariectomized rats the administration of genistein decreased the body weight gain, improved insulin
sensitivity and reduced plasma TG and cholesterol [329]. In liver, genistein blocked the lipogenic
pathway by inhibiting p-ACC, SREBP-1, FASN and CD36 proteins. In retroperitoneal WAT, genistein
diminished adiposity and adipocyte hypertrophy, inflammatory phenotype and induced browning.
In iWAT, genistein-supplemented rats exhibited higher levels of UCP1, PRDM16, PGC-1α and
CIDEA proteins and Ppargc1a and Ucp-1 mRNAs [329]. Furthermore, isoflavones supplementation
can modulate the metabolic effects of estradiol treatments in ovariectomized rats [330]. Finally,
calycosin has demonstrated positive effects perivascular adipose tissue of obese mice. Through the
adiponectin/AMPK/ endothelial nitric oxide synthase (eNOS) pathway, calycosin is able to restore at
least in part the perivascular adipose tissue functionality [331].
7.3. Isoflavones Have Become Engaging Flavonoids in Neuronal Diseases due to Their Estrogenic-Like Structure
and Its High Antioxidant Capacity
Obesity is a risk factor for neurodegenerative diseases essentially because it causes the
neuroinflammation and oxidative stress. Isoflavones can ameliorate part of these effects as well
as affect food intake and feeding behavior.
It has been described that daidzein administered to HFD-fed rats reduced food intake and
attenuated body weight gain as well as improved glucose tolerance, adiponectin and leptin levels
and increased the 17b-estradiol. In rat hippocampus, daidzein enhanced cell proliferation and
reduced apoptosis and gliosis, thus exerting a neuroprotective effect against the brain injuries
caused by diet [332]. On the other side, doenjang, a Korean traditional fermented soybean pastry
alleviated hippocampal neuronal loss and enhanced cell proliferation in HFD-fed mice as well as
reduced oxidative stress markers (less oxidative metabolites and lower levels of oxidative stress- and
neuroinflammation-related genes). Dietary doenjang reduced Aβ and tau phosphorylation [333].
Furthermore, genistein has shown the capacity to improve metabolism and induce browning via
hypothalamus gene expression regulation. Through a transcriptome analysis it was identified that
the hypothalamic expression of urocortin 3 (Ucn3), decidual protein induced by progesterone (Depp), and
stanniocalcin1 (Stc1) correlated with the browning markers in WAT and with insulin sensitivity [324].
Regarding neurodegenerative diseases isoflavones have shown protective properties. An extract of
soybean isoflavone reduced the elevated oxidative stress parameters and reversed the overproduction
of Aβ in rats with colchicine-induced neuronal damage [334]. In the same way, daidzein alone or
mixed with genistein and glycitin isoflavones could reverse the cognitive impairments produced
by scopolamine injection by activating the cholinergic system and the BDNF/ERK/CREB signaling
pathway in mice [335,336], thus reinforcing the idea that soy isoflavones may be a good candidate for
the treatment of neurodegenerative diseases. Besides the BDNF/ERK/CREB signaling pathway, it has
been postulated that the Nrf2 signaling pathway can also be underlying the neuroprotective effects of
isoflavones [337].
8. Flavones
Flavones is one of the largest groups of flavonoids with a high degree of chemical diversity.
Some of the richest sources of flavones are parsley, celery, peppermint, and sage, which predominantly
contain apigenin and luteolin as well as maize and citrus fruits. In general, flavones are found as
glucosides in citrus fruits, vegetables, herbs and grains and although they represent a small fraction of
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the total flavonoid intake, they have shown health effects and anti-obesity properties [338,339]. As it is
going to described latter, most of the studies that investigate the beneficial effects of flavones use them
as aglycone and a scarce number of approaches deepen on the effects of flavones when consumed
within the whole food and a feasible doses or in combination with other bioactive compounds.
8.1. Flavones Improved Liver Steatosis and Hepatic Inflammation
Flavones such as apigenin, luteolin, baicalin, vitexin, nobiletin among others prevented NAFLD
and hepatic steatosis mainly by modulating lipid metabolism (increasing FAO and decreasing
lipogenesis) and reducing oxidative stress and inflammation [340–345].
As many other flavonoids, some flavones also exert their hepatic effects by activating the
AMPK enzyme. Vitexin, an apigenin flavone glucoside, for instance, when administered to HFD-fed
mice reduced body and liver weight, triglyceride and cholesterol content in serum and liver and
circulating levels of ALT and AST. Moreover, vitexin regulated lipid metabolism suppressing de novo
lipogenesis by downregulating the expression of Pparγ, C/ebpα, Srebp1c, Fasn, and Acc and enhancing
FAO and lipolysis by increasing the expression of Pparα, Cpt1a and Atgl) in an AMPK-dependent way
that has been suggested may be activated by the binding of vitexin to the Leptin receptor [345].
In a similar way, luteolin, the principal yellow dye compound from Reseda luteola,
or luteolin-enriched artichoke leaf extract alleviated hepatic alterations caused by a HFD by exerting
anti-inflammatory activities and modulating lipid metabolism. Luteolin treatment of HFD-fed mice
reduced hepatic lipotoxicity by improving the inflammatory profile, decreasing the extracellular matrix,
enhancing the antioxidant capacity of the liver and increasing the FFA flux between liver and WAT [346].
A crosstalk between adipose tissue and liver has been suggested to explain the effects of luteolin on
hepatic steatosis [347]. Moreover, luteolin and luteolin-enriched artichoke leaf extract administered
to HFD-fed mice prevented hepatic steatosis (less and smaller lipid droplets, lower levels of Cidea)
and insulin resistance by suppressing lipogenesis and gluconeogenesis (suppression of PEPCK and
G6Pase activities) and increasing FAO (more CPT1a activity and higher expression of Pparα, Pgc1α and
Pgc1β) [342]. The repression of hepatocyte nuclear factor 4a and of LXR/SREBP1c signaling pathway
has been described as putative molecular mechanisms for luteolin improvement of liver steatosis and
NAFLD [348,349].
Regarding the capacity of flavones to modulate FAO, it has been described through a quantitative
proteomic study that baicalin may act as an allosteric activator of CPT1a enzyme thus increasing the
FA entrance to the mitochondria to undergo the β-oxidation in the liver [343]. Moreover, baicalin
attenuated liver alterations by regulating the AMPK/ACC pathway in diet-induced obese mice [350].
Finally, baicalin is also a potent anti-inflammatory and antioxidant compound in a way that as other
flavones also implied the nuclear erythroid 2-related factor 2 (Nrf2) activity in a cholestatic mice
model [351].
It has been described that some flavones exert their hepatoprotective effects via the activation
of the Nrf2 transcription factor. Nrf2 is a positive regulator of the expression of genes involved in
the protection against oxidative stress as well as a negative regulator of genes that promote hepatic
steatosis [352,353]. In this context, apigenin and scutellarin exerted their hepatoprotective activity via
the activation of Nrf2. Scutellarin is a natural compound of Erigeron breviscapus (vant.) that in a HFD-fed
mice attenuated obesity. It repressed lipogenesis and promoted FAO and cholesterol output besides its
anti-inflammatory activity [340]. Moreover it has been described that scutellarin increased mRNA
and/or protein levels of PPARγ, PGC1α, Nrf2, haem oxygenase-1 (HO-1), glutathione S-transferase
(GST), NAD(P)H quinone dehydrogenase 1 (NQO1) and PI3K and AKT, whilst reduced nuclear
factor kappa B (NF-κB), Kelch-like ECH-associated protein 1 (Keap1) [354,355]. By contrast, apigenin
administration to HFD-fed mice inhibited the expression of PPARγ target genes via the translocation
to the nucleus and activation of the Nrf2 transcription factor that seems to block PPARγ activity.
Apigenin treatment downregulated the expression of genes related to lipid droplet formation (Cidea,
Plin2, fat storage inducing transmembrane protein 1 and 2 and) as well as genes involved in FA uptake
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(Fabp1 and Lpl), FAO (Cpt1a, Pdk4, Acox1, Acaa2) and lipogenesis (Fasn, Scd11, Acaca) [341]. On the
other side, apigenin may act as a PPARγ modulator in a mouse model of obesity where it activated
the p65/PPARγ complex translocation into the nucleus, thereby decreasing the NF-κB activation and
favoring the M2 macrophage polarization [356] or blocking NLRP3 inflammasome assembly and the
ROS production [357]. The capacity of flavones to modulate PPARγ activity and induce macrophage
polarization to M2 phenotype has also been described for Chrysin in a HFD-fed mice model [358].
Finally, wogonin have shown beneficial effects on the liver steatosis development in a mice
NAFLD model [359]. Concretely wogonin administration to HFD fed mice ameliorated the NAFLD
progression via enhancing the PPARα/Adiponectin receptor R2 (AdipoR2) pathway. Wogonin induced
the hepatic activity of PPARα and upregulated the levels of the AdipoR2. Moreover, wogonin also
reduced the inflammatory profile and alleviated the hepatic oxidative stress [359].
Besides their effects alone, the combination of flavones with other bioactive compounds or
polyphenols-rich extracts have also shown positive effects against hepatic steatosis [360].
8.2. Flavones Improved the Adipose Tissue Inflammation and Reduced the Macrophages Infiltration as Well as
Enhanced the Thermogenic Capacity
Although flavones have been widely studied for their antioxidant and anti-inflammatory
properties [338] their capacity to impact on adipose tissue metabolism and functionality cannot
be underestimated.
Besides its reduction of the inflammatory phenotype in adipose tissue, apigenin administration to
diet-induced obese mice ameliorated the body weight increment, reduced the visceral adiposity by
inhibiting the adipogenesis via a STAT3/CD36 signaling pathway [361], decreased leptin and increased
adiponectin [362] and induced energy expenditure mainly by promoting lipolysis and FAO as well as
browning of WAT [363]. In scWAT, apigenin-treated mice exhibited a downregulation of adipogenic
genes (Pparγ, Lpl and aP2) and of genes involved in lipogenesis (Fasn and Scd1) and a promotion of
lipolysis by increasing the mRNA levels of Atgl, Hsl, Forkhead box protein O1 (FoxO1) and Sirt1. In BAT
there is an increment of the p-AMPK and p-ACC levels, thus indicating that FAO is enhanced in
this fat depot after apigenin administration. Finally, apigenin activated the thermogenesis in BAT
(upregulation of Ucp1 and Pgc1α) and induced the browning phenotype in scWAT (upregulation of
Ucp1, Pgc1α, Tmem26, Cited1) [363]. Similar results were obtained with vitexin. Vitexin administration
reduced the adipocyte size of HFD-fed mice and increased the p-AMPK levels in eWAT followed by a
downregulation of C/EBPa and FASN protein levels [364].
In the case of nobiletin and luteolin, their administration to HFD-fed mice improved the
fibrotic and inflammatory profile in adipose tissue and reduced the macrophage infiltration and
polarization [344,346,365,366]; but in contrast with other flavones they increased the mRNA expression
of FAO- (Pparα, Cox8b, and Cpt1a) and lipogenic (Pparγ, Srebp1c, Fasn and Scd1) -related genes
simultaneously [342,344] as well as CPT1 and FASN activity [344] in WAT. The simultaneously
activation of both metabolic pathways in adipose tissues has been demonstrated as a way to maintain
thermogenesis in BAT [367,368] and as a marker of browning in WAT [82]. In the case of luteolin,
its administration either in HFD-fed or low-fat-fed mice activated browning and thermogenesis in mice
via the AMPK/PGC1α cascade. Under the AMPK/PGC1α signal, luteolin increased energy expenditure
in HFD-fed mice and upregulated the mRNA levels of Pgc1α, PPARα, Cidea and Sirt1 in BAT as well as
Ucp1 Pgc1α, Tmem26, Cidea, PPARα, Sirt1, Elovl3 and Cited1 in scWAT [369]. Moreover, the increased of
PPARγ protein levels in WAT has been linked to an alleviation of the hepatic lipotoxicity in HFD-fed
mice [347]. Similar effects were observed with baicalein that administered to HFD-fed mice decreased
pP38MAPK, pERK and PPARγ levels and increased pAKT, PGC1α and UCP1 as well as the presence
of GLUT4 in cell membranes of the eWAT. Globally, baicalein reversed the glucose intolerance and
insulin resistance produced by HFD [370].
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Besides the effects of each compound by itself some flavones-rich extracts or foods or combinations
of different bioactive compounds have been evaluated regarding their potential therapeutic role against
obesity and its metabolic and inflammatory features [371,372].
8.3. Flavones and Obesity in the CNS: No Clear Evidences
There are few studies describing the potential role of flavones in obesity-related central alterations.
Just luteolin has been demonstrated a protective effect against HFD-induced cognitive effects in
obese mice. Luteolin administration alleviated neuroinflammation, oxidative stress and neuronal insulin
resistance as well as improved the Morris water maze (MWM) and step-through task and increased
the levels of BDNF [373]. Other effects of flavones described recently are anxiolytic-like activity [374],
neuroprotection against gamma-radiation [375] treatment of glioblastoma [376], amelioration of the
hypoxia-reoxygenation injury [377] or inhibition of the neuroinflammation caused by LPS [378].
9. Chalcones
Chalcones is a group of polyphenolic compounds with a broad structural diversity. Chalcones are
precursors of other flavonoids and responsible for the golden yellow pigments found in flowers, fruits,
vegetables, spices, teas and different plant tissues. Although their metabolism in the gastrointestinal
tract and their rate of absorption are not still completely known, chalcones have shown a wide
variety of biological activities. Several studies have demonstrated that, either from natural sources or
synthetic, chalcones can impact on glucose and lipid metabolism and their health benefits have been
studied in relation to type 2 diabetes [379]. Chalcones have shown hypoglycemic capacity, the ability
to modulate food intake and activate AMPK, as well as antioxidant, anti-inflammatory, anticancer,
anti-obesity, hepatoprotective and neuroprotective properties [380–392] Although there are no many
studies in humans the effects of chalcones in the obese phenotype in animal models are similar to the
ones described for other flavonoids, thus suggesting a potential therapeutic role of these group of
bioactive compounds.
9.1. The Hepatoprotective Role of Chalcones
Chalcones have hepatoprotective properties in NAFLD, alcoholic fatty liver, drug- and
toxicant-induced liver injury, and liver cancer [381]. It has been described that chalcones are able to
inhibit the synthesis of triglycerides and the lipogenesis, to increase FAO, and to modulate adiponectin
production and signaling.
Licochalcone F, a novel synthetic retrochalcone, has shown anti-inflammatory properties when
administered to diet-induced obese mice. Licochalcone F inhibited TNFa-induced NF-kB activation
and the mRNA expression of several pro-inflammatory markers. In the liver licochalcone F alleviated
hepatic steatosis, by decreasing lipid droplets and glycogen deposition [380]. On its side, Licochalcone A,
a chalcone isolated from Glycyrrhiza uralensis, administered to HFD-fed mice, reduced body weight,
decreased serum triglycerides, LDL free fatty acids and fasting blood glucose, ameliorated hepatic
steatosis, reduced lipid droplet accumulation [393]. In the liver, licochalcone A downregulated the
protein levels of SREBP1c, PPARγ, and FASN as well as increased the phosphorylation of HSL, ATGL
and ACC enzymes [393]. Moreover, licochalcone A increase the protein levels of CPT1A and stimulated
SIRT1 and AMPK activity [393]. Taken together, licochalcone A ameliorated obesity and NAFLD in
mice at least in part by reducing the fatty acid synthesis and increasing lipolysis and FAO via the
activation of the SIRT1/AMPK pathway.
In a mouse model of HFD-induced obesity, trans-chalcone reduced the ALT levels and increased
the HDL [394]. Similarly, in a mouse model of non-alcoholic steatohepatitis KK-Ay mice, xanthohumol,
the chalcone from beer hops (Humulus lupulus L.), diminished hepatic inflammation and prevented
from the expression of profibrogenic genes in the liver [395] as well as lowered hepatic fatty acid
synthesis through the downregulation of Srebp1c expression and promoted FAO by upregulating the
mRNA expression of Pparα in KK-Ay mice [396]. Moreover, in HFD-fed mice, xanthohumol prevented
175
Nutrients 2020, 12, 2393
body weight gain; decreased glycemia, triglyceride and cholesterol, and improved insulin sensitivity.
Xanthohumol activated the hepatic and skeletal muscle AMPK, downregulated the expression of
Srebp1c and Fasn and inhibited the activity of ACC, thus reducing the lipogenic pathway [386,397].
According to these data, aspalathin a C-glucosyl dihydrochalcone present in rooibos tea from
Aspalathus linearis, also activated AMPK and reduced the expression of hepatic enzymes and
transcriptional regulators that are associated with either gluconeogenesis and/or lipogenesis (Acc, Fasn,
Scd) in diabetic ob/ob mice [388,398]. Furthermore, Aspalathin-enriched green rooibos extract (GRE)
improved hepatic insulin resistance via the regulation of the PI3K/AKT and AMPK Pathways [399].
In obese insulin resistant rats GRE upregulated the expression of Glut2, insulin receptor (Insr), Irs1 and
Irs2, as well as Cpt1a [399]. Finally, Isoliquiritigenin at a low dose ameliorated insulin resistance and
NAFLD in diet-induced obese mice. Isoliquiritigenin administration to HFD-fed mice decreased body
fat mass and plasma cholesterol as well as alleviated hepatic steatosis (smaller lipid droplets) with no
changes in TG and FFA serum levels [400]. It has been described that isoliquiritigenin suppressed the
expression of lipogenic genes (Fasn and Scd1) and increased FAO activity. Moreover, isoliquiritigenin
improved the insulin signaling in the liver and muscle [400].
Besides chalcones, chalcones-enriched products like Safflower yellow or ashitaba have
demonstrated hepatoprotective properties. In mice fed with HFD, Safflower yellow improved
lipid profile and alleviated fatty liver in a mechanism that has been associated to a reduction of the
biosynthesis of intracellular cholesterol. Safflower yellow significantly reduced the levels of total
cholesterol, triglycerides, LDL-cholesterol and the LDL/HDL ratio [401]. On its side, ashitaba (Angelica
keiskei) extract showed hepatoprotective activity in fructose-induced dyslipidemia due to increased
expression of FAO genes in the liver. Treatment with this extract upregulated the expression of the
Acox1, Mcad, ATP-binding membrane cassette transporter A1 (ABCA1) and apolipoprotein A1 (Apo-A1) [402].
In a similar way, this extract exerted hepatoprotective effects in HFD-fed mice. Ashitaba extract
reduced plasma levels of cholesterol, glucose, and insulin, lowered triglyceride and cholesterol content
in the liver, inhibited hepatic lipogenesis by downregulating Srebp1 and Fasn and activated FAO by
upregulating the expression of Cpt1A and Pparα [403]. The proposed mechanism underlying this
hepatic metabolic effects is an activation of the AMPK enzyme in the liver [403].
In some of the studies the hepatoprotective role of chalcones has been linked to the adiponectin
production. Concretely, trans-chalcone administration to high cholesterol diet-induced liver fibrosis
increased the serum levels of adiponectin and the hepatic antioxidant enzymes, thus alleviating liver
damage [404]. Similarly, xanthohumol and ashitaba extract or licochalcone A also increased the
adiponectin expression and secretion [393,403,405].
9.2. Chalcones in the Adipose Tissue, Upregulation of Adiponectin, Induction of Browning and Enhancement of
Energy Expenditure
As has been mentioned above, chalcones induce adiponectin expression and secretion but also
improve adipocytes function and reduce fat depots. Different molecular mechanisms underlying these
effects has been described.
The treatment of obese mice with licochalcone F to reduced adipocyte size and ameliorated
macrophage infiltration in WAT depots as well as enhanced Akt signaling and reduced p38 MAPK
pathway [380]. On its side, the administration of Licochalcone A, isoliquiritigenin or a Glycyrrhiza
uralensis extract containing licochalcone A, isoliquiritigenin, and liquiritigenin to diet-induced obese
mice reduced body weight gain and adipose tissues depots [393,400,406]. In this case, Licochalcone A
and Glycyrrhiza uralensis extract induced the browning phenotype in the iWAT this fat depot [393,406]
as it is demonstrated by the enhanced expression of brown fat markers such as Ucp1, Prdm16 and
Pgc1α [406]. By contrast, isoliquiritigenin elevated energy expenditure by increasing the expression of
thermogenic genes (Ucp1 and Prdm16) as well as Sirt1 that is linked to mitochondrial biogenesis [407]
in interscapular BAT [400].
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Finally, butein, besides its anti-inflammatory activity via the p38 MAPK/Nrf2/HO-1 pathway that
leads to a reduction of the adipocyte hypertrophy [408] is also capable to enhance energy expenditure
and increase thermogenesis. Butein induced the browning phenotype in the iWAT (upregulation of
Ucp1, Prdm16, cytochrome C oxidase 8b, and Cidea) and increased the UCP1 protein levels in BAT in
HFD-fed mice as well as in lean mice. The proposed molecular mechanism underlying these effects is
the induction of the PR domain containing 4 (Prdm4) and the activation of the PI3Kα/Akt1/PR domain
containing 4 (Prdm4) axis [409,410]. The browning effect of butein was not observed in other mice
models such as ThermoMouse strain nor in methionine- and choline-deficient diet-fed mice [411].
Butein actions have also been linked to its capacity to downregulate PPARγ expression [387,410].
Finally, chalcone-rich extracts such as Safflower yellow or Ashitaba extract have also demonstrated
effects in adipose tissues. Concretely, in mice fed with HFD, Safflower yellow administration
exerts anti-obesity and insulin-sensitizing effects by upregulating the expression of Pgc1α that may
indicate a browning phenotype of the scWAT as well as activating the protein levels of AKT and
GSK3β in visceral WAT [412]. On its side, Ashitaba extract suppressed the HF diet-induced body
weight gain and fat deposition in WAT, increased the adiponectin level and the phosphorylation
AMPK, inhibited lipogenesis by downregulating Pparγ, CCAAT/enhancer-binding protein α (C/ebpα) and
Srebp1 [403].
9.3. Chalcones in CNS: A Potential Neuroprotective Role
The antioxidant and anti-inflammatory properties of chalcones has been linked to some of
their neuroprotective effects [382,383,389] but no studies with obesity-related neuronal damage has
been found. Further studies are needed to identify the potential therapeutic role of chalcones on this
obesity side effect.
10. Concluding Remarks
Undoubtedly flavonoids are potential therapeutic agents against metabolic disorders such as
obesity, type 2 diabetes or NAFLD. Their impact in CNS, liver, and adipose tissue has been extensively
studied and the results let us to be optimistic. Several metabolic effects and signaling pathways have
been described underlying the anti-obesity effects of flavonoids specially in liver, EAT and BAT but
also in CNS. Globally theses effects go to control body weight, improve insulin sensitivity, reduce fat
accumulation in adipose tissues as well in ectopic depots and to increase energy expenditure (Figure 1).
Furthermore, the data presented in this review highlight that:
• Flavonoids are effective over a high variety of obesity and obesity-related diseases models.
• The anti-obesity effects of flavonoids are robust and consistent as they can be achieved using
different sources, ways of administration and doses.
• Most of the molecular mechanisms underlying the anti-obesity effects of flavonoids are shared for
the different subclasses of flavonoids (Tables 2 and 3).
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Figure 1. Summary of the metabolic and signaling pathways underlying the anti-obesity effects of
flavonoids. Molecular mechanisms underlying the beneficial effects of flavonoids have been widely
studied and, in many cases, involved the activation of the AMP-activated protein kinase (AMPK).
AMPK is a key enzyme for the control of lipid metabolism and adipogenesis. AMPK phosphorylation
and activation promote catabolic processes such as FAO, glucose uptake, or glycolysis as well as inhibits
anabolic pathways such as fatty acid synthesis or gluconeogenesis.
Even so more research is needed to confirm their therapeutically functionality in humans, the doses
and times needed for their effectiveness or the better combination of bioactive compounds. Nowadays
is still difficult to answer some crucial questions such as what is the effective dose of polyphenols; and
for how long do we need to intake them to get positive effects? It is obvious that differences among
experimental diets to induce fatty liver, dosages of bioactive compounds as well as the presence of other
food compounds or the use of isolated or extracted polyphenols could influence the outcomes obtained.
Furthermore, the use of flavonoids as a preventive or for treatment also show different results. Usually,
the doses used in published papers are much higher than the ones reached from fruits and vegetables
consumed as a whole.
The Predimed study determined that Spanish adults should intake around 820 ± 323 mg of
polyphones/day in a 2000 Kcal diet to get their beneficial effects [25,27] but probably these effects at
this dose are closely related to the MedDiet lifestyle. It is evident that, as MedDiet, some other dietary
patterns include high amounts of fruits, vegetables or polyphenols-rich beverages that make possible to
reach the optimal doses of polyphenols and by extension of flavonoids. Then, the question is: Are the
effects of polyphenols linked to the dietary pattern where they are included? Two recent systematic
reviews analyzed if there are enough evidence to define a health promoting polyphenol-rich dietary
pattern and concluded that the high variability in the experimental approaches and methods used to
evaluate polyphenols intake and health outcomes make difficult to stablish specific polyphenol intake
recommendations and to clarify whether total flavonoids or rather individual subclasses may exert
beneficial effects [30,36].
Moreover, low is known about the effects of combining different bioactive compounds from
different families. Are they going to have synergic, additive or antagonic effects? And not less
important is the need to identify the role of the food matrix on polyphenols and flavonoid effects.
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The bioavailability of polyphenols is low and not just their basic chemical structures (aglycons) are
key but also the attachment of additional groups. There are described around 8000 structures
of polyphenols with different physiological impact and several chemical structures, but all of
them with at least one a phenolic ring with one or more hydroxyl groups attached [38,413,414].
The polyphenols absorption in human body is dose- and type-dependent and their effects are related to
their bioavailability and pharmacokinetics. They show a low absorption rate and limited stability during
pass through the intestinal tract where microbiome may contribute to their absorption. Once absorbed,
polyphenols enter portal circulation and are metabolized in the liver. This first pass metabolism
modifies the polyphenol structure and in consequence its bioavailability and bioactivity [415,416].
Finally, the conjugate metabolites reach the bloodstream and the target tissues [415–418].
Several studies have demonstrated that the bioavailability and safety of polyphenols changed
when they are included in a food matrix [419–421]. Although most of the assays has been done
with in vitro models of digestion [422] it seems that the food matrices protect bioactive compounds
from intestinal degradation [420,423]. Finally, also cooking processes would have an impact in the
polyphenols content and bioavailability of some preparations [424–426]. On the other side, it has
been described that bioactive compounds with antioxidant properties are safe and beneficial but that
exogenous supplementation with isolated compounds can be toxic [427].
The role of intestinal digestion and microbiota impact on polyphenols’ effects must be also
considered. Besides their direct action in the liver, some flavonoids may exert their metabolic effects
through the gut microbiota modulation. An experimental approach with rabbits described that
procyanidin b2 may downregulated fatty acid synthesis genes and protected against obesity and
NAFLD by increasing the ratio of Bacteroidetes and Akkermansia [159]. Similar results were obtained
with green tea oolong tea and black tea water extracts that administered to HFD-fed mice improved the
glucose tolerance and reduced the weight gained caused by the HFD. Moreover, these animals showed
a better hepatic lipid profile and a reduced mass of the WAT. These effects were accompanied by a
reduction in plasma LPS, thus indicating less production and a significant increase in the production of
short-chain fatty acids (SCFAs). A metagenomic analysis indicated that the tea extracts changed the
gut microbiota’s composition [428]. In the same way also flavones ‘effects on obesity has been linked to
gut microbiota modifications [338]. Oral hydroxysafflor yellow A (HSYA) reversed the HFD-induced
gut microbiota dysbiosis and reduced the obese phenotype [429].
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Influence of In Vitro Digestion on Composition, Bioaccessibility and Antioxidant Activity of Food
Polyphenols-A Non-Systematic Review. Nutrients 2020, 12, 1401. [CrossRef] [PubMed]
423. Tarko, T.; Duda-Chodak, A. Influence of Food Matrix on the Bioaccessibility of Fruit Polyphenolic Compounds.
J. Agric. Food Chem. 2020, 68, 1315–1325. [CrossRef] [PubMed]
424. Rinaldi de Alvarenga, J.F.; Quifer-Rada, P.; Francetto Juliano, F.; Hurtado-Barroso, S.; Illan, M.; Torrado-Prat, X.;
Lamuela-Raventós, R.M. Using Extra Virgin Olive Oil to Cook Vegetables Enhances Polyphenol and
Carotenoid Extractability: A Study Applying the sofrito Technique. Molecules 2019, 24, 1555. [CrossRef]
[PubMed]
203
Nutrients 2020, 12, 2393
425. Beltrán Sanahuja, A.; De Pablo Gallego, S.L.; Maestre Pérez, S.E.; Valdés García, A.; Prats Moya, M.S. Influence
of Cooking and Ingredients on the Antioxidant Activity, Phenolic Content and Volatile Profile of Different
Variants of the Mediterranean Typical Tomato Sofrito. Antioxidants 2019, 8, 551. [CrossRef] [PubMed]
426. Rinaldi de Alvarenga, J.F.; Quifer-Rada, P.; Westrin, V.; Hurtado-Barroso, S.; Torrado-Prat, X.;
Lamuela-Raventós, R.M. Mediterranean sofrito home-cooking technique enhances polyphenol content
in tomato sauce. J. Sci. Food Agric. 2019, 99, 6535–6545. [CrossRef] [PubMed]
427. Bouayed, J.; Bohn, T. Exogenous antioxidants—Double-edged swords in cellular redox state: Health beneficial
effects at physiologic doses versus deleterious effects at high doses. Oxid. Med. Cell. Longev. 2010, 3, 228–237.
[CrossRef]
428. Liu, J.; Hao, W.; He, Z.; Kwek, E.; Zhao, Y.; Zhu, H.; Liang, N.; Ma, K.Y.; Lei, L.; He, W.-S.; et al. Beneficial
effects of tea water extracts on the body weight and gut microbiota in C57BL/6J mice fed with a high-fat diet.
Food Funct. 2019, 10, 2847–2860. [CrossRef]
429. Liu, J.; Yue, S.; Yang, Z.; Feng, W.; Meng, X.; Wang, A.; Peng, C.; Wang, C.; Yan, D. Oral hydroxysafflor yellow
A reduces obesity in mice by modulating the gut microbiota and serum metabolism. Pharmacol. Res. 2018,
134, 40–50. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Antidiabetic Effects of Flavan-3-ols and Their
Microbial Metabolites
Estefanía Márquez Campos, Linda Jakobs and Marie-Christine Simon *
Department of Nutrition and Food Sciences, Nutrition and Microbiota, University of Bonn, 53115 Bonn,
Germany; estefania.marquezc@gmail.com (E.M.C.); ljakobs@uni-bonn.de (L.J.)
* Correspondence: marie-christine.simon@uni-bonn.de; Tel.: +49-228-73-36-80
Received: 25 April 2020; Accepted: 26 May 2020; Published: 29 May 2020
Abstract: Diet is one of the pillars in the prevention and management of diabetes mellitus. Particularly,
eating patterns characterized by a high consumption of foods such as fruits or vegetables and beverages
such as coffee and tea could influence the development and progression of type 2 diabetes. Flavonoids,
whose intake has been inversely associated with numerous negative health outcomes in the last few
years, are a common constituent of these food items. Therefore, they could contribute to the observed
positive effects of certain dietary habits in individuals with type 2 diabetes. Of all the different
flavonoid subclasses, flavan-3-ols are consumed the most in the European region. However, a large
proportion of the ingested flavan-3-ols is not absorbed. Therefore, the flavan-3-ols enter the large
intestine where they become available to the colonic bacteria and are metabolized by the microbiota.
For this reason, in addition to the parent compounds, the colonic metabolites of flavan-3-ols could
take part in the prevention and management of diabetes. The aim of this review is to present the
available literature on the effect of both the parent flavan-3-ol compounds found in different food
sources as well as the specific microbial metabolites of diabetes in order to better understand their
potential role in the prevention and treatment of the disease.
Keywords: polyphenol; diabetes; flavonoids; catechins
1. Introduction
Diabetes can be classified into type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes
mellitus (GDM). Its prevalence has increased over the last decade, with 463 million people registered
as suffering from it in 2019 (9.3% of the global population) [1]. In the case of T2D, whose prevalence
constitutes around 90% of the total number of diabetes cases, its increase is directly related to ageing,
increased urbanization, and obesogenic environments [1]. A rising prevalence of T1D has also been
observed, but in this case the causes are not completely clear [2].
In general terms, glucose homeostasis involves glucose absorption in the intestine, glucose
uptake and metabolism by organs and tissues, and glucose hepatic production [3]. In T2D, peripheral
glucose uptake, mainly in muscle, is decreased. This, together with an increased endogenous glucose
production, leads to a hyperglycemic status. Moreover, lipolysis is increased and the resulting
free fatty acids (FFAs) and intermediary lipid metabolites all lead to a more pronounced glucose
output, decreased glucose utilization, and impaired activity of beta cells. Pancreatic beta cells are
stimulated to compensate the hyperglycemic state by secreting insulin, but this function deteriorates
over time. Glucagon secretion by pancreatic alpha cells is, moreover, impaired. A deterioration in the
incretin effect could be the cause of both the impaired insulin and glucagon secretion since there is an
inadequate release of, or response to, the gastrointestinal incretin hormones post-prandially. Moreover,
renal tubular glucose reabsorption is increased [3].
Due to the adverse effects that the most commonly used antidiabetic drugs can have [4], finding
natural substances for preventing or treating T2D has become an attractive potential alternative.
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Flavan-3-ols, the most commonly ingested flavonoids [5], have been related to different health
promoting outcomes such as the prevention of cardiovascular disease [6] and cancer [7]. Regarding
their effects on T2D, epidemiological data show that some foods rich in flavan-3-ols, such as green tea,
could lower the risk of the disease [8–10].
This review presents in vitro, in vivo, and clinical studies regarding the effects of flavan-3-ols on
diabetes both in their original form and their microbial metabolites in order to better comprehend the
underlying molecular mechanisms on diabetes prevention.
2. Search Criteria
A literature search was performed in Medline via PubMed for in vitro, in vivo, and human
intervention trials published between 2005 and 2019 investigating the protective role of flavan-3-ols
and their colonic metabolites on diabetes. Search terms included flavan-3-ol, flavanol, catechin,
epicatechin, epigallocatechin, gallocatechin, procyanidin, theaflavin, γ-valerolactone, valeric acid,
3,4-dihydroxyphenyl propionic acid, 3-hydroxyphenyl propionic acid, 3-hydroxyphenylacetic acid,
3,4-dihydoxyphenylacetic acid, homovanillic acid, protocatechuic acid, 3-hydroxybenzoic acid,
green tea, grape seed extract, cacao, diabetes, glucose, insulin, insulin resistance, beta cell, pancreas,
glucagon, incretin effect, and vasodilation. In vitro and in vivo studies included both diabetic models
and non-diabetic models. Only human trials with a study population presenting an impaired glucose
metabolism (type 1 or type 2 diabetes mellitus, gestational diabetes, or pre-diabetes) were considered.
The focus was on studies that primarily investigated effects on glucose metabolism.
3. Flavan-3-ols: Intake and Metabolism
Flavan-3-ols constitute a flavonoid subclass naturally present in food as monomers (catechin (C)
and epicatechin (EC)), oligomers, polymers (proanthocyanidins), and other derived compounds (such
as theaflavins and thearubigins) [11].
Monomeric forms of flavan-3-ols are commonly present in cocoa beans, nuts, and fruits
such as berries, stone fruits, apples, and pears [12]. Cocoa, berries, and nuts are also rich in
proanthocyanidins [12]. Green tea is rich in gallocatechins while fermented black and oolong teas are
sources of theaflavins and thearubigins [13].
The mean flavan-3-ol intake seems to range between 77 mg/day and 182 mg/day depending on
the region, representing a much higher intake than that of other polyphenols [5]. Although the intake
of flavan-3-ols is the highest among other polyphenols, the amount as well as the subtype ingested
differ among countries. For example, the UK was shown to be the country with the highest total
flavan-3-ol consumption in Europe, which is probably due to the widespread and high consumption of
tea [14]. Therefore, monomer (especially epigallocatechin-3-gallate (EGCG)) and theaflavin (TF) intake
were the highest in the UK [5,14]. Nevertheless, proanthocyanidin intake was statistically higher in
Mediterranean countries, with the main sources there being stone and pome fruits [5,14].
After ingestion, the monomeric forms of the flavan-3-ols are absorbed directly in the small
intestine by passive diffusion before undergoing reactions lead by the phase II enzymes [11].
These enzymatic reactions, which first take place in the enterocyte and later in the liver, are performed
by uridine-5’-diphosphate glucuronosyltransferases (UGT), catechol-O-methyltransferases (COMT),
and sulfotransferases (SULT). The conjugated metabolites (glucuronides, O-methyl-esters,
and sulphates, respectively) are then released [11]. The conjugated metabolites are water-soluble and
can circulate through the human body via the systemic blood stream or be removed from the body in
the urine and bile [11,15,16]. When the conjugated metabolites are eliminated via the bile, they can
be recycled because they can be transported to the duodenum, where they will undergo enzymatic
modifications and be reabsorbed [15].
The remaining unabsorbed ingested oligomeric and polymeric forms of flavan-3-ols, as well
as a fraction of the structures already absorbed in the small intestine, go to the colon [11]. There,
the microbiota can perform metabolic transformations of the flavan-3-ols aided by hydrolysis reactions
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(O-deglycosylation and ester hydrolysis), cleavage (C-ring cleavage, delactonization, demethylation),
and reductions (dehydroxylation and double bond reduction) [17,18]. Specific colonic metabolites
for flavan-3-ols are γ-valerolactones, while further phenolic compounds are also common after the
microbial catabolism of other flavonoids [11].
After absorption, flavan-3-ols’ colonic metabolites go through phase II metabolism in the liver
and their conjugated forms reach the organs and tissues, where they exert their potential positive
effects [11]. Since the microbial metabolites could be the active substances with beneficial physiological
effects in addition to their precursor compounds, flavan-3-ol-derived metabolites formed by the colonic
microbiota have been given significant attention [11].
4. Antidiabetic Effects of Flavan-3-ols: In Vitro and In Vivo Studies
Flavan-3-ols and their colonic metabolites can modulate the molecular mechanisms involved
in the pathogenesis of diabetes, including the glucose absorption rate in the gut, glucose peripheral
uptake, glucose secretion, the modulation of beta cell function, the modulation of insulin secretion,
and the modulation of the incretin effect (Figure 1).
Figure 1. Potential molecular mechanisms underlying the antidiabetic properties of flavan-3-ols. ↑:
increase; ↓: decrease; Akt: protein kinase B; AMPK: 5’ adenosine monophosphate-activated protein
kinase; G-6-Pase: glucose-6-phosphatase; GLUT4: glucose transporter type 4; GS: glycogen synthase;
GSK3: glycogen synthase kinase 3; hIAPP: human islet amyloid polypeptide; IKK: IκB kinase; IR: insulin
receptor; IRS-1: insulin receptor substrate 1; JNK: c-Jun N-terminal kinases; mRNA: messenger RNA;
PEPCK: phosphoenolpyruvate carboxykinase; PI3K: phosphoinositide 3-kinase; PKC: protein kinase C;
PPARγ: peroxisome proliferator-activated receptor-γ; PTP1B: protein-tyrosine phosphatase 1B.
4.1. Glucose Absorption in the Gut
The first factor contributing to the postprandial glycemic level in the plasma is the absorption of
glucose in the gastrointestinal tract. This process is regulated by key enzymes such as α-glucosidase,
which releases glucose from complex carbohydrates. Inhibition of α-glucosidase activity by
a green tea water extract, a green tea polyphenol mixture, and EGCG has been shown to be
207
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stronger than by acarbose (half maximal inhibitory concentration (IC50) values were 4.421 ± 0.018,
10.019 ± 0.017, and 5.272 ± 0.009 μg/mL for flavan-3-ols, respectively, and 4822.783 ± 26.042 μg/mL for
acarbose) [19] (Table 1). In addition, grape seed extract (GSE) (86% gallic acid equivalents) inhibited
α-glucosidase activity (IC50 = 1.2 ± 0.2 μg/mL) more strongly than acarbose (IC50 = 91.0 ± 10.8 μg/mL),
and of the individual catechin 3-gallates, EGCG was the one with the strongest inhibitory effect
(IC50 = 0.3 ± 0.1 μg/mL) [20].
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Similarly, epicatechin-3-O-(3-O-methyl) gallate (ECG3”Me), epigallocatechin-3-O-(3-O-methyl)
gallate (EGCG3”Me), EGCG, and epicatechin-3-O-gallate (ECG) inhibited α-glucosidase, and in
this case EGCG3”Me had the strongest effect. Their IC50 values were 14.7, 8.1, 13.3, and 61.1 μM
respectively [21]. C was also shown to inhibitα-glucosidase stronger than acarbose (IC50 = 87.55 μg/mL
vs. 199.53 ± 1.12 μg/mL, respectively) [22].
Interestingly, isolated procyanidins B2, B5 (dimeric), and C1 (trimeric) also had stronger
α-glucosidase inhibitory activities than acarbose (IC50 = 4.7 ± 0.2, 5.5 ± 0.1, and 3.8 ± 0.2 μg/mL, versus
IC50 = 130.0 ± 20.0 μg/mL, respectively), suggesting that the inhibitory activity could be correlated to
the molecular weight of the compound [23].
For α-amylase, another digestive enzyme responsible for starch hydrolysis, GSE (86% gallic
acid equivalents) inhibited its activity (IC50 = 8.7 ± 0.8 μg/mL), with the same potency as acarbose
(IC50 = 6.9 ± 0.8 μg/mL) [20]. However, α-amylase was not strongly inhibited by tea extracts and
individual catechin 3-gallates [20].
These effects have also been observed in mice fed with proanthocyanidins with different degrees of
polymerization [52] (Table 2). Mice fed with proanthocyanidins with a high degree of polymerization
showed a stronger inhibition of α-amylase activity both in the small intestine and in the pancreas
than those fed with a low degree of polymerization proanthocyanidins. The rates of inhibition
compared to the control group were 41% in the small intestine and 45% in the pancreas for high
degree of polymerization proanthocyanidins, and 21% and 26% for low degree of polymerization
proanthocyanidins [52].
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4.2. Insulin Signaling Pathways and Glucose Peripheral Uptake
Due to the polar nature of glucose, its transport into the cell requires the use of transporter proteins
in the cell membrane. These glucose transporters have different tissue distributions and a specific
affinity for carbohydrates [69]. The insulin-regulatable glucose transporter type 4 (GLUT4) is found
in insulin-sensitive tissues: skeletal muscle, cardiomyocytes, and adipocytes. Under physiological
conditions, the insulin-mediated translocation of intracellular GLUT4 from the cytoplasm to the plasma
membrane results in the uptake of glucose. This process is influenced by phosphoinositide 3-kinase
(PI3K), protein kinase B (PKB or Akt), and protein kinase C zeta type (PKCζ). In short, insulin binding
to insulin receptor (IR) leads to the phosphorylation of the beta subunit which, at the same time,
phosphorylates the insulin receptor substrate (IRS). Upon tyrosine phosphorylation, which could be
inhibited by serine phosphorylation of insulin receptor substrate 1 (IRS-1), PI3K binds to IRS and
activates the Akt/PKB and the PKCζ cascades. Activated Akt induces glycogen synthesis via the
inhibition of glycogen synthase kinase (GSK-3). Eventually, the Rab GTPase-activating protein AS160
(Akt substrate of 160 kDa) is activated, leading to the translocation of GLUT4 to the plasma membrane
and glucose uptake [70].
When the translocation of intracellular GLUT4 to the plasma membrane is impaired, insulin
resistance (IRes) takes place. T2D develops when both IRes and defects in insulin secretion occur [3].
Since approximately 80% of insulin-stimulated glucose uptake in the postprandial state takes
place in the skeletal muscle, this tissue plays a key role in maintaining glucose homeostasis; therefore,
many studies have focused on the effect of flavan-3-ols on GLUT4 translocation in skeletal muscle.
In vitro, a cacao liquor procyanidin (CLP) extract (1–10 μg/mL), consisting of EC, C, and other
procyanidins, dose-dependently enhanced glucose uptake and promoted GLUT4 translocation to the
plasma membrane of L6 myotubes after 15 min of incubation [53].
A mixture of TF, theaflavin-3-gallate (TF-3-G), theaflavin-3′-gallate (TF-3′-G),
and theaflavin-3,3′-digallate (TFDG) (2.5–10 μg/mL, 24 h treatment) improved
IRes induced by palmitic acid in HepG2 cells, as measured by the increase in
2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) uptake using metformin as a
positive control [24]. Total GLUT4 and protein levels of GLUT4 bound to the membrane were increased
by theaflavins in a dose-dependent manner [24]. They reversed the reduction of the phosphorylation
level of Akt induced by palmitic acid and led to an increased phosphorylation of IRS-1 (Ser307) in
HepG2 cells [24].
Interestingly, Ojelabi et al. showed that EGCG and ECG dose-dependently inhibited sugar uptake
by glucose transporter type 1 (GLUT1), which was measured using 3-O-methylglucose uptake. It was
found that low concentrations of the flavan-3-ols activated sugar uptake, while higher concentrations
inhibited sugar uptake and noncompetitively inhibited sugar exit [25].
Glucose uptake in induced insulin-resistant 3T3-L1 adipocytes significantly increased after
incubation with EGCG at 5 μM. Moreover, EGCG dose-dependently reversed the dexamethasone (Dex)
and tumor necrosis factor (TNFα)-induced increase of c-Jun N-terminal kinases (JNK) phosphorylation
levels and promoted GLUT4 translocation (1 μM) [26].
In vivo studies showed similar results. KK-Ay mice, when supplemented with green tea catechins
(98% pure) at a low as well as at high concentrations (150 mg/kg/day and 300 mg/kg/day), showed a
reduced JNK phosphorylation in adipose tissues when compared to untreated animals and an increased
GLUT4 content in the plasma membrane [26].
Yamashita et al. administered a CLP extract as a single dose (250 mg/kg) to mice at the Institute of
Cancer Research (ICR). After carbohydrate ingestion, CLP suppressed the hyperglycemic response
and improved GLUT4 translocation in skeletal muscle [53]. In fact, the GLUT4 translocation was
approximately 3.9-fold higher in comparison with the control group, who were only administered
water and no glucose [53]. These results were further confirmed by a consecutive administration
of a CLP-supplemented (0.5%) diet to C57BL/6 mice for 7 days, which had the same effects on
skeletal muscle GLUT4 after glucose load [53]. Similarly, procyanidins (both low and high degree
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of polymerization, 10 mg/kg) from a CLP extract prevented hyperglycemia through the promotion
of GLUT4 translocation in the skeletal muscle of ICR mice [54]. This could be explained by the
significantly increased phosphorylation of 5’ adenosine monophosphate-activated protein kinase
(AMPK), ß-subunit of IR (IRβ), IRS-1, and PI3K by procyanidins with both low and high degrees of
polymerization [54].
After the oral administration of EC, procyanidin B2, procyanidin C1,
EC-(4β–6)-EC-(4β–8)-EC-(4β–8)-EC (PA4-1), and cinnamtannin A2 (PA4–2) (10 μg/kg) to ICR
mice, GLUT4 translocation in skeletal muscle significantly increased compared to in control mice [55].
Trimeric and tetrameric procyanidins significantly promoted phosphorylation of PI3K, and PA4-1 was
able to significantly induce phosphorylation of Akt1 at both serine 473 and threonine 308 [55]. The latter
compound was the only one able to significantly promote the phosphorylation of IRS-1 as well as
increase the insulin plasma level. Similarly, all compounds significantly induced phosphorylation of
AMPK [55].
In a model of T1D, streptozotocin (STZ)-induced rats were administered a green tea extract (GTE)
for 12 days composed of the following catechins: C, EC, (−)-gallocatechin (GC), (−)-epigallocatechin
(EGC), (−)-catechin gallate (CG), ECG, (−)-gallocatechin gallate (GCG), EGCG, and caffeine [56].
After an oral glucose tolerance test (OGTT), high blood glucose induced by STZ was significantly
reduced with the GTE treatment when compared to the control group. When the possible mechanisms
were investigated, the authors found that the GTE treatment increased the translocation of GLUT4 in
the skeletal muscle to a normal level when compared to untreated rats. In contrast, the level of the
IRß was not changed. These results imply that the green tea improved hyperglycemia in T1D rats
without having an influence on insulin secretion from pancreatic beta cells, by promoting GLUT4
translocation in skeletal muscle. In addition to these findings, the degree of protein glycation induced
by STZ measured by fructosamine and glycated hemoglobin (HbA1c) significantly decreased after
the treatment with the GTE. This result suggests not only a protective role of green tea against the
manifestation of diabetic complications but also an ability to improve those already presenting [56].
In a parallel experiment, an OGTT in KK-Ay mice was also performed, but in this case, mice were
treated with GTE for 63 days (one group) or for 42 days directly after the appearance of hyperglycemia
(another group). The authors found that the blood glucose after green tea intake was significantly
lower when compared to the control and GLUT4 translocation in the skeletal muscle was significantly
increased when compared to the control, but the level of IRß remained unaltered [56]. Another result
from this experiment is the significant reduction of protein glycation and triacylglycerol by green
tea [56].
In a study from Cremonini et al., EC supplementation (20 mg/kg) in high-fat-diet-induced obese
and diabetic C57BL/6 mice improved insulin sensitivity and glucose homeostasis when compared to
non-supplemented and control mice. The impairment of the insulin signaling cascade in the liver and the
adipose tissue induced by the high-fat diet was prevented and the upregulation/activation of proteins
which inhibit the insulin pathway (IκB kinase (IKK), protein kinase C (PKC), JNK, and protein-tyrosine
phosphatase 1B (PTP1B)) was prevented [57].
Bettaieb et al. found that the supplementation of the diet of high-fructose-fed rats with EC
(20 mg/kg) for 8 weeks mitigated the IRes induced by the high fructose concentrations, and it
reversed both the impaired activation of the insulin signaling cascade (IR, IRS-1, Akt, and extracellular
signal–regulated kinases 1/2 (ERK1/2)) as well as the upregulation of negative regulators (PKC, IKK,
JNK, and PTP1B) in the liver and adipose tissue [58].
Glucose uptake has been shown to be promoted not only by the flavan-3-ols in their original form
but also by some of their microbial metabolites. Specifically, 5-(3,5-dihydroxyphenyl)-γ-valerolactone
promoted GLUT4 translocation in L6 skeletal muscle cells and soleus muscle by phosphorylation of the
AMP-activated protein kinase (AMPK) signaling pathway both in vitro and in vivo at concentrations
of 1–3 μM and 32 mg/kg, respectively [27]. At 32 mg/kg it caused suppression of hyperglycemia after
an OGTT, while a higher dosage of 64 mg/kg only influenced AMPK phosphorylation [27].
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Other microbial metabolites unspecific to flavan-3-ols have also been shown to modulate molecular
mechanisms related to diabetes. Scazzocchio et al. investigated whether protocatechuic acid exerted
an effect on glucose transport in adipocytes [28]. Incubation of the metabolite at 100 μM for 18 h with
human and murine adipocytes treated with oxidized low density lipoprotein (oxLDL) significantly
improved glucose uptake, GLUT4 translocation, and adiponectin secretion. These effects were
observed after stimulation with insulin and also without it [28]. Glucose uptake was significantly
and dose-dependently enhanced in non-oxLDL-treated human and murine adipocytes without the
presence of insulin up to 40% and 60%, respectively [28]. These results indicate an insulin-like activity.
A reversion of the oxLDL-induced diminishment of mRNA expression and activity of the peroxisome
proliferator-activated receptor-γ (PPARγ) was also observed, and its inhibition impeded both the
adiponectin and GLUT4 upregulation suggesting its implication in the insulin-like activity [28].
Both EC at 10 μM and 2,3-dihydroxybenzoic acid (2,3-DHB) at 20 μM increased IR and IRS-1
tyrosine phosphorylated and total protein levels in rat renal NRK-52E cells. In addition, phosphorylated
levels of Akt and GSK-3 increased and those of glycogen synthase (GS) decreased [29]. Similarly,
after treatment of renal tubular NRK-52E cells with high glucose levels and either EC at 5–20 μM or
3,4-dihydroxyphenylacetic-acid (3,4-DHPA) at 10–20 μM, the induced impairment of glucose uptake
was restored. At 10 μM, EC and 3,4-DHPA increased tyrosine phosphorylated levels and total levels
of IR, reversed the inhibition of the PI3K/Akt pathway involved in the insulin signaling cascade,
and prevented the high-glucose-induced downregulation of AMPK phosphorylation [30].
4.3. Beta Cell Viability and Function
In the situation of IRes, pancreatic beta cells try to maintain glucose levels by enhancing insulin
production and increasing islet size and beta cell mass. However, an increased insulin response does
not mean that beta cells are functioning normally. In fact, beta cells in this situation are kept under a
high workload which, when maintained over time, results in functional exhaustion, dedifferentiation,
and eventually beta cell death [71]. Apoptosis of beta cells is mainly induced by glucotoxicity,
lipotoxicity, and deposits of islet amyloid polypeptide (IAPP) [72,73].
Glucose-stimulated insulin secretion (GSIS) in the beta cell line INS-1D after treatment with
catechins was studied by Kaneko et al. [31]. Both EGCG at 10 μM as well as GCG at 30 μM significantly
inhibited the GSIS. Furthermore, at 100 μM they almost eliminated GSIS. EC and C did not modify
GSIS at concentrations up to 100 μM. At 10 μM, EGC nearly eliminated GSIS, while GC and ECG
partially inhibited it. CG did not alter GSIS at concentrations up to 100 μM. Apart from this, EGCG,
and not EC, inhibited the variation of intracellular Ca2+ concentration. These results suggest that,
at concentrations higher than physiological levels, some catechins have an inhibitory effect on GSIS,
which is induced by the structure-dependent inhibition of voltage-dependent Ca2+-channels [31].
Supporting these results, a treatment with EC at a physiological dose of 0.3 μmol/L but not at
30 μmol/L improved GSIS of saturated fatty acid (SFA)-impaired INS-1 cells [32]. This was thought to be
due to a modulation of the cell secretory capacity via the activation of the Ca2+/calmodulin-dependent
protein kinase II (CaMKII) pathway and possibly through the GPR40 receptor [32].
In humans and animals, beta cell functionality can be measured by several methods. Some of
the most commonly used methods include the homeostasis model assessment (HOMA), OGTT or
intravenous glucose tolerance tests and the hyperglycemic clamp procedure [74]. The ability of
flavan-3-ols to affect these has been as well assessed. In a study from Othman et al., treatment of
diabetic rats with EGCG (2 mg/kg) every other day over one month significantly decreased the HOMA
of insulin resistance (HOMA-IR) value and increased insulin levels when compared to untreated
diabetic rats [59].
In a model where male Wistar rats were contrived to be obese through a cafeteria diet, a 21-day
treatment with grape seed procyanidin extract (GSPE) at 25 mg/kg (defined composition) improved
IRes measured by HOMA-IR [60]. The HOMA of beta cell function (HOMA-β) index also decreased.
Insulin gene expression in the pancreas tended to decrease in treated rats, and a significant decrease in
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the expression of carboxypeptidase E (Cpe) was also shown [60]. On the other hand, treatment with
GSPE enhanced the increase in the Bcl-2-associated X protein (Bax) levels induced by the cafeteria diet,
which suggests an increased apoptosis in the pancreas in contrast to results from other studies [60].
Gan et al. suggested that EGCG dose-dependently improved IRes in high-fat diet non-alcoholic
fatty liver disease (NAFLD) mice by enhancing the insulin clearance of the hepatic insulin degrading
enzyme (IDE) [61]. In this study, NAFLD mice were administered 10, 20, and 40 mg/kg EGCG
intraperitoneally. Hyperglycemia, hyperinsulinemia, and IRes observed in mice fed a high-fat diet
without EGCG were reversed by the polyphenol [61].
Insulin deficiency and IRes have been described in ß-thalassemia patients with iron overload,
which is probably a secondary effect of a diminished pancreatic beta cell function. The incubation of
iron-loaded rat insulinoma pancreatic β-cells with a GTE (2.29 μg EGCG equivalent) increased insulin
secretion levels 2.5-fold and decreased cellular levels of iron and reactive oxygen species (ROS) [33].
The effect of flavan-3-ols directly on beta cell viability was also assessed. Cinnamtannin B1,
procyanidin C1, and cinnamtannin D1 from cinnamon extracts were shown to dose-dependently
protect INS-1 cells from palmitic acid and H2O2-induced reduction in terms of cell viability [34].
At 25 μmol/L, they enhanced insulin secretion in lipotoxic INS-1 cells [34]. However, the flavan-3-ols
EC and procyanidin B2 had no significant effects [34].
In db/dayb mice, treatment with EGCG (10 g/kg diet, 1% (w/w)) for 10 weeks improved glucose
tolerance and additionally increased GSIS similarly to rosiglitazone, although no significant effect was
found in IRes (HOMA-IR and quantitative insulin sensitivity check index (QUICKI)). This effect may
be mediated by changes in pancreatic islets, since the number and size of pancreatic islets increased,
together with a reduction of islet endoplasmic reticulum stress markers ex vivo [62].
The literature suggests that human islet amyloid polypeptide (hIAPP) fibril formation contributes
to T2D by causing beta cell dysfunction and apoptosis. For this reason, the inhibition of the formation
of toxic hIAPP oligomers and fibrils may be a good therapeutic strategy for the management of
T2D. Some authors have therefore tried to elucidate the role of flavan-3-ols in the prevention of their
formation. In hemizygous non-diabetic hIAPP transgenic mice treated with EGCG (0.4 mg/mL) for
three weeks, EGCG reduced amyloid fiber intensity suggesting a beneficial effect on pancreatic amyloid
fibrils in vivo [63]. However, there was no effect on diabetic hIAPP transgenic mice. This, therefore,
suggests that EGCG would be effective as an early therapeutic method.
Mo et al. went further and examined the molecular process by which EGCG could inhibit
hIAPP aggregation [35]. The authors found that in vitro EGCG could block the inter-peptide
hydrophobic/aromatic interactions responsible for inter-peptideβ-sheet formation and the intra-peptide
interaction related to ß-hairpin formation. Thus, the three-stranded β-sheet structures were removed
and loosely packed coil-rich conformations were formed. This EGCG-induced conformational
shift of the hIAPP dimer was related to hydrophobic, aromatic stacking, cation-π, and H-bonding
interactions [35].
Adding to these results, Meng et al. proved that EGCG inhibited in vitro amyloid formation
by IAPP and disaggregated IAPP amyloid fibrils. At the same time, EGCG protected cultured rat
INS-1 cells against IAPP-induced toxicity at 30 μM [36]. EGCG (2–32 μM) was also shown to inhibit
the nucleation and fibrillation of hIAPP by forming hIAPP amorphous aggregates instead of ordered
fibrils [37]. Moreover, a complex of Al(III)/EGCG was able to inhibit hIAPP fibrillation more effectively
than the flavan-3-ol alone [37].
T-cell-mediated destruction of pancreatic beta cells leads to insulin deficiency in T1D. In addition,
inflammation is known to play a role in the pathogenesis of T1D [3]. In this regard, EGCG prevented
the onset of T1D in non-obese diabetic (NOD) mice when administered at 0.05% in drinking water
(60–90 mg/kg body weight (b.w.), equivalent to 4.5–6.8 g/day by a 75 kg person) for 32 weeks [64].
Compared to control mice, plasma insulin levels were higher, HbA1c concentrations were lower,
and circulating anti-inflammatory cytokine interleukin 10 (IL-10) levels were increased. However,
no effect on pancreatic insulitis was observed. When human pancreatic islets were incubated with
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inflammatory cytokines, addition of EGCG (1 and 10 μM) promoted islet viability [64]. Similarly,
the administration of EC at 0.5% in drinking water (equivalent to an intake of 250 g dark chocolate
containing 6% EC) for 32 weeks also delayed the development of T1D [65]. Importantly, pancreatic
islet mass was preserved and the lymphatic infiltration into islets was lower meaning an improvement
in the insulitis. Anti-inflammatory cytokine IL-10 levels increased [65]. HbA1c concentrations were,
in this case, significantly lower and plasma insulin levels were significantly higher in mice treated with
EC than in untreated mice [65].
The effect of low molecular weight phenolics produced after colonic metabolism of flavan-3-ols
on beta cell functionality and viability has also been assessed. Fernández-Millán et al. found
out a significant increase in GSIS in INS-1E pancreatic beta cells and isolated rat islets after
treatment with 3,4-DHPA and 3-hydroxyphenyl propionic acid (3-HPP) at low concentrations (5
and 1 μM, respectively) [38]. Under oxidative stress induced by tert-butyl hydroperoxide (t-BOOH),
both metabolites restored GSIS to control levels and significantly decreased cell death [38]. PKC and
ERK could play a role in producing the observed effect, since their phosphorylation levels increased
after treatment [38].
3,4-DHPA (250μM) could also prevent the diminished insulin secretion induced by high cholesterol
on Min6 pancreatic beta cells [39]. Moreover, it dose-dependently prevented cholesterol-induced
cytotoxicity and apoptosis. Oxidative stress and mitochondrial dysfunction were also prevented [39].
5-Phenylvaleric acid, hippuric acid and homovanillic acid improved GSIS in beta cells more
effectively than EC at concentrations up to 100 μM [40]. In addition to stimulating beta cell function,
the microbial metabolites enhanced glucose utilization in skeletal muscle [40].
4.4. Endogenous Glucose Production
The liver’s inability to perceive insulin signals directly after glucose ingestion leads to the
continuing production of glucose and, therefore, importantly contributes to a hyperglycemic status [3].
The maintained glucose output by the liver can be a consequence of two processes: gluconeogenesis and
glycogenolysis [3]. However, the latter has a less important role in the increased glucose production
of T2D patients [75]. The mechanisms responsible for the increase in hepatic gluconeogenesis
include hyperglucagonemia, higher circulating levels of gluconeogenic precursors (lactate, alanine,
and glycerol), elevated FFA oxidation, enhanced sensitivity to glucagon, and reduced sensitivity to
insulin [3].
Increased activity of insulin-influenced phosphoenolpyruvate carboxykinase 1 (PCK1) and
glucose-6-phosphatase (G-6-Pase) seems to contribute to the accelerated rate of hepatic glucose
production [3]. In this sense, studies have shown how flavan-3-ols affect the expression of key
regulators of the gluconeogenesis pathway.
Waltner-Law et al. studied the effects of green tea compounds on insulin signaling pathways,
gene expression, and glucose production [41]. The authors found that EGCG had insulin-like activities
in hepatoma cells. At 25μM, EGCG reduced glucose production to basal levels in a similar way to insulin
(10 nM) and these effects were already significant at lower concentrations (12.5 μM). When studying the
impact of the flavan-3-ol on the expression of genes encoding gluconeogenic enzymes, EGCG reduced
phosphoenolpyruvate carboxykinase (PEPCK) mRNA in a dose-dependent manner (12.5–100 μM)
and both PEPCK mRNA and G-6-Pase in a phosphoinositide 3-kinase (PI3K)-dependent manner [41].
In addition, 50 μM EGCG could activate PI3K within 10 min, similar to insulin (10 nM), but the
activation of other kinases such as PKB and p70s6k was much slower and not significant. The authors
suggested that EGCG has a similar mechanism to insulin in reducing glucose production and expressing
the PEPCK and G-6-Pase genes by modulation of the redox state of the cell [41].
Smaller amounts of EGCG (0.25–1 μM) suppressed gluconeogenesis in mouse cyclic adenosine
monophosphate dexamethasone (cAMP-Dex)-stimulated hepatocytes and blocked the expression of
the PEPCK and G-6-Pase genes [42]. However, no effect on the stimulation of tyrosine phosphorylation
of IRS-1 or Akt, nor an influence of the PI3K inhibitor LY294002, was found suggesting an
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independent mechanism to the insulin signaling pathway [42]. The other known suppressor of
hepatic gluconeogenesis, apart from the insulin signaling, is AMPK. In this case, EGCG increased the
AMPK and acetyl-CoA carboxylase (ACC) phosphorylation in a time- and dose-dependent manner,
and the suppression of AMPK resulted in the reversion of the effect of EGCG on the expression of the
PEPCK and G-6-Pase genes in a calcium/calmodulin-dependent protein kinase kinase (CaMKK)- and
ROS-dependent manner [42].
Yadollah et al. showed that 40 μM EGCG significantly reduced the expression of PEPCK and
G-6-Pase in insulin-resistant HepG2 cells by 53% and 67%, respectively [43]. This effect was similar
to that of 10 μM pioglitazone, which is a medication used to treat T2D. A combination of EGCG and
pioglitazone induced a stronger reduction in the expression of PEPCK and G-6-Pase. The authors also
proved that glucose production in HepG2 cells was significantly reduced by 50% by EGCG, by 55% by
pioglitazone, and by 69% by a combination of both EGCG and pioglitazone [43].
Aside from the liver, the kidneys are also involved in glucose homeostasis and gluconeogenesis.
EC (5–20 μM) and 2,3-DHB (20 μM) reduced cellular glucose uptake in rat renal NRK-52E cells similarly
to the sodium-glucose cotransporter-2 (SGLT-2) antagonist phlorizin, leaving the expression of SGLT-2
and glucose transporter type 2 (GLUT2) unaltered [29]. A reduction in glucose production and PEPCK
levels was also observed [29]. Moreover, the authors showed that Akt was involved in the modulation
of both PEPCK levels and glucose production in NRK-52E cells [29].
Treatment of renal tubular NRK-52E cells with EC (10–20 μM) and 3,4-DHPA (10 μM) separately
alleviated the alterations in glucose production and the upregulation of PEPCK induced by high
glucose [30]. However, the protective effect disappeared when Akt and AMPK were inhibited.
Therefore, both Akt and AMPK seem to be key molecules in the modulation of the glucose homeostasis
and the preservation of renal tubular functionality [30].
4.5. Incretin Effect
Incretin hormones include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1). They are gut peptides secreted after the intake of nutrients, such as glucose, and are
responsible for the incretin effect, which is the increased stimulation of insulin secretion by oral glucose
rather than by intravenous glucose infusion. This effect is impaired in patients with T2D due to
the reduced insulinotropic effect of GIP and GLP-1 [76]. In addition to the insulinotropic activity,
the incretin hormones work together to regulate glucagon secretion: GIP stimulates glucagon secretion
while GLP-1 inhibits glucagon secretion by alpha cells. In diabetic patients, glucagon secretion is
altered since it is not inhibited in hyperglycemic conditions [70].
Yamashita et al. studied if isolated dimeric, trimeric, and tetrameric procyanidins from cacao
liquor administered as a single-dose (10 μg/kg) in mice could influence GLP-1 and insulin levels in
plasma [66]. The tetrameric procyanidin cinnamtannin A2 was the only compound able to increase
the plasma insulin level without a glucose load as well as significantly increase the GLP-1 secretion
levels in plasma 60 min after oral administration [66]. In vitro experiments revealed an increased
phosphorylation of proteins IRß and IRS-1 in the soleus muscle as a result of the action of insulin.
Procyanidins (low and high degree of polymerization, 10 mg/kg) from a CLP-rich extract increased
GLP-1 secretion with or without glucose load in mice [54].
González-Abuín et al. evaluated the modulation of the mechanisms that have an influence on
GLP-1 secretion in STC-1 cells by GSPE [44]. The authors found out that 0.05 mg/L GSPE induced
depolarization, while 50 mg/L induced hyperpolarization in enteroendocrine cells [44]. This high extract
concentration suppressed GLP-1 secretion by around 40%. Under nutrient-stimulated conditions,
50 mg/L GSPE reduced the membrane depolarization induced by nutrients and reduced GLP-1 secretion
by 20% in glucose- and proline-stimulated cells. These results indicate the importance of the GSPE
concentration in depolarization and GLP-1 secretion by STC-1 cells, as well as the influence that
nutrients have on GLP-1 secretion by enteroendocrine cells [44].
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Glycogen synthesis is also one of the functions of incretin hormones. Its secretion rate in muscle
is controlled by GS, which is also enhanced by insulin. Therefore, this stimulates a cascade of
phosphorylation-dephosphorylation reactions [3]. Glycogen synthase phosphatase (PP1) is activated
by the phosphorylation of serine phosphorylation site 1 in the regulatory subunit (G) of PP1 by insulin
and this phosphorylation is catalyzed by insulin-stimulated protein kinase 1 (ISPK-1). Phosphorylation
of site 2 by cAMP-dependent kinase (PKA) leads, on the contrary, to its inactivation [3].
Some authors have studied how flavan-3-ols influence glycogen synthesis. Kim et al. showed
that green tea polyphenols consisting of 68% EGCG were able to enhance glycogen synthesis by up
to a factor of 2 (10 μM) in high glucose treated HepG2 cells under 100 nM insulin stimulation [45].
The molecular mechanism can involve the regulation of enzymes such as glycogen synthase kinase
3-beta (GSK3ß) and GS since expression of phospho-GSK3β (Ser9) and phospho-GS (Ser461) were
enhanced by EGCG [45].
4.6. Other Mechanisms
The production of cellular oxidants may affect insulin sensitivity via the negative regulation of
insulin signaling pathways (JNK, IKK), the promotion of sustained chronic inflammation, and oxidative
stress. Flavan-3-ols are known to have antioxidative functions, and these could exert a protective
effect against diabetes and its complications via controlling the oxidative stress. Cinnamtannin B1,
procyanidin C1, and cinnamtannin D1 (12.5–50μmol/L) from cinnamon extracts inhibited H2O2-induced
ROS generation as well as increased cell viability of INS-1 cells [34]. Similarly, under t-BOOH-induced
oxidative stress, the microbial metabolites 3,4-DHPA and 3-HPP (5 and 1 μM, respectively) significantly
decreased rat pancreatic beta cell death and ROS and carbonyl group production [38]. While EC at
a low dose of 0.3 μmol/L, but not at a higher dose of 30 μmol/L, improved GSIS of SFA-impaired
INS-1 cells, only the highest dose of EC significantly reduced ROS after treatment with H2O2 and high
glucose [32].
Bettaieb et al. found that the supplementation of high-fructose-fed rats with EC (20 mg/kg) for
8 weeks, mitigated the IRes induced by high fructose concentrations. EC supplementation (20 mg/kg)
in high-fructose-fed rats showed an ability to inhibit the expression and activity of NADPH oxidase
and the activation of redox-sensitive signals [58].
Treatment of STZ-induced diabetic rats with C (20 and 40 mg/kg/day) significantly decreased
glucose levels, while superoxide dismutase (SOD), catalase (CAT), and glutathione S-transferase (GST)
levels increased in a concentration-dependent manner, especially after treatment with 80 mg/kg/day [67].
Haidari et al. showed that a GTE given to STZ-induced diabetic rats at 200 mg/kg for 4 weeks,
significantly decreased their serum glucose levels as well as the serum and hepatic malondialdehyde
(MDA) concentration when compared to the diabetic control group. Total antioxidant capacity (TAC)
was significantly increased after treatment [68].
Plasma glucose levels could also be controlled by the modulation of lipid digestion and the
reduction of hyperlipidemia [77]. C treatment of STZ-induced diabetic rats dose-dependently
decreased the serum levels of total cholesterol (TC), triglycerides, LDL, apoprotein B, and glucose
levels, while it increased the serum levels of high density lipoprotein (HDL) and apoprotein A-I
(20–80 mg/kg) [67]. EGCG dose-dependently reversed increased serum lipid levels including TC,
TG, and LDL, and increased HDL in high-fat diet NAFLD mice compared with control mice [61].
EC (20 mg/kg body weight) prevented the high-fat-diet-induced increase in plasma TG and FFA in
C57BL/6 mice [57]. Treatment of HepG2 cells with 100 nM insulin and 0.1–10 μM EGCG reduced
lipogenesis to 65% compared to cells treated with insulin alone through increased expressions of
phosphor-AMPKα and phosphor-ACC [45].
Inflammation contributes to impaired glucose management by adipocytes, hepatocytes, and muscle
cells and interferes with insulin production and insulin signaling [78]. TNFα plays an important role
in the activation of signaling cascades in adipocytes related to inflammation and IRes. In this context,
EC (0.5–10 μM) has been shown to dose-dependently reduce TNFα-mediated JNK, ERK1/2, and p-38
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phosphorylation, and nuclear AP-1-DNA binding in 3T3-L1 adipocytes [46]. It also inhibited the
activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling cascade
preventing the p65 nuclear transport and nuclear NF-κB-DNA binding. Moreover, EC reversed the
TNFα-mediated downregulation of PPARγ expression and reduced nuclear DNA binding. The altered
transcription of genes involved in inflammation and insulin signaling (monocyte chemoattractant
protein 1 (MCP-1), IL-6, TNFα, resistin and protein-tyrosine phosphatase 1B) mediated by TNFα was
inhibited by EC [46].
EC supplementation (20 mg/kg) in high-fructose-fed rats inhibited the expression of NF-κB
regulated pro-inflammatory cytokines and chemokines [58].
The colonic metabolites of flavan-3-ols have also been shown to exert beneficial effects in diabetes
other than those directly related to glycemia. One of them is the positive effect on vascular function,
which is known to be directly linked to diabetes [79]. As reported in several studies, low molecular
weight phenolics such as 2,3-dihydroxybenzoic acid (2,3-DHB), 3-HPP, and 3,4-DHPA could exert
vasodilatory activities by stimulating NO production [47–49]. Apart from this, dihydroferulic acid,
3-hydroxyphenylacetic acid (3-HPA), 3,4-DHPA, and homovanillic acid could reduce the formation of
advanced glycation end-products (AGEs) [50,51], which are thought to be linked to the development
of diabetes and insulin resistance and to the occurrence of diabetic complications [80].
5. Antidiabetic Effects of Flavan-3-ols: Clinical Intervention Trials
Some authors have studied the effect of the supplementation of pure flavan-3-ols on antidiabetic
effects in order to exclude potential interactions with other compounds and with other flavonoids
present in flavan-3-ol-rich food. Zhang et al. investigated the effects of a daily intake of EGCG
(500 mg/day) in women with a diagnosed GDM at the beginning of the third quarter of pregnancy
(29 weeks). HOMA-IR, HOMA-β fasting blood glucose and insulin levels decreased whereas the
insulin sensitivity as measured by QUICKI increased due to the intervention. Furthermore, neonatal
complications at birth, such as low birth weight or hypoglycemia, were significantly reduced in the
intervention group [81] (Table 3).
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Hsu et al. found no statistical differences in several parameters (fasting glucose, insulin, HOMA-IR,
HbA1c, lipoproteins, hormones (leptin, ghrelin, adiponectin), blood pressure, anthropometrics) between
a decaffeinated GTE-supplemented group (3 × 500 mg/day; 856 mg EGCG) of T2D obese patients and
the placebo group. However, 16 weeks of treatment led to a significant reduction of HbA1c, HOMA-IR
index and the insulin level from the baseline to the end of the treatment (within-group changes) [84].
A randomized controlled trial (RCT) assessed the effect of a daily consumption of 100 g of
flavanol-rich dark chocolate (FRC; 1008 mg total phenols and 36.12 g C) for 15 days on IRes and
showed a significant reduction of HOMA-IR, an enhancement of the insulin sensitivity and an increase
in the beta cell activity in hypertensive individuals with impaired glucose tolerance [82]. Furthermore,
the consumption of FRC decreased TC and LDL when compared to the baseline values and the
control, but it did not affect HDL and TG. High-sensitivity C-reactive protein (hsCRP) did not change
either [82]. Similarly, the daily consumption of 27 g FRC (850 mg flavan-3-ols and 90 mg EC) and
100 mg isoflavones for one year reduced HOMA-IR, LDL, and the TC:HDL ratio and increased QUICKI
and the HDL:LDL ratio in postmenopausal women with T2D. These metabolic improvements resulted
in a lower 10-year total coronary heart disease (CHD) risk compared to the control [83].
A clinical trial investigating the effects of the daily intake of green tea (340 mL) and GTE (582.8 mg
catechins/day) for 12 weeks showed an increased insulin level and an increase in the adiponectin
level (only within-group changes) in subjects with T2D. Furthermore, there was a reduction of FFA
compared to the baseline and a decrease of the TC level when compared to the control. Fasting blood
glucose and HbA1c remained unchanged [85].
The daily supplementation with a GTE (one packet/day; 544 mg polyphenols, 456 mg C) for two
months improved the HbA1c value in individuals with glucose abnormalities when compared to the
baseline. No other parameters of glucose metabolism (fasting blood glucose, insulin, HOMA-IR) or
lipid metabolism (TC, LDL, HDL, TG) were affected by the intervention [86]. Furthermore, the daily
intake of a GTE powder did not improve the hsCRP level [86]. In individuals with borderline T2D or
T2D, GTE (544 mg polyphenols, 456 mg C) decreased the IRes, as measured by HOMA-IR, the fasting
blood glucose, the insulin levels and the HbA1c when compared to the baseline. No significant
differences between the intervention and the control were observed [87].
However, not all studies showed unambiguous protective effects against diabetes. A daily intake
of 9 g green tea in 900 mL hot water for four weeks did not affect the IRes, the fasting blood glucose
or the insulin concentration in subjects suffering from T2D. Furthermore, no beneficial effects on
the lipid metabolism, hsCRP or IL-6 were shown [88]. Similarly, daily supplementation of GSE
(2 × 300 mg/day) for four weeks did not improve the IRes [89]. Fasting blood glucose, insulin level,
and HOMA-IR remained unchanged in individuals with T2D and a high cardiovascular risk. Moreover,
the supplementation did not result in an improved lipoprotein status apart from a decrease in TC level.
However, the regular intake of the GSE significantly decreased fructosamine concentration, decreased
hsCRP, and increased the reduced glutathione (GSH) compared to the baseline value. Total antioxidant
status (TAOS) and the concentration of oxidized glutathione (GSSG) remained unchanged [89].
A daily intake of 2.5 g cacao powder (ACTICOA TM; 207.5 mg flavanols) for 12 weeks did not
enhance the glucose or lipid metabolism in T2D hypertensive patients [90]. The consumption of two
cacao beverages per day (2 × 28 g cacao powder/day) containing 180 mg, 400 mg or 900 mg flavanols on
five consecutive days did not affect fasting and postprandial glucose parameters in obese individuals
who were at risk of IRes either. However, hsCRP, 8-isoprostane, and IL-6 decreased as the dose of
flavanols increased. These effects were only significant when compared to the baseline values but not
when compared to the control [91].
Acute cacao studies also showed no distinct improvement of postprandial glycemia and the
insulin response in participants with T2D. The acute supplementation of a cacao beverage (960 mg
polyphenols; 480 mg flavanols) with a high-fat fast-food-style breakfast (766 kcal, 50 g fat) elicited a
higher insulin response and a decreased IRes, as measured by HOMA-IR. HDL increased while the
concentration of TC, LDL, TG, and hsCRP remained unchanged [92]. No effects could be observed after
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an acute supplementation of 2.5 g cacao powder (ACTICOATM; 40.4 mg EC) with a diabetic-suitable
breakfast in hypertensive, overweight or obese subjects with T2D [93].
6. Concluding Remarks
Increasing evidence suggests that flavan-3-ols are responsible for the protective role of certain
foods, such as green tea, against diabetes. Possible molecular mechanisms by which they could prevent
or treat diabetes include the promotion of beta cell functionality and viability, the amelioration of
glucose transport in muscle and adipose tissue by the promotion of the insulin signaling pathway,
the enhancement of the incretin effect, and the decrease of endogenous glucose production.
Microbial metabolites of flavan-3-ols are suggested to be the actual active form by which
these compounds exert their potential health benefits, such as the antidiabetic effect. However,
the evidence regarding this is still scarce and only few studies assessed the effects of flavan-3-ol specific
microbial metabolites.
One of the determinants of the possible antidiabetic effect of flavan-3-ols seems to be their
concentration. In this regard, when interpreting the results of in vitro studies, it is necessary to
consider not only the bioavailability of the compounds investigated but also their physiological plasma
concentration after absorption. Some of the studies used higher concentrations than those found in
human plasma after ingestion. Conjugated flavan-3-ols have been detected in plasma in low nanomolar
ranges [94,95]. Their colonic metabolites phenyl-γ-valerolactones and phenylvaleric acids have been
detected in plasma at concentrations under 1 μM [95–99]. The lower weight phenolics are usually found
in plasma at concentrations lower than 0.5 μM [96–99], although phenylacetic acid, protocatechuic
acid, and hippuric acid were also detected at concentrations ≈ 40 μmol/L [96–100].
Although many studies used physiological concentrations of the compound and microbial
metabolites, some tested higher concentrations and suggested that, in some cases, supraphysiological
ranges could induce an opposite response to that from lower ranges. A careful evaluation of the
flavan-3-ol dose would, therefore, be needed when used as nutraceutical.
Under physiological concentrations, flavan-3-ols and their microbial metabolites exert different
biological activities at varying concentrations. The concentration needed to exert a specific function
by a particular compound might not be the same than the one needed to exert another biological
activity. For example, 3,4-DHPA IC50 on vasodilation is lower than on AGEs formation [101,102].
In the prevention and management of diabetes, low concentrations of flavan-3-ols and their microbial
metabolites could influence determined molecular mechanisms while higher concentrations could be
needed to positively influence other mechanisms, as shown in many of the presented studies.
Although increasing evidence supports the stated mechanisms of action, the results of many
studies are inconclusive, with some of them exhibiting contradictory outcomes or even negative effects.
Possible reasons for the varying results could be not only the different compound concentrations
used, but also the different methodologies used in each study. As for the in vitro and animal studies,
a variety of models for diabetes was used. In the literature described in this review, the most frequent
in vitro techniques used insulin-secreting cell line INS-1 and pancreatic beta cell lines, and they also
included in vitro studies on glucose uptake mainly in skeletal muscle cells but also in 3T3-L1 adipocytes.
In addition, assays on α-amylase inhibition and inhibition of α-glucosidase activity were performed.
In vivo studies included spontaneous diabetic obese animal models, mice genetically predisposed to
obesity and T2D, and others used chemicals to induce the disease, mainly streptozotocin. However,
not all models were specific for diabetes mellitus. Therefore, although many of these studies showed
positive effects on diabetic parameters, concluding that they are beneficial for the treatment of diabetes
mellitus would not be appropriate. For the proper elucidation of the effect of a substance regarding
diabetes management suitable models are required. For this reason, more in vitro and animal studies
using the adequate models for the disease should be performed.
Moreover, it is worth mentioning that some of the used treatment samples often include other
bioactive components. Therefore, the flavan-3-ol fraction does not always represent the exclusive
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component present in the sample, which must be taken into account when attributing positive effects
to these compounds.
In the case of human clinical trials, the compliance of the patients to the treatment was not measured
in all cases and the diet during the intervention was not always recorded. In addition, other confounders,
such as body composition, were often insufficiently registered. Therefore, these factors could have
influenced the studies’ results. Moreover, not only the concentration of the flavan-3-ols might be a
determinant of the possible antidiabetic effect, but also, the duration of the intervention could be a
determinant. Further methodological weaknesses in some of the human trials presented are the absence
of a wash-out phase, or not choosing the dietary restrictions of the control groups appropriately.
It is known that the individual gut microbiota composition has an influence on both the
bioavailability and the metabolization of flavan-3-ols [3]. However, none of the included clinical
trials investigated the bioavailability and the metabolization of the ingested flavan-3-ols in the study
population. Therefore, no conclusion can be reached about whether there is a positive association
between the blood concentration of the flavan-3-ols or their metabolites, the administered dose, and the
putative effect. That is, it is not possible to know to what extent different metabolic effects are related
to a different bioavailability and metabolization of the flavan-3-ols by individuals. In order to better
understand the effects of flavan-3-ols and their metabolites on the prevention and management
of diabetes, it is relevant to record not only metabolic parameters after treatment but also the
pharmacokinetics of these substances.
For all these reasons, the use of homogeneous and more appropriate methods is essential for the
clarification of flavan-3-ol’s antidiabetic effect and mechanisms of action.
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